0001551152-19-000023.txt : 20190805 0001551152-19-000023.hdr.sgml : 20190805 20190805123334 ACCESSION NUMBER: 0001551152-19-000023 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 92 CONFORMED PERIOD OF REPORT: 20190630 FILED AS OF DATE: 20190805 DATE AS OF CHANGE: 20190805 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AbbVie Inc. CENTRAL INDEX KEY: 0001551152 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 320375147 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-35565 FILM NUMBER: 19998059 BUSINESS ADDRESS: STREET 1: 1 NORTH WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 BUSINESS PHONE: (847) 932-7900 MAIL ADDRESS: STREET 1: 1 NORTH WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 10-Q 1 abbv-20190630x10q.htm 10-Q Document
5000000006100000031000000110000008000000false--12-31Q220190001551152Common Stock, par value $0.01 per shareABBV10800000000.00.010.0140000000004000000000177651087117810558773600000000P5YP3Y0.21000390000000000000000007000000160000006000000120000001600000019000000500000060000001800000017000000200000090000000297686473302685326 0001551152 2019-01-01 2019-06-30 0001551152 exch:XNYS us-gaap:CommonStockMember 2019-01-01 2019-06-30 0001551152 exch:XCHI us-gaap:CommonStockMember 2019-01-01 2019-06-30 0001551152 2019-07-29 0001551152 2019-04-01 2019-06-30 0001551152 2018-04-01 2018-06-30 0001551152 2018-01-01 2018-06-30 0001551152 2018-12-31 0001551152 2019-06-30 0001551152 us-gaap:RetainedEarningsMember 2017-12-31 0001551152 us-gaap:CommonStockMember 2018-01-01 2018-06-30 0001551152 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-04-01 2018-06-30 0001551152 us-gaap:TreasuryStockMember 2018-03-31 0001551152 us-gaap:RetainedEarningsMember 2018-12-31 0001551152 us-gaap:CommonStockMember 2018-04-01 2018-06-30 0001551152 us-gaap:TreasuryStockMember 2018-04-01 2018-06-30 0001551152 us-gaap:AdditionalPaidInCapitalMember 2018-04-01 2018-06-30 0001551152 us-gaap:TreasuryStockMember 2019-06-30 0001551152 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0001551152 us-gaap:RetainedEarningsMember 2018-06-30 0001551152 us-gaap:TreasuryStockMember 2018-01-01 2018-06-30 0001551152 us-gaap:RetainedEarningsMember 2018-03-31 0001551152 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-06-30 0001551152 us-gaap:TreasuryStockMember 2017-12-31 0001551152 us-gaap:AdditionalPaidInCapitalMember 2019-04-01 2019-06-30 0001551152 us-gaap:CommonStockMember 2019-03-31 0001551152 us-gaap:RetainedEarningsMember 2018-04-01 2018-06-30 0001551152 2017-12-31 0001551152 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-30 0001551152 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-06-30 0001551152 us-gaap:CommonStockMember 2019-04-01 2019-06-30 0001551152 us-gaap:CommonStockMember 2018-06-30 0001551152 us-gaap:RetainedEarningsMember 2018-01-01 2018-06-30 0001551152 us-gaap:CommonStockMember 2017-12-31 0001551152 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-06-30 0001551152 us-gaap:CommonStockMember 2018-12-31 0001551152 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-06-30 0001551152 2018-01-01 0001551152 us-gaap:TreasuryStockMember 2019-04-01 2019-06-30 0001551152 us-gaap:RetainedEarningsMember 2019-04-01 2019-06-30 0001551152 us-gaap:TreasuryStockMember 2018-01-01 0001551152 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 0001551152 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0001551152 us-gaap:RetainedEarningsMember 2018-01-01 0001551152 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-04-01 2019-06-30 0001551152 us-gaap:RetainedEarningsMember 2019-01-01 2019-06-30 0001551152 us-gaap:CommonStockMember 2019-01-01 2019-06-30 0001551152 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-03-31 0001551152 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-06-30 0001551152 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001551152 us-gaap:TreasuryStockMember 2018-12-31 0001551152 us-gaap:CommonStockMember 2019-06-30 0001551152 2018-06-30 0001551152 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 0001551152 us-gaap:CommonStockMember 2018-03-31 0001551152 us-gaap:TreasuryStockMember 2019-01-01 2019-06-30 0001551152 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0001551152 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001551152 us-gaap:TreasuryStockMember 2019-03-31 0001551152 2019-03-31 0001551152 us-gaap:RetainedEarningsMember 2019-06-30 0001551152 us-gaap:TreasuryStockMember 2018-06-30 0001551152 us-gaap:AdditionalPaidInCapitalMember 2018-03-31 0001551152 2018-03-31 0001551152 us-gaap:RetainedEarningsMember 2019-03-31 0001551152 us-gaap:AdditionalPaidInCapitalMember 2018-06-30 0001551152 us-gaap:CommonStockMember 2018-01-01 0001551152 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0001551152 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0001551152 us-gaap:AccountingStandardsUpdate201602Member 2019-01-01 0001551152 abbv:June2019BridgeCreditFacilityMember us-gaap:BridgeLoanMember 2019-06-25 0001551152 abbv:AllerganplcMember us-gaap:ScenarioForecastMember 2020-01-01 0001551152 2019-06-24 0001551152 abbv:July2019364DayTermLoanTrancheMember us-gaap:LoansPayableMember us-gaap:SubsequentEventMember 2019-07-12 2019-07-12 0001551152 abbv:June2019BridgeCreditFacilityMember us-gaap:BridgeLoanMember 2019-01-01 2019-06-30 0001551152 abbv:CalicoLifeSciencesLlcMember us-gaap:CollaborativeArrangementMember 2018-06-01 2018-06-30 0001551152 abbv:June2019BridgeCreditFacilityMember us-gaap:BridgeLoanMember 2019-06-25 2019-06-25 0001551152 us-gaap:CollaborativeArrangementMember 2018-06-01 2018-06-30 0001551152 abbv:AllerganplcMember us-gaap:ScenarioForecastMember 2020-01-01 2020-03-31 0001551152 abbv:July2019ThreeYearTermLoanTrancheMember us-gaap:LoansPayableMember us-gaap:SubsequentEventMember 2019-07-12 0001551152 abbv:July2019TermLoanCreditAgreementMember us-gaap:LoansPayableMember us-gaap:SubsequentEventMember 2019-07-12 0001551152 abbv:June2019BridgeCreditFacilityMember us-gaap:BridgeLoanMember us-gaap:SubsequentEventMember 2019-07-12 0001551152 abbv:July2019364DayTermLoanTrancheMember us-gaap:LoansPayableMember us-gaap:SubsequentEventMember 2019-07-12 0001551152 abbv:CalicoLifeSciencesLlcMember us-gaap:CollaborativeArrangementMember 2018-01-01 2018-06-30 0001551152 abbv:July2019FiveYearTermLoanTrancheMember us-gaap:LoansPayableMember us-gaap:SubsequentEventMember 2019-07-12 0001551152 abbv:July2019TermLoanCreditAgreementMember us-gaap:LoansPayableMember us-gaap:SubsequentEventMember 2019-07-12 2019-07-12 0001551152 abbv:July2019FiveYearTermLoanTrancheMember us-gaap:LoansPayableMember us-gaap:SubsequentEventMember 2019-07-12 2019-07-12 0001551152 abbv:July2019ThreeYearTermLoanTrancheMember us-gaap:LoansPayableMember us-gaap:SubsequentEventMember 2019-07-12 2019-07-12 0001551152 abbv:JanssenBiotechIncMember us-gaap:CollaborativeArrangementMember 2018-12-31 0001551152 abbv:JanssenBiotechIncMember us-gaap:CollaborativeArrangementMember 2019-06-30 0001551152 abbv:JanssenBiotechIncMember us-gaap:CollaborativeArrangementMember 2019-01-01 2019-06-30 0001551152 us-gaap:CollaborativeArrangementMember 2019-01-01 2019-06-30 0001551152 us-gaap:NonUsMember us-gaap:CollaborativeArrangementMember 2019-04-01 2019-06-30 0001551152 abbv:JanssenBiotechIncMember country:US us-gaap:CollaborativeArrangementMember 2018-04-01 2018-06-30 0001551152 us-gaap:NonUsMember us-gaap:CollaborativeArrangementMember 2019-01-01 2019-06-30 0001551152 us-gaap:CollaborativeArrangementMember 2018-01-01 2018-06-30 0001551152 us-gaap:NonUsMember us-gaap:CollaborativeArrangementMember 2018-04-01 2018-06-30 0001551152 abbv:JanssenBiotechIncMember country:US us-gaap:CollaborativeArrangementMember 2019-01-01 2019-06-30 0001551152 abbv:JanssenBiotechIncMember country:US us-gaap:CollaborativeArrangementMember 2018-01-01 2018-06-30 0001551152 us-gaap:NonUsMember us-gaap:CollaborativeArrangementMember 2018-01-01 2018-06-30 0001551152 abbv:JanssenBiotechIncMember country:US us-gaap:CollaborativeArrangementMember 2019-04-01 2019-06-30 0001551152 us-gaap:CollaborativeArrangementMember 2019-04-01 2019-06-30 0001551152 us-gaap:CollaborativeArrangementMember 2018-04-01 2018-06-30 0001551152 abbv:StemcentrxInc.Member us-gaap:InProcessResearchAndDevelopmentMember 2018-10-01 2018-12-31 0001551152 abbv:StemcentrxInc.Member us-gaap:InProcessResearchAndDevelopmentMember 2018-12-31 0001551152 abbv:SKYRIZIMember 2019-04-01 2019-04-30 0001551152 us-gaap:DevelopedTechnologyRightsMember 2018-12-31 0001551152 us-gaap:DevelopedTechnologyRightsMember 2019-06-30 0001551152 us-gaap:LicensingAgreementsMember 2019-06-30 0001551152 us-gaap:LicensingAgreementsMember 2018-12-31 0001551152 abbv:SKYRIZIMember us-gaap:DevelopedTechnologyRightsMember 2019-04-01 2019-04-30 0001551152 abbv:LongTermDebtandFinanceLeaseObligationsCurrentMember 2019-06-30 0001551152 us-gaap:OtherNoncurrentLiabilitiesMember 2019-06-30 0001551152 abbv:LongTermDebtandFinanceLeaseObligationsMember 2019-06-30 0001551152 us-gaap:AccountsPayableAndAccruedLiabilitiesMember 2019-06-30 0001551152 us-gaap:OtherNoncurrentAssetsMember 2019-06-30 0001551152 us-gaap:PropertyPlantAndEquipmentMember 2019-06-30 0001551152 us-gaap:AccountsReceivableMember 2019-01-01 2019-06-30 0001551152 us-gaap:ForeignExchangeForwardMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-06-30 0001551152 abbv:ChangeInAssumedDiscountRateMember us-gaap:ChangeDuringPeriodFairValueDisclosureMember 2019-01-01 2019-06-30 0001551152 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:SeniorNotesMember 2018-01-01 2018-06-30 0001551152 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:SeniorNotesMember 2019-01-01 2019-06-30 0001551152 abbv:May2018TermLoanCreditAgreementMember us-gaap:LoansPayableMember 2019-03-01 2019-03-31 0001551152 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0001551152 abbv:ChangeInAssumedProbabilityRateMember us-gaap:ChangeDuringPeriodFairValueDisclosureMember 2019-01-01 2019-06-30 0001551152 us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-01-01 2019-06-30 0001551152 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2018-01-01 2018-06-30 0001551152 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-01-01 2019-06-30 0001551152 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2019-01-01 2019-06-30 0001551152 us-gaap:CommercialPaperMember 2018-06-30 0001551152 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2019-06-30 0001551152 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:SeniorNotesMember 2019-04-01 2019-06-30 0001551152 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2018-12-31 0001551152 abbv:SKYRIZIMember 2019-04-01 2019-06-30 0001551152 us-gaap:CommercialPaperMember 2019-06-30 0001551152 us-gaap:AccountsReceivableMember us-gaap:GeographicConcentrationRiskMember 2019-01-01 2019-06-30 0001551152 us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:SeniorNotesMember 2019-06-30 0001551152 us-gaap:ShortTermInvestmentsMember 2019-06-30 0001551152 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:SeniorNotesMember 2018-04-01 2018-06-30 0001551152 us-gaap:ShortTermInvestmentsMember 2018-12-31 0001551152 abbv:May2018TermLoanCreditAgreementMember us-gaap:LoansPayableMember 2018-05-01 2018-05-31 0001551152 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-06-30 0001551152 us-gaap:CommercialPaperMember 2018-12-31 0001551152 us-gaap:AccountsReceivableMember us-gaap:GeographicConcentrationRiskMember 2018-01-01 2018-06-30 0001551152 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-06-30 0001551152 us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-04-01 2018-06-30 0001551152 us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-01-01 2018-06-30 0001551152 us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-04-01 2019-06-30 0001551152 us-gaap:FairValueInputsLevel2Member 2018-12-31 0001551152 us-gaap:FairValueInputsLevel3Member 2018-12-31 0001551152 us-gaap:FairValueInputsLevel1Member 2018-12-31 0001551152 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2018-12-31 0001551152 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2018-12-31 0001551152 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-06-30 0001551152 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0001551152 us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0001551152 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-06-30 0001551152 us-gaap:OtherNoncurrentAssetsMember us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0001551152 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2018-12-31 0001551152 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0001551152 us-gaap:OtherLiabilitiesMember us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-06-30 0001551152 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2019-06-30 0001551152 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-06-30 0001551152 us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2018-12-31 0001551152 us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-06-30 0001551152 us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2019-06-30 0001551152 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0001551152 us-gaap:OtherLiabilitiesMember us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0001551152 us-gaap:OtherNoncurrentAssetsMember us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-06-30 0001551152 us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-06-30 0001551152 us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-06-30 0001551152 us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0001551152 us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0001551152 us-gaap:OtherDebtSecuritiesMember 2018-12-31 0001551152 us-gaap:AssetBackedSecuritiesMember 2018-12-31 0001551152 us-gaap:CorporateDebtSecuritiesMember 2018-12-31 0001551152 us-gaap:FairValueInputsLevel3Member 2019-06-30 0001551152 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2019-06-30 0001551152 us-gaap:FairValueInputsLevel2Member 2019-06-30 0001551152 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-06-30 0001551152 us-gaap:FairValueInputsLevel1Member 2019-06-30 0001551152 us-gaap:FairValueMeasurementsRecurringMember 2019-06-30 0001551152 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-06-30 0001551152 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-06-30 0001551152 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-06-30 0001551152 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-06-30 0001551152 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-06-30 0001551152 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-06-30 0001551152 us-gaap:ForeignExchangeContractMember us-gaap:FairValueMeasurementsRecurringMember 2019-06-30 0001551152 us-gaap:OtherDebtSecuritiesMember 2019-06-30 0001551152 us-gaap:AssetBackedSecuritiesMember 2019-06-30 0001551152 us-gaap:CorporateDebtSecuritiesMember 2019-06-30 0001551152 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001551152 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001551152 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001551152 us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001551152 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001551152 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001551152 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:BankTimeDepositsMember 2018-12-31 0001551152 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001551152 us-gaap:ForeignExchangeContractMember us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001551152 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:BankTimeDepositsMember 2018-12-31 0001551152 us-gaap:FairValueMeasurementsRecurringMember us-gaap:BankTimeDepositsMember 2018-12-31 0001551152 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:BankTimeDepositsMember 2018-12-31 0001551152 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2018-01-01 2018-06-30 0001551152 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CostOfSalesMember 2018-04-01 2018-06-30 0001551152 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember us-gaap:ForeignCurrencyGainLossMember 2018-01-01 2018-06-30 0001551152 us-gaap:FairValueHedgingMember us-gaap:InterestExpenseMember 2019-04-01 2019-06-30 0001551152 us-gaap:FairValueHedgingMember us-gaap:InterestExpenseMember 2019-01-01 2019-06-30 0001551152 us-gaap:ForeignExchangeForwardMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2018-01-01 2018-06-30 0001551152 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CostOfSalesMember 2018-01-01 2018-06-30 0001551152 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember us-gaap:ForeignCurrencyGainLossMember 2019-04-01 2019-06-30 0001551152 us-gaap:ForeignExchangeForwardMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2019-04-01 2019-06-30 0001551152 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2019-01-01 2019-06-30 0001551152 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2018-04-01 2018-06-30 0001551152 us-gaap:ForeignExchangeForwardMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2018-04-01 2018-06-30 0001551152 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember us-gaap:ForeignCurrencyGainLossMember 2019-01-01 2019-06-30 0001551152 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CostOfSalesMember 2019-04-01 2019-06-30 0001551152 us-gaap:ForeignExchangeForwardMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2019-01-01 2019-06-30 0001551152 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember us-gaap:ForeignCurrencyGainLossMember 2018-04-01 2018-06-30 0001551152 us-gaap:FairValueHedgingMember us-gaap:InterestExpenseMember 2018-04-01 2018-06-30 0001551152 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2019-04-01 2019-06-30 0001551152 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CostOfSalesMember 2019-01-01 2019-06-30 0001551152 us-gaap:FairValueHedgingMember us-gaap:InterestExpenseMember 2018-01-01 2018-06-30 0001551152 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0001551152 us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:SeniorNotesMember 2018-12-31 0001551152 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2018-04-01 2018-06-30 0001551152 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2018-01-01 2018-06-30 0001551152 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2019-01-01 2019-06-30 0001551152 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2019-04-01 2019-06-30 0001551152 us-gaap:PensionPlansDefinedBenefitMember 2018-01-01 2018-06-30 0001551152 us-gaap:PensionPlansDefinedBenefitMember 2019-01-01 2019-06-30 0001551152 us-gaap:PensionPlansDefinedBenefitMember 2019-04-01 2019-06-30 0001551152 us-gaap:PensionPlansDefinedBenefitMember 2018-04-01 2018-06-30 0001551152 us-gaap:CostOfSalesMember 2019-04-01 2019-06-30 0001551152 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2018-04-01 2018-06-30 0001551152 us-gaap:CostOfSalesMember 2019-01-01 2019-06-30 0001551152 us-gaap:ResearchAndDevelopmentExpenseMember 2019-04-01 2019-06-30 0001551152 us-gaap:CostOfSalesMember 2018-01-01 2018-06-30 0001551152 us-gaap:ResearchAndDevelopmentExpenseMember 2018-04-01 2018-06-30 0001551152 us-gaap:ResearchAndDevelopmentExpenseMember 2018-01-01 2018-06-30 0001551152 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2018-01-01 2018-06-30 0001551152 us-gaap:CostOfSalesMember 2018-04-01 2018-06-30 0001551152 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-06-30 0001551152 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-01-01 2019-06-30 0001551152 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-04-01 2019-06-30 0001551152 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-01-01 2018-06-30 0001551152 us-gaap:AccumulatedTranslationAdjustmentMember 2018-01-01 2018-06-30 0001551152 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-01-01 2018-06-30 0001551152 abbv:AccumulatedNetGainLossFromNetInvestmentHedgesAttributableToParentMember 2017-12-31 0001551152 abbv:AccumulatedNetGainLossFromNetInvestmentHedgesAttributableToParentMember 2018-01-01 2018-06-30 0001551152 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2017-12-31 0001551152 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2017-12-31 0001551152 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2017-12-31 0001551152 abbv:AccumulatedNetGainLossFromNetInvestmentHedgesAttributableToParentMember 2018-06-30 0001551152 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2018-01-01 2018-06-30 0001551152 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-06-30 0001551152 us-gaap:AccumulatedTranslationAdjustmentMember 2018-06-30 0001551152 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2018-06-30 0001551152 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-06-30 0001551152 us-gaap:AccumulatedTranslationAdjustmentMember 2017-12-31 0001551152 abbv:December2018StockRepurchaseAuthorizationMember 2019-01-01 2019-06-30 0001551152 abbv:RestrictedStockUnitsAndPerformanceSharesMember 2019-06-30 0001551152 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-06-30 0001551152 abbv:RestrictedStockUnitsAndPerformanceSharesMember 2019-01-01 2019-06-30 0001551152 us-gaap:EmployeeStockOptionMember 2019-06-30 0001551152 abbv:February2017StockRepurchaseProgramMember 2018-01-01 2018-06-30 0001551152 us-gaap:AccumulatedTranslationAdjustmentMember 2019-01-01 2019-06-30 0001551152 2018-06-14 2018-06-14 0001551152 2018-09-07 2018-09-07 0001551152 2018-02-15 2018-02-15 0001551152 2019-06-20 2019-06-20 0001551152 2019-02-21 2019-02-21 0001551152 2018-11-02 2018-11-02 0001551152 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-06-30 0001551152 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-01-01 2019-06-30 0001551152 abbv:AccumulatedNetGainLossFromNetInvestmentHedgesAttributableToParentMember 2019-06-30 0001551152 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-01-01 2019-06-30 0001551152 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-06-30 0001551152 abbv:AccumulatedNetGainLossFromNetInvestmentHedgesAttributableToParentMember 2019-01-01 2019-06-30 0001551152 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-01-01 2019-06-30 0001551152 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-06-30 0001551152 us-gaap:AccumulatedTranslationAdjustmentMember 2019-06-30 0001551152 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-12-31 0001551152 us-gaap:AccumulatedTranslationAdjustmentMember 2018-12-31 0001551152 abbv:AccumulatedNetGainLossFromNetInvestmentHedgesAttributableToParentMember 2018-12-31 0001551152 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2018-12-31 0001551152 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-12-31 0001551152 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-04-01 2018-06-30 0001551152 us-gaap:NetInvestmentHedgingMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentParentMember 2018-04-01 2018-06-30 0001551152 us-gaap:NetInvestmentHedgingMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentParentMember 2018-01-01 2018-06-30 0001551152 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-04-01 2019-06-30 0001551152 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2018-01-01 2018-06-30 0001551152 us-gaap:NetInvestmentHedgingMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentParentMember 2019-01-01 2019-06-30 0001551152 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-04-01 2019-06-30 0001551152 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2018-04-01 2018-06-30 0001551152 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-01-01 2019-06-30 0001551152 us-gaap:NetInvestmentHedgingMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentParentMember 2019-04-01 2019-06-30 0001551152 abbv:TestosteroneReplacementTherapyProductsLiabilityLitigationMember 2019-06-30 0001551152 abbv:NiaspanMember 2019-01-01 2019-06-30 0001551152 abbv:AndroGelAntitrustLitigationMember 2019-01-01 2019-06-30 0001551152 abbv:DepakoteMember 2019-06-30 0001551152 abbv:NovartisVaccinesandDiagnosticsIncandGrifolsWorldwideOperationsLtdMember 2017-03-01 2017-03-31 0001551152 abbv:ElliottAssociatesL.P.Member 2016-06-01 2016-06-30 0001551152 abbv:AndroGelAntitrustLitigationMember abbv:DisgorgementRemedyMember 2018-06-01 2018-06-30 0001551152 abbv:AndroGelAntitrustLitigationMember 2019-06-30 0001551152 2014-11-01 2014-11-30 0001551152 abbv:AndroGelAntitrustLitigationMember 2014-09-01 2014-09-30 0001551152 abbv:HematologicOncologyMember abbv:ImbruvicaMember 2019-01-01 2019-06-30 0001551152 abbv:HCVMember abbv:VIEKIRAMember 2018-04-01 2018-06-30 0001551152 abbv:HematologicOncologyMember abbv:ImbruvicaMember country:US 2019-04-01 2019-06-30 0001551152 abbv:OtherKeyProductsMember abbv:SevofluraneMember 2018-01-01 2018-06-30 0001551152 abbv:HematologicOncologyMember abbv:ImbruvicaMember us-gaap:NonUsMember 2018-04-01 2018-06-30 0001551152 abbv:OtherKeyProductsMember abbv:LupronMember 2018-01-01 2018-06-30 0001551152 abbv:HCVMember abbv:VIEKIRAMember 2018-01-01 2018-06-30 0001551152 abbv:OtherKeyProductsMember abbv:DuodopaMember 2018-04-01 2018-06-30 0001551152 abbv:OtherKeyProductsMember abbv:CreonMember country:US 2018-01-01 2018-06-30 0001551152 abbv:OtherKeyProductsMember abbv:KaletraMember country:US 2018-04-01 2018-06-30 0001551152 abbv:OtherKeyProductsMember abbv:LupronMember us-gaap:NonUsMember 2019-01-01 2019-06-30 0001551152 abbv:ImmunologyMember abbv:HUMIRAMember us-gaap:NonUsMember 2019-01-01 2019-06-30 0001551152 abbv:OtherProductsMember 2018-04-01 2018-06-30 0001551152 abbv:ImmunologyMember abbv:HUMIRAMember country:US 2018-04-01 2018-06-30 0001551152 abbv:HematologicOncologyMember abbv:ImbruvicaMember us-gaap:NonUsMember 2019-04-01 2019-06-30 0001551152 abbv:HCVMember abbv:MAVYRETMember us-gaap:NonUsMember 2019-04-01 2019-06-30 0001551152 abbv:HematologicOncologyMember abbv:VENCLEXTAMember us-gaap:NonUsMember 2018-04-01 2018-06-30 0001551152 abbv:HCVMember abbv:MAVYRETMember 2019-01-01 2019-06-30 0001551152 abbv:OtherKeyProductsMember abbv:SevofluraneMember country:US 2019-01-01 2019-06-30 0001551152 abbv:ImmunologyMember abbv:SKYRIZIMember country:US 2019-01-01 2019-06-30 0001551152 abbv:OtherKeyProductsMember abbv:ORILISSAMember us-gaap:NonUsMember 2019-01-01 2019-06-30 0001551152 abbv:HCVMember abbv:MAVYRETMember country:US 2018-04-01 2018-06-30 0001551152 abbv:ImmunologyMember abbv:SKYRIZIMember 2018-01-01 2018-06-30 0001551152 abbv:HCVMember abbv:MAVYRETMember country:US 2019-04-01 2019-06-30 0001551152 abbv:ImmunologyMember abbv:HUMIRAMember us-gaap:NonUsMember 2018-04-01 2018-06-30 0001551152 abbv:HematologicOncologyMember abbv:VENCLEXTAMember 2019-01-01 2019-06-30 0001551152 abbv:OtherKeyProductsMember abbv:ORILISSAMember 2018-01-01 2018-06-30 0001551152 abbv:ImmunologyMember abbv:HUMIRAMember 2018-04-01 2018-06-30 0001551152 abbv:ImmunologyMember abbv:HUMIRAMember 2018-01-01 2018-06-30 0001551152 abbv:OtherKeyProductsMember abbv:SynagisMember us-gaap:NonUsMember 2018-04-01 2018-06-30 0001551152 abbv:ImmunologyMember abbv:HUMIRAMember 2019-01-01 2019-06-30 0001551152 abbv:HCVMember abbv:VIEKIRAMember country:US 2019-04-01 2019-06-30 0001551152 abbv:HCVMember abbv:VIEKIRAMember us-gaap:NonUsMember 2018-04-01 2018-06-30 0001551152 abbv:OtherKeyProductsMember abbv:LupronMember us-gaap:NonUsMember 2018-04-01 2018-06-30 0001551152 abbv:OtherKeyProductsMember abbv:AndroGelMember country:US 2018-01-01 2018-06-30 0001551152 abbv:OtherKeyProductsMember abbv:SevofluraneMember 2019-01-01 2019-06-30 0001551152 abbv:OtherKeyProductsMember abbv:CreonMember country:US 2018-04-01 2018-06-30 0001551152 abbv:HematologicOncologyMember abbv:VENCLEXTAMember us-gaap:NonUsMember 2019-01-01 2019-06-30 0001551152 abbv:OtherKeyProductsMember abbv:LupronMember 2018-04-01 2018-06-30 0001551152 abbv:HematologicOncologyMember abbv:VENCLEXTAMember us-gaap:NonUsMember 2019-04-01 2019-06-30 0001551152 abbv:OtherKeyProductsMember abbv:DuodopaMember country:US 2019-04-01 2019-06-30 0001551152 abbv:HCVMember abbv:MAVYRETMember 2018-01-01 2018-06-30 0001551152 abbv:OtherKeyProductsMember abbv:AndroGelMember country:US 2019-04-01 2019-06-30 0001551152 abbv:HematologicOncologyMember abbv:ImbruvicaMember 2019-04-01 2019-06-30 0001551152 abbv:OtherProductsMember 2018-01-01 2018-06-30 0001551152 abbv:HCVMember abbv:VIEKIRAMember country:US 2019-01-01 2019-06-30 0001551152 abbv:OtherKeyProductsMember abbv:ORILISSAMember country:US 2018-04-01 2018-06-30 0001551152 abbv:OtherKeyProductsMember abbv:SevofluraneMember 2019-04-01 2019-06-30 0001551152 abbv:OtherKeyProductsMember abbv:ORILISSAMember country:US 2019-01-01 2019-06-30 0001551152 abbv:HematologicOncologyMember abbv:ImbruvicaMember us-gaap:NonUsMember 2019-01-01 2019-06-30 0001551152 abbv:ImmunologyMember abbv:HUMIRAMember country:US 2019-01-01 2019-06-30 0001551152 abbv:ImmunologyMember abbv:SKYRIZIMember 2019-01-01 2019-06-30 0001551152 abbv:HCVMember abbv:MAVYRETMember 2019-04-01 2019-06-30 0001551152 abbv:HCVMember abbv:VIEKIRAMember country:US 2018-01-01 2018-06-30 0001551152 abbv:OtherKeyProductsMember abbv:SevofluraneMember country:US 2018-01-01 2018-06-30 0001551152 abbv:ImmunologyMember abbv:SKYRIZIMember us-gaap:NonUsMember 2019-04-01 2019-06-30 0001551152 abbv:OtherKeyProductsMember abbv:LupronMember country:US 2018-04-01 2018-06-30 0001551152 abbv:OtherKeyProductsMember abbv:DuodopaMember country:US 2019-01-01 2019-06-30 0001551152 abbv:HCVMember abbv:MAVYRETMember country:US 2018-01-01 2018-06-30 0001551152 abbv:OtherKeyProductsMember abbv:LupronMember us-gaap:NonUsMember 2018-01-01 2018-06-30 0001551152 abbv:HematologicOncologyMember abbv:VENCLEXTAMember country:US 2018-04-01 2018-06-30 0001551152 abbv:OtherKeyProductsMember abbv:SevofluraneMember 2018-04-01 2018-06-30 0001551152 abbv:HCVMember abbv:MAVYRETMember us-gaap:NonUsMember 2018-04-01 2018-06-30 0001551152 abbv:HCVMember abbv:MAVYRETMember us-gaap:NonUsMember 2018-01-01 2018-06-30 0001551152 abbv:HematologicOncologyMember abbv:ImbruvicaMember us-gaap:NonUsMember 2018-01-01 2018-06-30 0001551152 abbv:OtherKeyProductsMember abbv:KaletraMember 2018-04-01 2018-06-30 0001551152 abbv:OtherKeyProductsMember abbv:SevofluraneMember us-gaap:NonUsMember 2018-04-01 2018-06-30 0001551152 abbv:HematologicOncologyMember abbv:VENCLEXTAMember country:US 2019-04-01 2019-06-30 0001551152 abbv:OtherKeyProductsMember abbv:SevofluraneMember country:US 2018-04-01 2018-06-30 0001551152 abbv:HCVMember abbv:VIEKIRAMember country:US 2018-04-01 2018-06-30 0001551152 abbv:HematologicOncologyMember abbv:ImbruvicaMember 2018-01-01 2018-06-30 0001551152 abbv:OtherKeyProductsMember abbv:KaletraMember country:US 2019-01-01 2019-06-30 0001551152 abbv:ImmunologyMember abbv:HUMIRAMember 2019-04-01 2019-06-30 0001551152 abbv:HCVMember abbv:VIEKIRAMember us-gaap:NonUsMember 2019-04-01 2019-06-30 0001551152 abbv:ImmunologyMember abbv:HUMIRAMember us-gaap:NonUsMember 2018-01-01 2018-06-30 0001551152 abbv:OtherKeyProductsMember abbv:LupronMember country:US 2019-01-01 2019-06-30 0001551152 abbv:OtherKeyProductsMember abbv:LupronMember 2019-04-01 2019-06-30 0001551152 abbv:OtherKeyProductsMember abbv:SynthroidMember country:US 2018-04-01 2018-06-30 0001551152 abbv:HematologicOncologyMember abbv:ImbruvicaMember 2018-04-01 2018-06-30 0001551152 abbv:HematologicOncologyMember abbv:ImbruvicaMember country:US 2019-01-01 2019-06-30 0001551152 abbv:HCVMember abbv:VIEKIRAMember 2019-04-01 2019-06-30 0001551152 abbv:OtherKeyProductsMember abbv:KaletraMember 2019-01-01 2019-06-30 0001551152 abbv:HematologicOncologyMember abbv:VENCLEXTAMember 2019-04-01 2019-06-30 0001551152 abbv:OtherKeyProductsMember abbv:ORILISSAMember us-gaap:NonUsMember 2018-01-01 2018-06-30 0001551152 abbv:ImmunologyMember abbv:SKYRIZIMember country:US 2018-01-01 2018-06-30 0001551152 abbv:OtherKeyProductsMember abbv:KaletraMember country:US 2019-04-01 2019-06-30 0001551152 abbv:HematologicOncologyMember abbv:VENCLEXTAMember us-gaap:NonUsMember 2018-01-01 2018-06-30 0001551152 abbv:OtherKeyProductsMember abbv:LupronMember us-gaap:NonUsMember 2019-04-01 2019-06-30 0001551152 abbv:ImmunologyMember abbv:SKYRIZIMember us-gaap:NonUsMember 2019-01-01 2019-06-30 0001551152 abbv:HCVMember abbv:VIEKIRAMember 2019-01-01 2019-06-30 0001551152 abbv:ImmunologyMember abbv:SKYRIZIMember 2019-04-01 2019-06-30 0001551152 abbv:ImmunologyMember abbv:HUMIRAMember country:US 2018-01-01 2018-06-30 0001551152 abbv:OtherKeyProductsMember abbv:SynagisMember us-gaap:NonUsMember 2019-01-01 2019-06-30 0001551152 abbv:OtherKeyProductsMember abbv:KaletraMember us-gaap:NonUsMember 2019-01-01 2019-06-30 0001551152 abbv:HematologicOncologyMember abbv:VENCLEXTAMember 2018-04-01 2018-06-30 0001551152 abbv:HCVMember abbv:VIEKIRAMember us-gaap:NonUsMember 2019-01-01 2019-06-30 0001551152 abbv:OtherKeyProductsMember abbv:DuodopaMember country:US 2018-04-01 2018-06-30 0001551152 abbv:OtherKeyProductsMember abbv:LupronMember country:US 2019-04-01 2019-06-30 0001551152 abbv:OtherKeyProductsMember abbv:ORILISSAMember 2019-01-01 2019-06-30 0001551152 abbv:OtherKeyProductsMember abbv:SynagisMember us-gaap:NonUsMember 2018-01-01 2018-06-30 0001551152 abbv:HematologicOncologyMember abbv:ImbruvicaMember country:US 2018-01-01 2018-06-30 0001551152 abbv:OtherKeyProductsMember abbv:SynagisMember us-gaap:NonUsMember 2019-04-01 2019-06-30 0001551152 abbv:HematologicOncologyMember abbv:ImbruvicaMember country:US 2018-04-01 2018-06-30 0001551152 abbv:OtherKeyProductsMember abbv:CreonMember country:US 2019-01-01 2019-06-30 0001551152 abbv:OtherKeyProductsMember abbv:LupronMember country:US 2018-01-01 2018-06-30 0001551152 abbv:OtherKeyProductsMember abbv:ORILISSAMember 2018-04-01 2018-06-30 0001551152 abbv:OtherKeyProductsMember abbv:DuodopaMember 2018-01-01 2018-06-30 0001551152 abbv:ImmunologyMember abbv:SKYRIZIMember us-gaap:NonUsMember 2018-01-01 2018-06-30 0001551152 abbv:OtherKeyProductsMember abbv:SynthroidMember country:US 2018-01-01 2018-06-30 0001551152 abbv:OtherKeyProductsMember abbv:DuodopaMember us-gaap:NonUsMember 2019-01-01 2019-06-30 0001551152 abbv:ImmunologyMember abbv:SKYRIZIMember country:US 2019-04-01 2019-06-30 0001551152 abbv:OtherKeyProductsMember abbv:AndroGelMember country:US 2019-01-01 2019-06-30 0001551152 abbv:OtherKeyProductsMember abbv:AndroGelMember country:US 2018-04-01 2018-06-30 0001551152 abbv:OtherKeyProductsMember abbv:LupronMember 2019-01-01 2019-06-30 0001551152 abbv:HematologicOncologyMember abbv:VENCLEXTAMember country:US 2018-01-01 2018-06-30 0001551152 abbv:OtherKeyProductsMember abbv:KaletraMember us-gaap:NonUsMember 2019-04-01 2019-06-30 0001551152 abbv:HematologicOncologyMember abbv:VENCLEXTAMember country:US 2019-01-01 2019-06-30 0001551152 abbv:OtherKeyProductsMember abbv:SevofluraneMember country:US 2019-04-01 2019-06-30 0001551152 abbv:OtherKeyProductsMember abbv:ORILISSAMember 2019-04-01 2019-06-30 0001551152 abbv:OtherKeyProductsMember abbv:ORILISSAMember us-gaap:NonUsMember 2018-04-01 2018-06-30 0001551152 abbv:OtherKeyProductsMember abbv:CreonMember country:US 2019-04-01 2019-06-30 0001551152 abbv:OtherKeyProductsMember abbv:DuodopaMember us-gaap:NonUsMember 2019-04-01 2019-06-30 0001551152 abbv:HematologicOncologyMember abbv:VENCLEXTAMember 2018-01-01 2018-06-30 0001551152 abbv:OtherKeyProductsMember abbv:ORILISSAMember country:US 2018-01-01 2018-06-30 0001551152 abbv:ImmunologyMember abbv:HUMIRAMember us-gaap:NonUsMember 2019-04-01 2019-06-30 0001551152 abbv:HCVMember abbv:MAVYRETMember 2018-04-01 2018-06-30 0001551152 abbv:OtherKeyProductsMember abbv:KaletraMember 2019-04-01 2019-06-30 0001551152 abbv:OtherKeyProductsMember abbv:KaletraMember country:US 2018-01-01 2018-06-30 0001551152 abbv:OtherProductsMember 2019-01-01 2019-06-30 0001551152 abbv:OtherKeyProductsMember abbv:SynthroidMember country:US 2019-01-01 2019-06-30 0001551152 abbv:OtherKeyProductsMember abbv:SynthroidMember country:US 2019-04-01 2019-06-30 0001551152 abbv:OtherKeyProductsMember abbv:ORILISSAMember us-gaap:NonUsMember 2019-04-01 2019-06-30 0001551152 abbv:HCVMember abbv:MAVYRETMember country:US 2019-01-01 2019-06-30 0001551152 abbv:OtherKeyProductsMember abbv:ORILISSAMember country:US 2019-04-01 2019-06-30 0001551152 abbv:OtherKeyProductsMember abbv:SevofluraneMember us-gaap:NonUsMember 2019-04-01 2019-06-30 0001551152 abbv:OtherKeyProductsMember abbv:SevofluraneMember us-gaap:NonUsMember 2019-01-01 2019-06-30 0001551152 abbv:ImmunologyMember abbv:SKYRIZIMember us-gaap:NonUsMember 2018-04-01 2018-06-30 0001551152 abbv:OtherKeyProductsMember abbv:KaletraMember us-gaap:NonUsMember 2018-04-01 2018-06-30 0001551152 abbv:OtherKeyProductsMember abbv:DuodopaMember 2019-04-01 2019-06-30 0001551152 abbv:OtherKeyProductsMember abbv:DuodopaMember us-gaap:NonUsMember 2018-01-01 2018-06-30 0001551152 abbv:HCVMember abbv:MAVYRETMember us-gaap:NonUsMember 2019-01-01 2019-06-30 0001551152 abbv:OtherKeyProductsMember abbv:KaletraMember 2018-01-01 2018-06-30 0001551152 abbv:OtherKeyProductsMember abbv:DuodopaMember us-gaap:NonUsMember 2018-04-01 2018-06-30 0001551152 abbv:OtherKeyProductsMember abbv:KaletraMember us-gaap:NonUsMember 2018-01-01 2018-06-30 0001551152 abbv:OtherProductsMember 2019-04-01 2019-06-30 0001551152 abbv:HCVMember abbv:VIEKIRAMember us-gaap:NonUsMember 2018-01-01 2018-06-30 0001551152 abbv:ImmunologyMember abbv:HUMIRAMember country:US 2019-04-01 2019-06-30 0001551152 abbv:OtherKeyProductsMember abbv:DuodopaMember country:US 2018-01-01 2018-06-30 0001551152 abbv:ImmunologyMember abbv:SKYRIZIMember country:US 2018-04-01 2018-06-30 0001551152 abbv:ImmunologyMember abbv:SKYRIZIMember 2018-04-01 2018-06-30 0001551152 abbv:OtherKeyProductsMember abbv:DuodopaMember 2019-01-01 2019-06-30 0001551152 abbv:OtherKeyProductsMember abbv:SevofluraneMember us-gaap:NonUsMember 2018-01-01 2018-06-30 iso4217:USD iso4217:USD xbrli:shares xbrli:pure abbv:wholesaler xbrli:shares iso4217:GBP iso4217:EUR iso4217:CHF abbv:company abbv:segment abbv:direct_purchaser abbv:lawsuit abbv:investment_fund abbv:individual abbv:claim abbv:class_action abbv:end_payor_purchaser


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)

☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2019

OR

☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                                    to                                   

Commission File Number: 001-35565

abbvieimage1a25.jpg
AbbVie Inc.
(Exact name of registrant as specified in its charter)
Delaware
 
32-0375147
(State or other jurisdiction of incorporation or organization)
 
(I.R.S. employer identification number) 

1 North Waukegan Road
North Chicago, Illinois 60064
Telephone: (847) 932-7900
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.        Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).        Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large Accelerated Filer
☒
Accelerated Filer
☐
Non-Accelerated Filer
☐
Smaller reporting company
☐
 
 
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).        Yes ☐ No ☒
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
 
Trading Symbol(s)
 
Name of each exchange on which registered
Common Stock, par value $0.01 per share
 
ABBV
 
New York Stock Exchange
 
 
 
 
Chicago Stock Exchange
As of July 29, 2019, AbbVie Inc. had 1,478,483,838 shares of common stock at $0.01 par value outstanding.



AbbVie Inc. and Subsidiaries
Table of Contents



2019 Form 10-Q | abbvieimage2a12.gif
1



PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
 
AbbVie Inc. and Subsidiaries
Condensed Consolidated Statements of Earnings (unaudited)

 
 
Three months ended
June 30,
 
Six months ended
June 30,
(in millions, except per share data)
 
2019
 
2018
 
2019
 
2018
Net revenues
 
$
8,255

 
$
8,278

 
$
16,083

 
$
16,212

 
 
 
 
 
 
 
 
 
Cost of products sold
 
1,819

 
1,934

 
3,513

 
3,861

Selling, general and administrative
 
1,654

 
1,760

 
3,334

 
3,551

Research and development
 
1,291

 
1,322

 
2,580

 
2,566

Acquired in-process research and development
 
91

 
—

 
246

 
69

Other expense
 
—

 
500

 
—

 
500

Total operating costs and expenses
 
4,855

 
5,516

 
9,673

 
10,547

Operating earnings
 
3,400

 
2,762

 
6,410

 
5,665

 
 
 
 
 
 
 
 
 
Interest expense, net
 
309

 
272

 
634

 
523

Net foreign exchange loss
 
6

 
8

 
12

 
16

Other expense, net
 
2,278

 
470

 
2,413

 
317

Earnings before income tax expense
 
807

 
2,012

 
3,351

 
4,809

Income tax expense
 
66

 
29

 
154

 
43

Net earnings
 
$
741

 
$
1,983

 
$
3,197

 
$
4,766

 
 
 
 
 
 
 
 
 
Per share data
 
 
 
 
 
 
 
 
Basic earnings per share
 
$
0.49

 
$
1.26

 
$
2.15

 
$
3.00

Diluted earnings per share
 
$
0.49

 
$
1.26

 
$
2.14

 
$
2.99

 
 
 
 
 
 
 
 
 
Weighted-average basic shares outstanding
 
1,480

 
1,568

 
1,480

 
1,579

Weighted-average diluted shares outstanding
 
1,484

 
1,572

 
1,483

 
1,584


The accompanying notes are an integral part of these condensed consolidated financial statements.

2019 Form 10-Q | abbvieimage2a12.gif
2



AbbVie Inc. and Subsidiaries
Condensed Consolidated Statements of Comprehensive Income (unaudited)

 
Three months ended
June 30,
 
Six months ended
June 30,
(in millions)
2019
 
2018
 
2019
 
2018
Net earnings
$
741

 
$
1,983

 
$
3,197

 
$
4,766

 
 
 
 
 
 
 
 
Foreign currency translation adjustments, net of tax expense (benefit) of $5 for the three months and $6 for the six months ended June 30, 2019 and $(16) for the three months and $(19) for the six months ended June 30, 2018
71

 
(469
)
 
(32
)
 
(280
)
Net investment hedging activities, net of tax expense (benefit) of $(11) for the three months and $8 for the six months ended June 30, 2019 and $61 for the three months and $31 for the six months ended June 30, 2018
(37
)
 
209

 
28

 
105

Pension and post-employment benefits, net of tax expense (benefit) of $6 for the three months and $12 for the six months ended June 30, 2019 and $7 for the three months and $16 for the six months ended June 30, 2018
20

 
49

 
45

 
71

Marketable security activities, net of tax expense (benefit) of $— for the three months and $— for the six months ended June 30, 2019 and $— for the three months and $— for the six months ended June 30, 2018
4

 
5

 
11

 
(2
)
Cash flow hedging activities, net of tax expense (benefit) of $(2) for the three months and $(9) for the six months ended June 30, 2019 and $18 for the three months and $17 for the six months ended June 30, 2018
(33
)
 
197

 
(63
)
 
194

Other comprehensive income (loss)
25

 
(9
)
 
(11
)
 
88

Comprehensive income
$
766

 
$
1,974

 
$
3,186

 
$
4,854


The accompanying notes are an integral part of these condensed consolidated financial statements.





2019 Form 10-Q | abbvieimage2a12.gif
3



AbbVie Inc. and Subsidiaries
Condensed Consolidated Balance Sheets

(in millions, except share data)
June 30,
2019
 
December 31,
2018
 
(unaudited)
 
 
Assets
 
 
 
Current assets
 
 
 
Cash and equivalents
$
5,172

 
$
7,289

Short-term investments
244

 
772

Accounts receivable, net
5,482

 
5,384

Inventories
1,895

 
1,605

Prepaid expenses and other
2,307

 
1,895

Total current assets
15,100

 
16,945

 
 
 
 
Investments
1,473

 
1,420

Property and equipment, net
2,879

 
2,883

Intangible assets, net
20,459

 
21,233

Goodwill
15,642

 
15,663

Other assets
1,589

 
1,208

Total assets
$
57,142

 
$
59,352

 
 
 
 
Liabilities and Equity
 
 
 
Current liabilities
 
 
 
Short-term borrowings
$
306

 
$
3,699

Current portion of long-term debt and finance lease obligations
5,335

 
1,609

Accounts payable and accrued liabilities
11,300

 
11,931

Total current liabilities
16,941

 
17,239

 
 
 
 
Long-term debt and finance lease obligations
31,619

 
35,002

Deferred income taxes
1,148

 
1,067

Other long-term liabilities
16,000

 
14,490

 
 
 
 
Commitments and contingencies


 


 
 
 
 
Stockholders’ equity (deficit)
 
 
 
Common stock, $0.01 par value, 4,000,000,000 shares authorized, 1,781,055,877 shares issued as of June 30, 2019 and 1,776,510,871 as of December 31, 2018
18

 
18

Common stock held in treasury, at cost, 302,685,326 shares as of June 30, 2019 and 297,686,473 as of December 31, 2018
(24,505
)
 
(24,108
)
Additional paid-in capital
15,028

 
14,756

Retained earnings
3,384

 
3,368

Accumulated other comprehensive loss
(2,491
)
 
(2,480
)
Total stockholders’ equity (deficit)
(8,566
)
 
(8,446
)
 
 
 
 
Total liabilities and equity
$
57,142

 
$
59,352


The accompanying notes are an integral part of these condensed consolidated financial statements.

2019 Form 10-Q | abbvieimage2a12.gif
4



AbbVie Inc. and Subsidiaries
Condensed Consolidated Statements of Equity (unaudited)

(in millions)
Common shares outstanding
 
Common stock
 
Treasury stock
 
Additional paid-in capital
 
Retained earnings
 
Accumulated other comprehensive loss
 
Total
Balance at March 31, 2018
1,587

 
$
18

 
$
(13,331
)
 
$
14,519

 
$
4,977

 
$
(2,630
)
 
$
3,553

Net earnings
—

 
—

 
—

 
—

 
1,983

 
—

 
1,983

Other comprehensive loss, net of tax
—

 
—

 
—

 
—

 
—

 
(9
)
 
(9
)
Dividends declared
—

 
—

 
—

 
—

 
(1,465
)
 
—

 
(1,465
)
Purchases of treasury stock
(73
)
 
—

 
(7,516
)
 
—

 
—

 
—

 
(7,516
)
Stock-based compensation plans and other
—

 
—

 
2

 
77

 
—

 
—

 
79

Balance at June 30, 2018
1,514

 
$
18

 
$
(20,845
)
 
$
14,596

 
$
5,495

 
$
(2,639
)
 
$
(3,375
)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Balance at March 31, 2019
1,478

 
$
18

 
$
(24,502
)
 
$
14,940

 
$
4,234

 
$
(2,516
)
 
$
(7,826
)
Net earnings
—

 
—

 
—

 
—

 
741

 
—

 
741

Other comprehensive income, net of tax
—

 
—

 
—

 
—

 
—

 
25

 
25

Dividends declared
—

 
—

 
—

 
—

 
(1,591
)
 
—

 
(1,591
)
Purchases of treasury stock
—

 
—

 
(3
)
 
—

 
—

 
—

 
(3
)
Stock-based compensation plans and other
—

 
—

 
—

 
88

 
—

 
—

 
88

Balance at June 30, 2019
1,478


$
18


$
(24,505
)

$
15,028


$
3,384


$
(2,491
)

$
(8,566
)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Balance at December 31, 2017
1,592

 
$
18

 
$
(11,923
)
 
$
14,270

 
$
5,459

 
$
(2,727
)
 
$
5,097

Adoption of new accounting standards
—

 
—

 
—

 
—

 
(1,733
)
 
—

 
(1,733
)
Net earnings
—

 
—

 
—

 
—

 
4,766

 
—

 
4,766

Other comprehensive income, net of tax
—

 
—

 
—

 
—

 
—

 
88

 
88

Dividends declared
—

 
—

 
—

 
—

 
(2,997
)
 
—

 
(2,997
)
Purchases of treasury stock
(85
)
 
—

 
(8,947
)
 
—

 
—

 
—

 
(8,947
)
Stock-based compensation plans and other
7

 
—

 
25

 
326

 
—

 
—

 
351

Balance at June 30, 2018
1,514

 
$
18

 
$
(20,845
)
 
$
14,596

 
$
5,495

 
$
(2,639
)
 
$
(3,375
)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Balance at December 31, 2018
1,479

 
$
18

 
$
(24,108
)
 
$
14,756

 
$
3,368

 
$
(2,480
)
 
$
(8,446
)
Net earnings
—

 
—

 
—

 
—

 
3,197

 
—

 
3,197

Other comprehensive loss, net of tax
—

 
—

 
—

 
—

 
—

 
(11
)
 
(11
)
Dividends declared
—

 
—

 
—

 
—

 
(3,181
)
 
—

 
(3,181
)
Purchases of treasury stock
(5
)
 
—

 
(422
)
 
—

 
—

 
—

 
(422
)
Stock-based compensation plans and other
4

 
—

 
25

 
272

 
—

 
—

 
297

Balance at June 30, 2019
1,478

 
$
18

 
$
(24,505
)
 
$
15,028

 
$
3,384

 
$
(2,491
)
 
$
(8,566
)

The accompanying notes are an integral part of these condensed consolidated financial statements.

2019 Form 10-Q | abbvieimage2a12.gif
5



AbbVie Inc. and Subsidiaries
Condensed Consolidated Statements of Cash Flows (unaudited)

 
Six months ended
June 30,
(in millions) (brackets denote cash outflows)
2019
 
2018
Cash flows from operating activities
 
 
 
Net earnings
$
3,197

 
$
4,766

Adjustments to reconcile net earnings to net cash from operating activities:
 
 
 
Depreciation
232

 
234

Amortization of intangible assets
773

 
654

Change in fair value of contingent consideration liabilities
2,473

 
337

Stock-based compensation
276

 
276

Upfront costs and milestones related to collaborations
321

 
656

Other, net
(10
)
 
118

Changes in operating assets and liabilities:
 
 
 
Accounts receivable
(96
)
 
(805
)
Inventories
(288
)
 
(191
)
Prepaid expenses and other assets
(97
)
 
(546
)
Accounts payable and other liabilities
(1,287
)
 
12

Cash flows from operating activities
5,494

 
5,511

 
 
 
 
Cash flows from investing activities
 
 
 
Acquisitions and investments
(440
)
 
(401
)
Acquisitions of property and equipment
(235
)
 
(233
)
Purchases of investment securities
(558
)
 
(637
)
Sales and maturities of investment securities
1,066

 
1,511

Cash flows from investing activities
(167
)
 
240

 
 
 
 
Cash flows from financing activities
 
 
 
Net change in commercial paper borrowings
(393
)
 
111

Proceeds from issuance of other short-term borrowings
—

 
3,000

Repayments of other short-term borrowings
(3,000
)
 
—

Repayments of long-term debt and finance lease obligations
(4
)
 
(3,013
)
Debt issuance costs
(171
)
 
—

Dividends paid
(3,180
)
 
(2,668
)
Purchases of treasury stock
(623
)
 
(8,947
)
Proceeds from the exercise of stock options
5

 
64

Payments of contingent consideration liabilities
(108
)
 
(39
)
Other, net
21

 
5

Cash flows from financing activities
(7,453
)
 
(11,487
)
Effect of exchange rate changes on cash and equivalents
9

 
(20
)
Net change in cash and equivalents
(2,117
)
 
(5,756
)
Cash and equivalents, beginning of period
7,289

 
9,303

 
 
 
 
Cash and equivalents, end of period
$
5,172

 
$
3,547


The accompanying notes are an integral part of these condensed consolidated financial statements.

2019 Form 10-Q | abbvieimage2a12.gif
6



AbbVie Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements (unaudited)
Note 1    Basis of Presentation
 

Basis of Historical Presentation
The unaudited interim condensed consolidated financial statements of AbbVie Inc. (AbbVie or the company) have been prepared pursuant to the rules and regulations of the U.S. Securities and Exchange Commission. Accordingly, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP) have been omitted. These unaudited interim condensed consolidated financial statements should be read in conjunction with the company’s audited consolidated financial statements and notes included in the company’s Annual Report on Form 10-K for the year ended December 31, 2018.
It is management’s opinion that these financial statements include all normal and recurring adjustments necessary for a fair presentation of the company’s financial position and operating results. Net revenues and net earnings for any interim period are not necessarily indicative of future or annual results. Certain reclassifications were made to conform the prior period interim condensed consolidated financial statements to the current period presentation.
Recent Accounting Pronouncements
Recently Adopted Accounting Pronouncements
ASU No. 2016-02
In February 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2016-02, Leases (Topic 842). The standard outlined a comprehensive lease accounting model that superseded the previous lease guidance and required lessees to recognize lease liabilities and corresponding right-of-use assets for all leases with lease terms greater than 12 months. The guidance also changed the definition of a lease and expanded the disclosure requirements of lease arrangements. AbbVie adopted the standard in the first quarter of 2019 using the modified retrospective method. Results for reporting periods beginning after December 31, 2018 have been presented in accordance with the standard, while results for prior periods have not been adjusted and continue to be reported in accordance with AbbVie's historical accounting. The cumulative effect of initially applying the new leases standard was recognized as an adjustment to the opening condensed consolidated balance sheet as of January 1, 2019.
The company elected a package of practical expedients for leases that commenced prior to January 1, 2019 and did not reassess historical conclusions on: (i) whether any expired or existing contracts are or contain leases; (ii) lease classification for any expired or existing leases; and (iii) initial direct costs capitalization for any existing leases.
Under the new standard, on January 1, 2019, the company recognized a cumulative-effect adjustment to its condensed consolidated balance sheet primarily related to the recognition of liabilities and corresponding right-of-use assets for operating leases. The adjustment to the condensed consolidated balance sheet included: (i) a $405 million increase to other assets; (ii) a $115 million increase to accounts payable and accrued liabilities; and (iii) a $290 million increase to other long-term liabilities. Other cumulative-effect adjustments to the condensed consolidated balance sheet were insignificant.
Adoption of the standard did not have a significant impact on AbbVie's condensed consolidated statements of earnings for the three and six months ended June 30, 2019.
ASU No. 2018-02
In February 2018, the FASB issued ASU No. 2018-02, Income Statement - Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income, which allowed a reclassification from accumulated other comprehensive income (AOCI) to retained earnings for stranded tax effects related to adjustments to deferred taxes resulting from the December 2017 enactment of the Tax Cuts and Jobs Act (the Act). AbbVie adopted the standard in the first quarter of 2019. Upon adoption, the company made an election to not reclassify the income tax effects of the Act from AOCI to retained earnings. Therefore, the adoption of the standard had no impact on AbbVie's consolidated financial statements.

2019 Form 10-Q | abbvieimage2a12.gif
7



Recent Accounting Pronouncements Not Yet Adopted
ASU No. 2016-13
In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326). The standard changes how credit losses are measured for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other financial instruments, the standard requires the use of a new forward-looking "expected credit loss" model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, the standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. Additionally, the standard requires new disclosures and will be effective for AbbVie starting with the first quarter of 2020. With certain exceptions, adjustments are to be applied using a modified-retrospective approach by reflecting adjustments through a cumulative-effect impact to retained earnings as of the beginning of the fiscal year of adoption. AbbVie is currently assessing the impact of adopting this guidance on its consolidated financial statements.
Note 2    Supplemental Financial Information
 

Interest Expense, Net
 
 
Three months ended
June 30,
 
Six months ended
June 30,
(in millions)
 
2019
 
2018
 
2019
 
2018
Interest expense
 
$
358

 
$
320

 
$
745

 
$
629

Interest income
 
(49
)
 
(48
)
 
(111
)
 
(106
)
Interest expense, net
 
$
309

 
$
272

 
$
634

 
$
523


Inventories
(in millions)
June 30, 2019
 
December 31, 2018
Finished goods
$
638

 
$
473

Work-in-process
969

 
862

Raw materials
288

 
270

Inventories
$
1,895

 
$
1,605


Property and Equipment
(in millions)
June 30, 2019
 
December 31, 2018
Property and equipment, gross
$
8,443

 
$
8,396

Accumulated depreciation
(5,564
)
 
(5,513
)
Property and equipment, net
$
2,879

 
$
2,883


Depreciation expense was $114 million for the three months and $232 million for the six months ended June 30, 2019 and $119 million for the three months and $234 million for the six months ended June 30, 2018.
Note 3    Earnings Per Share
 

AbbVie grants certain restricted stock units (RSUs) that are considered to be participating securities. Due to the presence of participating securities, AbbVie calculates earnings per share (EPS) using the more dilutive of the treasury stock or the two-class method. For all periods presented, the two-class method was more dilutive.


2019 Form 10-Q | abbvieimage2a12.gif
8



The following table summarizes the impact of the two-class method:

 
 
Three months ended
June 30,
 
Six months ended
June 30,
(in millions, except per share data)
 
2019
 
2018
 
2019
 
2018
Basic EPS
 
 
 
 
 
 
 
 
Net earnings
 
$
741

 
$
1,983

 
$
3,197

 
$
4,766

Earnings allocated to participating securities
 
8

 
10

 
17

 
22

Earnings available to common shareholders
 
$
733

 
$
1,973

 
$
3,180

 
$
4,744

Weighted-average basic shares outstanding
 
1,480

 
1,568

 
1,480

 
1,579

Basic earnings per share
 
$
0.49

 
$
1.26

 
$
2.15

 
$
3.00

 
 
 
 
 
 
 
 
 
Diluted EPS
 
 
 
 
 
 
 
 
Net earnings
 
$
741

 
$
1,983

 
$
3,197

 
$
4,766

Earnings allocated to participating securities
 
8

 
10

 
17

 
22

Earnings available to common shareholders
 
$
733

 
$
1,973

 
$
3,180

 
$
4,744

Weighted-average shares of common stock outstanding
 
1,480

 
1,568

 
1,480

 
1,579

Effect of dilutive securities
 
4

 
4

 
3

 
5

Weighted-average diluted shares outstanding
 
1,484

 
1,572

 
1,483

 
1,584

Diluted earnings per share
 
$
0.49

 
$
1.26

 
$
2.14

 
$
2.99



Certain shares issuable under stock-based compensation plans were excluded from the computation of EPS because the effect would have been antidilutive. The number of common shares excluded was insignificant for all periods presented.
Note 4 Licensing, Acquisitions and Other Arrangements
 

Proposed Acquisition of Allergan plc
On June 25, 2019, AbbVie announced that it entered into a definitive transaction agreement under which AbbVie will acquire Allergan plc (Allergan) in a cash and stock transaction for a transaction equity value of approximately $63 billion, based on the closing price of AbbVie’s common stock of $78.45 on June 24, 2019. Under the terms of the transaction agreement, Allergan shareholders will receive 0.8660 AbbVie shares and $120.30 in cash for each Allergan share.
In connection with the proposed acquisition of Allergan, on June 25, 2019, AbbVie entered into a $38.0 billion 364-day bridge credit agreement. On July 12, 2019, AbbVie entered into a term loan credit agreement with an aggregate principal amount of $6.0 billion consisting of a $1.5 billion 364-day term loan tranche, a $2.5 billion three-year term loan tranche and a $2.0 billion five-year term loan tranche, with the commitments under the bridge credit agreement to be reduced by such amount to $32.0 billion. No amounts have been drawn under the bridge credit agreement or term loan credit agreement.
Allergan is a global pharmaceutical leader focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world. Allergan markets a portfolio of brands and products primarily focused on key therapeutic areas including medical aesthetics, eye care, neuroscience, gastroenterology and women's health.
The transaction is expected to close in early 2020, subject to regulatory and Allergan shareholder approvals.
Other Licensing & Acquisitions Activity
Cash outflows related to other acquisitions and investments totaled $440 million for the six months ended June 30, 2019 and $401 million for the six months ended June 30, 2018. AbbVie recorded acquired in-process research and development (IPR&D) charges of $91 million for the three months and $246 million for the six months ended June 30, 2019. AbbVie recorded no acquired IPR&D charges for the three months ended June 30, 2018 and recorded acquired IPR&D charges of $69 million for the six months ended June 30, 2018.

2019 Form 10-Q | abbvieimage2a12.gif
9



Calico Life Sciences LLC
In June 2018, AbbVie and Calico Life Sciences LLC (Calico) entered into an extension of a collaboration to discover, develop and bring to market new therapies for patients with age-related diseases, including neurodegeneration and cancer. Under the terms of the agreement, AbbVie and Calico will each contribute an additional $500 million to the collaboration and the term was extended for an additional three years. Calico will be responsible for research and early development until 2022 and will advance collaboration projects through Phase 2a through 2027. Following completion of Phase 2a, AbbVie will have the option to exclusively license collaboration compounds. AbbVie will support Calico in its early research and development efforts and, upon exercise, would be responsible for late-stage development and commercial activities. Collaboration costs and profits will be shared equally by both parties post option exercise. During the six months ended June 30, 2018, AbbVie recorded $500 million in other expense in the condensed consolidated statement of earnings related to its commitments under the agreement.
Note 5 Collaboration with Janssen Biotech, Inc.
 

In December 2011, Pharmacyclics, a wholly-owned subsidiary of AbbVie, entered into a worldwide collaboration and license agreement with Janssen Biotech, Inc. and its affiliates (Janssen), one of the Janssen Pharmaceutical companies of Johnson & Johnson, for the joint development and commercialization of IMBRUVICA, a novel, orally active, selective covalent inhibitor of Bruton's tyrosine kinase (BTK) and certain compounds structurally related to IMBRUVICA, for oncology and other indications, excluding all immune and inflammatory mediated diseases or conditions and all psychiatric or psychological diseases or conditions, in the United States and outside the United States.

The collaboration provides Janssen with an exclusive license to commercialize IMBRUVICA outside of the United States and co-exclusively with AbbVie in the United States. Both parties are responsible for the development, manufacturing and marketing of any products generated as a result of the collaboration. The collaboration has no set duration or specific expiration date and provides for potential future development, regulatory and approval milestone payments of up to $200 million to AbbVie. The collaboration also includes a cost sharing arrangement for associated collaboration activities. Except in certain cases, Janssen is responsible for approximately 60% of collaboration development costs and AbbVie is responsible for the remaining 40% of collaboration development costs.

In the United States, both parties have co-exclusive rights to commercialize the products; however, AbbVie is the principal in the end-customer product sales. AbbVie and Janssen share pre-tax profits and losses equally from the commercialization of products. Sales of IMBRUVICA are included in AbbVie's net revenues. Janssen's share of profits is included in AbbVie's cost of products sold. Other costs incurred under the collaboration are reported in their respective expense line items, net of Janssen's share.

Outside the United States, Janssen is responsible for and has exclusive rights to commercialize IMBRUVICA. AbbVie and Janssen share pre-tax profits and losses equally from the commercialization of products. AbbVie's share of profits is included in AbbVie's net revenues. Other costs incurred under the collaboration are reported in their respective expense line items, net of Janssen's share.

The following table shows the profit and cost sharing relationship between Janssen and AbbVie:

 
 
Three months ended
June 30,
 
Six months ended
June 30,
(in millions)
 
2019
 
2018
 
2019
 
2018
United States - Janssen's share of profits (included in cost of products sold)
 
$
422

 
$
325

 
$
808

 
$
601

International - AbbVie's share of profits (included in net revenues)
 
213

 
157

 
406

 
295

Global - AbbVie's share of other costs (included in respective line items)
 
77

 
80

 
149

 
151



AbbVie’s receivable from Janssen, included in accounts receivable, net, was $230 million at June 30, 2019 and $177 million at December 31, 2018. AbbVie’s payable to Janssen, included in accounts payable and accrued liabilities, was $405 million at June 30, 2019 and $376 million at December 31, 2018.

2019 Form 10-Q | abbvieimage2a12.gif
10



Note 6    Goodwill and Intangible Assets
 

Goodwill

The following table summarizes the changes in the carrying amount of goodwill:
(in millions)
 
Balance as of December 31, 2018
$
15,663

Foreign currency translation adjustments
(21
)
Balance as of June 30, 2019
$
15,642



The company performs its annual goodwill impairment assessment in the third quarter, or earlier if impairment indicators exist. As of June 30, 2019, there were no accumulated goodwill impairment losses.
Intangible Assets, Net

The following table summarizes intangible assets:
 
June 30, 2019
 
December 31, 2018
(in millions)
Gross
carrying
amount
 
Accumulated
amortization
 
Net
carrying
amount
 
Gross
carrying
amount
 
Accumulated
amortization
 
Net
carrying
amount
Definite-lived intangible assets
 
 
 
 
 
 
 
 
 
 
 
Developed product rights
$
19,611

 
$
(5,963
)
 
$
13,648

 
$
15,872

 
$
(5,614
)
 
$
10,258

License agreements
7,798

 
(2,017
)
 
5,781

 
7,865

 
(1,810
)
 
6,055

Total definite-lived intangible assets
27,409

 
(7,980
)
 
19,429

 
23,737

 
(7,424
)
 
16,313

Indefinite-lived research and development
1,030

 
—

 
1,030

 
4,920

 
—

 
4,920

Total intangible assets, net
$
28,439

 
$
(7,980
)
 
$
20,459

 
$
28,657

 
$
(7,424
)
 
$
21,233


Indefinite-Lived Intangible Assets
Indefinite-lived intangible assets represent acquired IPR&D associated with products that have not yet received regulatory approval. The company performs its annual impairment assessment of indefinite-lived intangible assets in the third quarter, or earlier if impairment indicators exist. No indefinite-lived intangible asset impairment charges were recorded for the six months ended June 30, 2019 and 2018.
In April 2019, the U.S. Food and Drug Administration (FDA) and the European Commission approved SKYRIZI (risankizumab) for the treatment of moderate to severe plaque psoriasis. As a result, AbbVie reclassified $3.9 billion of indefinite-lived intangible assets related to SKYRIZI to developed product rights definite-lived intangible assets. This amount will be amortized over its estimated useful life using the estimated pattern of economic benefit.
In the fourth quarter of 2018, the company recorded an impairment charge of $5.1 billion related to IPR&D acquired as part of the 2016 Stemcentrx acquisition following the decision to stop enrollment in the TAHOE trial. AbbVie continues to evaluate information as it becomes available with respect to the Stemcentrx-related clinical development programs and will monitor the remaining $1.0 billion of IPR&D assets for further impairment.
Definite-Lived Intangible Assets
Amortization expense was $388 million for the three months and $773 million for the six months ended June 30, 2019 and $324 million for the three months and $654 million for the six months ended June 30, 2018. Amortization expense was included in cost of products sold in the condensed consolidated statements of earnings. No definite-lived intangible asset impairment charges were recorded for the six months ended June 30, 2019 and 2018.

2019 Form 10-Q | abbvieimage2a12.gif
11



Note 7    Restructuring Plans
 

AbbVie recorded restructuring charges of $19 million for the three months and $186 million for the six months ended June 30, 2019 and $1 million for the three months and $23 million for the six months ended June 30, 2018. Restructuring charges for the three and six months ended June 30, 2019 primarily related to severance costs.

The following table summarizes the cash activity in the restructuring reserve for the six months ended June 30, 2019:
(in millions)
 
Accrued balance as of December 31, 2018
$
99

Restructuring charges
172

Payments and other adjustments
(80
)
Accrued balance as of June 30, 2019
$
191


Note 8 Leases    
 
AbbVie's lease portfolio primarily consists of real estate properties, vehicles and equipment. Short-term leases with a term of 12 months or less are not recorded on the balance sheet. For leases commencing or modified in 2019 or later, AbbVie does not separate lease components from non-lease components.
The company records lease liabilities based on the present value of lease payments over the lease term. AbbVie generally uses an incremental borrowing rate to discount its lease liabilities, as the rate implicit in the lease is typically not readily determinable. Certain lease agreements include renewal options that are under the company's control. AbbVie includes optional renewal periods in the lease term only when it is reasonably certain that AbbVie will exercise its option.
Variable lease payments include payments to lessors for taxes, maintenance, insurance and other operating costs as well as payments that are adjusted based on an index or rate. The company's lease agreements do not contain any significant residual value guarantees or restrictive covenants.
The following table summarizes the amounts and location of operating and finance leases on the condensed consolidated balance sheet:
(in millions)
Balance sheet caption
June 30,
2019
Assets
 
 
Operating
Other assets
$
380

Finance
Property and equipment, net
27

Total lease assets
 
$
407

Liabilities
 
 
Operating
 
 
Current
Accounts payable and accrued liabilities
$
111

Noncurrent
Other long-term liabilities
290

Finance
 
 
Current
Current portion of long-term debt and finance lease obligations
9

Noncurrent
Long-term debt and finance lease obligations
22

Total lease liabilities
 
$
432



2019 Form 10-Q | abbvieimage2a12.gif
12



The following table summarizes the lease costs recognized in the condensed consolidated statements of earnings:
 
 
Three months ended
June 30,
 
Six months ended
June 30,
(in millions)
 
2019
 
2019
Operating lease cost
 
$
32

 
$
64

Finance lease cost
 
 
 
 
Amortization of right-of-use assets
 
2

 
4

Interest on lease liabilities
 
—

 
—

Short-term lease cost
 
9

 
15

Variable lease cost
 
14

 
29

Total lease cost
 
$
57

 
$
112


Sublease income was insignificant for the three and six months ended June 30, 2019.
The following table presents the weighted-average remaining lease term and weighted-average discount rate for operating and finance leases:
 
June 30,
2019
Weighted-average remaining lease term (in years)
 
Operating
6

Finance
3

Weighted-average discount rate
 
Operating
4.0
%
Finance
4.4
%

The following table presents supplementary cash flow information regarding the company's operating and finance leases:
 
Six months ended
June 30,
(in millions)
2019
Cash paid for amounts included in the measurement of lease liabilities
 
Operating cash flows from operating leases
$
58

Operating cash flows from finance leases
—

Financing cash flows from finance leases
4

Right-of-use assets obtained in exchange for new finance lease liabilities
—

Right-of-use assets obtained in exchange for new operating lease liabilities
15



2019 Form 10-Q | abbvieimage2a12.gif
13



The following table summarizes the future maturities of AbbVie's operating and finance lease liabilities as of June 30, 2019:
(in millions)
Operating
leases
 
Finance
leases
 
Total (a)(b)
2019
$
65

 
$
8

 
$
73

2020
121

 
11

 
132

2021
100

 
9

 
109

2022
55

 
3

 
58

2023
35

 
1

 
36

Thereafter
79

 
—

 
79

Total lease payments
455

 
32

 
487

Less: Interest
54

 
1

 
55

Present value of lease liabilities
$
401

 
$
31

 
$
432


(a) Total lease payments exclude approximately $350 million of contractual minimum lease payments for leases executed but not yet commenced. These leases will commence between years 2019 and 2020 with lease terms of approximately 11 years.
(b) Lease payments recognized as part of lease liabilities for optional renewal periods are insignificant.
Note 9    Financial Instruments and Fair Value Measures
 

Risk Management Policy

See Note 10 to the company's Annual Report on Form 10-K for the year ended December 31, 2018 for a summary of AbbVie's risk management policy and use of derivative instruments.
Financial Instruments

Various AbbVie foreign subsidiaries enter into foreign currency forward exchange contracts to manage exposures to changes in foreign exchange rates for anticipated intercompany transactions denominated in a currency other than the functional currency of the local entity. These contracts, with notional amounts totaling $503 million at June 30, 2019 and $1.4 billion at December 31, 2018, are designated as cash flow hedges and are recorded at fair value. The durations of these forward exchange contracts were generally less than 18 months. Accumulated gains and losses as of June 30, 2019 will be reclassified from AOCI and included in cost of products sold at the time the products are sold, generally not exceeding six months from the date of settlement.

The company also enters into foreign currency forward exchange contracts to manage its exposure to foreign currency denominated trade payables and receivables and intercompany loans. These contracts are not designated as hedges and are recorded at fair value. Resulting gains or losses are reflected in net foreign exchange gain or loss in the consolidated statements of earnings and are generally offset by losses or gains on the foreign currency exposure being managed. These contracts had notional amounts totaling $7.9 billion at June 30, 2019 and $8.6 billion at December 31, 2018.
The company also uses foreign currency forward exchange contracts or foreign currency denominated debt to hedge its net investments in certain foreign subsidiaries and affiliates. The company continued to designate €3.6 billion aggregate principal amount of senior Euro notes as net investment hedges at June 30, 2019 and December 31, 2018. In addition, in the second quarter of 2019, the company entered into foreign currency forward exchange contracts with notional amounts totaling €971 million, £204 million and CHF62 million and designated the instruments as net investment hedges. The company uses the spot method of assessing hedge effectiveness for derivative instruments designated as net investment hedges. Realized and unrealized gains and losses from these hedges are included in AOCI and the initial fair value of hedge components excluded from the assessment of effectiveness is recognized in interest expense, net over the life of the hedging instrument.

AbbVie is a party to interest rate hedge contracts designated as fair value hedges with notional amounts totaling $10.8 billion at June 30, 2019 and December 31, 2018. The effect of the hedge contracts is to change a fixed-rate interest obligation to a floating rate for that portion of the debt. AbbVie records the contracts at fair value and adjusts the carrying amount of the fixed-rate debt by an offsetting amount.


2019 Form 10-Q | abbvieimage2a12.gif
14



No amounts are excluded from the assessment of effectiveness for cash flow hedges or fair value hedges.

The following table summarizes the amounts and location of AbbVie’s derivative instruments on the condensed consolidated balance sheets:
 
Fair value –
Derivatives in asset position
 
Fair value –
Derivatives in liability position
(in millions)
Balance sheet caption
June 30,
2019
December 31, 2018
 
Balance sheet caption
June 30,
2019
December 31, 2018
Foreign currency forward exchange contracts
 
 
 
 
 
 
 
Designated as cash flow hedges
Prepaid expenses and
other
$
22

$
113

 
Accounts payable and accrued liabilities
$
—

$
—

Designated as net investment hedges
Prepaid expenses and
other
11

—

 
Accounts payable and accrued liabilities
1

—

Not designated as hedges
Prepaid expenses and
other
40

19

 
Accounts payable and accrued liabilities
38

26

Interest rate swaps designated as fair value hedges
Prepaid expenses and other
—

—

 
Accounts payable and accrued liabilities
8

—

Interest rate swaps designated as fair value hedges
Other assets
24

—

 
Other long-term liabilities
117

466

Total derivatives
 
$
97

$
132

 
 
$
164

$
492


While certain derivatives are subject to netting arrangements with the company’s counterparties, the company does not offset derivative assets and liabilities within the condensed consolidated balance sheets.

The following table presents the pre-tax amounts of gains (losses) from derivative instruments recognized in other comprehensive income (loss):
 
 
Three months ended
June 30,
 
Six months ended
June 30,
(in millions)
 
2019
 
2018
 
2019
 
2018
Foreign currency forward exchange contracts
 
 
 
 
 
 
 
 
Designated as cash flow hedges
 
$
2

 
$
169

 
$
5

 
$
121

Designated as net investment hedges
 
10

 
—

 
10

 
—



Assuming market rates remain constant through contract maturities, the company expects to reclass pre-tax gains of $90 million into cost of products sold for foreign currency cash flow hedges during the next 12 months.

Related to AbbVie’s non-derivative, foreign currency denominated debt designated as net investment hedges, the company recognized in other comprehensive income (loss) a pre-tax loss of $49 million for the three months and a pre-tax gain of $35 million for the six months ended June 30, 2019 and recognized pre-tax gains of $270 million for the three months and $136 million for the six months ended June 30, 2018.
The following table summarizes the pre-tax amounts and location of derivative instrument net gains (losses) recognized in the condensed consolidated statements of earnings, including the net gains (losses) reclassified out of AOCI into net earnings. See Note 11 for the amount of net gains (losses) reclassified out of AOCI.

 
 
 
Three months ended
June 30,
 
Six months ended
June 30,
(in millions)
Statement of earnings caption
 
2019
 
2018
 
2019
 
2018
Foreign currency forward exchange contracts
 
 
 
 
 
 
 
 
 
Designated as cash flow hedges
Cost of products sold
 
$
37

 
$
(46
)
 
$
77

 
$
(90
)
Designated as net investment hedges
Interest expense, net
 
9

 
—

 
9

 
—

Not designated as hedges
Net foreign exchange loss
 
(25
)
 
128

 
(40
)
 
69

Interest rate swaps designated as fair value hedges
Interest expense, net
 
253

 
(59
)
 
365

 
(243
)
Debt designated as hedged item in fair value hedges
Interest expense, net
 
(253
)
 
59

 
(365
)
 
243



2019 Form 10-Q | abbvieimage2a12.gif
15




Fair Value Measures

The fair value hierarchy consists of the following three levels:

•
Level 1 – Valuations based on unadjusted quoted prices in active markets for identical assets that the company has the ability to access;
•
Level 2 – Valuations based on quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuations in which all significant inputs are observable in the market; and
•
Level 3 – Valuations using significant inputs that are unobservable in the market and include the use of judgment by the company’s management about the assumptions market participants would use in pricing the asset or liability.

The following table summarizes the bases used to measure certain assets and liabilities carried at fair value on a recurring basis on the condensed consolidated balance sheet as of June 30, 2019:
 
 
 
Basis of fair value measurement
(in millions)
Total
 
Quoted prices in active markets for
identical assets
(Level 1)
 
Significant other
observable
inputs
(Level 2)
 
Significant
unobservable
inputs
(Level 3)
Assets
 
 
 
 
 
 
 
Cash and equivalents
$
5,172

 
$
1,388

 
$
3,784

 
$
—

Debt securities
1,573

 
—

 
1,573

 
—

Equity securities
79

 
79

 
—

 
—

Interest rate hedges
24

 
—

 
24

 
—

Foreign currency contracts
73

 
—

 
73

 
—

Total assets
$
6,921

 
$
1,467

 
$
5,454

 
$
—

Liabilities
 
 
 
 
 
 
 
Interest rate hedges
$
125

 
$
—

 
$
125

 
$
—

Foreign currency contracts
39

 
—

 
39

 
—

Contingent consideration
6,789

 
—

 
—

 
6,789

Total liabilities
$
6,953

 
$
—

 
$
164

 
$
6,789


2019 Form 10-Q | abbvieimage2a12.gif
16



The following table summarizes the bases used to measure certain assets and liabilities carried at fair value on a recurring basis on the condensed consolidated balance sheet as of December 31, 2018:
 
 
 
Basis of fair value measurement
(in millions)
Total
 
Quoted prices in active markets for
identical assets
(Level 1)
 
Significant other
observable
inputs
(Level 2)
 
Significant
unobservable
inputs
(Level 3)
Assets
 
 
 
 
 
 
 
Cash and equivalents
$
7,289

 
$
1,209

 
$
6,080

 
$
—

Time deposits
568

 
—

 
568

 
—

Debt securities
1,536

 
—

 
1,536

 
—

Equity securities
4

 
4

 
—

 
—

Foreign currency contracts
132

 
—

 
132

 
—

Total assets
$
9,529

 
$
1,213

 
$
8,316

 
$
—

Liabilities
 
 
 
 
 
 
 
Interest rate hedges
$
466

 
$
—

 
$
466

 
$
—

Foreign currency contracts
26

 
—

 
26

 
—

Contingent consideration
4,483

 
—

 
—

 
4,483

Total liabilities
$
4,975

 
$
—

 
$
492

 
$
4,483


The fair values of time deposits approximate their amortized cost due to the short maturities of these instruments. The fair values of available-for-sale debt securities were determined based on prices obtained from commercial pricing services. Equity securities consist of investments for which the fair values were determined by using the published market price per unit multiplied by the number of units held, without consideration of transaction costs. The derivatives entered into by the company were valued using published spot curves for interest rate hedges and published forward curves for foreign currency contracts. The fair value measurements of the contingent consideration liabilities were determined based on significant unobservable inputs, including the discount rate, estimated probabilities and timing of achieving specified development, regulatory and commercial milestones and the estimated amount of future sales of the acquired products. Changes to the fair value of the contingent consideration liabilities can result from changes to one or a number of inputs, including discount rates, the probabilities of achieving the milestones, the time required to achieve the milestones and estimated future sales. Significant judgment is employed in determining the appropriateness of these inputs. Changes to the inputs described above could have a material impact on the company's financial position and results of operations in any given period. At June 30, 2019, a 50 basis point increase/decrease in the assumed discount rate would have decreased/increased the value of the contingent consideration liabilities by approximately $270 million. Additionally, at June 30, 2019, a five percentage point increase/decrease in the assumed probability of success across all potential indications still in development would have increased/decreased the value of the contingent consideration liabilities by approximately $210 million.
There have been no transfers of assets or liabilities between the fair value measurement levels. The following table presents the changes in fair value of contingent consideration liabilities which are measured using Level 3 inputs:
 
 
Six months ended
June 30,
(in millions)
 
2019
 
2018
Beginning balance
 
$
4,483

 
$
4,534

Change in fair value recognized in net earnings
 
2,473

 
337

Milestone payments
 
(167
)
 
(50
)
Ending balance
 
$
6,789

 
$
4,821


The change in fair value recognized in net earnings is recorded in other expense, net in the condensed consolidated statements of earnings. During the second quarter of 2019, the company recorded a $2.3 billion increase in the SKYRIZI contingent consideration liability due to higher probabilities of success, higher estimated future sales and declining interest rates. The higher probabilities of success resulted from the April 2019 regulatory approvals of SKYRIZI for the treatment of moderate to severe plaque psoriasis.

2019 Form 10-Q | abbvieimage2a12.gif
17



Certain financial instruments are carried at historical cost or some basis other than fair value. The book values, approximate fair values and bases used to measure the approximate fair values of certain financial instruments as of June 30, 2019 are shown in the table below:
 
 
 
 
Basis of fair value measurement
(in millions)
Book value
Approximate fair value
 
Quoted prices
in active markets for
identical assets
(Level 1)
 
Significant
other 
observable
inputs
(Level 2)
 
Significant
unobservable
inputs
(Level 3)
Liabilities
 
 
 
 
 
 
 
 
Short-term borrowings
$
306

$
306

 
$
—

 
$
306

 
$
—

Current portion of long-term debt and finance lease obligations, excluding fair value hedges
5,343

5,357

 
5,348

 
9

 
—

Long-term debt and finance lease obligations, excluding fair value hedges
31,712

32,753

 
32,731

 
22

 
—

Total liabilities
$
37,361

$
38,416

 
$
38,079

 
$
337

 
$
—


The book values, approximate fair values and bases used to measure the approximate fair values of certain financial instruments as of December 31, 2018 are shown in the table below:
 
 
 
 
Basis of fair value measurement
(in millions)
Book value
Approximate fair value
 
Quoted prices
in active markets for
identical assets
(Level 1)
 
Significant
other 
observable
inputs
(Level 2)
 
Significant
unobservable
inputs
(Level 3)
Liabilities
 
 
 
 
 
 
 
 
Short-term borrowings
$
3,699

$
3,693

 
$
—

 
$
3,693

 
$
—

Current portion of long-term debt and finance lease obligations, excluding fair value hedges
1,609

1,617

 
1,609

 
8

 
—

Long-term debt and finance lease obligations, excluding fair value hedges
35,468

34,052

 
34,024

 
28

 
—

Total liabilities
$
40,776

$
39,362

 
$
35,633

 
$
3,729

 
$
—


AbbVie also holds investments in equity securities that do not have readily determinable fair values. The company records these investments at cost and remeasures them to fair value based on certain observable price changes or impairment events as they occur. The carrying amount of these investments was $65 million as of June 30, 2019 and $84 million as of December 31, 2018. No significant cumulative upward or downward adjustments have been recorded for these investments as of June 30, 2019.
Available-for-sale Securities
Substantially all of the company’s investments in debt securities were classified as available-for-sale with changes in fair value recognized in other comprehensive income. Debt securities classified as short-term were $244 million as of June 30, 2019 and $204 million as of December 31, 2018. Long-term debt securities mature primarily within five years. Estimated fair values of available-for-sale debt securities were generally determined based on prices obtained from commercial pricing services.
The following table summarizes available-for-sale securities by type as of June 30, 2019:
 
Amortized cost
 
Gross unrealized
 
Fair value
(in millions)
 
Gains
 
Losses
 
Asset backed securities
$
375

 
$
—

 
$
(1
)
 
$
374

Corporate debt securities
1,095

 
4

 
(2
)
 
1,097

Other debt securities
102

 
—

 
—

 
102

Total
$
1,572

 
$
4

 
$
(3
)
 
$
1,573



2019 Form 10-Q | abbvieimage2a12.gif
18



The following table summarizes available-for-sale securities by type as of December 31, 2018:
 
Amortized cost
 
Gross unrealized
 
Fair value
(in millions)
 
Gains
 
Losses
 
Asset backed securities
$
423

 
$
—

 
$
(2
)
 
$
421

Corporate debt securities
1,042

 
1

 
(9
)
 
1,034

Other debt securities
81

 
—

 
—

 
81

Total
$
1,546

 
$
1

 
$
(11
)
 
$
1,536


AbbVie had no other-than-temporary impairments as of June 30, 2019. Net realized gains and losses were insignificant for both the three and six months ended June 30, 2019 and 2018.
Concentrations of Risk
Of total net accounts receivable, three U.S. wholesalers accounted for 66% as of June 30, 2019 and 63% as of December 31, 2018, and substantially all of AbbVie’s net revenues in the United States were to these three wholesalers.
HUMIRA (adalimumab) is AbbVie’s single largest product and accounted for approximately 58% of AbbVie’s total net revenues for the six months ended June 30, 2019 and 61% for the six months ended June 30, 2018.
Debt and Credit Facilities
Short-Term Borrowings
Short-term borrowings included commercial paper borrowings of $306 million as of June 30, 2019 and $699 million as of December 31, 2018. The weighted-average interest rate on commercial paper borrowings was 2.7% for the six months ended June 30, 2019 and 1.9% for the six months ended June 30, 2018.
In March 2019, AbbVie repaid its $3.0 billion 364-day term loan credit agreement that was scheduled to mature in June 2019.
In connection with the proposed acquisition of Allergan, on June 25, 2019, AbbVie entered into a 364-day bridge credit agreement and on July 12, 2019, AbbVie entered into a term loan credit agreement. See Note 4 for additional information.
Note 10 Post-Employment Benefits
 

The following table summarizes net periodic benefit cost relating to the company’s defined benefit and other post-employment plans:
 
Defined
benefit plans
 
Other post-
employment plans
 
Three months ended
June 30,
 
Six months ended
June 30,
 
Three months ended
June 30,
 
Six months ended
June 30,
(in millions)
2019
 
2018
 
2019
 
2018
 
2019
 
2018
 
2019
 
2018
Service cost
$
68

 
$
72

 
$
135

 
$
144

 
$
7

 
$
5

 
$
13

 
$
13

Interest cost
66

 
57

 
130

 
114

 
9

 
4

 
15

 
12

Expected return on plan assets
(119
)
 
(110
)
 
(238
)
 
(221
)
 
—

 
—

 
—

 
—

Amortization of actuarial losses and prior service cost (credit)
29

 
39

 
55

 
76

 
1

 
(3
)
 
—

 
1

Net periodic benefit cost
$
44

 
$
58

 
$
82

 
$
113

 
$
17

 
$
6

 
$
28

 
$
26


The components of net periodic benefit cost other than service cost are included in other expense, net in the condensed consolidated statements of earnings.

2019 Form 10-Q | abbvieimage2a12.gif
19



Note 11 Equity
 

Stock-Based Compensation

Stock-based compensation expense is principally related to awards issued pursuant to the AbbVie 2013 Incentive Stock Program and is summarized as follows:
 
 
Three months ended
June 30,
 
Six months ended
June 30,
(in millions)
 
2019
 
2018
 
2019
 
2018
Cost of products sold
 
$
5

 
$
12

 
$
20

 
$
16

Research and development
 
33

 
35

 
105

 
107

Selling, general and administrative
 
49

 
38

 
151

 
153

Pre-tax compensation expense
 
87

 
85

 
276

 
276

Tax benefit
 
16

 
19

 
49

 
48

After-tax compensation expense
 
$
71

 
$
66

 
$
227

 
$
228



Stock Options

During the six months ended June 30, 2019, primarily in connection with the company's annual grant, AbbVie granted 1.0 million stock options with a weighted-average grant-date fair value of $12.54. As of June 30, 2019, $8.5 million of unrecognized compensation cost related to stock options is expected to be recognized as expense over approximately the next two years.

RSUs and Performance Shares

During the six months ended June 30, 2019, primarily in connection with the company's annual grant, AbbVie granted 5.4 million RSUs and performance shares with a weighted-average grant-date fair value of $78.68. As of June 30, 2019, $434 million of unrecognized compensation cost related to RSUs and performance shares is expected to be recognized as expense over approximately the next two years.

Cash Dividends

The following table summarizes quarterly cash dividends declared during 2019 and 2018:
2019
 
2018
Date Declared
 
Payment Date
 
Dividend Per Share
 
Date Declared
 
Payment Date
 
Dividend Per Share
06/20/19
 
08/15/19
 
$
1.07

 
11/02/18
 
02/15/19
 
$
1.07

02/21/19
 
05/15/19
 
$
1.07

 
09/07/18
 
11/15/18
 
$
0.96


 

 


 
06/14/18
 
08/15/18
 
$
0.96


 

 


 
02/15/18
 
05/15/18
 
$
0.96



2019 Form 10-Q | abbvieimage2a12.gif
20



Stock Repurchase Program
The company's stock repurchase authorization permits purchases of AbbVie shares from time to time in open-market or private transactions at management's discretion. The program has no time limit and can be discontinued at any time. Shares repurchased under these programs are recorded at acquisition cost, including related expenses, and are available for general corporate purposes.
AbbVie repurchased 4 million shares for $300 million during the six months ended June 30, 2019 and 84 million shares for $8.8 billion during the six months ended June 30, 2018. AbbVie's remaining stock repurchase authorization was approximately $4.0 billion as of June 30, 2019.
Accumulated Other Comprehensive Loss
The following table summarizes the changes in each component of accumulated other comprehensive loss, net of tax, for the six months ended June 30, 2019:
(in millions)
Foreign currency
translation adjustments
 
Net investment
hedging activities
 
Pension 
and post-
employment
benefits
 
Marketable
security activities
 
Cash flow hedging
activities
 
Total
Balance as of December 31, 2018
$
(830
)
 
$
(65
)
 
$
(1,722
)
 
$
(10
)
 
$
147

 
$
(2,480
)
Other comprehensive income (loss) before reclassifications
(32
)
 
35

 
2

 
10

 
7

 
22

Net losses (gains) reclassified from accumulated other comprehensive loss
—

 
(7
)
 
43

 
1

 
(70
)
 
(33
)
Net current-period other comprehensive income (loss)
(32
)
 
28

 
45

 
11

 
(63
)
 
(11
)
Balance as of June 30, 2019
$
(862
)
 
$
(37
)
 
$
(1,677
)
 
$
1

 
$
84

 
$
(2,491
)


Other comprehensive loss for the six months ended June 30, 2019 included foreign currency translation adjustments totaling a loss of $32 million, which was principally due to the weakening of the Euro in the six months ended June 30, 2019 on the translation of the company’s assets denominated in the Euro.

The following table summarizes the changes in each component of accumulated other comprehensive loss, net of tax, for the six months ended June 30, 2018:
(in millions)
Foreign currency
translation adjustments
 
Net investment
hedging activities
 
Pension 
and post-
employment
benefits
 
Marketable
 security activities
 
Cash flow hedging
activities
 
Total
Balance as of December 31, 2017
$
(439
)
 
$
(203
)
 
$
(1,919
)
 
$
—

 
$
(166
)
 
$
(2,727
)
Other comprehensive income (loss) before reclassifications
(280
)
 
105

 
9

 
(6
)
 
110

 
(62
)
Net losses reclassified from accumulated other comprehensive loss
—

 
—

 
62

 
4

 
84

 
150

Net current-period other comprehensive income (loss)
(280
)
 
105

 
71

 
(2
)
 
194

 
88

Balance as of June 30, 2018
$
(719
)
 
$
(98
)
 
$
(1,848
)
 
$
(2
)
 
$
28

 
$
(2,639
)


Other comprehensive income for the six months ended June 30, 2018 included foreign currency translation adjustments totaling a loss of $280 million, which was principally due to the weakening of the Euro in the six months ended June 30, 2018 on the translation of the company’s assets denominated in the Euro.


2019 Form 10-Q | abbvieimage2a12.gif
21



The following table presents the impact on AbbVie’s condensed consolidated statements of earnings for significant amounts reclassified out of each component of accumulated other comprehensive loss:
 
Three months ended
June 30,
 
Six months ended
June 30,
(in millions) (brackets denote gains)
2019
 
2018
 
2019
 
2018
Pension and post-employment benefits
 
 
 
 
 
 
 
Amortization of actuarial losses and other(a)
$
30

 
$
36

 
$
55

 
$
77

Tax benefit
(7
)
 
(7
)
 
(12
)
 
(15
)
Total reclassifications, net of tax
$
23

 
$
29

 
$
43

 
$
62

Cash flow hedging activities
 
 
 
 
 
 
 
Losses (gains) on designated cash flow hedges(b)
$
(37
)
 
$
46

 
$
(77
)
 
$
90

Tax expense (benefit)
2

 
(4
)
 
7

 
(6
)
Total reclassifications, net of tax
$
(35
)
 
$
42

 
$
(70
)
 
$
84

Net investment hedging activities
 
 
 
 
 
 
 
Gains on derivative amount excluded from effectiveness testing(c)
$
(9
)
 
$
—

 
$
(9
)
 
$
—

Tax expense
2

 
—

 
2

 
—

Total reclassifications, net of tax
$
(7
)
 
$
—

 
$
(7
)
 
$
—


(a) Amounts are included in the computation of net periodic benefit cost (see Note 10).
(b) Amounts are included in cost of products sold (see Note 9).
(c) Amounts are included in interest expense, net (see Note 9).
Note 12 Income Taxes
 

The effective tax rate was 8% for the three months and 5% for the six months ended June 30, 2019 and 2% for the three months and 1% for the six months ended June 30, 2018. The effective tax rate in each period differed from the U.S. statutory tax rate of 21% principally due to the benefit from foreign operations which reflects the impact of lower income tax rates in locations outside the United States, tax incentives in Puerto Rico and other foreign tax jurisdictions and business development activities. The increase in the effective tax rate for the three and six months ended June 30, 2019 over the prior year was principally due to the beneficial impact of the timing of provisions of the Act related to earnings from certain foreign subsidiaries in prior year and changes in the jurisdictional mix of earnings, including a change in fair value of contingent consideration liabilities. These increases were partially offset by the favorable resolution of various tax positions in the current year.

Due to the potential for resolution of federal, state and foreign examinations and the expiration of various statutes of limitations, it is reasonably possible that the company’s gross unrecognized tax benefits balance may change within the next twelve months by up to $41 million.
Note 13 Legal Proceedings and Contingencies
 

AbbVie is subject to contingencies, such as various claims, legal proceedings and investigations regarding product liability, intellectual property, commercial, securities and other matters that arise in the normal course of business. Loss contingency provisions are recorded for probable losses at management’s best estimate of a loss, or when a best estimate cannot be made, a minimum loss contingency amount within a probable range is recorded. The recorded accrual balance for litigation was approximately $330 million as of June 30, 2019 and $350 million as of December 31, 2018. Initiation of new legal proceedings or a change in the status of existing proceedings may result in a change in the estimated loss accrued by AbbVie. While it is not feasible to predict the outcome of all proceedings and exposures with certainty, management believes that their ultimate disposition should not have a material adverse effect on AbbVie’s consolidated financial position, results of operations or cash flows.


2019 Form 10-Q | abbvieimage2a12.gif
22



Subject to certain exceptions specified in the separation agreement by and between Abbott and AbbVie, AbbVie assumed the liability for, and control of, all pending and threatened legal matters related to its business, including liabilities for any claims or legal proceedings related to products that had been part of its business, but were discontinued prior to the distribution, as well as assumed or retained liabilities, and will indemnify Abbott for any liability arising out of or resulting from such assumed legal matters.

Four lawsuits against Unimed Pharmaceuticals, Inc., Solvay Pharmaceuticals, Inc. (a company Abbott acquired in February 2010 and now known as AbbVie Products LLC) and others are consolidated for pre-trial purposes in the United States District Court for the Northern District of Georgia under the Multi-District Litigation (MDL) Rules as In re: AndroGel Antitrust Litigation, MDL No. 2084. These cases, brought by direct AndroGel purchasers, generally allege Solvay's 2006 patent litigation settlement agreements and related agreements with three generic companies violate federal antitrust laws. Plaintiffs seek monetary damages and attorneys' fees.

Lawsuits are pending against AbbVie and others generally alleging that the 2005 patent litigation settlement involving Niaspan entered into between Kos Pharmaceuticals, Inc. (a company acquired by Abbott in 2006 and presently a subsidiary of AbbVie) and a generic company violates federal and state antitrust laws and state unfair and deceptive trade practices and unjust enrichment laws. Plaintiffs generally seek monetary damages and/or injunctive relief and attorneys' fees. The lawsuits consist of four individual plaintiff lawsuits and two consolidated purported class actions: one brought by Niaspan direct purchasers and one brought by Niaspan end-payers. The cases are pending in the United States District Court for the Eastern District of Pennsylvania for coordinated or consolidated pre-trial proceedings under the MDL Rules as In re: Niaspan Antitrust Litigation, MDL No. 2460. In October 2016, the Orange County, California District Attorney’s Office filed a lawsuit on behalf of the State of California regarding the Niaspan patent litigation settlement in Orange County Superior Court, asserting a claim under the unfair competition provision of the California Business and Professions Code seeking injunctive relief, restitution, civil penalties and attorneys’ fees. In May 2018, the California Court of Appeal ruled that the District Attorney’s Office may not bring monetary claims beyond the scope of Orange County, which the District Attorney’s Office is appealing.

In September 2014, the FTC filed a lawsuit against AbbVie and others in the United States District Court for the Eastern District of Pennsylvania, alleging that the 2011 patent litigation with two generic companies regarding AndroGel was sham litigation and the settlements of that litigation violated federal antitrust law. In May 2015, the court dismissed the FTC’s settlement-related claim. In June 2018, following a bench trial, the court found for the FTC on its sham litigation claim and ordered a disgorgement remedy of $448 million, plus prejudgment interest. The court denied the FTC’s request for injunctive relief. AbbVie is appealing the court’s liability and disgorgement rulings and, based on an assessment of the merits of that appeal, no liability has been accrued for this matter. The FTC is also appealing aspects of the court’s trial ruling and the dismissal of its settlement-related claim. One purported class action on behalf of direct AndroGel purchasers based on the trial court’s ruling in the FTC’s case is also pending in the United States District Court for the Eastern District of Pennsylvania and is stayed pending the appeals in the FTC’s case.

In January and February 2019, two shareholder derivative lawsuits, Brown v. Gonzalez, et al., and Elfers v. Gonzalez, et al., were filed in the United States District Court for the Northern District of Illinois, alleging that certain AbbVie directors and officers breached their fiduciary duties in connection with HUMIRA patient and reimbursement support services and other services and items of value, as alleged in the State of California case discussed below.

Between March and May 2019, 12 putative class action lawsuits were filed in the United States District Court for the Northern District of Illinois by indirect HUMIRA purchasers, alleging that AbbVie’s settlements with biosimilar manufacturers and AbbVie’s HUMIRA patent portfolio violate state and federal antitrust laws.

In November 2014, a putative class action lawsuit, Medical Mutual of Ohio v. AbbVie Inc., et al., was filed against several manufacturers of testosterone replacement therapies (TRTs), including AbbVie, in the United States District Court for the Northern District of Illinois on behalf of all insurance companies, health benefit providers, and other third party payers who paid for TRTs, including AndroGel. The claims asserted include violations of the federal RICO Act and state consumer fraud and deceptive trade practices laws. The complaint seeks monetary damages and injunctive relief. In July 2018, the court denied the plaintiff’s motion for class certification. In February 2019, the court granted the defendants’ summary judgment motion.

In September 2018, the Commissioner of the California Department of Insurance intervened in a qui tam lawsuit, State of California and Lazaro Suarez v. AbbVie Inc., et al., brought under the California Insurance Frauds Prevention Act, in California Superior Court for Alameda County. The Department of Insurance’s complaint alleges that, through patient and reimbursement support services and other services and items of value provided in connection with HUMIRA, AbbVie caused the submission of fraudulent commercial insurance claims for HUMIRA in violation of the California statute. The complaint seeks injunctive relief, an assessment of up to three times the amount of the claims at issue, and civil penalties. In addition, a federal securities lawsuit (Holwill v. AbbVie Inc., et al.) is

2019 Form 10-Q | abbvieimage2a12.gif
23



pending in the United States District Court for the Northern District of Illinois) against AbbVie, its chief executive officer and former chief financial officer, alleging that reasons stated for HUMIRA sales growth in financial filings between 2013 and 2017 were misleading because they omitted the conduct alleged in the Department of Insurance’s complaint.

In November 2014, five individuals filed a putative class action lawsuit, Rubinstein, et al. v Gonzalez, et al., on behalf of purchasers and sellers of certain Shire plc (Shire) securities between June 20 and October 14, 2014, against AbbVie and its chief executive officer in the United States District Court for the Northern District of Illinois alleging that the defendants made and/or are responsible for material misstatements in violation of federal securities laws in connection with AbbVie's proposed transaction with Shire. In July 2019, the court granted preliminary approval to the parties’ settlement agreement.

In June 2016, a lawsuit, Elliott Associates, L.P., et al. v. AbbVie Inc., was filed by five investment funds against AbbVie in the Cook County, Illinois Circuit Court alleging that AbbVie made misrepresentations and omissions in connection with its proposed transaction with Shire. Similar lawsuits were filed between July 2017 and October 2018 against AbbVie and in some instances its chief executive officer in the same court by additional investment funds. Plaintiffs seek compensatory and punitive damages.

Product liability cases were filed in which plaintiffs generally allege that AbbVie and other manufacturers of TRTs did not adequately warn about risks of certain injuries, primarily heart attacks, strokes and blood clots. Approximately 3,900 claims against AbbVie are consolidated for pre-trial purposes in the United States District Court for the Northern District of Illinois under the MDL Rules as In re: Testosterone Replacement Therapy Products Liability Litigation, MDL No. 2545. Approximately 200 claims against AbbVie are pending in various state courts. Plaintiffs generally seek compensatory and punitive damages. In November 2018, AbbVie entered into a Master Settlement Agreement with the Plaintiffs’ Steering Committee in the MDL encompassing existing claims in all courts. All proceedings in pending cases are effectively stayed during the settlement administration process.

Product liability cases are pending in which plaintiffs generally allege that AbbVie did not adequately warn about risk of certain injuries, primarily various birth defects, arising from use of Depakote. Approximately 150 cases are pending in the United States District Court for the Southern District of Illinois, and approximately six others are pending in various state courts. Plaintiffs generally seek compensatory and punitive damages. Approximately ninety percent of these pending cases, plus other unfiled claims, are subject to confidential settlement agreements and are expected to be dismissed with prejudice.

Beginning in May 2016, the Patent Trial & Appeal Board of the U.S. Patent & Trademark Office (PTO) instituted five inter partes review proceedings brought by Coherus Biosciences and Boehringer Ingelheim related to three AbbVie patents covering methods of treatment of rheumatoid arthritis using adalimumab. In these proceedings, the PTO reviewed the validity of the patents and issued decisions of invalidity in May, June and July of 2017. AbbVie’s appeal of the decisions is pending in the Court of Appeals for the Federal Circuit.

In March 2017, AbbVie filed a lawsuit, AbbVie Inc. v. Novartis Vaccines and Diagnostics, Inc. and Grifols Worldwide Operations Ltd., in the United States District Court for the Northern District of California against Novartis Vaccines and Grifols Worldwide seeking a declaratory judgment that 11 HCV-related patents licensed to AbbVie in 2002 are invalid.

AbbVie is seeking to enforce certain patent rights related to adalimumab (a drug AbbVie sells under the trademark HUMIRA®). In a case filed in United States District Court for the District of Delaware in August 2017, AbbVie alleges that Boehringer Ingelheim International GmbH’s, Boehringer Ingelheim Pharmaceutical, Inc.’s, and Boehringer Ingelheim Fremont, Inc.’s proposed biosimilar adalimumab product infringes certain AbbVie patents. AbbVie seeks declaratory and injunctive relief. In May 2019, the parties settled this case and it was dismissed without prejudice.

Pharmacyclics LLC, a wholly owned subsidiary of AbbVie, is seeking to enforce its patent rights relating to ibrutinib capsules (a drug Pharmacyclics sells under the trademark IMBRUVICA®). In February 2018, cases were filed in the United States District Court for the District of Delaware against the following defendants: Fresenius Kabi USA, LLC, Fresenius Kabi USA, Inc., and Fresenius Kabi Oncology Limited; Sun Pharma Global FZE and Sun Pharmaceutical Industries Ltd.; Cipla Limited and Cipla USA Inc.; and Zydus Worldwide DMCC, Cadila Healthcare Limited, Sandoz Inc., and Lek Pharmaceuticals D.D. In each case, Pharmacyclics alleges the defendant’s proposed generic ibrutinib product infringes certain Pharmacyclics patents and seeks declaratory and injunctive relief. Janssen Biotech, Inc. which is in a global collaboration with Pharmacyclics concerning the development and marketing of IMBRUVICA, is the co-plaintiff in these suits.

Pharmacyclics LLC, a wholly owned subsidiary of AbbVie, is seeking to enforce its patent rights relating to ibrutinib tablets (a drug Pharmacyclics sells under the trademark IMBRUVICA®). In a case filed in the United States District Court for the District of Delaware in March 2019, Pharmacyclics alleges that Alvogen Pine Brook LLC’s and Natco Pharma Ltd.’s proposed generic ibrutinib tablet

2019 Form 10-Q | abbvieimage2a12.gif
24



product infringes certain Pharmacyclics patents. Pharmacyclics seeks declaratory and injunctive relief. Janssen Biotech, Inc. which is in a global collaboration with Pharmacyclics concerning the development and marketing of IMBRUVICA, is the co-plaintiff in this suit.
Note 14 Segment Information
 

AbbVie operates in one business segment—pharmaceutical products. The following table details AbbVie’s worldwide net revenues:
 
 
 
Three months ended
June 30,
 
Six months ended
June 30,
 
 
 
 
(in millions)
 
 
2019
 
2018
 
2019
 
2018
Immunology
 
 
 
 
 
 
 
 
HUMIRA
United States
 
$
3,793

 
$
3,521

 
$
7,008

 
$
6,524

 
International
 
1,077

 
1,664

 
2,308

 
3,370

 
Total
 
$
4,870

 
$
5,185

 
$
9,316

 
$
9,894

SKYRIZI
United States
 
$
42

 
$
—

 
$
42

 
$
—

 
International
 
6

 
—

 
6

 
—

 
Total
 
$
48

 
$
—

 
$
48

 
$
—

Hematologic Oncology
 
 
 
 
 
 
 
 
IMBRUVICA
United States
 
$
886

 
$
693

 
$
1,715

 
$
1,317

 
Collaboration revenues
 
213

 
157

 
406

 
295

 
Total
 
$
1,099

 
$
850

 
$
2,121

 
$
1,612

VENCLEXTA
United States
 
$
117

 
$
47

 
$
222

 
$
88

 
International
 
52

 
18

 
98

 
36

 
Total
 
$
169

 
$
65

 
$
320

 
$
124

HCV
 
 
 
 
 
 
 
 
MAVYRET
United States
 
$
396

 
$
422

 
$
799

 
$
762

 
International
 
384

 
510

 
771

 
1,018

 
Total
 
$
780

 
$
932

 
$
1,570

 
$
1,780

VIEKIRA
United States
 
$
—

 
$
—

 
$
—

 
$
3

 
International
 
4

 
41

 
29

 
109

 
Total
 
$
4

 
$
41

 
$
29

 
$
112

Other Key Products
 
 
 
 
 
 
 
 
Creon
United States
 
$
257

 
$
219

 
$
484

 
$
428

Lupron
United States
 
$
168

 
$
180

 
$
359

 
$
357

 
International
 
41

 
43

 
79

 
85

 
Total
 
$
209

 
$
223

 
$
438

 
$
442

Synthroid
United States
 
$
203

 
$
193

 
$
385

 
$
375

Synagis
International
 
$
38

 
$
44

 
$
325

 
$
365

Duodopa
United States
 
$
24

 
$
20

 
$
46

 
$
38

 
International
 
91

 
88

 
180

 
173

 
Total
 
$
115

 
$
108

 
$
226

 
$
211

Sevoflurane
United States
 
$
18

 
$
19

 
$
35

 
$
36

 
International
 
73

 
94

 
148

 
183

 
Total
 
$
91

 
$
113

 
$
183

 
$
219

Kaletra
United States
 
$
10

 
$
13

 
$
23

 
$
26

 
International
 
67

 
78

 
132

 
138

 
Total
 
$
77

 
$
91

 
$
155

 
$
164

AndroGel
United States
 
$
22

 
$
128

 
$
96

 
$
258

ORILISSA
United States
 
$
18

 
$
—

 
$
31

 
$
—

 
International
 
1

 
—

 
1

 
—

 
Total
 
$
19

 
$
—

 
$
32

 
$
—

All other
 
 
$
254

 
$
86

 
$
355

 
$
228

Total net revenues
 
$
8,255

 
$
8,278

 
$
16,083

 
$
16,212




2019 Form 10-Q | abbvieimage2a12.gif
25



ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
 

The following is a discussion and analysis of the financial condition of AbbVie Inc. (AbbVie or the company) as of June 30, 2019 and December 31, 2018 and the results of operations for the three and six months ended June 30, 2019 and 2018. This commentary should be read in conjunction with the condensed consolidated financial statements and accompanying notes appearing in Item 1, “Financial Statements and Supplementary Data.”
EXECUTIVE OVERVIEW
Company Overview
AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories (Abbott). AbbVie uses its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world’s most complex and serious diseases. AbbVie’s products are focused on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis; pain associated with endometriosis; as well as other serious health conditions. AbbVie also has a pipeline of promising new medicines in clinical development across such important medical specialties as immunology, oncology and neuroscience, with additional targeted investment in cystic fibrosis and women’s health.
AbbVie’s products are generally sold worldwide directly to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies and independent retailers from AbbVie-owned distribution centers and public warehouses. In the United States, AbbVie distributes pharmaceutical products principally through independent wholesale distributors, with some sales directly to pharmacies and patients. Outside the United States, AbbVie sells products primarily to customers or through distributors, depending on the market served. Certain products are co-marketed or co-promoted with other companies. AbbVie has approximately 30,000 employees. AbbVie operates in one business segment—pharmaceutical products.
On June 25, 2019, AbbVie announced that it entered into a definitive transaction agreement under which AbbVie will acquire Allergan plc (Allergan). See Note 4 to the condensed consolidated financial statements for additional information on the proposed acquisition.
2019 Strategic Objectives
AbbVie's mission is to be an innovation-driven, patient-focused specialty biopharmaceutical company capable of achieving top-tier financial performance through outstanding execution and a consistent stream of innovative new medicines. AbbVie intends to continue to advance its mission in a number of ways, including: (i) growing revenues by diversifying revenue streams, driving late-stage pipeline assets to the market and ensuring strong commercial execution of new product launches; (ii) continued investment and expansion in its pipeline in support of opportunities in immunology, oncology and neuroscience, with additional targeted investment in cystic fibrosis and women's health as well as continued investment in key on-market products; (iii) expanding operating margins; and (iv) returning cash to shareholders via dividends and share repurchases. In addition, AbbVie anticipates several regulatory submissions and key data readouts from key clinical trials in the next twelve months.
Financial Results
The company's financial performance for the six months ended June 30, 2019 included delivering worldwide net revenues of $16.1 billion, operating earnings of $6.4 billion, diluted earnings per share of $2.14 and cash flows from operations of $5.5 billion. Worldwide net revenues decreased by 0.8% and increased 0.9% on a constant currency basis, primarily driven by revenue growth related to IMBRUVICA and VENCLEXTA as well as the continued strength of U.S. HUMIRA revenues, offset by international HUMIRA biosimilar competition.
Diluted earnings per share was $2.14 for the six months ended June 30, 2019 and included the following after-tax costs: (i) $2.5 billion for the change in fair value of contingent consideration liabilities; (ii) $639 million related to the amortization of intangible assets; (iii) $241 million for acquired in-process research and development (IPR&D); (iv) $139 million of restructuring charges; (v) $75 million for milestone payments; and (vi) $27 million of expenses related to the proposed Allergan acquisition. These costs were partially offset by an after-tax benefit of $267 million due to the favorable resolution of various tax positions. Additionally,

2019 Form 10-Q | abbvieimage2a12.gif
26



financial results reflected continued funding to support all stages of AbbVie’s emerging pipeline assets and continued investment in AbbVie’s on-market brands.
In addition to these financial results, AbbVie continued to advance and augment its pipeline as further described below under the heading “Research and Development.”
Research and Development
Research and innovation are the cornerstones of AbbVie’s business as a global biopharmaceutical company. AbbVie’s long-term success depends to a great extent on its ability to continue to discover and develop innovative pharmaceutical products and acquire or collaborate on compounds currently in development by other biotechnology or pharmaceutical companies.
AbbVie’s pipeline currently includes more than 50 compounds or indications in clinical development individually or under collaboration or license agreements and is focused on such important medical specialties as immunology, oncology and neuroscience along with targeted investments in cystic fibrosis and women’s health. Of these programs, approximately 30 are in mid- and late-stage development.
The following sections summarize transitions of significant programs from Phase 2 development to Phase 3 development as well as developments in significant Phase 3 and registration programs. AbbVie expects multiple Phase 2 programs to transition into Phase 3 programs in the next twelve months.
Significant Programs and Developments
Immunology
Upadacitinib
•
In February 2019, the U.S. Food and Drug Administration (FDA) accepted for priority review AbbVie's New Drug Application (NDA) for upadacitinib, an investigational oral JAK1-selective inhibitor, for the treatment of adult patients with moderate to severe rheumatoid arthritis (RA).
•
In February 2019, AbbVie initiated a Phase 3 clinical trial to evaluate the efficacy and safety of upadacitinib in subjects with giant cell arteritis.
SKYRIZI
•
In March 2019, AbbVie initiated two Phase 3 clinical trials to evaluate the efficacy and safety of risankizumab, an investigational interleukin-23 (IL-23) inhibitor, in subjects with psoriatic arthritis.
•
In April 2019, the FDA approved SKYRIZI (risankizumab) for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
•
In April 2019, the European Commission granted marketing authorization for SKYRIZI for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy.
Oncology
IMBRUVICA
•
In January 2019, the FDA approved IMBRUVICA, in combination with GAZYVA (obinutuzumab), for adult patients with previously untreated chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
•
In June 2019, AbbVie announced results from the Phase 3 CLL12 trial, evaluating IMBRUVICA in patients with previously untreated CLL, which demonstrated that IMBRUVICA significantly improved event- and progression-free survival.
VENCLEXTA
•
In March 2019, AbbVie announced that the FDA placed a partial clinical hold on all clinical trials evaluating VENCLEXTA for the investigational treatment of multiple myeloma (MM). The partial clinical hold followed a review of data from the ongoing Phase 3 BELLINI trial, a study in relapsed/refractory MM, in which a higher proportion of deaths was observed in the VENCLEXTA arm compared to the control arm of the trial. In June 2019, AbbVie announced that the FDA lifted the partial clinical hold placed on the Phase 3 CANOVA trial, evaluating VENCLEXTA for the investigational treatment of relapsed/refractory MM positive for the translocation (11;14) abnormality, based upon agreement on revisions to the

2019 Form 10-Q | abbvieimage2a12.gif
27



CANOVA study protocol, including new risk mitigation measures, protocol-specified guidelines and updated futility criteria. All other clinical trials evaluating VENCLEXTA in patients with MM remain on partial clinical hold while next steps continue to be evaluated with the FDA. This action does not impact any of the approved indications for VENCLEXTA, such as CLL or acute myeloid leukemia (AML).
•
In May 2019, the FDA approved VENCLEXTA, in combination with obinutuzumab, for adult patients with previously untreated CLL/SLL.
•
In June 2019, AbbVie announced results from the Phase 3 CLL14 trial, evaluating efficacy and safety of VENCLEXTA plus obinutuzumab versus obinutuzumab plus chlorambucil in previously untreated patients with CLL, which demonstrated that VENCLEXTA plus obinutuzumab prolonged progression-free survival and achieved higher rates of complete response and minimal residual disease-negativity compared to commonly used standard of care obinutuzumab plus chlorambucil.
Depatux-M
•
In May 2019, AbbVie announced the decision to discontinue the Phase 3 INTELLANCE-1 study of depatuxizumab mafodotin (Depatux-M, previously known as ABT-414) in patients with newly diagnosed glioblastoma, whose tumors have EGFR (epidermal growth factor receptor) amplification, at an interim analysis. An Independent Data Monitoring Committee recommended stopping enrollment in INTELLANCE-1 due to lack of survival benefit for patients receiving Depatux-M compared with placebo when added to the standard regimen of radiation and temozolomide. Enrollment has been halted in all ongoing Depatux-M studies.
Veliparib
•
In July 2019, AbbVie announced that top-line results from the Phase 3 BROCADE3 study evaluating veliparib, an investigational, oral poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitor, in combination with carboplatin and paclitaxel met its primary endpoint of progression-free survival in patients with HER2 negative germline BRCA-mutated advanced breast cancer.
•
In July 2019, AbbVie announced that top-line results from the Phase 3 VELIA study, conducted in collaboration with the GOG Foundation, Inc., evaluating veliparib with carboplatin and paclitaxel followed by veliparib maintenance therapy met its primary endpoint of progression-free survival in patients with newly diagnosed ovarian cancer, regardless of biomarker status.
Neuroscience
•
In May 2019, AbbVie initiated a Phase 3 clinical trial to evaluate the safety and tolerability of ABBV-951, a subcutaneous levodopa/carbidopa delivery system, in subjects with Parkinson's disease.
•
In July 2019, AbbVie announced the decision to discontinue the Phase 2 ARISE study evaluating ABBV-8E12, an investigational anti-tau antibody, in patients with progressive supranuclear palsy, after an Independent Data Monitoring Committee recommended stopping the trial for futility after the trial showed that ABBV-8E12 did not provide efficacy.
Other
•
In July 2019, AbbVie submitted an NDA to the FDA for elagolix in combination with estradiol/norethindrone acetate (E2/NETA) daily add-back therapy for the management of heavy menstrual bleeding associated with uterine fibroids.
For a more comprehensive discussion of AbbVie’s products and pipeline, see the company’s Annual Report on Form 10-K for the year ended December 31, 2018.

2019 Form 10-Q | abbvieimage2a12.gif
28



RESULTS OF OPERATIONS
Net Revenues
The comparisons presented at constant currency rates reflect comparative local currency net revenues at the prior year’s foreign exchange rates. This measure provides information on the change in net revenues assuming that foreign currency exchange rates had not changed between the prior and current periods. AbbVie believes that the non-GAAP measure of change in net revenues at constant currency rates, when used in conjunction with the GAAP measure of change in net revenues at actual currency rates, may provide a more complete understanding of the company’s operations and can facilitate analysis of the company’s results of operations, particularly in evaluating performance from one period to another.
 
 
Three months ended
June 30,
 
Percent change
 
Six months ended
June 30,
 
Percent change
 
 
 
At actual
currency rates
 
At constant
currency rates
 
 
At actual
currency rates
 
At constant
currency rates
(dollars in millions)
 
2019
 
2018
 
 
2019
 
2018
 
United States
 
$
5,964

 
$
5,449

 
9.5
 %
 
9.5
 %
 
$
11,234

 
$
10,239

 
9.7
 %
 
9.7
 %
International
 
2,291

 
2,829

 
(19.0
)%
 
(14.4
)%
 
4,849

 
5,973

 
(18.8
)%
 
(14.3
)%
Net revenues
 
$
8,255

 
$
8,278

 
(0.3
)%
 
1.3
 %
 
$
16,083

 
$
16,212

 
(0.8
)%
 
0.9
 %

2019 Form 10-Q | abbvieimage2a12.gif
29



The following table details AbbVie’s worldwide net revenues:
 
 
 
Three months ended
June 30,
 
Percent change
 
Six months ended
June 30,
 
Percent change
 
 
 
 
At actual
currency rates
 
At constant
currency rates
 
 
At actual
currency rates
 
At constant
currency rates
(dollars in millions)
 
2019
 
2018
 
 
2019
 
2018
 
Immunology
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HUMIRA
United States
 
$
3,793

 
$
3,521

 
7.7
 %
 
7.7
 %
 
$
7,008

 
$
6,524

 
7.4
 %
 
7.4
 %
 
International
 
1,077

 
1,664

 
(35.2
)%
 
(31.0
)%
 
2,308

 
3,370

 
(31.5
)%
 
(27.0
)%
 
Total
 
$
4,870

 
$
5,185

 
(6.1
)%
 
(4.8
)%
 
$
9,316

 
$
9,894

 
(5.8
)%
 
(4.3
)%
SKYRIZI
United States
 
$
42

 
$
—

 
n/m

 
n/m

 
$
42

 
$
—

 
n/m

 
n/m

 
International
 
6

 
—

 
n/m

 
n/m

 
6

 
—

 
n/m

 
n/m

 
Total
 
$
48

 
$
—

 
n/m

 
n/m

 
$
48

 
$
—

 
n/m

 
n/m

Hematologic Oncology
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IMBRUVICA
United States
 
$
886

 
$
693

 
27.9
 %
 
27.9
 %
 
$
1,715

 
$
1,317

 
30.2
 %
 
30.2
 %
 
Collaboration revenues
 
213

 
157

 
35.9
 %
 
35.9
 %
 
406

 
295

 
37.6
 %
 
37.6
 %
 
Total
 
$
1,099

 
$
850

 
29.3
 %
 
29.3
 %
 
$
2,121

 
$
1,612

 
31.6
 %
 
31.6
 %
VENCLEXTA
United States
 
$
117

 
$
47

 
>100.0%

 
>100.0%

 
$
222

 
$
88

 
>100.0%

 
>100.0%

 
International
 
52

 
18

 
>100.0%

 
>100.0%

 
98

 
36

 
>100.0%

 
>100.0%

 
Total
 
$
169

 
$
65

 
>100.0%

 
>100.0%

 
$
320

 
$
124

 
>100.0%

 
>100.0%

HCV
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MAVYRET
United States
 
$
396

 
$
422

 
(6.0
)%
 
(6.0
)%
 
$
799

 
$
762

 
4.8
 %
 
4.8
 %
 
International
 
384

 
510

 
(24.7
)%
 
(20.4
)%
 
771

 
1,018

 
(24.3
)%
 
(20.5
)%
 
Total
 
$
780

 
$
932

 
(16.3
)%
 
(14.0
)%
 
$
1,570

 
$
1,780

 
(11.8
)%
 
(9.6
)%
VIEKIRA
United States
 
$
—

 
$
—

 
n/m

 
n/m

 
$
—

 
$
3

 
(100.0
)%
 
(100.0
)%
 
International
 
4

 
41

 
(88.8
)%
 
(86.4
)%
 
29

 
109

 
(72.7
)%
 
(69.1
)%
 
Total
 
$
4

 
$
41

 
(90.3
)%
 
(87.9
)%
 
$
29

 
$
112

 
(74.2
)%
 
(70.6
)%
Other Key Products
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Creon
United States
 
$
257

 
$
219

 
17.5
 %
 
17.5
 %
 
$
484

 
$
428

 
13.1
 %
 
13.1
 %
Lupron
United States
 
$
168

 
$
180

 
(6.4
)%
 
(6.4
)%
 
$
359

 
$
357

 
0.5
 %
 
0.5
 %
 
International
 
41

 
43

 
(4.5
)%
 
3.2
 %
 
79

 
85

 
(6.7
)%
 
1.0
 %
 
Total
 
$
209

 
$
223

 
(6.0
)%
 
(4.5
)%
 
$
438

 
$
442

 
(0.9
)%
 
0.6
 %
Synthroid
United States
 
$
203

 
$
193

 
4.9
 %
 
4.9
 %
 
$
385

 
$
375

 
2.7
 %
 
2.7
 %
Synagis
International
 
$
38

 
$
44

 
(11.9
)%
 
(3.9
)%
 
$
325

 
$
365

 
(10.9
)%
 
(6.6
)%
Duodopa
United States
 
$
24

 
$
20

 
12.8
 %
 
12.8
 %
 
$
46

 
$
38

 
20.1
 %
 
20.1
 %
 
International
 
91

 
88

 
3.6
 %
 
11.0
 %
 
180

 
173

 
3.9
 %
 
11.3
 %
 
Total
 
$
115

 
$
108

 
5.3
 %
 
11.3
 %
 
$
226

 
$
211

 
6.8
 %
 
12.8
 %
Sevoflurane
United States
 
$
18

 
$
19

 
(3.3
)%
 
(3.3
)%
 
$
35

 
$
36

 
(2.0
)%
 
(2.0
)%
 
International
 
73

 
94

 
(21.9
)%
 
(16.3
)%
 
148

 
183

 
(19.1
)%
 
(13.2
)%
 
Total
 
$
91

 
$
113

 
(18.8
)%
 
(14.1
)%
 
$
183

 
$
219

 
(16.3
)%
 
(11.4
)%
Kaletra
United States
 
$
10

 
$
13

 
(33.9
)%
 
(33.9
)%
 
$
23

 
$
26

 
(15.0
)%
 
(15.0
)%
 
International
 
67

 
78

 
(12.9
)%
 
(6.8
)%
 
132

 
138

 
(3.9
)%
 
1.7
 %
 
Total
 
$
77

 
$
91

 
(16.0
)%
 
(10.8
)%
 
$
155

 
$
164

 
(5.7
)%
 
(1.0
)%
AndroGel
United States
 
$
22

 
$
128

 
(83.0
)%
 
(83.0
)%
 
$
96

 
$
258

 
(62.8
)%
 
(62.8
)%
ORILISSA
United States
 
$
18

 
$
—

 
n/m

 
n/m

 
$
31

 
$
—

 
n/m

 
n/m

 
International
 
1

 
—

 
n/m

 
n/m

 
1

 
—

 
n/m

 
n/m

 
Total
 
$
19

 
$
—

 
n/m

 
n/m

 
$
32

 
$
—

 
n/m

 
n/m

All other
 
 
$
254

 
$
86

 
>100.0%

 
>100.0%

 
$
355

 
$
228

 
55.2
 %
 
61.3
 %
Total net revenues
 
$
8,255

 
$
8,278

 
(0.3
)%
 
1.3
 %
 
$
16,083

 
$
16,212

 
(0.8
)%
 
0.9
 %
n/m – Not meaningful
The following discussion and analysis of AbbVie’s net revenues by product is presented on a constant currency basis.

Global HUMIRA sales decreased 5% for the three months and 4% for the six months ended June 30, 2019 primarily as a result of direct biosimilar competition in certain international markets, partially offset by market growth across therapeutic categories. In the United States, HUMIRA sales increased 8% for the three months and 7% for the six months ended June 30, 2019 driven by market growth across all indications. Internationally, HUMIRA sales decreased 31% for the three months and 27% for the six months ended

2019 Form 10-Q | abbvieimage2a12.gif
30



June 30, 2019 primarily driven by direct biosimilar competition in certain international markets following the expiration of the European Union composition of matter patent for adalimumab in October 2018. Biosimilar competition for HUMIRA is not expected in the United States until 2023. AbbVie continues to pursue strategies intended to further differentiate HUMIRA from competing products and add to the sustainability of HUMIRA.

Net revenues for SKYRIZI were $48 million for the three and six months ended June 30, 2019 following the April 2019 regulatory approvals for the treatment of moderate to severe plaque psoriasis.

Net revenues for IMBRUVICA represent product sales in the United States and collaboration revenues outside of the United States related to AbbVie’s 50% share of IMBRUVICA profit. AbbVie's global IMBRUVICA revenues increased 29% for the three months and 32% for the six months ended June 30, 2019 as a result of continued penetration of IMBRUVICA for patients with CLL as well as favorable pricing.

Net revenues for VENCLEXTA increased by more than 100% for the three and six months ended June 30, 2019 primarily due to market share gains following additional regulatory approvals of VENCLEXTA for the treatment of patients with relapsed/refractory CLL and AML in 2018.

Global MAVYRET sales decreased by 14% for the three months and 10% for the six months ended June 30, 2019 primarily driven by lower patient volumes in certain international markets.

Net revenues for Creon increased 18% for the three months and 13% for the six months ended June 30, 2019 primarily driven by continued market growth and favorable pricing. Creon maintains market leadership in the pancreatic enzyme market.

Net revenues for Duodopa increased 11% for the three months and 13% for the six months ended June 30, 2019 primarily driven by increased market penetration.
Gross Margin
 
 
Three months ended
June 30,
 
Six months ended
June 30,
(dollars in millions)
 
2019
 
2018
 
% change
 
2019
 
2018
 
% change
Gross margin
 
$
6,436

 
$
6,344

 
1
%
 
$
12,570

 
$
12,351

 
2
%
as a % of net revenues
 
78
%
 
77
%
 
 
 
78
%
 
76
%
 
 
Gross margin as a percentage of net revenues increased for the three and six months ended June 30, 2019 compared to the prior year. Gross margin percentage for the three and six months ended June 30, 2019 was favorably impacted primarily by the expiration of HUMIRA royalties, partially offset by higher intangible asset amortization and the IMBRUVICA profit sharing arrangement.
Selling, General and Administrative
 
 
Three months ended
June 30,
 
Six months ended
June 30,
(dollars in millions)
 
2019
 
2018
 
% change
 
2019
 
2018
 
% change
Selling, general and administrative
 
$
1,654

 
$
1,760

 
(6
)%
 
$
3,334

 
$
3,551

 
(6
)%
as a % of net revenues
 
20
%
 
21
%
 
 
 
21
%
 
22
%
 
 
Selling, general and administrative (SG&A) expenses as a percentage of net revenues decreased for the three and six months ended June 30, 2019 compared to the prior year. SG&A expense percentage for the three and six months ended June 30, 2019 was favorably impacted by lower charitable contributions, as $120 million of prior year contributions to certain U.S. not-for-profit organizations did not recur, and by international HUMIRA expense reductions, partially offset by new product launch expenses and $24 million of transaction costs associated with the proposed Allergan acquisition. In addition, for the six months ended June 30, 2019, SG&A expense percentage was unfavorably impacted by restructuring charges, offset by a $98 million decrease in litigation reserve charges.

2019 Form 10-Q | abbvieimage2a12.gif
31



Research and Development and Acquired In-Process Research and Development
 
 
Three months ended
June 30,
 
Six months ended
June 30,
(dollars in millions)
 
2019
 
2018
 
% change
 
2019
 
2018
 
% change
Research and development
 
$
1,291

 
$
1,322

 
(2
)%
 
$
2,580

 
$
2,566

 
1
%
as a % of net revenues
 
16
%
 
16
%
 
 
 
16
%
 
16
%
 
 
Acquired in-process research and development
 
$
91

 
$
—

 
n/m

 
$
246

 
$
69

 
>100
%
Research and development (R&D) expenses as a percentage of net revenues were flat for the three and six months ended June 30, 2019 compared to the prior year. R&D expenses included continued funding to support all stages of the company's emerging pipeline assets.

Acquired IPR&D expenses reflect upfront payments related to various collaborations. There were no individually significant transactions during both the three and six months ended June 30, 2019 and 2018.
Other Operating Expenses
There were no other operating expenses for the three and six months ended June 30, 2019. Other operating expenses for the six months ended June 30, 2018 included a $500 million charge related to the extension of the previously announced collaboration with Calico Life Sciences LLC (Calico) to discover, develop and bring to market new therapies for patients with age-related diseases, including neurodegeneration and cancer.
Other Non-Operating Expenses
 
 
Three months ended
June 30,
 
Six months ended
June 30,
(in millions)
 
2019
 
2018
 
2019
 
2018
Interest expense
 
$
358

 
$
320

 
$
745

 
$
629

Interest income
 
(49
)
 
(48
)
 
(111
)
 
(106
)
Interest expense, net
 
$
309

 
$
272

 
$
634

 
$
523

 
 
 
 
 
 
 
 
 
Net foreign exchange loss
 
$
6

 
$
8

 
$
12

 
$
16

Other expense, net
 
2,278

 
470

 
2,413

 
317

Interest expense, net increased for the three and six months ended June 30, 2019 compared to the prior year primarily due to the unfavorable impact of higher interest rates on the company's debt obligations and higher average outstanding debt balances.

Other expense, net included charges related to changes in fair value of contingent consideration liabilities of $2.3 billion for the three months and $2.5 billion for the six months ended June 30, 2019 compared to charges of $485 million for the three months and $337 million for the six months ended June 30, 2018. The fair value of contingent consideration liabilities is impacted by the passage of time and multiple other inputs, including the probability of success of achieving regulatory/commercial milestones, discount rates, the estimated amount of future sales of the acquired products and other market-based factors. For the three and six months ended June 30, 2019, the change in fair value represented higher probabilities of success, higher estimated future sales and declining interest rates. The higher probabilities of success resulted from the April 2019 regulatory approvals of SKYRIZI for the treatment of moderate to severe plaque psoriasis. For the three and six months ended June 30, 2018, the change in fair value represented higher estimated future sales and the passage of time partially offset by the effect of rising interest rates.

2019 Form 10-Q | abbvieimage2a12.gif
32



Income Tax Expense
The effective tax rate was 8% for the three months and 5% for the six months ended June 30, 2019 and 2% for the three months and 1% for the six months ended June 30, 2018. The effective tax rate in each period differed from the U.S. statutory tax rate of 21% principally due to the benefit from foreign operations which reflects the impact of lower income tax rates in locations outside the United States, tax incentives in Puerto Rico and other foreign tax jurisdictions and business development activities. The increase in the effective tax rate for the three and six months ended June 30, 2019 over the prior year was principally due to the beneficial impact of the timing of provisions of the Tax Cuts and Jobs Act (the Act) related to earnings from certain foreign subsidiaries in prior year and changes in the jurisdictional mix of earnings, including a change in fair value of contingent consideration liabilities. These increases were partially offset by the favorable resolution of various tax positions in the current year.
FINANCIAL POSITION, LIQUIDITY AND CAPITAL RESOURCES
 
Six months ended
June 30,
(in millions)
2019
 
2018
Cash flows provided by (used in):
 
 
 
Operating activities
$
5,494

 
$
5,511

Investing activities
(167
)
 
240

Financing activities
(7,453
)
 
(11,487
)
Operating cash flows for the six months ended June 30, 2019 were flat compared to the prior year due to improved results of operations resulting from an increase in operating earnings and lower defined benefit plan contributions, offset by higher payments for income taxes and interest. AbbVie’s contributions to its defined benefit plans were $203 million for the six months ended June 30, 2019 and $822 million for the six months ended June 30, 2018.

Investing cash flows for the six months ended June 30, 2019 included net sales and maturities of investment securities totaling $508 million, payments made for acquisitions and investments of $440 million and capital expenditures of $235 million. Investing cash flows for the six months ended June 30, 2018 included net sales and maturities of investment securities totaling $874 million, payments made for acquisitions and investments of $401 million and capital expenditures of $233 million.

Financing cash flows for the six months ended June 30, 2019 included the repayment of AbbVie's $3.0 billion 364-day term loan credit agreement that was scheduled to mature in June 2019.

The company made cash dividend payments of $3.2 billion for the six months ended June 30, 2019 and $2.7 billion for the six months ended June 30, 2018. The increase in cash dividend payments was driven by an increase in the quarterly dividend rate. On June 20, 2019, the board of directors declared a quarterly cash dividend of $1.07 per share for stockholders of record at the close of business on July 15, 2019, payable on August 15, 2019. The timing, declaration, amount of and payment of any dividends by AbbVie in the future is within the discretion of its board of directors and will depend upon many factors, including AbbVie’s financial condition, earnings, capital requirements of its operating subsidiaries, covenants associated with certain of AbbVie’s debt service obligations, legal requirements, regulatory constraints, industry practice, ability to access capital markets and other factors deemed relevant by its board of directors.

The company's stock repurchase authorization permits purchases of AbbVie shares from time to time in open-market or private transactions at management's discretion. The program has no time limit and can be discontinued at any time. AbbVie repurchased 4 million shares for $300 million during the six months ended June 30, 2019 and 84 million shares for $8.8 billion during the six months ended June 30, 2018. AbbVie cash-settled $201 million of its December 2018 open-market purchases in January 2019.
During the six months ended June 30, 2019, AbbVie made $167 million of contingent consideration payments related to the commercial launch of SKYRIZI in certain geographies. $108 million of these payments were included in financing cash flows and $59 million of the payments were included in operating cash flows.
During the six months ended June 30, 2019 and 2018, the company issued and redeemed commercial paper. The balance of commercial paper outstanding was $306 million as of June 30, 2019 and $699 million as of December 31, 2018. AbbVie may issue additional commercial paper or retire commercial paper to meet liquidity requirements as needed.

2019 Form 10-Q | abbvieimage2a12.gif
33



In connection with the proposed acquisition of Allergan, on June 25, 2019, AbbVie entered into a 364-day bridge credit agreement and on July 12, 2019, AbbVie entered into a term loan credit agreement. See Note 4 to the condensed consolidated financial statements for additional information. During the six months ended June 30, 2019, AbbVie paid debt issuance costs of $171 million related to the bridge credit agreement.
Credit Risk
AbbVie monitors economic conditions, the creditworthiness of customers and government regulations and funding, both domestically and abroad. AbbVie regularly communicates with its customers regarding the status of receivable balances, including their payment plans and obtains positive confirmation of the validity of the receivables. AbbVie establishes an allowance against accounts receivable when it is probable they will not be collected. AbbVie may also utilize factoring arrangements to mitigate credit risk, although the receivables included in such arrangements have historically not been a significant amount of total outstanding receivables.
Credit Facility, Access to Capital and Credit Ratings
Credit Facility
AbbVie currently has a $3.0 billion five-year revolving credit facility which matures in August 2023. The revolving credit facility enables the company to borrow funds on an unsecured basis at variable interest rates and contains various covenants. At June 30, 2019, the company was in compliance with all its credit facility covenants. Commitment fees under the credit facility were insignificant. No amounts were outstanding under the credit facility as of June 30, 2019 and December 31, 2018.
Access to Capital
The company intends to fund short-term and long-term financial obligations as they mature through cash on hand, future cash flows from operations or by issuing additional debt. The company’s ability to generate cash flows from operations, issue debt or enter into financing arrangements on acceptable terms could be adversely affected if there is a material decline in the demand for the company’s products or in the solvency of its customers or suppliers, deterioration in the company’s key financial ratios or credit ratings or other material unfavorable changes in business conditions. At the current time, the company believes it has sufficient financial flexibility to issue debt, enter into other financing arrangements and attract long-term capital on acceptable terms to support the company’s growth objectives.
Credit Ratings
On June 25, 2019, following the announcement of the proposed acquisition of Allergan, Moody's Investor Service affirmed its Baa2 senior unsecured long-term rating and Prime-2 short-term rating with a stable outlook. S&P Global Ratings revised its ratings outlook to negative from stable and expects to lower the issuer credit rating by one notch to BBB+ from A- and the short-term rating to A-2 from A-1 when the acquisition is complete.
Unfavorable changes to the ratings may have an adverse impact on future financing arrangements; however, they would not affect the company’s ability to draw on its credit facility and would not result in an acceleration of scheduled maturities of any of the company’s outstanding debt.
CRITICAL ACCOUNTING POLICIES
A summary of the company’s significant accounting policies is included in Note 2, “Summary of Significant Accounting Policies” in AbbVie's Annual Report on Form 10-K for the year ended December 31, 2018. Significant changes in the company’s application of its critical accounting policies include the adoption of a new accounting standard that establishes a new lease accounting framework. See Notes 1 and 8 to the condensed consolidated financial statements for additional information.

2019 Form 10-Q | abbvieimage2a12.gif
34



FORWARD-LOOKING STATEMENTS
Some statements in this quarterly report on Form 10-Q may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words “believe,” “expect,” “anticipate,” “project,” and similar expressions, among others, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, and changes to laws and regulations applicable to our industry. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie’s operations is set forth in Item 1A, “Risk Factors,” in AbbVie’s Annual Report on Form 10-K for the year ended December 31, 2018, which has been filed with the Securities and Exchange Commission. AbbVie notes these factors for investors as permitted by the Private Securities Litigation Reform Act of 1995. AbbVie undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
 

For a discussion of the company's market risk, see Item 7A, "Quantitative and Qualitative Disclosures About Market Risk" in AbbVie's Annual Report on Form 10-K for the year ended December 31, 2018.

2019 Form 10-Q | abbvieimage2a12.gif
35



ITEM 4. CONTROLS AND PROCEDURES
 

DISCLOSURE CONTROLS AND PROCEDURES

Evaluation of disclosure controls and procedures. The Chief Executive Officer, Richard A. Gonzalez, and the Chief Financial Officer, Robert A. Michael, evaluated the effectiveness of AbbVie’s disclosure controls and procedures as of the end of the period covered by this report, and concluded that AbbVie’s disclosure controls and procedures were effective to ensure that information AbbVie is required to disclose in the reports that it files or submits with the Securities and Exchange Commission under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported, within the time periods specified in the Commission’s rules and forms, and to ensure that information required to be disclosed by AbbVie in the reports that it files or submits under the Exchange Act is accumulated and communicated to AbbVie’s management, including its principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

INTERNAL CONTROL OVER FINANCIAL REPORTING

Changes in internal control over financial reporting. There were no changes in AbbVie’s internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) that have materially affected, or are reasonably likely to materially affect, AbbVie’s internal control over financial reporting during the quarter ended June 30, 2019.

Inherent Limitations on Effectiveness of Controls. AbbVie’s management, including its Chief Executive Officer and its Chief Financial Officer, do not expect that AbbVie’s disclosure controls or internal control over financial reporting will prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system’s objectives will be met. The design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls.

The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Projections of any evaluation of controls effectiveness to future periods are subject to risks. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures.

2019 Form 10-Q | abbvieimage2a12.gif
36



PART II. OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
 

Information pertaining to legal proceedings is provided in Note 13 to the condensed consolidated financial statements and is incorporated by reference herein.
ITEM 1A. RISK FACTORS
 

There have been no material changes to the risk factors disclosed in AbbVie’s Annual Report on Form 10-K for the fiscal year ended December 31, 2018, except for the following:
The proposed acquisition of Allergan plc (“Allergan”) may not be completed on the currently contemplated timeline or terms, or at all, and may not achieve the intended benefits.
Consummation of the acquisition of Allergan by AbbVie is conditioned on, among other things, obtaining necessary governmental, regulatory and Allergan shareholder approvals. If any of the conditions to the acquisition is not satisfied, it could delay or prevent the proposed acquisition from occurring, which could negatively impact AbbVie’s share price and future business and financial results. Further, as a condition to their approval of the acquisition, agencies may impose requirements, limitations or costs or require divestitures or place restrictions on the conduct of AbbVie’s business after the closing. These requirements, limitations, costs, divestitures or restrictions could jeopardize or delay the consummation of the acquisition or may reduce the anticipated benefits of the transaction. AbbVie will incur increased indebtedness to fund the cash consideration for the acquisition and such indebtedness could adversely affect AbbVie's business, financial condition, or results of operations. Following the proposed acquisition, AbbVie may not realize the proposed acquisition’s intended benefits within the expected timeframe or at all.
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
 

(c)  Issuer Purchases of Equity Securities

Period
(a) Total
Number of
Shares 
(or Units)
Purchased
 
(b) Average
Price Paid
per Share
(or Unit)
 
(c) Total Number
of Shares (or
Units) Purchased
as Part of Publicly
Announced Plans
or Programs
 

(d) Maximum
Number (or
Approximate
Dollar Value) of
Shares (or Units)
that May Yet Be
Purchased Under
the Plans or
Programs
 
April 1, 2019 – April 30, 2019
1,204

(1) 
$83.93
(1) 
—

 
$3,950,021,071
 
May 1, 2019 – May 31, 2019
1,371

(1) 
$77.84
(1) 
—

 
$3,950,021,071
 
June 1, 2019 – June 30, 2019
1,138

(1) 
$77.58
(1) 
—

 
$3,950,021,071
 
Total
3,713

(1) 
$79.74
(1) 
—

 
$3,950,021,071
 

1.
In addition to AbbVie shares repurchased on the open market under a publicly announced program, if any, these shares also included the shares purchased on the open market for the benefit of participants in the AbbVie Employee Stock Purchase Plan – 1,204 in April; 1,371 in May; and 1,138 in June.

These shares do not include the shares surrendered to AbbVie to satisfy minimum tax withholding obligations in connection with the vesting or exercise of stock-based awards.

2019 Form 10-Q | abbvieimage2a12.gif
37



ITEM 6. EXHIBITS
 

Exhibits 32.1 and 32.2 are furnished herewith and should not be deemed to be “filed” under the Securities Exchange Act of 1934.

Exhibit No.
 
Exhibit Description
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
101
 
The following financial statements and notes from the AbbVie Inc. Quarterly Report on Form 10-Q for the quarter ended June 30, 2019, filed on August 5, 2019, formatted in iXBRL (Inline eXtensible Business Reporting Language): (i) Condensed Consolidated Statements of Earnings; (ii) Condensed Consolidated Statements of Comprehensive Income; (iii) Condensed Consolidated Balance Sheets; (iv) Condensed Consolidated Statements of Equity; (v) Condensed Consolidated Statements of Cash Flows; and (vi) the Notes to Condensed Consolidated Financial Statements.

_______________________________________________________________________________
*  Incorporated herein by reference. Commission file number 001-35565.
** Denotes management contract or compensatory plan or arrangement required to be filed as an exhibit hereto.

 


2019 Form 10-Q | abbvieimage2a12.gif
38



SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


 
 
ABBVIE INC.
 
 
 
 
 
 
 
By:
/s/ Robert A. Michael
 
 
Robert A. Michael
 
 
Executive Vice President,
 
 
Chief Financial Officer


Date: August 5, 2019

2019 Form 10-Q | abbvieimage2a12.gif
39

 EX-10.2 2 abbv-20190630xex102.htm EXHIBIT 10.2 Exhibit
Exhibit 10.2

ABBVIE SUPPLEMENTAL PENSION PLAN
(Amended and Restated Effective as of January 1, 2019)




ABBVIE
SUPPLEMENTAL PENSION PLAN
SECTION 1
INTRODUCTION
1-1.    The Board of Directors of AbbVie Inc. (“AbbVie”) adopted this AbbVie Supplemental Pension Plan (the “Supplemental Plan” or “Plan”) effective as of January 1, 2013. The Plan provides for payment of (a) pension benefits calculated under the AbbVie Pension Plan (the “Pension Plan”) in excess of those which may be paid under that plan under the limits imposed by Section 415 of the U.S. Internal Revenue Code, as amended (the “Code”), and the Employee Retirement Income Security Act, as amended (“ERISA”), and (b) the additional pension benefits that would be payable under the Pension Plan if deferred awards under certain AbbVie non-qualified deferred compensation plans were included in “final earnings” as defined in the Pension Plan. The Plan is hereby amended and restated effective as of January 1, 2019.
1-2.    The Supplemental Plan shall apply to employees of AbbVie and its subsidiaries and affiliates existing as of the date of adoption of the Supplemental Plan or thereafter created or acquired. AbbVie and each of such subsidiaries and affiliates are hereinafter referred to as an “employer” and collectively as the “employers.”
1-3.    All benefits provided under the Supplemental Plan shall be provided from the general assets of the employers and not from any trust fund or other designated asset. All participants in the Supplemental Plan shall be general creditors of the employers with no priority over other creditors.
1-4.    The Supplemental Plan shall be administered by the AbbVie Employee Benefit Board of Review appointed and acting under the Pension Plan (the “Board of Review”). Except as stated below, the Board of Review shall perform all powers and duties with respect to the Supplemental Plan, including the power to direct payment of benefits, allocate costs among employers, adopt amendments and determine questions of interpretation. The Board of Directors of AbbVie (the “Board of Directors”) shall have the sole authority to terminate the Supplemental Plan.
1-5.    As part of the Separation and Distribution Agreement by and between Abbott Laboratories and AbbVie Inc. dated as of November 28, 2012, Abbott Laboratories (“Abbott”) and AbbVie entered into the Employee Matters Agreement dated as of December 31, 2012 (the “EMA”). In accordance with the EMA, all liabilities for AbbVie Employees (as defined in the EMA) under the Abbott Laboratories Supplemental Pension Plan were transferred to the Plan and the Plan became liable to pay all such benefits to such participants. Supplement A to the Plan sets forth the additional rules applicable to the transferred benefits and transferred participants.

1



SECTION 2
ERISA PENSION PLAN SUPPLEMENTAL BENEFIT
2-1.    The benefits described in this Section 2 shall apply to all participants in the Pension Plan who retire, or terminate with a vested pension, under that plan on or after January 1, 2013.
2-2.    Each Pension Plan participant whose retirement or vested pension under that plan would otherwise be limited by Code Section 415 shall receive a supplemental pension under this Supplemental Plan in an amount which, when added to his or her Pension Plan benefit (calculated as if such benefit had been payable based on the distribution rules established hereunder and the pension form selected by the participant as permitted by subsections 8-3 and 8-4), will equal the amount the participant would be entitled to under the Pension Plan as in effect from time to time, calculated as if such benefit had been payable based on the distribution rules established hereunder and the pension form selected by the participant as permitted by subsections 8-3 and 8-4, without regard to the limitations imposed by Code Section 415.
SECTION 3
1986 TAX REFORM ACT SUPPLEMENTAL BENEFIT
3-1.    The benefits described in this Section 3 shall apply to all participants in the Pension Plan who retire or terminate on or after January 1, 2013 with a vested pension under that plan.
3-2.    Each Pension Plan participant shall receive a supplemental pension under this Supplemental Plan in an amount determined as follows:
(a)    The supplemental pension shall be the difference, if any, between:
(i)the hypothetical monthly benefit that would have been payable under the Pension Plan based on the distribution rules established hereunder and the pension form selected by the participant as permitted by subsections 8-3 and 8-4 plus any supplement provided by Section 2; and
(ii)the hypothetical monthly benefit that would have been payable under the Pension Plan, calculated based on the distribution rules established hereunder and the pension form selected by the participant as permitted by subsections 8-3 and 8-4 (without regard to the limits imposed by Code Section 415) if the participant’s “final earnings,” as defined in the Pension Plan, had included compensation in excess of the limits imposed by Code Section 401(a)(17), and any “pre-tax contributions” made by the participant under the AbbVie Supplemental Savings Plan.

2



SECTION 4
DEFERRED COMPENSATION PLAN PENSION PLAN SUPPLEMENTAL BENEFIT
4-1.    The benefits described in this Section 4 shall apply to all participants in the Pension Plan who retire or terminate on or after January 1, 2013 with a vested pension under that plan, and who made a Deferral Election under the AbbVie Deferred Compensation Plan (the “Deferred Compensation Plan”) with respect to any calendar month during the one hundred twenty consecutive calendar months immediately preceding retirement or termination of employment.
4-2.    Each Pension Plan participant shall receive a supplemental pension under this Supplemental Plan in an amount determined as follows:
(a)    The supplemental pension shall be the difference, if any, between:
(i)the hypothetical monthly benefit that would have been payable under the Pension Plan based on the distribution rules established hereunder and the pension form selected by the participant as permitted by subsections 8-3 and 8-4 plus any supplement provided by Section 2 and Section 3; and
(ii)the hypothetical monthly benefit that would have been payable under the Pension Plan, calculated based on the distribution rules established hereunder and the pension form selected by the participant as permitted by subsections 8-3 and 8-4 (without regard to the limits imposed by Code Section 415) if the participant’s “base earnings,” as defined in the Pension Plan, included deferrals made under the Deferred Compensation Plan and any compensation in excess of the limits imposed by Code Section 401(a)(17).
SECTION 5
DEFERRED MIP PENSION PLAN SUPPLEMENTAL BENEFIT
5-1.    The benefits described in this Section 5 shall apply to all participants in the Pension Plan who retire or terminate on or after January 1, 2013 with a vested pension under that plan and who received Management Incentive Plan awards for any calendar year during the ten consecutive calendar years ending with the year of retirement or termination of employment.
5-2.    Each Pension Plan participant shall receive a supplemental pension under this Supplemental Plan in an amount determined as follows:
(a)    The supplemental pension shall be the difference, if any, between:
(i)the hypothetical monthly benefit that would have been payable under the Pension Plan based on the distribution rules established hereunder and the pension form selected by the participant as permitted by subsections 8-3 and 8-4 plus any supplement provided by Section 2, Section 3, and Section 4; and
(ii)the hypothetical monthly benefit that would have been payable under the Pension Plan, calculated based on the distribution rules established hereunder

3



and the pension form selected by the participant as permitted by subsections 8-3 and 8-4 (without regard to the limits imposed by Code Section 415) if the participant’s “final earnings,” as defined in the Pension Plan, were one-sixtieth of the sum of:
a.the participant’s total “basic earnings” (excluding any payments under the Management Incentive Plan, any division incentive plan or any comparable incentive plan) received in the sixty consecutive calendar months for which his or her basic earnings (excluding any payments under the Management Incentive Plan, any division incentive plan or any comparable incentive plan) were highest; and
b.the amount of the participant’s total awards under the Management Incentive Plan, any division incentive plan and any comparable incentive plan (whether paid immediately or deferred) made for the five consecutive calendar years during the ten consecutive calendar years ending with the year of retirement or termination for which such amount is the greatest and (for participants granted Management Incentive Plan awards for less than five consecutive calendar years during such ten year period) which include all Management Incentive Plan awards granted for consecutive calendar years within such ten year period.
(b)    That portion of any Management Incentive Plan award which the Compensation Committee of the Board of Directors of AbbVie (“Committee”) has determined shall be excluded from the participant’s “basic earnings” shall be excluded from the calculation of “final earnings” for purposes of this subsection 5-2. “Final earnings” for purposes of this subsection 5-2 shall include any compensation in excess of the limits imposed by Code Section 401(a)(17).
(c)    In the event the period described in subsection 5-2(a)(ii)(B) is the final five calendar years of employment and a Management Incentive Plan award is made to the participant subsequent to retirement for the participant’s final calendar year of employment, the supplemental pension shall be adjusted by adding such new award and subtracting a portion of the earliest Management Incentive Plan award included in the calculation, from the amount determined under subsection 5-2(a)(ii)(B). The portion subtracted shall be equal to that portion of the participant’s final calendar year of employment during which the participant was employed by AbbVie.
(d)    Under no circumstance shall the total supplemental pension benefit of any participant who previously received distributions from the Supplemental Plan be less than the amount that would have been payable under section 5-2(a) had such participant retired as of December 31 of any prior year, determined pursuant to the applicable actuarial assumptions in effect on that date.

4



SECTION 6
CORPORATE OFFICER PENSION PLAN SUPPLEMENTAL BENEFIT
6-1.    The benefits described in this Section 6 shall apply to all participants in the Pension Plan who are corporate officers of AbbVie as of January 1, 2013 or who become corporate officers thereafter, and who retire or terminate with a vested pension under that plan on or after January 1, 2013. The term “corporate officer” for purposes of this Supplemental Plan shall mean an individual elected an officer of AbbVie by its Board of Directors (or designated as such for purposes of this Section 6 by the Compensation Committee), but shall not include assistant secretaries, assistant treasurers or other assistant officers.
6-2.    Subject to the limitations and adjustments described below, each participant described in subsection 6-1 shall receive a monthly supplemental pension under this Supplemental Plan commencing on the date determined in accordance with subsection 8-2 and payable as a life annuity, equal to 6/10 of 1 percent (.006) of the participant’s final earnings (as determined under subsection 5-2) for each of the first twenty years of the participant’s benefit service (as defined in the Pension Plan) occurring after the participant’s attainment of age 35.
6-3.    In no event shall the sum of (a) the participant’s aggregate percentage of final earnings calculated under subsection 6-2 and (b) the participant’s aggregate percentage of final earnings calculated under subsection 5.1 of the Pension Plan, excluding 5.1(a)(ii)(B), exceed the maximum aggregate percentage of final earnings allowed under subsection 5.1 (also excluding 5.1(a)(ii)(B)) of the Pension Plan (without regard to any limits imposed by the Internal Revenue Code), as in effect on the date of the participant’s retirement or termination. In the event the limitation described in this subsection 6-3 would be exceeded for any participant, the participant’s aggregate percentage calculated under subsection 6-2 shall be reduced until the limit is not exceeded.
6-4.    Benefit service occurring between the date a participant ceases to be a corporate officer of AbbVie and the date the participant again becomes a corporate officer of AbbVie shall be disregarded in calculating the participant’s aggregate percentage under subsection 6-2.
6-5.    Any supplemental pension otherwise due a participant under this Section 6 shall be reduced by the amount (if any) by which:
(a)    the hypothetical benefits that would be payable to such participant under the Pension Plan, based on the distribution rules established hereunder and the pension form selected by the participant as permitted by subsections 8-3 and 8-4, and this Supplemental Plan exceeds
(b)    the hypothetical maximum benefit that would be payable to the participant under the Pension Plan, calculated based on the distribution rules established hereunder and the pension form selected by the participant as permitted by subsections 8-3 and 8-4 (without regard to the limits imposed by Code Section 415) based on the participant’s final earnings (as determined under subsection 5-2), if the participant had accrued the maximum benefit service recognized by the Pension Plan.

5



6-6.    Any supplemental pension due a participant under this Section 6 shall be actuarially adjusted as provided in the Pension Plan to reflect the pension form selected by the participant as permitted by subsections 8-3 and 8-4 and the participant’s age at commencement of the pension as provided in Section 7.
SECTION 7
CORPORATE OFFICER PENSION PLAN
SUPPLEMENTAL EARLY RETIREMENT BENEFIT
7-1.    The benefits described in this Section 7 shall apply to all persons described in subsection 6-1.
7-2.    The supplemental pension due under Sections 2, 3, 4, 5 and 6 to each participant described in subsection 7-1 shall be reduced in accordance with the rules provided in subsections 5-3 and 5-6 of the Pension Plan for each month by which its commencement date precedes the last day of the month in which the participant will attain age 60. No reduction will be made for the period between the last day of the months in which the participant will attain age 60 and age 62.
7-3.    Each participant described in subsection 7-1 shall receive a monthly supplemental pension under this Supplemental Plan equal to any hypothetical reduction made in such participant’s Pension Plan pension in accordance with the rules provided in subsections 5.3 and 5.6 of the Pension Plan for the period between the last day of the months in which the participant will attain age 60 and age 62, calculated as if the participant had commenced receipt of the participant’s Pension Plan benefit on the same date on which the participant commences receipt of the participant’s supplemental pension based on the distribution rules established hereunder and the pension form selected by the participant as permitted by subsections 8-3 and 8-4.
SECTION 8
MISCELLANEOUS
8-1.    For purposes of this Supplemental Plan, the term “Management Incentive Plan” shall mean the AbbVie 2013 Management Incentive Plan, the AbbVie 2013 Performance Incentive Plan, the AbbVie Managerial Incentive Plan, and any successor or alternative to any of those plans.
8-2.    The monthly vested supplemental pension described in Sections 2, 3, 4, 5, 6 and 7 shall commence to be paid to the participant or his or her beneficiary on the last day of the month following the month in which:
(a)    For any Transferred Participant or Post-Distribution Participant (both as defined in Supplement A) who has an Old Formula Benefit (as defined in the Pension Plan) under the Pension Plan, the later of the date on which such participant attains age 50 and the date such participant’s employment is terminated; or
(b)    For any Transferred Participant or Post-Distribution Participant (both as defined in Supplement A) who does not have an Old Formula Benefit (as defined in the Pension Plan) under the Pension Plan and any participant who does not fall into the

6



preceding categories hired by AbbVie on or after January 1, 2013, the later of the date on which such participant attains age 55 and the date such participant’s employment is terminated.
Notwithstanding the foregoing provisions of this subsection 8-2, any participant eligible to make an election under Section 9 may make such election with respect to any accruals for services performed in the year following the year such election is made.
Notwithstanding the foregoing provisions of this subsection 8-2, in the event that the present value of participant’s supplemental pension under Sections 2, 3, 4, 5, 6 and 7 does not exceed in the aggregate $25,000 as of the commencement date of the pension payable to such participant or his or her beneficiary, and payment of such supplemental pension has not been previously made under Section 9, the present value of such supplemental pension shall be paid to such participant in a lump sum on such commencement date.
8-3.    Except as otherwise specifically provided, payment of the monthly vested supplemental pension described in Sections 2, 3, 4, 5, 6, and 7 shall be made to a participant as follows:
(a)    Life Annuity. A participant who is not legally married on the date as of which such payments commence shall receive a monthly retirement income or monthly deferred vested benefit in accordance with the plan payable on a life annuity basis, with the last payment to be made for the month in which his or her death occurs.
(b)    50% Joint and Survivor Annuity. A participant who is legally married on the date as of which such payments commence shall receive a 50% joint and survivor annuity which is actuarially equivalent to the amount of monthly retirement income or monthly deferred vested benefit otherwise payable to him or her in accordance with the plan on a life annuity basis. Such joint and survivor annuity shall consist of a reduced monthly retirement income or monthly deferred vested benefit continuing during the participant’s lifetime, and if the participant’s spouse is living at the date of the participant’s death, payment of one-half of such reduced monthly retirement income or monthly deferred vested benefit to such spouse until the spouse’s death occurs, with the last payment to be made for the month of the death of the last to die of the participant and his or her spouse. The joint and survivor annuity payable hereunder to or with respect to a participant who retires on a late retirement date shall be computed as if such participant had retired on his or her normal retirement date using for the age of his or her spouse as of his or her late retirement date, that spouse’s age as of his or her normal retirement date.
8-4.    In lieu of the form and amount of supplemental pension benefit specified in subsection 8-3, a participant may elect, prior to commencement, a supplemental pension benefit which is actuarially equivalent to the form of payment specified in subsection 8-3(a), in the annuity forms permitted by the Board of Review, provided that the scheduled date for the first annuity payment is not changed as a result of such election. For purposes of this provision, the term “actuarially equivalent” shall have the meaning provided by Treasury Regulation §1.409A-2(b)(2)(ii)(A), applying reasonable actuarial methods and assumptions, which must be

7



the same for each annuity payment option and otherwise comply with the rules provided by Treasury Regulation §1.409A-2(b)(2)(ii)(D).
An election under this subsection 8-4 must be in writing, signed by the participant, and filed with the Board of Review at such time and in such manner as the Board of Review shall determine; and will be effective only if the participant’s spouse, if any, consents to the election in writing, and such consent acknowledges the effect of the election and is witnessed by a plan representative or a notary public. In any case where a participant elects an optional form of benefit, the option shall be designed so that more than 50 percent of the actuarial reserve required to provide the participant’s monthly vested supplemental pension benefit in the normal form will be applied to provide the participant’s benefits under the option during the period of the participant’s life expectancy. Payment of an optional form of benefit will commence no later than the date on which the participant’s monthly supplemental pension benefit would otherwise commence. An election under this subsection 8-4 may not be changed after payment of the participant’s supplemental pension benefit has commenced.
8-5.    Notwithstanding any other provision of this Supplemental Plan, if a participant terminates employment within two (2) years following the occurrence of a Change in Control, the present value of his or her supplemental pension under Sections 2, 3, 4 and 5 (but excluding any amounts with respect to which an election under Section 9 has been made, whether or not then payable or vested) shall be paid to such participant in a lump sum, calculated using reasonable actuarial assumptions and methods, within thirty (30) days following the date of such termination of employment; provided that the event constituting a Change in Control is also a “change in control event,” as such term is defined in Treasury Regulation § 1.409A-3(i)(5). The supplemental pension under Section 2 shall be computed using as the applicable limit under Code Section 415, such limit as is in effect on the termination date and based on the assumption that the participant will receive his or her supplemental pension in the form of a straight life annuity with no ancillary benefits. The present values of the supplemental pensions under Sections 2, 3, 4 and 5 shall be computed as of the date of payment using an interest rate equal to the Pension Benefit Guaranty Corporation interest rate applicable to an immediate annuity, as in effect on the date of payment.
8-6.    For purposes of subsection 8-5, a “Change in Control” shall be deemed to have occurred on the earliest of the following dates:
(a)    the date any Person is or becomes the Beneficial Owner, directly or indirectly, of securities of AbbVie (not including in the securities beneficially owned by such Person any securities acquired directly from AbbVie or its Affiliates) representing 20% or more of the combined voting power of AbbVie’s then outstanding securities, excluding any Person who becomes such a Beneficial Owner in connection with a transaction described in clause (i) of paragraph (c) below; or
(b)    the date the following individuals cease for any reason to constitute a majority of the number of directors then serving: individuals who, on the date hereof, constitute the Board of Directors and any new director (other than a director whose initial assumption of office is in connection with an actual or threatened election contest, including but not limited to a consent solicitation, relating to the election of directors of

8



AbbVie) whose appointment or election by the Board of Directors or nomination for election by AbbVie’s shareholders was approved or recommended by a vote of at least two-thirds (2/3) of the directors then still in office who either were directors on the date hereof or whose appointment, election or nomination for election was previously so approved or recommended; or
(c)    the date on which there is consummated a merger or consolidation of AbbVie or any direct or indirect subsidiary of AbbVie with any other corporation or other entity, other than (i) a merger or consolidation (A) immediately following which the individuals who comprise the Board of Directors immediately prior thereto constitute at least a majority of the Board of Directors of AbbVie, the entity surviving such merger or consolidation or, if AbbVie or the entity surviving such merger or consolidation is then a subsidiary, the ultimate parent thereof and (B) which results in the voting securities of AbbVie outstanding immediately prior to such merger or consolidation continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or any parent thereof), in combination with the ownership of any trustee or other fiduciary holding securities under an employee benefit plan of AbbVie or any subsidiary of AbbVie, at least 50% of the combined voting power of the securities of AbbVie or such surviving entity or any parent thereof outstanding immediately after such merger or consolidation, or (ii) a merger or consolidation effected to implement a recapitalization of AbbVie (or similar transaction) in which no Person is or becomes the Beneficial Owner, directly or indirectly, of securities of AbbVie (not including in the securities Beneficially Owned by such Person any securities acquired directly from AbbVie or its Affiliates) representing 20% or more of the combined voting power of AbbVie’s then outstanding securities; or
(d)    the date the shareholders of AbbVie approve a plan of complete liquidation or dissolution of AbbVie or there is consummated an agreement for the sale or disposition by AbbVie of all or substantially all of AbbVie’s assets, other than a sale or disposition by AbbVie of all or substantially all of AbbVie’s assets to an entity, at least 50% of the combined voting power of the voting securities of which are owned by shareholders of AbbVie, in combination with the ownership of any trustee or other fiduciary holding securities under an employee benefit plan of AbbVie or any subsidiary of AbbVie, in substantially the same proportions as their ownership of AbbVie immediately prior to such sale.
Notwithstanding the foregoing, a “Change in Control” shall not be deemed to have occurred by virtue of the consummation of any transaction or series of integrated transactions immediately following which the record holders of the common stock of AbbVie immediately prior to such transaction or series of transactions continue to have substantially the same proportionate ownership in an entity which owns all or substantially all of the assets of AbbVie immediately following such transaction or series of transactions.
For purposes of this Supplemental Plan: “Affiliate” shall have the meaning set forth in Rule 12b-2 promulgated under Section 12 of the Exchange Act; “Beneficial Owner” shall have the

9



meaning set forth in Rule 13d-3 under the Exchange Act; “Exchange Act” shall mean the Securities Exchange Act of 1934, as amended from time to time; and “Person” shall have the meaning given in Section 3(a)(9) of the Exchange Act, as modified and used in Sections 13(d) and 14(d) thereof, except that such term shall not include (i) AbbVie or any of its subsidiaries, (ii) a trustee or other fiduciary holding securities under an employee benefit plan of AbbVie or any of its Affiliates, (iii) an underwriter temporarily holding securities pursuant to an offering of such securities, or (iv) a corporation owned, directly or indirectly, by the shareholders of AbbVie in substantially the same proportions as their ownership of stock of AbbVie.
8-7.    POTENTIAL CHANGE IN CONTROL. A “Potential Change in Control” shall exist during any period in which the circumstances described in paragraphs (a), (b), (c) or (d), below, exist (provided, however, that a Potential Change in Control shall cease to exist not later than the occurrence of a Change in Control):
(a)    AbbVie enters into an agreement, the consummation of which would result in the occurrence of a Change in Control, provided that a Potential Change in Control described in this paragraph (a) shall cease to exist upon the expiration or other termination of all such agreements.
(b)    Any Person (without regard to the exclusions set forth in subsections (i) through (iv) of such definition) publicly announces an intention to take or to consider taking actions the consummation of which would constitute a Change in Control; provided that a Potential Change in Control described in this paragraph (b) shall cease to exist upon the withdrawal of such intention, or upon a determination by the Board of Directors that there is no reasonable chance that such actions would be consummated.
(c)    Any Person becomes the Beneficial Owner, directly or indirectly, of securities of AbbVie representing 10% or more of either the then outstanding shares of common stock of AbbVie or the combined voting power of AbbVie’s then outstanding securities (not including any securities beneficially owned by such Person which are or were acquired directly from AbbVie or its Affiliates).
(d)    The Board of Directors adopts a resolution to the effect that, for purposes of this Agreement, a Potential Change in Control exists; provided that a Potential Change in Control described in this paragraph (d) shall cease to exist upon a determination by the Board of Directors that the reasons that gave rise to the resolution providing for the existence of a Potential Change in Control have expired or no longer exist.
8-8.    The provisions of subsections 8-5, 8-6, 8-7 and this subsection 8-8 may not be amended or deleted, nor superseded by any other provision of this Supplemental Plan, (a) during the pendency of a Potential Change in Control and (b) during the period beginning on the date of a Change in Control and ending on the date five (5) years following such Change in Control.
8-9.    All benefits due under this Supplemental Plan shall be paid by AbbVie and AbbVie shall be reimbursed for such payments by the employee’s employer. In the event the employee is employed by more than one employer, each employer shall reimburse AbbVie in proportion to the

10



period of time the employee was employed by such employer, as determined by the Board of Review in its sole discretion.
8-10.    The benefits under the Supplemental Plan are not in any way subject to the debts or other obligations of the persons entitled to benefits and may not be voluntarily or involuntarily sold, transferred or assigned.
8-11.    Nothing contained in this Supplemental Plan shall confer on any employee the right to be retained in the employ of AbbVie or any of its subsidiaries or affiliates.
8-12.    Upon adoption of this Supplemental Plan, the prior resolutions shall be deemed rescinded.
8-13.    A participant shall not become vested in the participant’s supplemental pension under Sections 2, 3, 4, 5, 6 and 7 until the participant has attained sixty (60) months of vesting service. For purposes of the Supplemental Plan, a participant shall be entitled to 1/12th of a year of vesting service for each calendar month (or portion thereof) during which the participant is employed by an employer. The payments required by Section 8 or Section 9 of the Supplemental Plan shall, in each case, relate only to the vested portion of a participant’s supplemental pension.
8-14.    To the extent applicable, it is intended that the Supplemental Plan comply with the provisions of Code Section 409A. The Supplemental Plan will be administered and interpreted in a manner consistent with this intent, and any provision that would cause the Supplemental Plan to fail to satisfy Code Section 409A will have no force and effect until amended to comply therewith (which amendment may be retroactive to the extent permitted by Code Section 409A). Notwithstanding anything contained herein to the contrary, a participant shall not be considered to have terminated employment with AbbVie or any employer hereunder for purposes of the Supplemental Plan and no payments shall be due under Supplemental Plan which are payable upon the participant’s termination of employment unless the participant would be considered to have incurred a “separation from service” from AbbVie within the meaning of Code Section 409A. To the extent required to avoid accelerated taxation and/or tax penalties under Code Section 409A and applicable guidance issued thereunder, amounts that would otherwise be payable pursuant to the Supplemental Plan during the six-month period immediately following the participant’s termination of employment shall instead be paid on the first business day after the date that is six months following the participant’s termination of employment (or upon the participant’s death, if earlier), plus interest thereon, at a rate equal to the applicable “Federal short-term rate” (as defined in Code Section 1274(d)) for the month in which such termination of employment occurs (to the extent that such interest is not already provided to the participant under subsection 9-8), from the respective dates on which such amounts would otherwise have been paid until the actual date of payment. With respect to expenses eligible for reimbursement under the terms of the Supplemental Plan, (a) the amount of such expenses eligible for reimbursement in any taxable year shall not affect the expenses eligible for reimbursement in another taxable year and (b) any reimbursements of such expenses shall be made no later than the end of the calendar year following the calendar year in which the related expenses were incurred, except, in each case, to the extent that the right to reimbursement does not provide for a “deferral of compensation” within the meaning of Code Section 409A.

11



8-15.    In accordance with Treasury Regulation § 1.409A-3(j)(4)(ii), distributions shall be made to an individual (other than to the participant) pursuant to the terms of a “domestic relations order” (as defined in Internal Revenue Code Section 414(p)(1)(B)), as determined and administered by the AbbVie Senior Vice President, Human Resources (or the individual holding equivalent duties and responsibilities) or his or her delegate, provided that such order (a) does not require the plan to provide any type or form of benefit, or any option not otherwise provided under the plan, (b) does not require the plan to provide increased benefits, and (c) does not require the payment of benefits to an alternate payee which are required to be paid to another alternate payee under another order.
SECTION 9
ALTERNATE PAYMENT OF SUPPLEMENTAL PENSIONS
The provisions of this Section 9 shall apply only to corporate officers who became Plan participants before January 1, 2015.
9-1.    A participant who is actively employed by AbbVie as a corporate officer as of December 31 of his or her first year as a corporate officer shall be entitled to receive payment of the present value of the vested supplemental pension described in Sections 2, 3, 4, 5, 6 and 7 which accrues with respect to the year and shall elect to receive such payment by either of the following methods: (a) current payment in cash directly to the participant, or (b) current payment of a portion of such present value in cash for the participant directly to a Grantor Trust established by the participant, determined to be substantially similar to the form of Grantor Trust attached hereto as Exhibit A, and current payment of the balance of such present value in cash paid directly to or withheld on behalf of the participant equal to the aggregate federal, state and local individual income and employment taxes owed with respect to the gross payment (as determined in accordance with subsection 9-10). The payment of any amount provided under this subsection 9-1 shall be made to the Grantor Trust established by the participant within the thirty (30)-day period beginning April 1 of the year following the year in which such present value is accrued.
9-2.    For each year subsequent to the year in which a participant becomes a corporate officer, if the present value of a participant’s vested and accrued supplemental pension has been paid to the participant (including amounts paid to the participant’s Grantor Trust) pursuant to subsection 9-1 then, with respect to each subsequent year of active participation, as of that December 31, a participant shall be entitled to a payment in an amount equal to (i) the present value (as of that December 31) of the participant’s vested supplemental pension described in Sections 2, 3, 4, 5, 6 and 7, less (ii) the current value (as of that December 31) of the payments previously made to the participant under subsections 9-1 and 9-2 (if any). Each year a participant who is a corporate officer may elect to receive payment of the amounts described in subparagraphs (i) and (ii) above for the year by either of the following methods: (a) current payment in cash directly to the participant, or (b) current payment of such amount in cash for the participant directly to a Grantor Trust established by the participant (less the aggregate federal, state and local individual income and employment taxes paid to or withheld on behalf of the participant (as determined in accordance with subsection 9-10)). The payment of any amount provided under this subsection 9-2 shall be made to the Grantor Trust established by the participant within the thirty

12



(30)-day period beginning April 1 of the year following the year in which such present value is accrued. No payments shall be made under this subsection 9-2 as of any December 31 after the calendar year in which the participant retires or otherwise terminates employment with AbbVie.
9-3.    Present values for the purposes of subsections 9-1 and 9-2 shall be determined using reasonable actuarial assumptions specified for this purpose by AbbVie and consistently applied in accordance with the requirements of Treasury Regulation §1.409A-2(b)(2)(ii)(D). The “current value” of the payments previously made to a participant under subsection 9-2 means the aggregate amount of such payments, with interest thereon (at the rate specified in subsection 9-7).
9-4.    AbbVie, as the administrator of the participant’s Grantor Trust, may direct the trustee to distribute to the participant from the income of such Grantor Trust an amount sufficient to pay the taxes on the Grantor Trust earnings for such year, to the extent a sufficient sum of money has not been paid to, or withheld on behalf of, the participant pursuant to subsection 9-8. The taxes shall be determined in accordance with subsection 9-10.
9-5.    Except as provided in subsection 9-9, a participant shall be deemed to have irrevocably waived and shall be foreclosed from any right to receive any supplemental pension benefits on that portion of the supplemental pension that the participant elects to be paid in cash under subsection 9-1 or 9-2. A participant who has elected to receive a payment under subsection 9-1 or 9-2 to a Grantor Trust must establish such trust in a form which AbbVie determines to be substantially similar to the trust attached to this Supplemental Plan as Exhibit A. If a participant fails to make an election under subsection 9-1 or 9-2, or if a participant makes an election under subsection 9-1 or 9-2 to receive payment in a Grantor Trust but fails to establish a Grantor Trust, then payment shall be made in cash directly to the participant.
9-6.    AbbVie will establish and maintain a separate Supplemental Pension Account in the name of each participant, a separate After-Tax Supplemental Pension Account in the name of each participant, and a separate Tax Payment Account in the name of each participant. The Supplemental Pension Account shall reflect any amounts: (a) paid to, or withheld on behalf of, a participant to satisfy the aggregate federal, state and local individual income and employment taxes (including amounts paid to a participant’s Grantor Trust) pursuant to subsections 9-1 and 9-2 and (b) disbursed to a participant for supplemental pension benefits (or which would have been disbursed to a participant if the participant had not elected to receive a cash disbursement pursuant to subsections 9-1 and 9-2). The After-Tax Supplemental Pension Account shall also reflect such amounts but shall be maintained on an after-tax basis. The accounts established pursuant to this subsection 9-6 are for administrative convenience, and no trust relationship with respect to such accounts is intended or should be implied.
9-7.    As of the end of each calendar year, a participant’s Supplemental Pension Account shall be credited with interest calculated at the rate of eight percent (8%) per year. Any amount so credited shall be referred to as a participant’s “Interest Accrual.” The calculation of the Interest Accrual shall be based on the balance of the payments made pursuant to subsections 9-1 and 9-2 and any Interest Accrual thereon from previous years. As of the end of each calendar year a participant’s After-Tax Supplemental Pension Account shall be credited with interest which shall be referred to as the After-Tax Interest Accrual. The “After-Tax Interest Accrual” shall be an

13



amount equal to the product of (a) the Interest Accrual credited to the participant’s Supplemental Pension Account for such year multiplied by (b) one minus the aggregate of the federal, state, and local individual income tax rates and employment tax rate (determined in accordance with subsection 9-10).
9-8.    In addition to any payment made to a participant for a calendar year pursuant to subsections 9-1 and 9-2, a participant shall also be entitled to a payment (an “Interest Payment”) for each year in which the Grantor Trust is in effect. For all participants who are Transferred Participants under Supplement A, the Interest Payment shall equal the excess of the gross amount of the participant’s Interest Accrual (as defined in subsection 9-7), over the net income of the participant’s Grantor Trust for the year, as adjusted by the amounts described in Schedule A, and shall be paid within the thirty (30)-day period beginning April 1 of the following fiscal year. A portion of such Interest Payment, equal to the excess, if any, of the Net Interest Accrual over the net earnings of the participant’s Grantor Trust, shall be deposited in the participant’s Grantor Trust, with the balance paid to, or withheld on behalf of, the Participant; provided, however, in the event that the net earnings of the participant’s Grantor Trust exceeds the Net Interest Accrual, a distribution from the Grantor Trust shall be required in accordance with subsection 9-4. A participant’s Net Interest Accrual for a year is an amount equal to the After-Tax Interest Accrual credited to the participant’s After-Tax Supplemental Pension Account for that year in accordance with subsection 9-7. No payments shall be made under this subsection 9-8 for any year following the year in which the participant dies, retires or otherwise terminates employment with AbbVie.
9-9.    In addition to and notwithstanding the payments made to a participant’s Grantor Trust under subsections 9-1 and 9-2 and subject only to the subsequent election requirements of Treasury Regulation § 1.409A-2(b), AbbVie shall make the monthly vested supplemental pension payments that would have been payable to the participant had no payments been made to the participant’s Grantor Trust under subsections 9-1 and 9-2 in the form provided by subsection 8-3. The monthly vested supplemental pension payments hereunder shall commence on the first business day of February following the sixth anniversary of the participant’s termination of employment and ending with the month of the participant’s (or surviving spouse’s) death. By way of example, (a) if a participant terminated employment on June 1, 2013, the commencement date would be the first business day in February, 2020, and (b) if a participant terminated employment on January 15, 2013, the commencement date would be the first business day in February, 2019. Payments under this subsection 9-9 shall be made by the employers (in such proportions as AbbVie shall designate) directly from their general corporate assets. Payment of the annuity required by this subsection 9-9 may be deferred by AbbVie in compliance with the subsequent election requirements of Treasury Regulation § 1.409A-2(b). Any election to defer payment hereunder shall not take effect until at least 12 months after the election is made; shall be made not less than 12 months before the annuity commencement date; and shall require payment to be deferred for a period of no less than five years from such annuity commencement date.
9-10.    For purposes of this Supplemental Plan, a participant’s federal income tax rate shall be deemed to be the highest marginal rate of federal individual income tax in effect in the calendar year in which a calculation under this Supplemental Plan is to be made; state and local tax rates shall be deemed to be the highest marginal rates of individual income tax in effect in the state and

14



locality of the participant’s residence in the calendar year for which such a calculation is to be made; and a participant’s employment tax rate shall be deemed to be the highest marginal rate of Federal Insurance Contributions Act tax in effect in the calendar year for which such a calculation is to be made, net of any federal tax benefits without a benefit for any net capital losses. Any employer shall be entitled, if necessary or desirable, to pay, or withhold the amount of any federal, state or local tax, attributable to any amounts payable by it under the Supplemental Plan, and may require payment or indemnification from the participant in an amount necessary to satisfy such taxes prior to remitting such taxes.
9-11.    Each participant’s Grantor Trust assets shall be invested solely in the instruments specified by investment guidelines established by the Committee. Such investment guidelines, once established, may be changed by the Committee, provided that any change shall not take effect until the year following the year in which the change is made and provided further that the instruments specified shall be consistent with the provisions of Section 3(b) of the form of Grantor Trust attached hereto as Exhibit A.
9-12.    Notwithstanding anything contained in the Supplemental Plan to the contrary, the Grantor Trusts established by the participants under the Supplemental Plan shall be funded in accordance with the requirements of Code Section 409A.



15



SUPPLEMENT A

SPECIAL RULES RELATED TO TRANSFER FROM ABBOTT LABORATORIES SUPPLEMENTAL PENSION PLAN

A-1.    Purpose and Effect. The purpose of this Supplement A is to provide for the transfer of liabilities from the Abbott Laboratories Supplemental Pension Plan (the “Abbott SERP”) to this Supplemental Plan with respect to Transferred Participants and Post-Distribution Participants as set forth in the Separation Agreement.
A-2.    Eligibility, Service and Compensation. Transferred Participants and Post-Distribution Participants shall (a) be eligible to participate in the AbbVie SERP to the extent they were eligible to participate in the Abbott SERP as of the applicable Transfer Date (as defined in the EMA), and (b) receive credit for vesting, eligibility and benefit service for all service credited for those purposes under the Abbott SERP as of the Transfer Date (as defined in the EMA) as if that service had been rendered to AbbVie (provided that in the event that any such Transferred Participant or Post-Distribution Participant receives a distribution from the Abbott SERP, the value of such distribution shall be offset against future benefits under the AbbVie SERP to the extent necessary to prevent a duplication of benefits). The compensation paid by Abbott and its subsidiaries to a Transferred Participant or a Post-Distribution Participant that was recognized under the Abbott SERP as of the Transfer Date (as defined in the EMA) shall be credited and recognized for all applicable purposes under the AbbVie SERP as though it were compensation from AbbVie or its Subsidiaries.
A-3.    Time and Form of Payment. The accrued benefit of each Transferred Participant and each Post-Distribution Participant under the Abbott SERP as of the applicable Transfer Date (as defined in the EMA) shall be payable under the AbbVie SERP at the time and in a form that would have been permitted under the Abbott SERP as in effect as of such Transfer Date (as defined in the EMA), with employment by Abbott or its subsidiaries prior to the Transfer Date (as defined in the EMA) treated as employment by the AbbVie or its affiliates under the AbbVie SERP for purposes of determining eligibility for optional forms of benefit, early retirement benefits, or other benefit forms; and the AbbVie SERP shall assume and honor the terms of all arrangements relating to beneficiaries and alternate payees in effect and honored under the Abbott SERP as of the applicable Transfer Date with respect to Transferred Participants and Post Distribution Participants.
A-4.    Initial Transfer of Liabilities from Abbott SERP. As soon as practicable after the Separation, and subject to such terms and conditions as the Plan Administrator may establish, the Plan shall assume all liabilities and the Abbott SERP shall transfer all liabilities for all obligations under the Abbott SERP for the benefits of Transferred Participants (and their beneficiaries and/or alternate payees) as determined on the applicable Transfer Date (as defined in the EMA).
A-5.    Subsequent Transfers. At such time or times as the Plan Administrator and Abbott (or its delegate) shall agree, and subject to such terms and conditions as the Plan Administrator may establish, the Plan shall assume all liabilities and the Abbott SERP shall transfer all liabilities

1



for all obligations under the Abbott SERP for the benefits of Post-Distribution Participants (and their beneficiaries and/or alternate payees) as determined on the applicable Transfer Date (as defined in the EMA).
A-6.    Definitions. For purposes of this Supplement A, the following terms are defined as follows:
(a)
“Post-Distribution Participant” means: (i) a Post-Distribution AbbVie Employee (as defined in the EMA) who (A) was an employee of Abbott Laboratories or its subsidiary as of immediately prior to the Separation (as defined in the Separation Agreement) and is transferred to or hired by AbbVie or its Subsidiary after the Separation (as defined in the Separation Agreement) and (B) had liabilities associated with his or her accrued benefits (including any accrued benefits with respect to beneficiaries or alternate payees) in the Abbott SERP transferred to this Plan in accordance with this Supplement A; and (ii) any other individual on whose behalf liabilities are transferred from an Abbott pension plan to the Pension Plan during the Transition Period (as described in the EMA).
(b)
“Transferred Participant” means an AbbVie Employee or an AbbVie LTD Participant (as defined in the EMA), excluding any Post-Distribution AbbVie Employee (as defined in the EMA), who accepts an offer of employment or continues employment with or is transferred to AbbVie Inc. under the EMA on or immediately after the Separation (as defined in the Separation Agreement).
A-7.    Grantor Trusts. Certain Transferred Participants and Post-Distribution Participants who participated in the Abbott SERP have established grantor trusts in connection with such plan. Abbott and AbbVie shall use their commercially reasonable best efforts to facilitate the amendment of each such grantor trust to provide that (a) AbbVie is the administrator of such trust and (b) distribution of amounts under such trust is made by reference to termination of employment with AbbVie and its subsidiaries and not termination of employment with the Abbott and its subsidiaries.
A-8.    Use of Terms. Terms used in this Supplement A have the meanings of those terms as set forth in the Plan, unless they are defined in this Supplement A. All of the terms and provisions of the Plan shall apply to this Supplement A except that where the terms of the Plan and this Supplement A conflict, the terms of this Supplement A shall govern.


2



SCHEDULE A



[TO BE INSERTED WHEN AMOUNTS ARE AVAILABLE]


1



EXHIBIT A
SUPPLEMENTAL BENEFIT
GRANTOR TRUST

THIS AGREEMENT, made this day of , 20 , by and between (the “grantor”) and The Northern Trust Company, located at Chicago, Illinois, as trustee (the “trustee”),
WITNESSETH THAT:
WHEREAS, the grantor desires to establish and maintain a trust to hold certain benefits received by the grantor under the AbbVie Supplemental Pension Plan, as it may be amended from time to time.
NOW, THEREFORE, IT IS AGREED as follows:
ARTICLE I
INTRODUCTION
I-1NAME. This agreement and the trust hereby evidenced (the “trust”) may be referred to as the “ Supplemental Benefit Grantor Trust.”
I-2THE TRUST FUND. The “trust fund” as at any date means all property then held by the trustee under this agreement.
I-3STATUS OF THE TRUST. The trust shall be irrevocable. The trust is intended to constitute a grantor trust under Sections 671-678 of the Internal Revenue Code, as amended, and shall be construed accordingly.
I-4THE ADMINISTRATOR. AbbVie Inc. (“AbbVie”) shall act as the “administrator” of the trust, and as such shall have certain powers, rights and duties under this agreement as described below. AbbVie will certify to the trustee from time to time the person or persons authorized to act on behalf of AbbVie as the administrator. The trustee may rely on the latest certificate received without further inquiry or verification.
I-5ACCEPTANCE. The trustee accepts the duties and obligations of the “trustee” hereunder, agrees to accept funds delivered to it by the grantor or the administrator, and agrees to hold such funds (and any proceeds from the investment of such funds) in trust in accordance with this agreement.

1



ARTICLE II
DISTRIBUTION OF THE TRUST FUND
II-1SUPPLEMENTAL PENSION ACCOUNT. The administrator shall maintain a “supplemental pension account” under the trust. As of the end of each calendar year, the administrator shall charge the account with all distributions made from the account during that year; and credit the account with its share of trust income and realized gains and charge the account with its share of trust expenses and realized losses for the year.
II-2DISTRIBUTIONS PRIOR TO THE GRANTOR’S DEATH. Principal and accumulated income shall not be distributed from the trust prior to the grantor’s retirement or other termination of employment with AbbVie or a subsidiary of AbbVie (the grantor’s “settlement date”); provided that, each year the administrator may direct the trustee to distribute to the grantor a portion of the income of the trust fund for that year, with the balance of such income to be accumulated in the trust. The administrator shall inform the trustee of the grantor’s settlement date. Thereafter, the trustee shall distribute the amounts from time to time credited to the supplemental pension account to the grantor, if then living, in the same manner, at the same time and over the same period as the pension payable to the grantor under AbbVie Pension Plan.
II-3DISTRIBUTIONS AFTER THE GRANTOR’S DEATH. The grantor, from time to time may name any person or persons (who may be named contingently or successively and who may be natural persons or fiduciaries) to whom the principal of the trust fund and all accrued or undistributed income thereof shall be distributed upon the grantor’s death. The grantor may direct that such amounts be distributed in a lump sum or, if the beneficiary is the grantor’s spouse (or a trust (a “Trust”) for which the grantor’s spouse is the sole income beneficiary), in the same manner, at the same time and over the same period as the pension payable to the grantor’s surviving spouse under the AbbVie Pension Plan. If the grantor directs the same method of distribution as the pension payable to the surviving spouse under the AbbVie Pension Plan to the spouse as beneficiary, any amounts remaining at the death of the spouse beneficiary shall be distributed in a lump sum to the executor or administrator of the spouse beneficiary’s estate. If the grantor directs the same method of distribution as the pension payable to the surviving spouse under the AbbVie Pension Plan to a Trust for which the grantor’s spouse is the sole income beneficiary, any amounts remaining at the death of the spouse shall be distributed in a lump sum to such Trust. Despite the foregoing, if (i) the beneficiary is a Trust for which the grantor’s spouse is the sole income beneficiary, (ii) payments are being made pursuant to this paragraph II-3 other than in a lump sum and (iii) income earned by the trust fund for the year exceeds the amount of the annual installment payment, then such Trust may elect to withdraw such excess income by written notice to the trustee. Each designation shall revoke all prior designations, shall be in writing and shall be effective only when filed by the grantor with the administrator during the grantor’s lifetime. If the grantor fails to direct a method of distribution, the distribution shall be made in a lump sum. If the grantor fails to designate a beneficiary as provided above, then on the grantor’s death, the trustee shall distribute the balance of the trust fund in a lump sum to the executor or administrator of the grantor’s estate.”

2



II-4FACILITY OF PAYMENT. When a person entitled to a distribution hereunder is under legal disability, or, in the trustee’s opinion, is in any way incapacitated so as to be unable to manage his or her financial affairs, the trustee may make such distribution to such person’s legal representative, or to a relative or friend of such person for such person’s benefit. Any distribution made in accordance with the preceding sentence shall be a full and complete discharge of any liability for such distribution hereunder.
II-5PERPETUITIES. Notwithstanding any other provisions of this agreement, on the day next preceding the end of 21 years after the death of the last to die of the grantor and the grantor’s descendants living on the date of this instrument, the trustee shall immediately distribute any remaining balance in the trust to the beneficiaries then entitled to distributions hereunder.
ARTICLE III
MANAGEMENT OF THE TRUST FUND
III-1GENERAL POWERS. The trustee shall, with respect to the trust fund, have the following powers, rights and duties in addition to those provided elsewhere in this agreement or by law:
(a)Subject to the limitations of subparagraph (b) next below, to sell, contract to sell, purchase, grant or exercise options to purchase, and otherwise deal with all assets of the trust fund, in such way, for such considerations, and on such terms and conditions as the trustee decides.
(b)To invest and reinvest the trust fund, without distinction between principal and income, in obligations of the United States Government and its agencies or which are backed by the full faith and credit of the United States Government and in any mutual funds, common trust funds or collective investment funds which invest solely in such obligations, provided that to the extent practicable no more than Ten Thousand Dollars ($10,000) shall be invested in such mutual funds, common trust funds or collective investment funds at any time; and any such investment made or retained by the trustee in good faith shall be proper despite any resulting risk or lack of diversification or marketability.
(c)To deposit cash in any depositary (including the banking department of the bank acting as trustee) without liability for interest, in amounts not in excess of those reasonably necessary to make distributions from the trust.
(d)To borrow from anyone, with the administrator’s approval, such sum or sums from time to time as the trustee considers desirable to carry out this trust, and to mortgage or pledge all or part of the trust fund as security.
(e)To retain any funds or property subject to any dispute without liability for interest and to decline to make payment or delivery thereof until final adjudication by a court of competent jurisdiction or until an appropriate release is obtained.

3



(f)To begin, maintain or defend any litigation necessary in connection with the administration of this trust, except that the trustee shall not be obliged or required to do so unless indemnified to the trustee’s satisfaction.
(g)To compromise, contest, settle or abandon claims or demands.
(h)To give proxies to vote stocks and other voting securities, to join in or oppose (alone or jointly with others) voting trusts, mergers, consolidations, foreclosures, reorganizations, liquidations, or other changes in the financial structure of any corporation, and to exercise or sell stock subscription or conversion rights.
(i)To hold securities or other property in the name of a nominee, in a depositary, or in any other way, with or without disclosing the trust relationship.
(j)To divide or distribute the trust fund in undivided interests or wholly or partly in kind.
(k)To pay any tax imposed on or with respect to the trust; to defer making payment of any such tax if it is indemnified to its satisfaction in the premises; and to require before making any payment such release or other document from any lawful taxing authority and such indemnity from the intended payee as the trustee considers necessary for its protection.
(l)To deal without restriction with the legal representative of the grantor’s estate or the trustee or other legal representative of any trust created by the grantor or a trust or estate in which a beneficiary has an interest, even though the trustee, individually, shall be acting in such other capacity, without liability for any loss that may result.
(m)Upon the prior written consent of the administrator, to appoint or remove by written instrument any bank or corporation qualified to act as successor trustee, wherever located, as special trustee as to part or all of the trust fund, including property as to which the trustee does not act, and such special trustee, except as specifically limited or provided by this or the appointing instrument, shall have all of the rights, titles, powers, duties, discretions and immunities of the trustee, without liability for any action taken or omitted to be taken under this or the appointing instrument.
(n)To appoint or remove by written instrument any bank, wherever located, as custodian of part or all of the trust fund, and each such custodian shall have such rights, powers, duties and discretions as are delegated to it by the trustee.
(o)To employ agents, attorneys, accountants or other persons, and to delegate to them such powers as the trustee considers desirable, and the trustee shall be protected in acting or refraining from acting on the advice of persons so employed without court action.

4



(p)To perform any and all other acts which in the trustee’s judgment are appropriate for the proper management, investment and distribution of the trust fund.
III-2PRINCIPAL AND INCOME. Any income earned on the trust fund which is not distributed as provided in Article II shall be accumulated and from time to time added to the principal of the trust. The grantor’s interest in the trust shall include all assets or other property held by the trustee hereunder, including principal and accumulated income.
III-3STATEMENTS. The trustee shall prepare and deliver monthly to the administrator and annually to the grantor, if then living, otherwise to each beneficiary then entitled to distributions under this agreement, a statement (or series of statements) setting forth (or which taken together set forth) all investments, receipts, disbursements and other transactions effected by the trustee during the reporting period; and showing the trust fund and the value thereof at the end of such period.
III-4COMPENSATION AND EXPENSES. All reasonable costs, charges and expenses incurred in the administration of this trust, including compensation to the trustee, any compensation to agents, attorneys, accountants and other persons employed by the trustee, and expenses incurred in connection with the sale, investment and reinvestment of the trust fund shall be paid from the trust fund.
ARTICLE IV
GENERAL PROVISIONS
IV-1INTERESTS NOT TRANSFERABLE. The interests of the grantor or other persons entitled to distributions hereunder are not subject to their debts or other obligations and may not be voluntarily or involuntarily sold, transferred, alienated, assigned or encumbered.
IV-2DISAGREEMENTS AS TO ACTS. If there is a disagreement between the trustee and anyone as to any act or transaction reported in any accounting, the trustee shall have the right to a settlement of its account by any court.
IV-3TRUSTEE’S OBLIGATIONS. No power, duty or responsibility is imposed on the trustee except as set forth in this agreement. The trustee is not obliged to determine whether funds delivered to or distributions from the trust are proper under the trust, or whether any tax is due or payable as a result of any such delivery or distribution. The trustee shall be protected in making any distribution from the trust as directed pursuant to Article II without inquiring as to whether the distributee is entitled thereto; the trustee shall not be liable for any distribution made in good faith without written notice or knowledge that the distribution is not proper under the terms of this agreement; and the trustee shall not be liable for any action taken because of the specific direction of the administrator.
IV-4GOOD FAITH ACTIONS. The trustee’s exercise or non-exercise of its powers and discretions in good faith shall be conclusive on all persons. No one shall be obliged to see to the application of any money paid or property delivered to the trustee. The certificate of the

5



trustee that it is acting according to this agreement will fully protect all persons dealing with the trustee.
IV-5WAIVER OF NOTICE. Any notice required under this agreement may be waived by the person entitled to such notice.
IV-6CONTROLLING LAW. The laws of the State of Illinois shall govern the interpretation and validity of the provisions of this agreement and all questions relating to the management, administration, investment and distribution of the trust hereby created.
IV-7SUCCESSORS. This agreement shall be binding on all persons entitled to distributions hereunder and their respective heirs and legal representatives, and on the trustee and its successors.
ARTICLE V
CHANGES IN TRUSTEE
V-1RESIGNATION OR REMOVAL OF TRUSTEE. The trustee may resign at any time by giving thirty days’ advance notice to the administrator and the grantor. The administrator may remove a trustee by written notice to the trustee and the grantor.
V-2APPOINTMENT OF SUCCESSOR TRUSTEE. The administrator shall fill any vacancy in the office of trustee as soon as practicable by written notice to the successor trustee; and shall give prompt written notice thereof to the grantor, if then living, otherwise to each beneficiary then entitled to payments or distributions under this agreement. A successor trustee shall be a bank (as defined in Section 581 of the Internal Revenue Code, as amended).
V-3DUTIES OF RESIGNING OR REMOVED TRUSTEE AND OF SUCCESSOR TRUSTEE. A trustee that resigns or is removed shall furnish promptly to the administrator and the successor trustee an account of its administration of the trust from the date of its last account. Each successor trustee shall succeed to the title to the trust fund vested in its predecessor without the signing or filing of any instrument, but each predecessor trustee shall execute all documents and do all acts necessary to vest such title of record in the successor trustee. Each successor trustee shall have all the powers conferred by this agreement as if originally named trustee. No successor trustee shall be personally liable for any act or failure to act of a predecessor trustee. With the approval of the administrator, a successor trustee may accept the account furnished and the property delivered by a predecessor trustee without incurring any liability for so doing, and such acceptance will be complete discharge to the predecessor trustee.
ARTICLE VI
AMENDMENT AND TERMINATION
VI-1AMENDMENT. With the consent of the administrator, this trust may be amended from time to time by the grantor, if then living, otherwise by a majority of the beneficiaries then entitled to payments or distributions hereunder, except as follows:

6



(a)The duties and liabilities of the trustee cannot be changed substantially without its consent.
(b)This trust may not be amended so as to make the trust revocable.
VI-2    TERMINATION. This trust shall not terminate, and all rights, titles, powers, duties, discretions and immunities imposed on or reserved to the trustee, the administrator, the grantor and the beneficiaries shall continue in effect, until all assets of the trust have been distributed by the trustee as provided in Article II.
* * *

7



IN WITNESS WHEREOF, the grantor and the trustee have executed this agreement as of the day and year first above written.

Grantor

The Northern Trust Company, as Trustee
By             
Its             


8

 EX-10.5 3 abbv-20190630xex105.htm EXHIBIT 10.5 Exhibit
Exhibit 10.5


ABBVIE 2013 INCENTIVE STOCK PROGRAM
SECOND AMENDMENT

    
WHEREAS, AbbVie Inc., a Delaware corporation (the “Company”), sponsors the AbbVie 2013 Incentive Stock Program (the “Program”);
 
WHEREAS, Section 14(f) of the Program provides that the Board of Directors (the “Board”) of the Company may amend the Program at any time, provided that the amendment does not materially and adversely modify any person’s rights under the express terms and conditions of an outstanding Benefit without such person’s written consent;
        
WHEREAS, the Company now desires to amend the Program to address the application of certain terms to substitute options granted in connection with a corporate transaction;

WHEREAS, neither the Program nor the NYSE Listed Company Manual requires stockholder approval of the proposed amendment;

WHEREAS, capitalized terms used but not defined herein shall have the same meanings as set forth in the Program;

WHEREAS, the proposed amendment does not impair the rights of any person with respect to an outstanding Benefit;

 NOW, THEREFORE, IT IS RESOLVED that the Program be and it hereby is amended, effective as of the date on which the Board approves the amendment, as follows:
 
1.    The following proviso is hereby added to the first sentence of the second paragraph of Section 6(a) of the Program:

“…, unless such option is granted in connection with a corporate transaction in substitution for an option previously granted by an entity involved in such corporate transaction (any such option, a “Substitute Option”).”

2.    The following proviso is hereby added to the last sentence of the third paragraph of Section 6(a) of the Program:

“…, unless such option is a Substitute Option.”

3.    Except as specifically amended above, the Program will remain in full force and effect.


    
 EX-31.1 4 abbv-20190630xex311.htm EXHIBIT 31.1 Exhibit


Exhibit 31.1

Certification of Chief Executive Officer
Required by Rule 13a-14(a) (17 CFR 240.13a-14(a))

I, Richard A. Gonzalez, certify that:

1.
I have reviewed this quarterly report on Form 10-Q of AbbVie Inc.;

2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of AbbVie as of, and for, the periods presented in this report;

4.
AbbVie’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for AbbVie and have:

a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to AbbVie, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)
Evaluated the effectiveness of AbbVie’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d)
Disclosed in this report any change in AbbVie’s internal control over financial reporting that occurred during AbbVie’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, AbbVie’s internal control over financial reporting; and

5.
AbbVie’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to AbbVie’s auditors and the audit committee of AbbVie’s board of directors:

a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect AbbVie’s ability to record, process, summarize and report financial information; and

b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in AbbVie’s internal control over financial reporting.

Date:
August 5, 2019
/s/ Richard A. Gonzalez
 
 
Richard A. Gonzalez, Chairman of the Board
 
 
and Chief Executive Officer




 EX-31.2 5 abbv-20190630xex312.htm EXHIBIT 31.2 Exhibit


Exhibit 31.2

Certification of Chief Financial Officer
Required by Rule 13a-14(a) (17 CFR 240.13a-14(a))

I, Robert A. Michael, certify that:

1.
I have reviewed this quarterly report on Form 10-Q of AbbVie Inc.;

2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of AbbVie as of, and for, the periods presented in this report;

4.
AbbVie’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for AbbVie and have:

a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to AbbVie, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)
Evaluated the effectiveness of AbbVie’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d)
Disclosed in this report any change in AbbVie’s internal control over financial reporting that occurred during AbbVie’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, AbbVie’s internal control over financial reporting; and

5.
AbbVie’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to AbbVie’s auditors and the audit committee of AbbVie’s board of directors:

a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect AbbVie’s ability to record, process, summarize and report financial information; and

b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in AbbVie’s internal control over financial reporting.

Date:
August 5, 2019
/s/ Robert A. Michael
 
 
Robert A. Michael, Executive Vice President,
 
 
Chief Financial Officer





 EX-32.1 6 abbv-20190630xex321.htm EXHIBIT 32.1 Exhibit


Exhibit 32.1

Certification Pursuant To
18 U.S.C. Section 1350
As Adopted Pursuant To
Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the Quarterly Report of AbbVie Inc. (the “Company”) on Form 10-Q for the period ended June 30, 2019 as filed with the Securities and Exchange Commission (the “Report”), I, Richard A. Gonzalez, Chairman of the Board and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1)
The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Richard A. Gonzalez
Richard A. Gonzalez
Chairman of the Board and Chief Executive Officer
August 5, 2019


A signed original of this written statement required by Section 906 has been provided to AbbVie Inc. and will be retained by AbbVie Inc. and furnished to the Securities and Exchange Commission or its staff upon request.




 EX-32.2 7 abbv-20190630xex322.htm EXHIBIT 32.2 Exhibit


Exhibit 32.2

Certification Pursuant To
18 U.S.C. Section 1350
As Adopted Pursuant To
Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the Quarterly Report of AbbVie Inc. (the “Company”) on Form 10-Q for the period ended June 30, 2019 as filed with the Securities and Exchange Commission (the “Report”), I, Robert A. Michael, Executive Vice President, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1)
The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Robert A. Michael
Robert A. Michael
Executive Vice President, Chief Financial Officer
August 5, 2019


A signed original of this written statement required by Section 906 has been provided to AbbVie Inc. and will be retained by AbbVie Inc. and furnished to the Securities and Exchange Commission or its staff upon request.




 EX-101.SCH 8 abbv-20190630.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2101100 - Disclosure - Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 2401402 - Disclosure - Basis of Presentation (Details) link:presentationLink link:calculationLink link:definitionLink 2201201 - Disclosure - Basis of Presentation (Policies) link:presentationLink link:calculationLink link:definitionLink 2106100 - Disclosure - Collaboration with Janssen Biotech, Inc. link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - Collaboration with Janssen Biotech, Inc. (Details) link:presentationLink link:calculationLink link:definitionLink 2306301 - Disclosure - Collaboration with Janssen Biotech, Inc. (Tables) link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 1003501 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1005000 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1002501 - Statement - Condensed Consolidated Statements of Comprehensive Income (Parenthetical) (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - Condensed Consolidated Statements of Earnings (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1004000 - Statement - Condensed Consolidated Statements of Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 2104100 - Disclosure - Earnings Per Share link:presentationLink link:calculationLink link:definitionLink 2404402 - Disclosure - Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 2304301 - Disclosure - Earnings Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 2112100 - Disclosure - Equity link:presentationLink link:calculationLink link:definitionLink 2412407 - Disclosure - Equity - Accumulated Other Comprehensive Loss (Details) link:presentationLink link:calculationLink link:definitionLink 2412408 - Disclosure - Equity - Amounts Reclassified Out Of Accumulated Other Comprehensive Income (Details) link:presentationLink link:calculationLink link:definitionLink 2412405 - Disclosure - Equity - Cash Dividends (Details) link:presentationLink link:calculationLink link:definitionLink 2412404 - Disclosure - Equity - RSUs and Performance Shares (Details) link:presentationLink link:calculationLink link:definitionLink 2412402 - Disclosure - Equity - Stock-Based Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 2412403 - Disclosure - Equity - Stock Options (Details) link:presentationLink link:calculationLink link:definitionLink 2412406 - Disclosure - Equity - Stock Repurchase Program (Details) link:presentationLink link:calculationLink link:definitionLink 2312301 - Disclosure - Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 2110100 - Disclosure - Financial Instruments and Fair Value Measures link:presentationLink link:calculationLink link:definitionLink 2410403 - Disclosure - Financial Instruments and Fair Value Measures - Amount Of Gain/(Loss) Recognized For Derivative Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 2410407 - Disclosure - Financial Instruments and Fair Value Measures - Available-for-sale Securities (Details) link:presentationLink link:calculationLink link:definitionLink 2410406 - Disclosure - Financial Instruments and Fair Value Measures - Bases Used To Measure The Approximate Fair Values Of Financial Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 2410408 - Disclosure - Financial Instruments and Fair Value Measures - Concentrations of Risk (Details) link:presentationLink link:calculationLink link:definitionLink 2410409 - Disclosure - Financial Instruments and Fair Value Measures - Debt and Credit Facilities (Details) link:presentationLink link:calculationLink link:definitionLink 2410404 - Disclosure - Financial Instruments and Fair Value Measures - Fair Value Measures (Details) link:presentationLink link:calculationLink link:definitionLink 2410402 - Disclosure - Financial Instruments and Fair Value Measures - Financial Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 2310301 - Disclosure - Financial Instruments and Fair Value Measures (Tables) link:presentationLink link:calculationLink link:definitionLink 2410405 - Disclosure - Financial Instruments and Fair Value Measures - Transfers of Assets or Liabilities Between The Fair Value Measurement Levels (Details) link:presentationLink link:calculationLink link:definitionLink 2107100 - Disclosure - Goodwill and Intangible Assets link:presentationLink link:calculationLink link:definitionLink 2407405 - Disclosure - Goodwill and Intangible Assets - Definite-Lived Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 2407402 - Disclosure - Goodwill and Intangible Assets - Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 2407404 - Disclosure - Goodwill and Intangible Assets - Indefinite-Lived Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 2407403 - Disclosure - Goodwill and Intangible Assets - Summary of Intangible Assets, Net (Details) link:presentationLink link:calculationLink link:definitionLink 2407403 - Disclosure - Goodwill and Intangible Assets - Summary of Intangible Assets, Net (Details) link:presentationLink link:calculationLink link:definitionLink 2307301 - Disclosure - Goodwill and Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 2113100 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 2413401 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 2109100 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 2409403 - Disclosure - Leases - Balance Sheet Disclosure (Details) link:presentationLink link:calculationLink link:definitionLink 2409406 - Disclosure - Leases - Cash Flow Disclosure (Details) link:presentationLink link:calculationLink link:definitionLink 2409404 - Disclosure - Leases - Cost (Details) link:presentationLink link:calculationLink link:definitionLink 2409407 - Disclosure - Leases - Maturities of Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2409407 - Disclosure - Leases - Maturities of Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2209201 - Disclosure - Leases (Policies) link:presentationLink link:calculationLink link:definitionLink 2309302 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 2409405 - Disclosure - Leases - Weighted-Average Remaining Lease Term and Discount Rate (Details) link:presentationLink link:calculationLink link:definitionLink 2114100 - Disclosure - Legal Proceedings and Contingencies link:presentationLink link:calculationLink link:definitionLink 2414401 - Disclosure - Legal Proceedings and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 2105100 - Disclosure - Licensing, Acquisitions, and Other Arrangements link:presentationLink link:calculationLink link:definitionLink 2405402 - Disclosure - Licensing, Acquisitions, and Other Arrangements - Other Licensing & Acquisitions Activity (Details) link:presentationLink link:calculationLink link:definitionLink 2405401 - Disclosure - Licensing, Acquisitions, and Other Arrangements - Proposed Acquisition of Allergan plc (Details) link:presentationLink link:calculationLink link:definitionLink 2111100 - Disclosure - Post-Employment Benefits link:presentationLink link:calculationLink link:definitionLink 2411402 - Disclosure - Post-Employment Benefits (Details) link:presentationLink link:calculationLink link:definitionLink 2311301 - Disclosure - Post-Employment Benefits (Tables) link:presentationLink link:calculationLink link:definitionLink 2108100 - Disclosure - Restructuring Plans link:presentationLink link:calculationLink link:definitionLink 2408402 - Disclosure - Restructuring Plans (Details) link:presentationLink link:calculationLink link:definitionLink 2308301 - Disclosure - Restructuring Plans (Tables) link:presentationLink link:calculationLink link:definitionLink 2115100 - Disclosure - Segment Information link:presentationLink link:calculationLink link:definitionLink 2415402 - Disclosure - Segment Information - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2415403 - Disclosure - Segment Information - Disaggregation of Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 2315301 - Disclosure - Segment Information (Tables) link:presentationLink link:calculationLink link:definitionLink 2103100 - Disclosure - Supplemental Financial Information link:presentationLink link:calculationLink link:definitionLink 2403402 - Disclosure - Supplemental Financial Information (Details) link:presentationLink link:calculationLink link:definitionLink 2303301 - Disclosure - Supplemental Financial Information (Tables) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 9 abbv-20190630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 10 abbv-20190630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 11 abbv-20190630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Organization, Consolidation and Presentation of Financial Statements [Abstract] Basis of Presentation Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Stockholders' Equity Note [Abstract] Reclassification out of Accumulated Other Comprehensive Income [Table] Reclassification out of Accumulated Other Comprehensive Income [Table] Hedging Relationship [Axis] Hedging Relationship [Axis] Hedging Relationship [Domain] Hedging Relationship [Domain] Net investment hedging activity Net Investment Hedging [Member] Reclassification out of Accumulated Other Comprehensive Income [Axis] Reclassification out of Accumulated Other Comprehensive Income [Axis] Reclassification out of Accumulated Other Comprehensive Income [Domain] Reclassification out of Accumulated Other Comprehensive Income [Domain] Reclassification out of accumulated other comprehensive income Reclassification out of Accumulated Other Comprehensive Income [Member] Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Pension and post-employment benefits Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member] Cash flow hedging activities Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member] AOCI, Derivative Qualifying as Hedge, Excluded Component, Parent [Member] AOCI, Derivative Qualifying as Hedge, Excluded Component, Parent [Member] Significant amounts reclassified out of each component of AOCI Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] Amortization of actuarial losses and other Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax Tax benefit Reclassification from AOCI, Current Period, Tax Total reclassifications, net of tax Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax Losses (gains) on designated cash flow hedges Cost of Goods and Services Sold Gains on derivative amount excluded from effectiveness testing Interest Income (Expense), Nonoperating, Net Tax expense (benefit) Income Tax Expense (Benefit) Total reclassifications, net of tax Net Income (Loss) Attributable to Parent Fair Value Disclosures [Abstract] Derivative Instruments, Gain (Loss) [Table] Derivative Instruments, Gain (Loss) [Table] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Senior notes Senior Notes [Member] Derivative Instrument [Axis] Derivative Instrument [Axis] Derivative Contract Type [Domain] Derivative Contract [Domain] Foreign currency forward exchange contracts Foreign Exchange Forward [Member] Interest rate swaps designated as fair value hedges Interest Rate Swap [Member] Cash flow hedges Cash Flow Hedging [Member] Net investment hedges Fair value hedges Fair Value Hedging [Member] Hedging Designation [Axis] Hedging Designation [Axis] Hedging Designation [Domain] Hedging Designation [Domain] Designated as hedging instrument Designated as Hedging Instrument [Member] Not designated as hedges Not Designated as Hedging Instrument [Member] Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Cost of products sold Cost of Sales [Member] Net foreign exchange loss Foreign Currency Gain (Loss) [Member] Interest expense, net Interest Expense [Member] Gain (loss) on derivatives Derivative Instruments, Gain (Loss) [Line Items] Pre-tax gains (losses) from derivative instruments designated as cash flow hedges recognized in other comprehensive income Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax Pre-tax gains (losses) from net investment hedge instruments recognized in other comprehensive income Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax Foreign currency cash flow hedge gain expected to be reclassified during next 12 months Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months Derivative gain (loss), net Derivative, Gain (Loss) on Derivative, Net Debt designated as hedged item in fair value hedges gain (loss) Increase (Decrease) in Fair Value of Hedged Item in Interest Rate Fair Value Hedge Income Tax Disclosure [Abstract] Effective tax rate Effective Income Tax Rate Reconciliation, Percent U.S. statutory tax rate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Potential change in unrecognized tax benefits Decrease in Unrecognized Tax Benefits is Reasonably Possible Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Goodwill and Intangible Assets Disclosure [Text Block] Statement of Financial Position [Abstract] Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Common stock, authorized (in shares) Common Stock, Shares Authorized Common stock, issued (in shares) Common Stock, Shares, Issued Common stock held in treasury, at cost (in shares) Treasury Stock, Shares Segment Reporting [Abstract] Schedule of worldwide net revenues Disaggregation of Revenue [Table Text Block] Income Taxes Income Tax Disclosure [Text Block] Class of Treasury Stock [Table] Class of Treasury Stock [Table] Share Repurchase Program [Axis] Share Repurchase Program [Axis] Share Repurchase Program [Domain] Share Repurchase Program [Domain] December 2018 Stock Repurchase Authorization December 2018 Stock Repurchase Authorization [Member] December 2018 Stock Repurchase Authorization February 2017 Stock Repurchase Program February 2017 Stock Repurchase Program [Member] February 2017 Stock Repurchase Program Equity, Class of Treasury Stock Equity, Class of Treasury Stock [Line Items] Shares repurchased (in shares) Treasury Stock, Shares, Acquired Payment for shares repurchased Treasury Stock, Value, Acquired, Cost Method Remaining share repurchase authorization amount Stock Repurchase Program, Remaining Authorized Repurchase Amount Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Accumulated other comprehensive loss AOCI Attributable to Parent [Member] Foreign currency translation adjustments Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Net investment hedging activities Accumulated Net Gain (Loss) From Net Investment Hedges Attributable To Parent [Member] Accumulated Net Gain (Loss) From Net Investment Hedges Attributable To Parent [Member] Marketable security activities Accumulated Net Investment Gain (Loss) Attributable to Parent [Member] Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Income (Loss) [Line Items] AOCI Attributable to Parent, Net of Tax AOCI Attributable to Parent, Net of Tax [Roll Forward] Beginning balance Stockholders' Equity Attributable to Parent Other comprehensive income (loss) before reclassifications OCI, before Reclassifications, Net of Tax, Attributable to Parent Net losses (gains) reclassified from accumulated other comprehensive loss Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent Other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Ending balance Equity Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Earnings Per Share [Abstract] Basic EPS Earnings Per Share, Basic, Two Class Method [Abstract] Net earnings Earnings allocated to participating securities Participating Securities, Distributed and Undistributed Earnings (Loss), Basic Earnings available to common shareholders Net Income (Loss) Available to Common Stockholders, Basic Weighted-average basic shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Basic Basic earnings per share (in dollars per share) Earnings Per Share, Basic Diluted EPS Earnings Per Share, Diluted, Two Class Method [Abstract] Earnings allocated to participating securities Participating Securities, Distributed and Undistributed Earnings (Loss), Diluted Earnings available to common shareholders Net Income (Loss) Available to Common Stockholders, Diluted Weighted-average basic shares outstanding (in shares) Effect of dilutive securities (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements Weighted-average diluted shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Diluted Diluted earnings per share (in dollars per share) Earnings Per Share, Diluted Summary of share-based compensation expense Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] Summary of quarterly cash dividends Schedule of Dividends Payable [Table Text Block] Summary of changes in balances of each component of accumulated other comprehensive loss Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Schedule of the significant amounts reclassified out of each component of accumulated other comprehensive loss Reclassification out of Accumulated Other Comprehensive Income [Table Text Block] Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value Measurements, Recurring and Nonrecurring [Table] Product and Service [Axis] Product and Service [Axis] Product and Service [Domain] Product and Service [Domain] SKYRIZI SKYRIZI [Member] Represents information pertaining to SKYRIZI, a product of the entity. Measurement Frequency [Axis] Measurement Frequency [Axis] Fair Value Measurement Frequency [Domain] Fair Value, Measurement Frequency [Domain] Recurring Fair Value, Measurements, Recurring [Member] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Fair Value Measurements Fair Value Hierarchy [Domain] Fair Value Hierarchy and NAV [Domain] Quoted prices in active markets for identical assets (Level 1) Fair Value, Inputs, Level 1 [Member] Significant other observable inputs (Level 2) Fair Value, Inputs, Level 2 [Member] Significant unobservable inputs (Level 3) Fair Value, Inputs, Level 3 [Member] Investment Type [Axis] Investment Type [Axis] Investment Type Categorization [Member] Investments [Domain] Time deposits Bank Time Deposits [Member] Foreign currency contracts Foreign Exchange Contract [Member] Measurement Basis [Axis] Measurement Basis [Axis] Fair Value Measurement [Domain] Fair Value Measurement [Domain] Portion at Fair Value Measurement [Member] Portion at Fair Value Measurement [Member] Changes Measurement Changes Measurement [Member] Contingent Consideration Change, By Type [Axis] Contingent Consideration Change, By Type [Axis] Contingent Consideration Change, By Type [Axis] Contingent Consideration Change, By Type [Domain] Contingent Consideration Change, By Type [Domain] [Domain] for Contingent Consideration Change, By Type [Axis] Change in assumed discount rate Change In Assumed Discount Rate [Member] Change In Assumed Discount Rate [Member] Change in assumed probability rate Change In Assumed Probability Rate [Member] Change In Assumed Probability Rate [Member] Fair value, asset and liability measures Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Assets Assets, Fair Value Disclosure [Abstract] Cash and equivalents Cash and Cash Equivalents, Fair Value Disclosure Time deposits Investments, Fair Value Disclosure Debt securities Debt Securities, Available-for-sale Equity securities Available-for-sale Securities, Equity Securities Interest rate hedges Interest Rate Derivative Assets, at Fair Value Foreign currency contracts Derivative Asset, Fair Value, Gross Asset Total assets Assets, Fair Value Disclosure Liabilities Liabilities, Fair Value Disclosure [Abstract] Interest rate hedges Interest Rate Derivative Liabilities, at Fair Value Foreign currency contracts Derivative Liability, Fair Value, Gross Liability Contingent consideration Business Combination, Contingent Consideration, Liability Total liabilities Financial and Nonfinancial Liabilities, Fair Value Disclosure Discount rate change Fair Value Inputs, Discount Rate Change Fair Value Inputs, Assumed Discount Rate Change Contingent consideration liability change Business Combination, Contingent Consideration Arrangements, Potential Change in Amount of Contingent Consideration, Liability Business Combination, Contingent Consideration Arrangements, Potential Change in Amount of Contingent Consideration, Liability Assumed probability rate change Fair Value Inputs, Assumed Probability Rate Change Fair Value Inputs, Assumed Probability Rate Change Change in fair value recognized in net earnings Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Concentration Risk [Table] Concentration Risk [Table] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Accounts receivable, net Accounts Receivable [Member] Total revenues Sales Revenue, Net [Member] Concentration Risk Type [Axis] Concentration Risk Type [Axis] Concentration Risk Type [Domain] Concentration Risk Type [Domain] Geographic Risk Geographic Concentration Risk [Member] HUMIRA Product Concentration Risk [Member] Concentration of Risk Concentration Risk [Line Items] Number of principal customers Number of Principal US Customers Represents the number of principal U.S. customers of the entity. Concentrations risk (as a percent) Concentration Risk, Percentage Schedule of Short-term Debt [Table] Schedule of Short-term Debt [Table] Short-term Debt, Type [Axis] Short-term Debt, Type [Axis] Short-term Debt, Type [Domain] Short-term Debt, Type [Domain] Commercial paper Commercial Paper [Member] Term loan facilities Loans Payable [Member] Bridge credit agreement Bridge Loan [Member] Debt Instrument [Axis] Debt Instrument [Axis] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] May 2018 term loan credit agreement May 2018 Term Loan Credit Agreement [Member] May 2018 Term Loan Credit Agreement June 2019 bridge credit agreement June 2019 Bridge Credit Facility [Member] June 2019 Bridge Credit Facility Short-Term Borrowings Short-term Debt [Line Items] Short-term borrowings Short-term Debt Weighted-average interest rate on commercial paper (as a percent) Short-term Debt, Weighted Average Interest Rate, at Point in Time Repayments of other short-term borrowings Repayments of Other Short-term Debt Credit agreement term Debt Instrument, Term Restructuring and Related Activities [Abstract] Summary of the cash activity in the restructuring reserve Restructuring and Related Costs [Table Text Block] Licensing, Acquisitions, and Other Arrangements Licensing, Acquisitions, and Other Arrangements Acquisitions Collaborations and Other Arrangements Disclosure [Text Block] The entire disclosure for acquisitions, collaborations and other arrangements of the entity. Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Developed product rights Developed Technology Rights [Member] Finite-Lived Intangible Assets Finite-Lived Intangible Assets [Line Items] Reclassification to definite-lived intangible assets Finite-Lived Intangible Assets, Period Increase (Decrease) Amortization of intangible assets Amortization of Intangible Assets Definite-lived intangible assets impairment charges Impairment of Intangible Assets, Finite-lived Postemployment Benefits [Abstract] Schedule of Defined Benefit Plans Disclosures [Table] Schedule of Defined Benefit Plans Disclosures [Table] Retirement Plan Type [Axis] Retirement Plan Type [Axis] Retirement Plan Type [Domain] Retirement Plan Type [Domain] Defined benefit plans Pension Plan [Member] Other post-employment plans Other Postretirement Benefits Plan [Member] Defined benefit and other post-employment plans Defined Benefit Plan Disclosure [Line Items] Service cost Defined Benefit Plan, Service Cost Interest cost Defined Benefit Plan, Interest Cost Expected return on plan assets Defined Benefit Plan, Expected Return (Loss) on Plan Assets Amortization of actuarial losses and prior service cost (credit) Defined Benefit Plan, Amortization Of Actuarial Gain (Loss), Prior Service Cost (Credit) The amount of amortization of actuarial losses and prior service costs included in the calculation of net periodic pension benefit cost. Net periodic benefit cost Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Supplemental Financial Information Supplemental Financial Information Additional Financial Information Disclosure [Text Block] Statement of Comprehensive Income [Abstract] Foreign currency translation adjustments, tax expense (benefit) Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax, Portion Attributable to Parent Net investment hedging activities, tax expense (benefit) Other Comprehensive Income (Loss), Net Investment Hedge, Tax, Portion Attributable to Parent Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on derivative instruments and nonderivative instruments designated and qualifying as net investment hedge, attributable to parent entity. Pension and post-employment benefits, tax expense (benefit) Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax, Attributable to Parent Marketable security activities, tax expense (benefit) Other Comprehensive Income (Loss), Available-for-sale Securities, Tax, Portion Attributable to Parent Cash flow hedging activities, tax expense (benefit) Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax, Parent Changes in the carrying amount of goodwill Goodwill [Roll Forward] Balance at the beginning of the period Goodwill Foreign currency translation adjustments Goodwill, Translation and Purchase Accounting Adjustments Balance at the end of the period Accumulated goodwill impairment losses Goodwill, Impaired, Accumulated Impairment Loss [Abstract] Accumulated goodwill impairment losses Goodwill, Impaired, Accumulated Impairment Loss Summary of changes in the carrying amount of goodwill Schedule of Goodwill [Table Text Block] Summary of definite-lived intangible assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Summary of indefinite-lived intangible assets Schedule of Indefinite-Lived Intangible Assets [Table Text Block] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Research and development Research and Development Expense [Member] Selling, general and administrative Selling, General and Administrative Expenses [Member] Share-based Compensation Arrangement by Share-based Payment Award Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Pre-tax compensation expense Allocated Share-based Compensation Expense Tax benefit Employee Service Share-based Compensation, Tax Benefit from Compensation Expense After-tax compensation expense Allocated Share-based Compensation Expense, Net of Tax Collaboration with Janssen Biotech, Inc. No definition available. Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table] Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table] Counterparty Name [Axis] Counterparty Name [Axis] Counterparty Name [Domain] Counterparty Name [Domain] Janssen Biotech Inc Janssen Biotech Inc [Member] Represents the information pertains to the entity Janssen Biotech Inc. Type of Arrangement and Non-arrangement Transactions [Axis] Type of Arrangement and Non-arrangement Transactions [Axis] Arrangements and Non-arrangement Transactions [Domain] Arrangements and Non-arrangement Transactions [Domain] Collaborative arrangement Collaborative Arrangement [Member] Geographical [Axis] Geographical [Axis] Geographical [Domain] Geographical [Domain] United States UNITED STATES International Non-US [Member] Collaborative and license agreements Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] Milestone payments Collaborative Arrangement Milestone Method Payments Receivable The maximum milestone payments that may be received by the entity based on the achievement of specified events under a collaborative arrangement. Share of collaboration development costs responsible by Janssen (as a percent) Collaborative Arrangements Percentage Of Share Of Development Costs Responsible By Third Party Represents the percentage of share in collaboration development costs responsible by Janssen under cost sharing arrangement. Share of collaboration development costs responsible by the entity (as a percent) Collaborative Arrangements Percentage Of Share Of Development Costs Represents the percentage of share in collaboration development costs responsible by the entity under cost sharing arrangement. United States - Janssen's share of profits (included in cost of products sold) Collaborative Arrangements Payment To Other Party As Share Of Profits Before Income Taxes Represents the amount paid or to be paid to other party as profit sharing in the contract which is recorded as expense for the company. International - AbbVie's share of profits (included in net revenues) Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606. Global - AbbVie's share of other costs (included in respective line items) Cost Sharing Expenses Represents cost sharing expenses. Accounts receivable, net Accounts Receivable, Net, Current Accounts payable and accrued liabilities Accounts Payable and Accrued Liabilities, Current Summary of amounts and location of derivatives on the condensed consolidated balance sheets Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block] Schedule of pre-tax amounts of derivatives recognized in other comprehensive income (loss) Schedule of Derivative Instruments, Effect on Other Comprehensive Income (Loss) [Table Text Block] Summary of pre-tax amounts and location of derivatives recognized in the condensed consolidated statements of earnings Derivative Instruments, Gain (Loss) [Table Text Block] Summary of bases used to measure assets and liabilities carried at fair value on a recurring basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Schedule of changes in fair value of Level 3 inputs Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Schedule of book values, approximate fair values and bases used to measure certain financial instruments Fair Value, by Balance Sheet Grouping [Table Text Block] Summary of available-for-sale securities by type Available-for-sale Securities [Table Text Block] Summary of net periodic benefit costs Schedule of Net Benefit Costs [Table Text Block] Schedule of Available-for-sale Securities [Table] Schedule of Available-for-sale Securities [Table] Financial Instrument [Axis] Financial Instrument [Axis] Financial Instruments [Domain] Financial Instruments [Domain] Short-term investments Short-term Investments [Member] Asset backed securities Asset-backed Securities [Member] Corporate debt securities Corporate Debt Securities [Member] Other debt securities Other Debt Obligations [Member] Available-for-sale Securities Debt Securities, Available-for-sale [Line Items] Maximum maturity period of long-term debt securities (in years) Debt Securities, Available-for-sale, Term Amortized cost Available-for-sale Securities, Amortized Cost Basis Gross unrealized, Gains Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax Gross unrealized, Losses Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax Fair value Available-for-sale Securities Other-than-temporary impairments Accumulated Other Comprehensive Income (Loss), Other than Temporary Impairment, Not Credit Loss, Net of Tax, Available-for-sale, Debt Securities Revenue from Contract with Customer [Abstract] Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Key Product Portfolio [Axis] Key Product Portfolio [Axis] Information concerning the company's portfolios of key products. Key Product Portfolio [Domain] Key Product Portfolio [Domain] [Domain] for Information concerning the company's portfolios of key products. Immunology Immunology [Member] Represents information pertaining to Immunology, a key product portfolio of the entity. Hematologic Oncology Hematologic Oncology [Member] Represents information pertaining to Hematologic Oncology, a key product portfolio of the entity. HCV HCV [Member] Represents information pertaining to HCV, a key product portfolio of the entity. Other Key Products Other Key Products [Member] Represents information pertaining to other key products of the entity. HUMIRA H U M I R A [Member] Represents information pertaining to HUMIRA, a product of the entity. IMBRUVICA Imbruvica [Member] Represents information pertaining to Imbruvica, a product of the entity. VENCLEXTA VENCLEXTA [Member] Represents information pertaining to VENCLEXTA, a product of the entity. MAVYRET MAVYRET [Member] Represents information pertaining to MAVYRET, a product of the entity. VIEKIRA VIEKIRA [Member] Represents information pertaining to VIEKIRA, a product of the entity. Creon Creon [Member] Represents information pertaining to Creon, a product of the entity. Lupron Lupron [Member] Represents information pertaining to Lupron, a product of the entity. Synthroid Synthroid [Member] Represents information pertaining to Synthroid, a product of the entity. Synagis Synagis [Member] Represents information pertaining to Synagis, a product of the entity. Duodopa Duodopa [Member] Represents information pertaining to Duodopa, a product of the entity. Sevoflurane Sevoflurane [Member] Represents information pertaining to Sevoflurane, a product of the entity. Kaletra Kaletra [Member] Represents information pertaining to Kaletra, a product of the entity. AndroGel Andro Gel [Member] Represents information pertaining to AndroGel, a product of the entity. ORILISSA ORILISSA [Member] Represents information pertaining to ORILISSA, a product of the entity. All other Other Products [Member] Represents information pertaining to other products of the entity not specified anywhere. Disaggregation of Revenue Disaggregation of Revenue [Line Items] Net revenues Revenue from Contract with Customer, Excluding Assessed Tax Collaboration revenues Total net revenues Revenues Schedule of interest expense, net Interest Income and Interest Expense Disclosure [Table Text Block] Schedule of inventories Schedule of Inventory, Current [Table Text Block] Schedule of property and equipment Property, Plant and Equipment [Table Text Block] Leases [Abstract] Leases Leases of Lessee Disclosure [Text Block] Earnings Per Share Earnings Per Share [Text Block] Weighted-average remaining lease term for operating leases Operating Lease, Weighted Average Remaining Lease Term Weighted-average remaining lease term for finance leases Finance Lease, Weighted Average Remaining Lease Term Weighted-average discount rate for operating leases Operating Lease, Weighted Average Discount Rate, Percent Weighted-average discount rate for finance leases Finance Lease, Weighted Average Discount Rate, Percent Award Type [Axis] Award Type [Axis] Equity Award [Domain] Equity Award [Domain] Stock Options Employee Stock Option [Member] Stock options granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Weighted-average grant-date fair value of the stock options granted (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Unrecognized compensation cost Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options Period for recognition of unrecognized compensation cost Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition Cash dividends declared per common share (in dollars per share) Common Stock, Dividends, Per Share, Declared Book value Reported Value Measurement [Member] Approximate fair value Estimate of Fair Value Measurement [Member] Bases used to measure the approximate fair values of the financial instruments Short-term borrowings Short-term Debt, Fair Value Current portion of long-term debt and finance lease obligations, excluding fair value hedges Long Term Debt and Capital Lease Obligations Current Fair Value Disclosure Represents the fair value amount of obligation related to long-term debt (excluding convertible debt) and capital leases, the portion which is due in one year or less in the future. Long-term debt and finance lease obligations, excluding fair value hedges Long Term Debt and Capital Lease Obligations Fair Value Disclosure Represents the fair value amount of as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year from the balance sheet date or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer plus capital lease obligations due to be paid more than one year after the balance sheet date. Carrying amount of investments in equity securities that do not have readily determinable fair values Equity Securities without Readily Determinable Fair Value, Amount Schedule of diluted earnings per share, impact of two-class method Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Operating lease cost Operating Lease, Cost Finance lease amortization of right-of-use assets Finance Lease, Right-of-Use Asset, Amortization Finance lease interest on lease liabilities Finance Lease, Interest Expense Short-term lease cost Short-term Lease, Cost Variable lease cost Variable Lease, Cost Total lease cost Lease, Cost Derivative [Table] Derivative [Table] Not designated as hedging instrument Interest rate contracts Balance Sheet Location [Axis] Balance Sheet Location [Axis] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Prepaid expenses and other Prepaid Expenses and Other Current Assets [Member] Accounts payable and accrued liabilities Accounts Payable and Accrued Liabilities [Member] Other assets Other Noncurrent Assets [Member] Other long-term liabilities Other Liabilities [Member] Derivative instruments, notional amount and fair value Derivatives, Fair Value [Line Items] Notional amount of derivative instruments Derivative, Notional Amount Duration of forward exchange contracts Derivative, Term of Contract Approximate length of time over which accumulated gains and losses will be recognized in Cost of products sold Maximum Length of Time Hedged in Cash Flow Hedge Principal amount of unsecured senior notes Debt Instrument, Face Amount Foreign currency contracts in asset position Foreign currency contracts in liability position Commitments and Contingencies Disclosure [Abstract] Loss Contingencies [Table] Loss Contingencies [Table] Litigation Case [Axis] Litigation Case [Axis] Litigation Case Type [Domain] Litigation Case [Domain] AndroGel Antitrust Litigation Andro Gel Antitrust Litigation [Member] Represents information pertaining to AndroGel Antitrust Litigation. Niaspan Niaspan [Member] Represents information pertaining to Niaspan, a product of the entity. Elliott Associates, L.P. Elliott Associates, L.P. [Member] Represents information pertaining to Elliot Associates, LP. Testosterone Replacement Therapy Products Liability Litigation Testosterone Replacement Therapy Products Liability Litigation [Member] Information relating to Testosterone Replacement Therapy Products Liability Litigation. Novartis Vaccines and Diagnostics Inc and Grifols Worldwide Operations Ltd [Member] Novartis Vaccines and Diagnostics Inc and Grifols Worldwide Operations Ltd [Member] Novartis Vaccines and Diagnostics, Inc. and Grifols Worldwide Operations Ltd. Loss Contingency Nature [Axis] Loss Contingency Nature [Axis] Loss Contingency Nature [Domain] Loss Contingency, Nature [Domain] Disgorgement remedy DisgorgementRemedy [Member] Disgorgement remedy Depakote Depakote [Member] Represents information concerning Depakote-related claims. Legal Proceedings and Contingencies Loss Contingencies [Line Items] Recorded accrual balance for litigation Loss Contingency Accrual Number of generic companies with whom certain litigation related agreements were entered into Loss Contingency Number of Generic Companies as Counterparty of Litigation Related Agreements Violated Certain Laws Represents the number of generic companies with whom certain litigation related agreements are entered into that violated federal and state antitrust laws and state consumer protection and unjust enrichment laws. Number of individual plaintiff lawsuits Loss Contingency Individual Plaintiff Lawsuits Number Represents the number of individual plaintiff lawsuits filed, pertaining to a loss contingency during the period. Number of purported class actions Loss Contingency Purported Class Actions Number Represents the number of purported class actions filed, pertaining to a loss contingency during the period. Number of healthcare benefit providers who filed lawsuits Loss Contingency, Number of Plaintiffs Damages awarded against company Loss Contingency, Damages Awarded, Value Number of individual putative class action lawsuit Putative Class Action Lawsuit Individual Number Represents number of the number of individual putative class action lawsuit. Number of parties to lawsuit (in investment funds) Loss Contingency, New Claims Filed, Number Numbers of claims consolidated for pre-trial purposes Number Of Claims Consolidated For Pre-Trial Purposes Numbers of claims are consolidated for pre-trial purposes. Number of claims pending Loss Contingency, Pending Claims, Number Percentage of claims subject to settlement agreements Percentage of Claims Subject to Settlement Agreements Percentage of claims subject to settlement agreements HCV-related patents Gain Contingency, Patents Allegedly Infringed upon, Number License agreements Licensing Agreements [Member] Gross carrying amount Finite-Lived Intangible Assets, Gross Accumulated amortization Finite-Lived Intangible Assets, Accumulated Amortization Net carrying amount Finite-Lived Intangible Assets, Net Indefinite-lived research and development Indefinite-lived Intangible Assets (Excluding Goodwill) Total intangible assets gross carrying amount Intangible Assets, Gross (Excluding Goodwill) Total intangible assets, net Intangible Assets, Net (Excluding Goodwill) RSUs and Performance Shares Restricted Stock Units And Performance Shares [Member] Restricted Stock Units And Performance Shares [Member] Shares granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Fair market value of awards vested (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Unrecognized compensation cost Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options Restructuring Plans Restructuring and Related Activities Disclosure [Text Block] Restructuring charges Restructuring Charges Restructuring reserve activity Restructuring Reserve [Roll Forward] Accrued balance beginning of the period Restructuring Reserve Restructuring charges Restructuring Reserve Cash Settled Restructuring Charges The change in the restructuring reserve related to the amount of restructuring charges during the period that are expected to be cash settled. Payments and other adjustments Restructuring Reserve Period Cash Settled and Other Adjustments The change in the restructuring reserve related to the amount of cash paid and other adjustments during the period. Accrued balance end of the period Income Statement [Abstract] Net revenues Cost of products sold Selling, general and administrative Selling, General and Administrative Expense Research and development Research and Development Expense (Excluding Acquired in Process Cost) Acquired in-process research and development Research and Development Asset Acquired Other than Through Business Combination, Written-off Other expense Other Expenses Total operating costs and expenses Costs and Expenses Operating earnings Operating Income (Loss) Interest expense, net Net foreign exchange loss Foreign Currency Transaction Gain (Loss), before Tax Other expense, net Other Nonoperating Income (Expense) Earnings before income tax expense Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Income tax expense Net earnings Per share data Earnings Per Share, Basic and Diluted [Abstract] Weighted-average diluted shares outstanding (in shares) Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Calico Life Sciences Llc Calico Life Sciences Llc [Member] Represents information pertaining to transactions with Calico Life Sciences LLC. Cash outflows related to acquisitions and investments Payments to Acquire Other Investments Additional contribution to collaboration Additional Contribution To Collaboration Represents the additional contribution amount to a collaboration. Additional contribution to collaboration by partner Additional Contribution To Collaboration By Partner Represents the additional contribution amount to a collaboration by partner. Term by which the agreement was extended Term By Which The Agreement Was Extended Represents the term by which the agreement was extended. Schedule of Indefinite-Lived Intangible Assets [Table] Schedule of Indefinite-Lived Intangible Assets [Table] Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-lived Intangible Assets, Major Class Name [Domain] In-Process Research and Development In Process Research and Development [Member] Business Acquisition [Axis] Business Acquisition [Axis] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Stemcentrx Inc. Stemcentrx Inc. [Member] Represents the information pertaining to acquisition of Stemcentrx, Inc. Indefinite-lived Intangible Assets Indefinite-lived Intangible Assets [Line Items] Indefinite-lived intangible asset impairment charges Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) Reclassification from indefinite-lived intangible assets Indefinite-lived Intangible Assets, Period Increase (Decrease) Indefinite-lived research and development assets Operating leases Operating Lease Liabilities, Payments Due [Abstract] 2019 Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year 2020 Lessee, Operating Lease, Liability, Payments, Due Year Two 2021 Lessee, Operating Lease, Liability, Payments, Due Year Three 2022 Lessee, Operating Lease, Liability, Payments, Due Year Four 2023 Lessee, Operating Lease, Liability, Payments, Due Year Five Thereafter Lessee, Operating Lease, Liability, Payments, Due after Year Five Total lease payments Lessee, Operating Lease, Liability, Payments, Due Less: Interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Present value of lease liabilities Operating Lease, Liability Finance leases Finance Lease Liabilities, Payments, Due [Abstract] 2019 Finance Lease, Liability, Payments, Remainder of Fiscal Year 2020 Finance Lease, Liability, Payments, Due Year Two 2021 Finance Lease, Liability, Payments, Due Year Three 2022 Finance Lease, Liability, Payments, Due Year Four 2023 Finance Lease, Liability, Payments, Due Year Five Thereafter Finance Lease, Liability, Payments, Due after Year Five Total lease payments Finance Lease, Liability, Payments, Due Less: Interest Finance Lease, Liability, Undiscounted Excess Amount Present value of lease liabilities Finance Lease, Liability Total Lease Liabiltiies, Payments, Due [Abstract] Lease Liabilities, Payments, Due 2019 Lease, Liability, Payments, Remainder of Fiscal Year Amount of lessee's undiscounted obligation for lease payments for operating and finance leases having an initial or remaining lease term in excess of one year due in remainder of fiscal year following latest fiscal year. 2020 Lease, Liability, Payments, Due Year Two Amount of lessee's undiscounted obligation for lease payments for operating and finance leases, due in second fiscal year following latest fiscal year. 2021 Lease, Liability, Payments, Due Year Three Amount of lessee's undiscounted obligation for lease payments for operating and finance leases, due in third fiscal year following latest fiscal year. 2022 Lease, Liability, Payments, Due Year Four Amount of lessee's undiscounted obligation for lease payments for operating and finance leases, due in fourth fiscal year following latest fiscal year. 2023 Lease, Liability, Payments, Due Year Five Amount of lessee's undiscounted obligation for lease payments for operating and finance leases, due in fifth fiscal year following latest fiscal year. Thereafter Lease, Liability, Payments, Due after Year Five Amount of lessee's undiscounted obligation for lease payments for operating and finance leases, due after fifth fiscal year following latest fiscal year. Total lease payments Lease, Liability, Payments, Due Amount of lessee's undiscounted obligation for lease payments for operating and finance leases. Less: Interest Lease, Liability, Undiscounted Excess Amount Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating and finance leases. Present value of lease liabilities Lease, Liability Present value of lessee's discounted obligation for lease payments from operating and finance leases. Contractual minimum lease payments for leases executed but not yet commenced Lessee, Lease, Lease Not yet Commenced, Contractual Minimum Payments Amount of lessee's contractual minimum lease payments for operating and finance leases that have not yet commenced. Lease term for leases executed but not yet commenced Lessee, Lease, Lease Not yet Commenced, Term of Contract Lessee, Lease, Lease Not yet Commenced, Term of Contract Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Property and equipment, net Property, Plant and Equipment [Member] Other long-term liabilities Other Noncurrent Liabilities [Member] Current portion of long-term debt and finance lease obligations LongTermDebtandFinanceLeaseObligationsCurrent [Member] Refers to long-term debt and finance lease obligations due within one year or the normal operating cycle, if longer. Long-term debt and finance lease obligations LongTermDebtandFinanceLeaseObligations [Member] Refers to long-term debt and finance lease obligations due after one year or beyond the normal operating cycle, if longer. Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Assets Assets [Abstract] Operating lease assets Operating Lease, Right-of-Use Asset Finance lease assets Finance Lease, Right-of-Use Asset Total lease assets Lease, Right-of-Use Asset Amount of lessee's right to use underlying asset under operating and finance leases. Liabilities Liabilities [Abstract] Current operating lease liabilities Operating Lease, Liability, Current Noncurrent operating lease liabilities Operating Lease, Liability, Noncurrent Current finance lease liabilities Finance Lease, Liability, Current Noncurrent finance lease liabilities Finance Lease, Liability, Noncurrent Total lease liabilities Interest Expense, Net Interest Revenue (Expense), Net [Abstract] Interest expense Interest Expense Interest income Investment Income, Interest Interest expense, net Inventories Inventory, Net [Abstract] Finished goods Inventory, Finished Goods, Net of Reserves Work-in-process Inventory, Work in Process, Net of Reserves Raw materials Inventory, Raw Materials, Net of Reserves Inventories Inventory, Net Property and Equipment Property, Plant and Equipment, Net [Abstract] Property and equipment, gross Property, Plant and Equipment, Gross Accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Property and equipment, net Property, Plant and Equipment, Net Depreciation expense Depreciation Operating cash flows from operating leases Operating Lease, Payments Operating cash flows from finance leases Finance Lease, Interest Payment on Liability Financing cash flows from finance leases Finance Lease, Principal Payments Right-of-use assets obtained in exchange for new finance lease liabilities Right-of-Use Asset Obtained in Exchange for Finance Lease Liability Right-of-use assets obtained in exchange for new operating lease liabilities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Schedule of profit and cost sharing relationship Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table Text Block] Transfers of assets or liabilities between the fair value measurement levels Fair Value, Transfers Between Level 1 and Level 2, Description and Policy [Abstract] Transfer of assets from level 1 to level 2 Fair Value, Assets, Level 1 to Level 2 Transfers, Amount Transfer of assets from level 2 to level 1 Fair Value, Assets, Level 2 to Level 1 Transfers, Amount Transfer of liabilities from level 1 to level 2 Fair Value, Liabilities, Level 1 to Level 2 Transfers, Amount Transfer of liabilities from level 2 to level 1 Fair Value, Liabilities, Level 2 to Level 1 Transfers, Amount Reconciliation of the fair value measurements that use significant unobservable inputs (Level 3) Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Beginning balance Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Milestone payments Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements Ending balance Number of operating segments Number of Operating Segments Post-Employment Benefits Postemployment Benefits Disclosure [Text Block] Legal Proceedings and Contingencies Legal Matters and Contingencies [Text Block] Leases Lessee, Leases [Policy Text Block] Short-Term Leases Short-term Leases [Policy Text Block] Statement of Stockholders' Equity [Abstract] Statement [Table] Statement [Table] Common stock Common Stock [Member] Treasury stock Treasury Stock [Member] Additional paid-in capital Additional Paid-in Capital [Member] Retained earnings Retained Earnings [Member] Statement Statement [Line Items] Increase (Decrease) in Stockholders' Equity Increase (Decrease) in Stockholders' Equity [Roll Forward] Beginning balance (in shares) Shares, Outstanding Adoption of new accounting standards Cumulative Effect of New Accounting Principle in Period of Adoption Other comprehensive income, net of tax Dividends declared Dividends, Common Stock, Cash Purchases of treasury stock Purchases of treasury stock (in shares) Stock-based compensation plans and other Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures Stock-based compensation plans and other (in shares) Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures Ending balance (in shares) Segment Information Segment Reporting Disclosure [Text Block] Statement of Cash Flows [Abstract] Cash flows from operating activities Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] Adjustments to reconcile net earnings to net cash from operating activities: Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Depreciation Change in fair value of contingent consideration liabilities Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Stock-based compensation Share-based Compensation Upfront costs and milestones related to collaborations Upfront Costs Related To Collaborations Represents the amount of upfront costs related to collaborations reported in the statement of cash flows. Other, net Other Noncash Income (Expense) Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Accounts receivable Increase (Decrease) in Accounts Receivable Inventories Increase (Decrease) in Inventories Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Accounts payable and other liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Cash flows from operating activities Net Cash Provided by (Used in) Operating Activities Cash flows from investing activities Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] Acquisitions and investments Acquisitions of property and equipment Payments to Acquire Property, Plant, and Equipment Purchases of investment securities Payments to Acquire Marketable Securities Sales and maturities of investment securities Proceeds from Sale, Maturity and Collection of Investments Cash flows from investing activities Net Cash Provided by (Used in) Investing Activities Cash flows from financing activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] Net change in commercial paper borrowings Proceeds from (Repayments of) Commercial Paper Proceeds from issuance of other short-term borrowings Proceeds from Other Short-term Debt Repayments of other short-term borrowings Repayments of long-term debt and finance lease obligations Repayments of Long-term Debt, Long-term Capital Lease Obligations, and Capital Securities Debt issuance costs Payment of Financing and Stock Issuance Costs Dividends paid Payments of Dividends Purchases of treasury stock Payments for Repurchase of Common Stock Proceeds from the exercise of stock options Proceeds from Stock Options Exercised Payments of contingent consideration liabilities Payment for Contingent Consideration Liability, Financing Activities Other, net Proceeds from (Payments for) Other Financing Activities Cash flows from financing activities Net Cash Provided by (Used in) Financing Activities Effect of exchange rate changes on cash and equivalents Effect of Exchange Rate on Cash and Cash Equivalents Net change in cash and equivalents Cash and Cash Equivalents, Period Increase (Decrease) Cash and equivalents, beginning of period Cash and Cash Equivalents, at Carrying Value Cash and equivalents, end of period Foreign currency translation adjustments, net of tax expense (benefit) of $5 for the three months and $6 for the six months ended June 30, 2019 and $(16) for the three months and $(19) for the six months ended June 30, 2018 Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent Net investment hedging activities, net of tax expense (benefit) of $(11) for the three months and $8 for the six months ended June 30, 2019 and $61 for the three months and $31 for the six months ended June 30, 2018 Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), After Reclassification and Tax, Portion Attributable to Parent Amount, after tax and reclassification, of gain (loss) from derivative instruments and nonderivative instruments designated and qualifying as net investment hedge, attributable to parent entity. Pension and post-employment benefits, net of tax expense (benefit) of $6 for the three months and $12 for the six months ended June 30, 2019 and $7 for the three months and $16 for the six months ended June 30, 2018 Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent Marketable security activities, net of tax expense (benefit) of $— for the three months and $— for the six months ended June 30, 2019 and $— for the three months and $— for the six months ended June 30, 2018 Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent Cash flow hedging activities, net of tax expense (benefit) of $(2) for the three months and $(9) for the six months ended June 30, 2019 and $18 for the three months and $17 for the six months ended June 30, 2018 Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent Comprehensive income Comprehensive Income (Loss), Net of Tax, Attributable to Parent New Accounting Pronouncements or Change in Accounting Principle [Table] New Accounting Pronouncements or Change in Accounting Principle [Table] Adjustments for New Accounting Pronouncements [Axis] Adjustments for New Accounting Pronouncements [Axis] Type of Adoption [Domain] Type of Adoption [Domain] Accounting Standards Update 2016-02 Accounting Standards Update 2016-02 [Member] New Accounting Pronouncements or Change in Accounting Principle New Accounting Pronouncements or Change in Accounting Principle [Line Items] Other assets Other Assets, Noncurrent Other long-term liabilities Liabilities, Other than Long-term Debt, Noncurrent Summary of amounts and location of operating and finance leases on the condensed consolidated balance sheet Operating and Finance Lease Balance Sheet Disclosure [Table Text Block] Operating and Finance Lease Balance Sheet Disclosure [Table Text Block] Summary of lease costs recognized in the condensed consolidated statement of earnings Lease, Cost [Table Text Block] Schedule of weighted-average remaining lease term and weighted-average discount rate for operating and finance leases Operating and Finance Lease Weighted-Average Remaining Lease Term and Discount Rate [Table Text Block] Operating and Finance Lease Weighted-Average Remaining Lease Term and Discount Rate [Table Text Block] Schedule of supplementary cash flow information regarding the company's operating and finance leases Operating and Finance Lease Cash Flow Disclosure [Table Text Block] Operating and Finance Lease Cash Flow Disclosure [Table Text Block] Summary of future maturities of AbbVie's operating lease liabilities Lessee, Operating Lease, Liability, Maturity [Table Text Block] Summary of future maturities of AbbVie's finance lease liabilities Finance Lease, Liability, Maturity [Table Text Block] Business Combinations [Abstract] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Allergan plc Allergan plc [Member] Represents the information pertaining to Allergan plc. Scenario [Axis] Scenario [Axis] Scenario, Unspecified [Domain] Scenario, Unspecified [Domain] Scenario, forecast Scenario, Forecast [Member] July 2019 term loan agreement July 2019 Term Loan Credit Agreement [Member] July 2019 Term Loan Credit Agreement July 2019 364-day term loan tranche July 2019 364-Day Term Loan Tranche [Member] July 2019 364-Day Term Loan Tranche July 2019 three-year term loan tranche July 2019 Three-Year Term Loan Tranche [Member] July 2019 Three-Year Term Loan Tranche July 2019 five-year term loan tranche July 2019 Five-Year Term Loan Tranche [Member] July 2019 Five-Year Term Loan Tranche Term loan agreement Subsequent Event Type [Axis] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Subsequent event Subsequent Event [Member] Business Acquisition Business Acquisition [Line Items] Total consideration Business Combination, Consideration Transferred Closing price of AbbVie's common stock Share Price Shares of AbbVie stock received by Allergan shareholders Business Combination Consideration Transferred Number Of Shares Issued Per One Share Of Acquired Entity Represents the number of shares issued by the acquiring entity per one share of acquired entity. Cash per share received by Allergan shareholders Business Acquisition, Share Price Bridge credit agreement maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Credit agreement term Principal amount of term loan Debt Instrument, Unused Borrowing Capacity, Amount Amount drawn under credit agreement Proceeds from Issuance of Debt Collaboration with Janssen Biotech, Inc. Collaborative Arrangement Disclosure [Text Block] Current assets Assets, Current [Abstract] Cash and equivalents Short-term investments Short-term Investments Inventories Prepaid expenses and other Prepaid Expense and Other Assets Total current assets Assets, Current Investments Long-term Investments Property and equipment, net Intangible assets, net Goodwill Total assets Assets Liabilities and Equity Liabilities and Equity [Abstract] Current liabilities Liabilities, Current [Abstract] Current portion of long-term debt and finance lease obligations Long-term Debt and Capital Lease Obligations, Current Total current liabilities Liabilities, Current Long-term debt and finance lease obligations Long-term Debt and Capital Lease Obligations Deferred income taxes Deferred Tax Liabilities, Net, Noncurrent Commitments and contingencies Commitments and Contingencies Stockholders’ equity (deficit) Stockholders' Equity Attributable to Parent [Abstract] Common stock, $0.01 par value, 4,000,000,000 shares authorized, 1,781,055,877 shares issued as of June 30, 2019 and 1,776,510,871 as of December 31, 2018 Common Stock, Value, Outstanding Common stock held in treasury, at cost, 302,685,326 shares as of June 30, 2019 and 297,686,473 as of December 31, 2018 Treasury Stock, Value Additional paid-in capital Additional Paid in Capital, Common Stock Retained earnings Retained Earnings (Accumulated Deficit) Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Total stockholders’ equity (deficit) Total liabilities and equity Liabilities and Equity Cover page. Entities [Table] Entities [Table] Class of Stock [Axis] Class of Stock [Axis] Class of Stock [Domain] Class of Stock [Domain] Common Stock [Member] Entity Listings, Exchange [Axis] Entity Listings, Exchange [Axis] Exchange [Domain] Exchange [Domain] NEW YORK STOCK EXCHANGE, INC. [Member] NEW YORK STOCK EXCHANGE, INC. [Member] CHICAGO STOCK EXCHANGE, INC [Member] CHICAGO STOCK EXCHANGE, INC [Member] Entity Information Entity Information [Line Items] Document Type Document Type Document Quarterly Report Document Quarterly Report Document Period End Date Document Period End Date Document Transition Report Document Transition Report Entity File Number Entity File Number Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Amendment Flag Amendment Flag Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Entity Current Reporting Status Entity Current Reporting Status Entity Interactive Data Current Entity Interactive Data Current Entity Filer Category Entity Filer Category Entity Small Business Entity Small Business Entity Emerging Growth Company Entity Emerging Growth Company Entity Shell Company Entity Shell Company Title of 12(b) Security Title of 12(b) Security Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Financial Instruments and Fair Value Measures Derivatives and Fair Value [Text Block] EX-101.PRE 12 abbv-20190630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 13 abbvieimage1a25.jpg begin 644 abbvieimage1a25.jpg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end GRAPHIC 14 abbvieimage2a12.gif begin 644 abbvieimage2a12.gif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end XML 15 abbv-20190630x10q_htm.xml IDEA: XBRL DOCUMENT 0001551152 2019-01-01 2019-06-30 0001551152 us-gaap:CommonStockMember exch:XNYS 2019-01-01 2019-06-30 0001551152 us-gaap:CommonStockMember exch:XCHI 2019-01-01 2019-06-30 0001551152 2019-07-29 0001551152 2019-04-01 2019-06-30 0001551152 2018-04-01 2018-06-30 0001551152 2018-01-01 2018-06-30 0001551152 2018-12-31 0001551152 2019-06-30 0001551152 us-gaap:RetainedEarningsMember 2017-12-31 0001551152 us-gaap:CommonStockMember 2018-01-01 2018-06-30 0001551152 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-04-01 2018-06-30 0001551152 us-gaap:TreasuryStockMember 2018-03-31 0001551152 us-gaap:RetainedEarningsMember 2018-12-31 0001551152 us-gaap:CommonStockMember 2018-04-01 2018-06-30 0001551152 us-gaap:TreasuryStockMember 2018-04-01 2018-06-30 0001551152 us-gaap:AdditionalPaidInCapitalMember 2018-04-01 2018-06-30 0001551152 us-gaap:TreasuryStockMember 2019-06-30 0001551152 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0001551152 us-gaap:RetainedEarningsMember 2018-06-30 0001551152 us-gaap:TreasuryStockMember 2018-01-01 2018-06-30 0001551152 us-gaap:RetainedEarningsMember 2018-03-31 0001551152 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-06-30 0001551152 us-gaap:TreasuryStockMember 2017-12-31 0001551152 us-gaap:AdditionalPaidInCapitalMember 2019-04-01 2019-06-30 0001551152 us-gaap:CommonStockMember 2019-03-31 0001551152 us-gaap:RetainedEarningsMember 2018-04-01 2018-06-30 0001551152 2017-12-31 0001551152 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-30 0001551152 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-06-30 0001551152 us-gaap:CommonStockMember 2019-04-01 2019-06-30 0001551152 us-gaap:CommonStockMember 2018-06-30 0001551152 us-gaap:RetainedEarningsMember 2018-01-01 2018-06-30 0001551152 us-gaap:CommonStockMember 2017-12-31 0001551152 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-06-30 0001551152 us-gaap:CommonStockMember 2018-12-31 0001551152 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-06-30 0001551152 2018-01-01 0001551152 us-gaap:TreasuryStockMember 2019-04-01 2019-06-30 0001551152 us-gaap:RetainedEarningsMember 2019-04-01 2019-06-30 0001551152 us-gaap:TreasuryStockMember 2018-01-01 0001551152 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 0001551152 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0001551152 us-gaap:RetainedEarningsMember 2018-01-01 0001551152 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-04-01 2019-06-30 0001551152 us-gaap:RetainedEarningsMember 2019-01-01 2019-06-30 0001551152 us-gaap:CommonStockMember 2019-01-01 2019-06-30 0001551152 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-03-31 0001551152 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-06-30 0001551152 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001551152 us-gaap:TreasuryStockMember 2018-12-31 0001551152 us-gaap:CommonStockMember 2019-06-30 0001551152 2018-06-30 0001551152 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 0001551152 us-gaap:CommonStockMember 2018-03-31 0001551152 us-gaap:TreasuryStockMember 2019-01-01 2019-06-30 0001551152 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0001551152 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001551152 us-gaap:TreasuryStockMember 2019-03-31 0001551152 2019-03-31 0001551152 us-gaap:RetainedEarningsMember 2019-06-30 0001551152 us-gaap:TreasuryStockMember 2018-06-30 0001551152 us-gaap:AdditionalPaidInCapitalMember 2018-03-31 0001551152 2018-03-31 0001551152 us-gaap:RetainedEarningsMember 2019-03-31 0001551152 us-gaap:AdditionalPaidInCapitalMember 2018-06-30 0001551152 us-gaap:CommonStockMember 2018-01-01 0001551152 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0001551152 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0001551152 us-gaap:AccountingStandardsUpdate201602Member 2019-01-01 0001551152 abbv:June2019BridgeCreditFacilityMember us-gaap:BridgeLoanMember 2019-06-25 0001551152 abbv:AllerganplcMember us-gaap:ScenarioForecastMember 2020-01-01 0001551152 2019-06-24 0001551152 abbv:July2019364DayTermLoanTrancheMember us-gaap:LoansPayableMember us-gaap:SubsequentEventMember 2019-07-12 2019-07-12 0001551152 abbv:June2019BridgeCreditFacilityMember us-gaap:BridgeLoanMember 2019-01-01 2019-06-30 0001551152 abbv:CalicoLifeSciencesLlcMember us-gaap:CollaborativeArrangementMember 2018-06-01 2018-06-30 0001551152 abbv:June2019BridgeCreditFacilityMember us-gaap:BridgeLoanMember 2019-06-25 2019-06-25 0001551152 us-gaap:CollaborativeArrangementMember 2018-06-01 2018-06-30 0001551152 abbv:AllerganplcMember us-gaap:ScenarioForecastMember 2020-01-01 2020-03-31 0001551152 abbv:July2019ThreeYearTermLoanTrancheMember us-gaap:LoansPayableMember us-gaap:SubsequentEventMember 2019-07-12 0001551152 abbv:July2019TermLoanCreditAgreementMember us-gaap:LoansPayableMember us-gaap:SubsequentEventMember 2019-07-12 0001551152 abbv:June2019BridgeCreditFacilityMember us-gaap:BridgeLoanMember us-gaap:SubsequentEventMember 2019-07-12 0001551152 abbv:July2019364DayTermLoanTrancheMember us-gaap:LoansPayableMember us-gaap:SubsequentEventMember 2019-07-12 0001551152 abbv:CalicoLifeSciencesLlcMember us-gaap:CollaborativeArrangementMember 2018-01-01 2018-06-30 0001551152 abbv:July2019FiveYearTermLoanTrancheMember us-gaap:LoansPayableMember us-gaap:SubsequentEventMember 2019-07-12 0001551152 abbv:July2019TermLoanCreditAgreementMember us-gaap:LoansPayableMember us-gaap:SubsequentEventMember 2019-07-12 2019-07-12 0001551152 abbv:July2019FiveYearTermLoanTrancheMember us-gaap:LoansPayableMember us-gaap:SubsequentEventMember 2019-07-12 2019-07-12 0001551152 abbv:July2019ThreeYearTermLoanTrancheMember us-gaap:LoansPayableMember us-gaap:SubsequentEventMember 2019-07-12 2019-07-12 0001551152 abbv:JanssenBiotechIncMember us-gaap:CollaborativeArrangementMember 2018-12-31 0001551152 abbv:JanssenBiotechIncMember us-gaap:CollaborativeArrangementMember 2019-06-30 0001551152 abbv:JanssenBiotechIncMember us-gaap:CollaborativeArrangementMember 2019-01-01 2019-06-30 0001551152 us-gaap:CollaborativeArrangementMember 2019-01-01 2019-06-30 0001551152 us-gaap:NonUsMember us-gaap:CollaborativeArrangementMember 2019-04-01 2019-06-30 0001551152 abbv:JanssenBiotechIncMember country:US us-gaap:CollaborativeArrangementMember 2018-04-01 2018-06-30 0001551152 us-gaap:NonUsMember us-gaap:CollaborativeArrangementMember 2019-01-01 2019-06-30 0001551152 us-gaap:CollaborativeArrangementMember 2018-01-01 2018-06-30 0001551152 us-gaap:NonUsMember us-gaap:CollaborativeArrangementMember 2018-04-01 2018-06-30 0001551152 abbv:JanssenBiotechIncMember country:US us-gaap:CollaborativeArrangementMember 2019-01-01 2019-06-30 0001551152 abbv:JanssenBiotechIncMember country:US us-gaap:CollaborativeArrangementMember 2018-01-01 2018-06-30 0001551152 us-gaap:NonUsMember us-gaap:CollaborativeArrangementMember 2018-01-01 2018-06-30 0001551152 abbv:JanssenBiotechIncMember country:US us-gaap:CollaborativeArrangementMember 2019-04-01 2019-06-30 0001551152 us-gaap:CollaborativeArrangementMember 2019-04-01 2019-06-30 0001551152 us-gaap:CollaborativeArrangementMember 2018-04-01 2018-06-30 0001551152 abbv:StemcentrxInc.Member us-gaap:InProcessResearchAndDevelopmentMember 2018-10-01 2018-12-31 0001551152 abbv:StemcentrxInc.Member us-gaap:InProcessResearchAndDevelopmentMember 2018-12-31 0001551152 abbv:SKYRIZIMember 2019-04-01 2019-04-30 0001551152 us-gaap:DevelopedTechnologyRightsMember 2018-12-31 0001551152 us-gaap:DevelopedTechnologyRightsMember 2019-06-30 0001551152 us-gaap:LicensingAgreementsMember 2019-06-30 0001551152 us-gaap:LicensingAgreementsMember 2018-12-31 0001551152 abbv:SKYRIZIMember us-gaap:DevelopedTechnologyRightsMember 2019-04-01 2019-04-30 0001551152 abbv:LongTermDebtandFinanceLeaseObligationsCurrentMember 2019-06-30 0001551152 us-gaap:OtherNoncurrentLiabilitiesMember 2019-06-30 0001551152 abbv:LongTermDebtandFinanceLeaseObligationsMember 2019-06-30 0001551152 us-gaap:AccountsPayableAndAccruedLiabilitiesMember 2019-06-30 0001551152 us-gaap:OtherNoncurrentAssetsMember 2019-06-30 0001551152 us-gaap:PropertyPlantAndEquipmentMember 2019-06-30 0001551152 us-gaap:AccountsReceivableMember 2019-01-01 2019-06-30 0001551152 us-gaap:ForeignExchangeForwardMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-06-30 0001551152 us-gaap:ChangeDuringPeriodFairValueDisclosureMember abbv:ChangeInAssumedDiscountRateMember 2019-01-01 2019-06-30 0001551152 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:SeniorNotesMember 2018-01-01 2018-06-30 0001551152 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:SeniorNotesMember 2019-01-01 2019-06-30 0001551152 abbv:May2018TermLoanCreditAgreementMember us-gaap:LoansPayableMember 2019-03-01 2019-03-31 0001551152 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0001551152 us-gaap:ChangeDuringPeriodFairValueDisclosureMember abbv:ChangeInAssumedProbabilityRateMember 2019-01-01 2019-06-30 0001551152 us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-01-01 2019-06-30 0001551152 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2018-01-01 2018-06-30 0001551152 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-01-01 2019-06-30 0001551152 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2019-01-01 2019-06-30 0001551152 us-gaap:CommercialPaperMember 2018-06-30 0001551152 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2019-06-30 0001551152 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:SeniorNotesMember 2019-04-01 2019-06-30 0001551152 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2018-12-31 0001551152 abbv:SKYRIZIMember 2019-04-01 2019-06-30 0001551152 us-gaap:CommercialPaperMember 2019-06-30 0001551152 us-gaap:AccountsReceivableMember us-gaap:GeographicConcentrationRiskMember 2019-01-01 2019-06-30 0001551152 us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:SeniorNotesMember 2019-06-30 0001551152 us-gaap:ShortTermInvestmentsMember 2019-06-30 0001551152 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:SeniorNotesMember 2018-04-01 2018-06-30 0001551152 us-gaap:ShortTermInvestmentsMember 2018-12-31 0001551152 abbv:May2018TermLoanCreditAgreementMember us-gaap:LoansPayableMember 2018-05-01 2018-05-31 0001551152 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-06-30 0001551152 us-gaap:CommercialPaperMember 2018-12-31 0001551152 us-gaap:AccountsReceivableMember us-gaap:GeographicConcentrationRiskMember 2018-01-01 2018-06-30 0001551152 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-06-30 0001551152 us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-04-01 2018-06-30 0001551152 us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-01-01 2018-06-30 0001551152 us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-04-01 2019-06-30 0001551152 us-gaap:FairValueInputsLevel2Member 2018-12-31 0001551152 us-gaap:FairValueInputsLevel3Member 2018-12-31 0001551152 us-gaap:FairValueInputsLevel1Member 2018-12-31 0001551152 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2018-12-31 0001551152 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2018-12-31 0001551152 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-06-30 0001551152 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0001551152 us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0001551152 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-06-30 0001551152 us-gaap:OtherNoncurrentAssetsMember us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0001551152 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2018-12-31 0001551152 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0001551152 us-gaap:OtherLiabilitiesMember us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-06-30 0001551152 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2019-06-30 0001551152 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-06-30 0001551152 us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2018-12-31 0001551152 us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-06-30 0001551152 us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2019-06-30 0001551152 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0001551152 us-gaap:OtherLiabilitiesMember us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0001551152 us-gaap:OtherNoncurrentAssetsMember us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-06-30 0001551152 us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-06-30 0001551152 us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-06-30 0001551152 us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0001551152 us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0001551152 us-gaap:OtherDebtSecuritiesMember 2018-12-31 0001551152 us-gaap:AssetBackedSecuritiesMember 2018-12-31 0001551152 us-gaap:CorporateDebtSecuritiesMember 2018-12-31 0001551152 us-gaap:FairValueInputsLevel3Member 2019-06-30 0001551152 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2019-06-30 0001551152 us-gaap:FairValueInputsLevel2Member 2019-06-30 0001551152 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-06-30 0001551152 us-gaap:FairValueInputsLevel1Member 2019-06-30 0001551152 us-gaap:FairValueMeasurementsRecurringMember 2019-06-30 0001551152 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-06-30 0001551152 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-06-30 0001551152 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-06-30 0001551152 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-06-30 0001551152 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-06-30 0001551152 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-06-30 0001551152 us-gaap:ForeignExchangeContractMember us-gaap:FairValueMeasurementsRecurringMember 2019-06-30 0001551152 us-gaap:OtherDebtSecuritiesMember 2019-06-30 0001551152 us-gaap:AssetBackedSecuritiesMember 2019-06-30 0001551152 us-gaap:CorporateDebtSecuritiesMember 2019-06-30 0001551152 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001551152 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001551152 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001551152 us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001551152 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001551152 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001551152 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:BankTimeDepositsMember 2018-12-31 0001551152 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001551152 us-gaap:ForeignExchangeContractMember us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001551152 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:BankTimeDepositsMember 2018-12-31 0001551152 us-gaap:FairValueMeasurementsRecurringMember us-gaap:BankTimeDepositsMember 2018-12-31 0001551152 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:BankTimeDepositsMember 2018-12-31 0001551152 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2018-01-01 2018-06-30 0001551152 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CostOfSalesMember 2018-04-01 2018-06-30 0001551152 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember us-gaap:ForeignCurrencyGainLossMember 2018-01-01 2018-06-30 0001551152 us-gaap:FairValueHedgingMember us-gaap:InterestExpenseMember 2019-04-01 2019-06-30 0001551152 us-gaap:FairValueHedgingMember us-gaap:InterestExpenseMember 2019-01-01 2019-06-30 0001551152 us-gaap:ForeignExchangeForwardMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2018-01-01 2018-06-30 0001551152 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CostOfSalesMember 2018-01-01 2018-06-30 0001551152 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember us-gaap:ForeignCurrencyGainLossMember 2019-04-01 2019-06-30 0001551152 us-gaap:ForeignExchangeForwardMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2019-04-01 2019-06-30 0001551152 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2019-01-01 2019-06-30 0001551152 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2018-04-01 2018-06-30 0001551152 us-gaap:ForeignExchangeForwardMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2018-04-01 2018-06-30 0001551152 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember us-gaap:ForeignCurrencyGainLossMember 2019-01-01 2019-06-30 0001551152 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CostOfSalesMember 2019-04-01 2019-06-30 0001551152 us-gaap:ForeignExchangeForwardMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2019-01-01 2019-06-30 0001551152 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember us-gaap:ForeignCurrencyGainLossMember 2018-04-01 2018-06-30 0001551152 us-gaap:FairValueHedgingMember us-gaap:InterestExpenseMember 2018-04-01 2018-06-30 0001551152 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2019-04-01 2019-06-30 0001551152 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CostOfSalesMember 2019-01-01 2019-06-30 0001551152 us-gaap:FairValueHedgingMember us-gaap:InterestExpenseMember 2018-01-01 2018-06-30 0001551152 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0001551152 us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:SeniorNotesMember 2018-12-31 0001551152 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2018-04-01 2018-06-30 0001551152 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2018-01-01 2018-06-30 0001551152 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2019-01-01 2019-06-30 0001551152 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2019-04-01 2019-06-30 0001551152 us-gaap:PensionPlansDefinedBenefitMember 2018-01-01 2018-06-30 0001551152 us-gaap:PensionPlansDefinedBenefitMember 2019-01-01 2019-06-30 0001551152 us-gaap:PensionPlansDefinedBenefitMember 2019-04-01 2019-06-30 0001551152 us-gaap:PensionPlansDefinedBenefitMember 2018-04-01 2018-06-30 0001551152 us-gaap:CostOfSalesMember 2019-04-01 2019-06-30 0001551152 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2018-04-01 2018-06-30 0001551152 us-gaap:CostOfSalesMember 2019-01-01 2019-06-30 0001551152 us-gaap:ResearchAndDevelopmentExpenseMember 2019-04-01 2019-06-30 0001551152 us-gaap:CostOfSalesMember 2018-01-01 2018-06-30 0001551152 us-gaap:ResearchAndDevelopmentExpenseMember 2018-04-01 2018-06-30 0001551152 us-gaap:ResearchAndDevelopmentExpenseMember 2018-01-01 2018-06-30 0001551152 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2018-01-01 2018-06-30 0001551152 us-gaap:CostOfSalesMember 2018-04-01 2018-06-30 0001551152 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-06-30 0001551152 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-01-01 2019-06-30 0001551152 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-04-01 2019-06-30 0001551152 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-01-01 2018-06-30 0001551152 us-gaap:AccumulatedTranslationAdjustmentMember 2018-01-01 2018-06-30 0001551152 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-01-01 2018-06-30 0001551152 abbv:AccumulatedNetGainLossFromNetInvestmentHedgesAttributableToParentMember 2017-12-31 0001551152 abbv:AccumulatedNetGainLossFromNetInvestmentHedgesAttributableToParentMember 2018-01-01 2018-06-30 0001551152 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2017-12-31 0001551152 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2017-12-31 0001551152 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2017-12-31 0001551152 abbv:AccumulatedNetGainLossFromNetInvestmentHedgesAttributableToParentMember 2018-06-30 0001551152 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2018-01-01 2018-06-30 0001551152 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-06-30 0001551152 us-gaap:AccumulatedTranslationAdjustmentMember 2018-06-30 0001551152 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2018-06-30 0001551152 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-06-30 0001551152 us-gaap:AccumulatedTranslationAdjustmentMember 2017-12-31 0001551152 abbv:December2018StockRepurchaseAuthorizationMember 2019-01-01 2019-06-30 0001551152 abbv:RestrictedStockUnitsAndPerformanceSharesMember 2019-06-30 0001551152 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-06-30 0001551152 abbv:RestrictedStockUnitsAndPerformanceSharesMember 2019-01-01 2019-06-30 0001551152 us-gaap:EmployeeStockOptionMember 2019-06-30 0001551152 abbv:February2017StockRepurchaseProgramMember 2018-01-01 2018-06-30 0001551152 us-gaap:AccumulatedTranslationAdjustmentMember 2019-01-01 2019-06-30 0001551152 2018-06-14 2018-06-14 0001551152 2018-09-07 2018-09-07 0001551152 2018-02-15 2018-02-15 0001551152 2019-06-20 2019-06-20 0001551152 2019-02-21 2019-02-21 0001551152 2018-11-02 2018-11-02 0001551152 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-06-30 0001551152 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-01-01 2019-06-30 0001551152 abbv:AccumulatedNetGainLossFromNetInvestmentHedgesAttributableToParentMember 2019-06-30 0001551152 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-01-01 2019-06-30 0001551152 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-06-30 0001551152 abbv:AccumulatedNetGainLossFromNetInvestmentHedgesAttributableToParentMember 2019-01-01 2019-06-30 0001551152 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-01-01 2019-06-30 0001551152 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-06-30 0001551152 us-gaap:AccumulatedTranslationAdjustmentMember 2019-06-30 0001551152 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-12-31 0001551152 us-gaap:AccumulatedTranslationAdjustmentMember 2018-12-31 0001551152 abbv:AccumulatedNetGainLossFromNetInvestmentHedgesAttributableToParentMember 2018-12-31 0001551152 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2018-12-31 0001551152 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-12-31 0001551152 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-04-01 2018-06-30 0001551152 us-gaap:NetInvestmentHedgingMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentParentMember 2018-04-01 2018-06-30 0001551152 us-gaap:NetInvestmentHedgingMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentParentMember 2018-01-01 2018-06-30 0001551152 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-04-01 2019-06-30 0001551152 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2018-01-01 2018-06-30 0001551152 us-gaap:NetInvestmentHedgingMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentParentMember 2019-01-01 2019-06-30 0001551152 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-04-01 2019-06-30 0001551152 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2018-04-01 2018-06-30 0001551152 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-01-01 2019-06-30 0001551152 us-gaap:NetInvestmentHedgingMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentParentMember 2019-04-01 2019-06-30 0001551152 abbv:TestosteroneReplacementTherapyProductsLiabilityLitigationMember 2019-06-30 0001551152 abbv:NiaspanMember 2019-01-01 2019-06-30 0001551152 abbv:AndroGelAntitrustLitigationMember 2019-01-01 2019-06-30 0001551152 abbv:DepakoteMember 2019-06-30 0001551152 abbv:NovartisVaccinesandDiagnosticsIncandGrifolsWorldwideOperationsLtdMember 2017-03-01 2017-03-31 0001551152 abbv:ElliottAssociatesL.P.Member 2016-06-01 2016-06-30 0001551152 abbv:AndroGelAntitrustLitigationMember abbv:DisgorgementRemedyMember 2018-06-01 2018-06-30 0001551152 abbv:AndroGelAntitrustLitigationMember 2019-06-30 0001551152 2014-11-01 2014-11-30 0001551152 abbv:AndroGelAntitrustLitigationMember 2014-09-01 2014-09-30 0001551152 abbv:ImbruvicaMember abbv:HematologicOncologyMember 2019-01-01 2019-06-30 0001551152 abbv:VIEKIRAMember abbv:HCVMember 2018-04-01 2018-06-30 0001551152 abbv:ImbruvicaMember country:US abbv:HematologicOncologyMember 2019-04-01 2019-06-30 0001551152 abbv:SevofluraneMember abbv:OtherKeyProductsMember 2018-01-01 2018-06-30 0001551152 abbv:ImbruvicaMember us-gaap:NonUsMember abbv:HematologicOncologyMember 2018-04-01 2018-06-30 0001551152 abbv:LupronMember abbv:OtherKeyProductsMember 2018-01-01 2018-06-30 0001551152 abbv:VIEKIRAMember abbv:HCVMember 2018-01-01 2018-06-30 0001551152 abbv:DuodopaMember abbv:OtherKeyProductsMember 2018-04-01 2018-06-30 0001551152 abbv:CreonMember country:US abbv:OtherKeyProductsMember 2018-01-01 2018-06-30 0001551152 abbv:KaletraMember country:US abbv:OtherKeyProductsMember 2018-04-01 2018-06-30 0001551152 abbv:LupronMember us-gaap:NonUsMember abbv:OtherKeyProductsMember 2019-01-01 2019-06-30 0001551152 abbv:HUMIRAMember us-gaap:NonUsMember abbv:ImmunologyMember 2019-01-01 2019-06-30 0001551152 abbv:OtherProductsMember 2018-04-01 2018-06-30 0001551152 abbv:HUMIRAMember country:US abbv:ImmunologyMember 2018-04-01 2018-06-30 0001551152 abbv:ImbruvicaMember us-gaap:NonUsMember abbv:HematologicOncologyMember 2019-04-01 2019-06-30 0001551152 abbv:MAVYRETMember us-gaap:NonUsMember abbv:HCVMember 2019-04-01 2019-06-30 0001551152 abbv:VENCLEXTAMember us-gaap:NonUsMember abbv:HematologicOncologyMember 2018-04-01 2018-06-30 0001551152 abbv:MAVYRETMember abbv:HCVMember 2019-01-01 2019-06-30 0001551152 abbv:SevofluraneMember country:US abbv:OtherKeyProductsMember 2019-01-01 2019-06-30 0001551152 abbv:SKYRIZIMember country:US abbv:ImmunologyMember 2019-01-01 2019-06-30 0001551152 abbv:ORILISSAMember us-gaap:NonUsMember abbv:OtherKeyProductsMember 2019-01-01 2019-06-30 0001551152 abbv:MAVYRETMember country:US abbv:HCVMember 2018-04-01 2018-06-30 0001551152 abbv:SKYRIZIMember abbv:ImmunologyMember 2018-01-01 2018-06-30 0001551152 abbv:MAVYRETMember country:US abbv:HCVMember 2019-04-01 2019-06-30 0001551152 abbv:HUMIRAMember us-gaap:NonUsMember abbv:ImmunologyMember 2018-04-01 2018-06-30 0001551152 abbv:VENCLEXTAMember abbv:HematologicOncologyMember 2019-01-01 2019-06-30 0001551152 abbv:ORILISSAMember abbv:OtherKeyProductsMember 2018-01-01 2018-06-30 0001551152 abbv:HUMIRAMember abbv:ImmunologyMember 2018-04-01 2018-06-30 0001551152 abbv:HUMIRAMember abbv:ImmunologyMember 2018-01-01 2018-06-30 0001551152 abbv:SynagisMember us-gaap:NonUsMember abbv:OtherKeyProductsMember 2018-04-01 2018-06-30 0001551152 abbv:HUMIRAMember abbv:ImmunologyMember 2019-01-01 2019-06-30 0001551152 abbv:VIEKIRAMember country:US abbv:HCVMember 2019-04-01 2019-06-30 0001551152 abbv:VIEKIRAMember us-gaap:NonUsMember abbv:HCVMember 2018-04-01 2018-06-30 0001551152 abbv:LupronMember us-gaap:NonUsMember abbv:OtherKeyProductsMember 2018-04-01 2018-06-30 0001551152 abbv:AndroGelMember country:US abbv:OtherKeyProductsMember 2018-01-01 2018-06-30 0001551152 abbv:SevofluraneMember abbv:OtherKeyProductsMember 2019-01-01 2019-06-30 0001551152 abbv:CreonMember country:US abbv:OtherKeyProductsMember 2018-04-01 2018-06-30 0001551152 abbv:VENCLEXTAMember us-gaap:NonUsMember abbv:HematologicOncologyMember 2019-01-01 2019-06-30 0001551152 abbv:LupronMember abbv:OtherKeyProductsMember 2018-04-01 2018-06-30 0001551152 abbv:VENCLEXTAMember us-gaap:NonUsMember abbv:HematologicOncologyMember 2019-04-01 2019-06-30 0001551152 abbv:DuodopaMember country:US abbv:OtherKeyProductsMember 2019-04-01 2019-06-30 0001551152 abbv:MAVYRETMember abbv:HCVMember 2018-01-01 2018-06-30 0001551152 abbv:AndroGelMember country:US abbv:OtherKeyProductsMember 2019-04-01 2019-06-30 0001551152 abbv:ImbruvicaMember abbv:HematologicOncologyMember 2019-04-01 2019-06-30 0001551152 abbv:OtherProductsMember 2018-01-01 2018-06-30 0001551152 abbv:VIEKIRAMember country:US abbv:HCVMember 2019-01-01 2019-06-30 0001551152 abbv:ORILISSAMember country:US abbv:OtherKeyProductsMember 2018-04-01 2018-06-30 0001551152 abbv:SevofluraneMember abbv:OtherKeyProductsMember 2019-04-01 2019-06-30 0001551152 abbv:ORILISSAMember country:US abbv:OtherKeyProductsMember 2019-01-01 2019-06-30 0001551152 abbv:ImbruvicaMember us-gaap:NonUsMember abbv:HematologicOncologyMember 2019-01-01 2019-06-30 0001551152 abbv:HUMIRAMember country:US abbv:ImmunologyMember 2019-01-01 2019-06-30 0001551152 abbv:SKYRIZIMember abbv:ImmunologyMember 2019-01-01 2019-06-30 0001551152 abbv:MAVYRETMember abbv:HCVMember 2019-04-01 2019-06-30 0001551152 abbv:VIEKIRAMember country:US abbv:HCVMember 2018-01-01 2018-06-30 0001551152 abbv:SevofluraneMember country:US abbv:OtherKeyProductsMember 2018-01-01 2018-06-30 0001551152 abbv:SKYRIZIMember us-gaap:NonUsMember abbv:ImmunologyMember 2019-04-01 2019-06-30 0001551152 abbv:LupronMember country:US abbv:OtherKeyProductsMember 2018-04-01 2018-06-30 0001551152 abbv:DuodopaMember country:US abbv:OtherKeyProductsMember 2019-01-01 2019-06-30 0001551152 abbv:MAVYRETMember country:US abbv:HCVMember 2018-01-01 2018-06-30 0001551152 abbv:LupronMember us-gaap:NonUsMember abbv:OtherKeyProductsMember 2018-01-01 2018-06-30 0001551152 abbv:VENCLEXTAMember country:US abbv:HematologicOncologyMember 2018-04-01 2018-06-30 0001551152 abbv:SevofluraneMember abbv:OtherKeyProductsMember 2018-04-01 2018-06-30 0001551152 abbv:MAVYRETMember us-gaap:NonUsMember abbv:HCVMember 2018-04-01 2018-06-30 0001551152 abbv:MAVYRETMember us-gaap:NonUsMember abbv:HCVMember 2018-01-01 2018-06-30 0001551152 abbv:ImbruvicaMember us-gaap:NonUsMember abbv:HematologicOncologyMember 2018-01-01 2018-06-30 0001551152 abbv:KaletraMember abbv:OtherKeyProductsMember 2018-04-01 2018-06-30 0001551152 abbv:SevofluraneMember us-gaap:NonUsMember abbv:OtherKeyProductsMember 2018-04-01 2018-06-30 0001551152 abbv:VENCLEXTAMember country:US abbv:HematologicOncologyMember 2019-04-01 2019-06-30 0001551152 abbv:SevofluraneMember country:US abbv:OtherKeyProductsMember 2018-04-01 2018-06-30 0001551152 abbv:VIEKIRAMember country:US abbv:HCVMember 2018-04-01 2018-06-30 0001551152 abbv:ImbruvicaMember abbv:HematologicOncologyMember 2018-01-01 2018-06-30 0001551152 abbv:KaletraMember country:US abbv:OtherKeyProductsMember 2019-01-01 2019-06-30 0001551152 abbv:HUMIRAMember abbv:ImmunologyMember 2019-04-01 2019-06-30 0001551152 abbv:VIEKIRAMember us-gaap:NonUsMember abbv:HCVMember 2019-04-01 2019-06-30 0001551152 abbv:HUMIRAMember us-gaap:NonUsMember abbv:ImmunologyMember 2018-01-01 2018-06-30 0001551152 abbv:LupronMember country:US abbv:OtherKeyProductsMember 2019-01-01 2019-06-30 0001551152 abbv:LupronMember abbv:OtherKeyProductsMember 2019-04-01 2019-06-30 0001551152 abbv:SynthroidMember country:US abbv:OtherKeyProductsMember 2018-04-01 2018-06-30 0001551152 abbv:ImbruvicaMember abbv:HematologicOncologyMember 2018-04-01 2018-06-30 0001551152 abbv:ImbruvicaMember country:US abbv:HematologicOncologyMember 2019-01-01 2019-06-30 0001551152 abbv:VIEKIRAMember abbv:HCVMember 2019-04-01 2019-06-30 0001551152 abbv:KaletraMember abbv:OtherKeyProductsMember 2019-01-01 2019-06-30 0001551152 abbv:VENCLEXTAMember abbv:HematologicOncologyMember 2019-04-01 2019-06-30 0001551152 abbv:ORILISSAMember us-gaap:NonUsMember abbv:OtherKeyProductsMember 2018-01-01 2018-06-30 0001551152 abbv:SKYRIZIMember country:US abbv:ImmunologyMember 2018-01-01 2018-06-30 0001551152 abbv:KaletraMember country:US abbv:OtherKeyProductsMember 2019-04-01 2019-06-30 0001551152 abbv:VENCLEXTAMember us-gaap:NonUsMember abbv:HematologicOncologyMember 2018-01-01 2018-06-30 0001551152 abbv:LupronMember us-gaap:NonUsMember abbv:OtherKeyProductsMember 2019-04-01 2019-06-30 0001551152 abbv:SKYRIZIMember us-gaap:NonUsMember abbv:ImmunologyMember 2019-01-01 2019-06-30 0001551152 abbv:VIEKIRAMember abbv:HCVMember 2019-01-01 2019-06-30 0001551152 abbv:SKYRIZIMember abbv:ImmunologyMember 2019-04-01 2019-06-30 0001551152 abbv:HUMIRAMember country:US abbv:ImmunologyMember 2018-01-01 2018-06-30 0001551152 abbv:SynagisMember us-gaap:NonUsMember abbv:OtherKeyProductsMember 2019-01-01 2019-06-30 0001551152 abbv:KaletraMember us-gaap:NonUsMember abbv:OtherKeyProductsMember 2019-01-01 2019-06-30 0001551152 abbv:VENCLEXTAMember abbv:HematologicOncologyMember 2018-04-01 2018-06-30 0001551152 abbv:VIEKIRAMember us-gaap:NonUsMember abbv:HCVMember 2019-01-01 2019-06-30 0001551152 abbv:DuodopaMember country:US abbv:OtherKeyProductsMember 2018-04-01 2018-06-30 0001551152 abbv:LupronMember country:US abbv:OtherKeyProductsMember 2019-04-01 2019-06-30 0001551152 abbv:ORILISSAMember abbv:OtherKeyProductsMember 2019-01-01 2019-06-30 0001551152 abbv:SynagisMember us-gaap:NonUsMember abbv:OtherKeyProductsMember 2018-01-01 2018-06-30 0001551152 abbv:ImbruvicaMember country:US abbv:HematologicOncologyMember 2018-01-01 2018-06-30 0001551152 abbv:SynagisMember us-gaap:NonUsMember abbv:OtherKeyProductsMember 2019-04-01 2019-06-30 0001551152 abbv:ImbruvicaMember country:US abbv:HematologicOncologyMember 2018-04-01 2018-06-30 0001551152 abbv:CreonMember country:US abbv:OtherKeyProductsMember 2019-01-01 2019-06-30 0001551152 abbv:LupronMember country:US abbv:OtherKeyProductsMember 2018-01-01 2018-06-30 0001551152 abbv:ORILISSAMember abbv:OtherKeyProductsMember 2018-04-01 2018-06-30 0001551152 abbv:DuodopaMember abbv:OtherKeyProductsMember 2018-01-01 2018-06-30 0001551152 abbv:SKYRIZIMember us-gaap:NonUsMember abbv:ImmunologyMember 2018-01-01 2018-06-30 0001551152 abbv:SynthroidMember country:US abbv:OtherKeyProductsMember 2018-01-01 2018-06-30 0001551152 abbv:DuodopaMember us-gaap:NonUsMember abbv:OtherKeyProductsMember 2019-01-01 2019-06-30 0001551152 abbv:SKYRIZIMember country:US abbv:ImmunologyMember 2019-04-01 2019-06-30 0001551152 abbv:AndroGelMember country:US abbv:OtherKeyProductsMember 2019-01-01 2019-06-30 0001551152 abbv:AndroGelMember country:US abbv:OtherKeyProductsMember 2018-04-01 2018-06-30 0001551152 abbv:LupronMember abbv:OtherKeyProductsMember 2019-01-01 2019-06-30 0001551152 abbv:VENCLEXTAMember country:US abbv:HematologicOncologyMember 2018-01-01 2018-06-30 0001551152 abbv:KaletraMember us-gaap:NonUsMember abbv:OtherKeyProductsMember 2019-04-01 2019-06-30 0001551152 abbv:VENCLEXTAMember country:US abbv:HematologicOncologyMember 2019-01-01 2019-06-30 0001551152 abbv:SevofluraneMember country:US abbv:OtherKeyProductsMember 2019-04-01 2019-06-30 0001551152 abbv:ORILISSAMember abbv:OtherKeyProductsMember 2019-04-01 2019-06-30 0001551152 abbv:ORILISSAMember us-gaap:NonUsMember abbv:OtherKeyProductsMember 2018-04-01 2018-06-30 0001551152 abbv:CreonMember country:US abbv:OtherKeyProductsMember 2019-04-01 2019-06-30 0001551152 abbv:DuodopaMember us-gaap:NonUsMember abbv:OtherKeyProductsMember 2019-04-01 2019-06-30 0001551152 abbv:VENCLEXTAMember abbv:HematologicOncologyMember 2018-01-01 2018-06-30 0001551152 abbv:ORILISSAMember country:US abbv:OtherKeyProductsMember 2018-01-01 2018-06-30 0001551152 abbv:HUMIRAMember us-gaap:NonUsMember abbv:ImmunologyMember 2019-04-01 2019-06-30 0001551152 abbv:MAVYRETMember abbv:HCVMember 2018-04-01 2018-06-30 0001551152 abbv:KaletraMember abbv:OtherKeyProductsMember 2019-04-01 2019-06-30 0001551152 abbv:KaletraMember country:US abbv:OtherKeyProductsMember 2018-01-01 2018-06-30 0001551152 abbv:OtherProductsMember 2019-01-01 2019-06-30 0001551152 abbv:SynthroidMember country:US abbv:OtherKeyProductsMember 2019-01-01 2019-06-30 0001551152 abbv:SynthroidMember country:US abbv:OtherKeyProductsMember 2019-04-01 2019-06-30 0001551152 abbv:ORILISSAMember us-gaap:NonUsMember abbv:OtherKeyProductsMember 2019-04-01 2019-06-30 0001551152 abbv:MAVYRETMember country:US abbv:HCVMember 2019-01-01 2019-06-30 0001551152 abbv:ORILISSAMember country:US abbv:OtherKeyProductsMember 2019-04-01 2019-06-30 0001551152 abbv:SevofluraneMember us-gaap:NonUsMember abbv:OtherKeyProductsMember 2019-04-01 2019-06-30 0001551152 abbv:SevofluraneMember us-gaap:NonUsMember abbv:OtherKeyProductsMember 2019-01-01 2019-06-30 0001551152 abbv:SKYRIZIMember us-gaap:NonUsMember abbv:ImmunologyMember 2018-04-01 2018-06-30 0001551152 abbv:KaletraMember us-gaap:NonUsMember abbv:OtherKeyProductsMember 2018-04-01 2018-06-30 0001551152 abbv:DuodopaMember abbv:OtherKeyProductsMember 2019-04-01 2019-06-30 0001551152 abbv:DuodopaMember us-gaap:NonUsMember abbv:OtherKeyProductsMember 2018-01-01 2018-06-30 0001551152 abbv:MAVYRETMember us-gaap:NonUsMember abbv:HCVMember 2019-01-01 2019-06-30 0001551152 abbv:KaletraMember abbv:OtherKeyProductsMember 2018-01-01 2018-06-30 0001551152 abbv:DuodopaMember us-gaap:NonUsMember abbv:OtherKeyProductsMember 2018-04-01 2018-06-30 0001551152 abbv:KaletraMember us-gaap:NonUsMember abbv:OtherKeyProductsMember 2018-01-01 2018-06-30 0001551152 abbv:OtherProductsMember 2019-04-01 2019-06-30 0001551152 abbv:VIEKIRAMember us-gaap:NonUsMember abbv:HCVMember 2018-01-01 2018-06-30 0001551152 abbv:HUMIRAMember country:US abbv:ImmunologyMember 2019-04-01 2019-06-30 0001551152 abbv:DuodopaMember country:US abbv:OtherKeyProductsMember 2018-01-01 2018-06-30 0001551152 abbv:SKYRIZIMember country:US abbv:ImmunologyMember 2018-04-01 2018-06-30 0001551152 abbv:SKYRIZIMember abbv:ImmunologyMember 2018-04-01 2018-06-30 0001551152 abbv:DuodopaMember abbv:OtherKeyProductsMember 2019-01-01 2019-06-30 0001551152 abbv:SevofluraneMember us-gaap:NonUsMember abbv:OtherKeyProductsMember 2018-01-01 2018-06-30 iso4217:USD iso4217:USD shares pure abbv:wholesaler shares iso4217:GBP iso4217:EUR iso4217:CHF abbv:company abbv:segment abbv:direct_purchaser abbv:lawsuit abbv:investment_fund abbv:individual abbv:claim abbv:class_action abbv:end_payor_purchaser 500000000 61000000 31000000 -11000000 8000000 false --12-31 Q2 2019 0001551152 Common Stock, par value $0.01 per share ABBV 10800000000.0 0.01 0.01 4000000000 4000000000 1776510871 1781055877 3600000000 P5Y P3Y 0.21 0 0 0 3900000000 0 0 0 0 0 0 0 0 0 0 -7000000 -16000000 -6000000 -12000000 -16000000 -19000000 5000000 6000000 18000000 17000000 -2000000 -9000000 0 297686473 302685326 10-Q true 2019-06-30 false 001-35565 AbbVie Inc. DE 32-0375147 1 North Waukegan Road North Chicago IL 60064 847 932-7900 Yes Yes Large Accelerated Filer false false false Common Stock, par value $0.01 per share ABBV NYSE CHX 1478483838 8255000000 8278000000 16083000000 16212000000 1819000000 1934000000 3513000000 3861000000 1654000000 1760000000 3334000000 3551000000 1291000000 1322000000 2580000000 2566000000 91000000 0 246000000 69000000 0 500000000 0 500000000 4855000000 5516000000 9673000000 10547000000 3400000000 2762000000 6410000000 5665000000 -309000000 -272000000 -634000000 -523000000 -6000000 -8000000 -12000000 -16000000 -2278000000 -470000000 -2413000000 -317000000 807000000 2012000000 3351000000 4809000000 66000000 29000000 154000000 43000000 741000000 1983000000 3197000000 4766000000 0.49 1.26 2.15 3.00 0.49 1.26 2.14 2.99 1480000000 1568000000 1480000000 1579000000 1484000000 1572000000 1483000000 1584000000 741000000 1983000000 3197000000 4766000000 71000000 -469000000 -32000000 -280000000 -37000000 209000000 28000000 105000000 -20000000 -49000000 -45000000 -71000000 4000000 5000000 11000000 -2000000 -33000000 197000000 -63000000 194000000 25000000 -9000000 -11000000 88000000 766000000 1974000000 3186000000 4854000000 5172000000 7289000000 244000000 772000000 5482000000 5384000000 1895000000 1605000000 2307000000 1895000000 15100000000 16945000000 1473000000 1420000000 2879000000 2883000000 20459000000 21233000000 15642000000 15663000000 1589000000 1208000000 57142000000 59352000000 306000000 3699000000 5335000000 1609000000 11300000000 11931000000 16941000000 17239000000 31619000000 35002000000 1148000000 1067000000 16000000000 14490000000 18000000 18000000 24505000000 24108000000 15028000000 14756000000 3384000000 3368000000 -2491000000 -2480000000 -8566000000 -8446000000 57142000000 59352000000 1587000000 18000000 -13331000000 14519000000 4977000000 -2630000000 3553000000 0 0 0 1983000000 0 1983000000 0 0 0 0 -9000000 -9000000 0 0 0 1465000000 0 1465000000 73000000 0 7516000000 0 0 0 7516000000 0 0 2000000 77000000 0 0 79000000 1514000000 18000000 -20845000000 14596000000 5495000000 -2639000000 -3375000000 1478000000 18000000 -24502000000 14940000000 4234000000 -2516000000 -7826000000 0 0 0 741000000 0 741000000 0 0 0 0 25000000 25000000 0 0 0 1591000000 0 1591000000 0 0 3000000 0 0 0 3000000 0 0 0 88000000 0 0 88000000 1478000000 18000000 -24505000000 15028000000 3384000000 -2491000000 -8566000000 1592000000 18000000 -11923000000 14270000000 5459000000 -2727000000 5097000000 0 0 0 -1733000000 0 -1733000000 0 0 0 4766000000 0 4766000000 0 0 0 0 88000000 88000000 0 0 0 2997000000 0 2997000000 85000000 0 8947000000 0 0 0 8947000000 7000000 0 25000000 326000000 0 0 351000000 1514000000 18000000 -20845000000 14596000000 5495000000 -2639000000 -3375000000 1479000000 18000000 -24108000000 14756000000 3368000000 -2480000000 -8446000000 0 0 0 3197000000 0 3197000000 0 0 0 0 -11000000 -11000000 0 0 0 3181000000 0 3181000000 5000000 0 422000000 0 0 0 422000000 4000000 0 25000000 272000000 0 0 297000000 1478000000 18000000 -24505000000 15028000000 3384000000 -2491000000 -8566000000 3197000000 4766000000 232000000 234000000 773000000 654000000 2473000000 337000000 276000000 276000000 321000000 656000000 10000000 -118000000 96000000 805000000 288000000 191000000 97000000 546000000 -1287000000 12000000 5494000000 5511000000 440000000 401000000 235000000 233000000 558000000 637000000 1066000000 1511000000 -167000000 240000000 -393000000 111000000 0 3000000000 3000000000 0 4000000 3013000000 171000000 0 3180000000 2668000000 623000000 8947000000 5000000 64000000 108000000 39000000 21000000 5000000 -7453000000 -11487000000 9000000 -20000000 -2117000000 -5756000000 7289000000 9303000000 5172000000 3547000000 <span style="font-family:Calibri,sans-serif;font-size:12pt;color:#444867;font-weight:bold;">Basis of Presentation</span><span style="font-family:Calibri,sans-serif;font-size:12pt;color:#444867;font-weight:bold;"> </span><div style="line-height:120%;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"/></tr><tr><td style="width:100%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#444867;font-weight:bold;">Basis of Historical Presentation </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">The unaudited interim condensed consolidated financial statements of AbbVie Inc. (AbbVie or the company) have been prepared pursuant to the rules and regulations of the U.S. Securities and Exchange Commission. Accordingly, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP) have been omitted. These unaudited interim condensed consolidated financial statements should be read in conjunction with the company’s audited consolidated financial statements and notes included in the company’s Annual Report on Form 10-K for the year ended </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">December 31, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">It is management’s opinion that these financial statements include all normal and recurring adjustments necessary for a fair presentation of the company’s financial position and operating results. Net revenues and net earnings for any interim period are not necessarily indicative of future or annual results. Certain reclassifications were made to conform the prior period interim condensed consolidated financial statements to the current period presentation.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#444867;font-weight:bold;">Recent Accounting Pronouncements</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">Recently Adopted Accounting Pronouncements</span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">ASU No. 2016-02</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">In February 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2016-02, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">Leases (Topic 842)</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">. The standard outlined a comprehensive lease accounting model that superseded the previous lease guidance and required lessees to recognize lease liabilities and corresponding right-of-use assets for all leases with lease terms greater than 12 months. The guidance also changed the definition of a lease and expanded the disclosure requirements of lease arrangements. AbbVie adopted the standard in the first quarter of 2019 using the modified retrospective method. Results for reporting periods beginning after December 31, 2018 have been presented in accordance with the standard, while results for prior periods have not been adjusted and continue to be reported in accordance with AbbVie's historical accounting. The cumulative effect of initially applying the new leases standard was recognized as an adjustment to the opening condensed consolidated balance sheet as of January 1, 2019.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">The company elected a package of practical expedients for leases that commenced prior to January 1, 2019 and did not reassess historical conclusions on: (i) whether any expired or existing contracts are or contain leases; (ii) lease classification for any expired or existing leases; and (iii) initial direct costs capitalization for any existing leases.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Under the new standard, on January 1, 2019, the company recognized a cumulative-effect adjustment to its condensed consolidated balance sheet primarily related to the recognition of liabilities and corresponding right-of-use assets for operating leases. The adjustment to the condensed consolidated balance sheet included: (i) a </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>$405 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> increase to other assets; (ii) a </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>$115 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> increase to accounts payable and accrued liabilities; and (iii) a </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>$290 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> increase to other long-term liabilities. Other cumulative-effect adjustments to the condensed consolidated balance sheet were insignificant.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Adoption of the standard did not have a significant impact on AbbVie's condensed consolidated statements of earnings for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">three and six months ended June 30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">ASU No. 2018-02</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">In February 2018, the FASB issued ASU No. 2018-02, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">Income Statement - Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">which allowed a reclassification from accumulated other comprehensive income (AOCI) to retained earnings for stranded tax effects related to adjustments to deferred taxes resulting from the December 2017 enactment of the Tax Cuts and Jobs Act (the Act). AbbVie adopted the standard in the first quarter of 2019. Upon adoption, the company made an election to not reclassify the income tax effects of the Act from AOCI to retained earnings. Therefore, the adoption of the standard had no impact on AbbVie's consolidated financial statements.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">ASU No. 2016-13</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">In June 2016, the FASB issued ASU No. 2016-13, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">Financial Instruments - Credit Losses (Topic 326)</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">. The standard changes how credit losses are measured for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other financial instruments, the standard requires the use of a new forward-looking "expected credit loss" model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, the standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. Additionally, the standard requires new disclosures and will be effective for AbbVie starting with the first quarter of 2020. With certain exceptions, adjustments are to be applied using a modified-retrospective approach by reflecting adjustments through a cumulative-effect impact to retained earnings as of the beginning of the fiscal year of adoption. AbbVie is currently assessing the impact of adopting this guidance on its consolidated financial statements.</span></div> <div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#444867;font-weight:bold;">Recent Accounting Pronouncements</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">Recently Adopted Accounting Pronouncements</span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">ASU No. 2016-02</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">In February 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2016-02, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">Leases (Topic 842)</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">. The standard outlined a comprehensive lease accounting model that superseded the previous lease guidance and required lessees to recognize lease liabilities and corresponding right-of-use assets for all leases with lease terms greater than 12 months. The guidance also changed the definition of a lease and expanded the disclosure requirements of lease arrangements. AbbVie adopted the standard in the first quarter of 2019 using the modified retrospective method. Results for reporting periods beginning after December 31, 2018 have been presented in accordance with the standard, while results for prior periods have not been adjusted and continue to be reported in accordance with AbbVie's historical accounting. The cumulative effect of initially applying the new leases standard was recognized as an adjustment to the opening condensed consolidated balance sheet as of January 1, 2019.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">The company elected a package of practical expedients for leases that commenced prior to January 1, 2019 and did not reassess historical conclusions on: (i) whether any expired or existing contracts are or contain leases; (ii) lease classification for any expired or existing leases; and (iii) initial direct costs capitalization for any existing leases.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Under the new standard, on January 1, 2019, the company recognized a cumulative-effect adjustment to its condensed consolidated balance sheet primarily related to the recognition of liabilities and corresponding right-of-use assets for operating leases. The adjustment to the condensed consolidated balance sheet included: (i) a </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>$405 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> increase to other assets; (ii) a </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>$115 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> increase to accounts payable and accrued liabilities; and (iii) a </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>$290 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> increase to other long-term liabilities. Other cumulative-effect adjustments to the condensed consolidated balance sheet were insignificant.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Adoption of the standard did not have a significant impact on AbbVie's condensed consolidated statements of earnings for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">three and six months ended June 30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">ASU No. 2018-02</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">In February 2018, the FASB issued ASU No. 2018-02, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">Income Statement - Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">which allowed a reclassification from accumulated other comprehensive income (AOCI) to retained earnings for stranded tax effects related to adjustments to deferred taxes resulting from the December 2017 enactment of the Tax Cuts and Jobs Act (the Act). AbbVie adopted the standard in the first quarter of 2019. Upon adoption, the company made an election to not reclassify the income tax effects of the Act from AOCI to retained earnings. Therefore, the adoption of the standard had no impact on AbbVie's consolidated financial statements.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">ASU No. 2016-13</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">In June 2016, the FASB issued ASU No. 2016-13, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">Financial Instruments - Credit Losses (Topic 326)</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">. The standard changes how credit losses are measured for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other financial instruments, the standard requires the use of a new forward-looking "expected credit loss" model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, the standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. Additionally, the standard requires new disclosures and will be effective for AbbVie starting with the first quarter of 2020. With certain exceptions, adjustments are to be applied using a modified-retrospective approach by reflecting adjustments through a cumulative-effect impact to retained earnings as of the beginning of the fiscal year of adoption. AbbVie is currently assessing the impact of adopting this guidance on its consolidated financial statements.</span></div> 405000000 115000000 290000000 <span style="font-family:Calibri,sans-serif;font-size:12pt;color:#444867;font-weight:bold;">Supplemental Financial Information</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"/></tr><tr><td style="width:100%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#444867;font-weight:bold;">Interest Expense, Net</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:48%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Three months ended<br/>June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Six months ended<br/>June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">(in millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Interest expense</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>358</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>320</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>745</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>629</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Interest income</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(49</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(48</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(111</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(106</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Interest expense, net </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>309</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>272</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>634</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>523</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#444867;font-weight:bold;">Inventories</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:75%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">June 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Finished goods</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>638</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>473</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Work-in-process</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>969</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>862</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Raw materials</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>288</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>270</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Inventories</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,895</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,605</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#444867;font-weight:bold;">Property and Equipment</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:75%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">June 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Property and equipment, gross</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>8,443</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>8,396</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Accumulated depreciation</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(5,564</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(5,513</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Property and equipment, net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,879</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,883</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Depreciation expense was </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>$114 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">for the three months and</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>$232 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">six months ended June 30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>$119 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">for the three months and</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>$234 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">six months ended June 30, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">.</span></div> <div style="line-height:120%;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#444867;font-weight:bold;">Interest Expense, Net</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:48%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Three months ended<br/>June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Six months ended<br/>June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">(in millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Interest expense</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>358</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>320</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>745</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>629</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Interest income</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(49</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(48</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(111</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(106</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Interest expense, net </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>309</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>272</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>634</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>523</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div> 358000000 320000000 745000000 629000000 49000000 48000000 111000000 106000000 -309000000 -272000000 -634000000 -523000000 <div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#444867;font-weight:bold;">Inventories</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:75%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">June 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Finished goods</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>638</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>473</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Work-in-process</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>969</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>862</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Raw materials</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>288</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>270</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Inventories</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,895</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,605</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div> 638000000 473000000 969000000 862000000 288000000 270000000 1895000000 1605000000 <div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#444867;font-weight:bold;">Property and Equipment</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:75%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">June 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Property and equipment, gross</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>8,443</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>8,396</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Accumulated depreciation</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(5,564</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(5,513</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Property and equipment, net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,879</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,883</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div> 8443000000 8396000000 5564000000 5513000000 2879000000 2883000000 114000000 232000000 119000000 234000000 <span style="font-family:Calibri,sans-serif;font-size:12pt;color:#444867;font-weight:bold;">Earnings Per Share</span><span style="font-family:Calibri,sans-serif;font-size:12pt;color:#444867;font-weight:bold;"> </span><div style="line-height:120%;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"/></tr><tr><td style="width:100%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">AbbVie grants certain restricted stock units (RSUs) that are considered to be participating securities. Due to the presence of participating securities, AbbVie calculates earnings per share (EPS) using the more dilutive of the treasury stock or the two-class method. For all periods presented, the two-class method was more dilutive.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">The following table summarizes the impact of the two-class method:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:48%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Three months ended<br/>June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Six months ended<br/>June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">(in millions, except per share data)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Basic EPS</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net earnings</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>741</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,983</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3,197</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,766</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Earnings allocated to participating securities</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>17</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>22</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Earnings available to common shareholders</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>733</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,973</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3,180</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,744</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Weighted-average basic shares outstanding</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,480</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,568</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,480</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,579</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Basic earnings per share</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>0.49</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1.26</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2.15</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3.00</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Diluted EPS</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net earnings</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>741</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,983</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3,197</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,766</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Earnings allocated to participating securities</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>17</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>22</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Earnings available to common shareholders</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>733</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,973</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3,180</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,744</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Weighted-average shares of common stock outstanding</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,480</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,568</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,480</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,579</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Effect of dilutive securities</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Weighted-average diluted shares outstanding</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,484</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,572</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,483</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,584</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Diluted earnings per share</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>0.49</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1.26</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2.14</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2.99</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Certain shares issuable under stock-based compensation plans were excluded from the computation of EPS because the effect would have been antidilutive. The number of common shares excluded was insignificant for all periods presented.</span></div> <div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">The following table summarizes the impact of the two-class method:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:48%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Three months ended<br/>June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Six months ended<br/>June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">(in millions, except per share data)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Basic EPS</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net earnings</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>741</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,983</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3,197</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,766</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Earnings allocated to participating securities</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>17</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>22</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Earnings available to common shareholders</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>733</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,973</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3,180</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,744</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Weighted-average basic shares outstanding</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,480</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,568</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,480</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,579</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Basic earnings per share</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>0.49</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1.26</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2.15</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3.00</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Diluted EPS</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net earnings</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>741</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,983</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3,197</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,766</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Earnings allocated to participating securities</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>17</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>22</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Earnings available to common shareholders</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>733</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,973</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3,180</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,744</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Weighted-average shares of common stock outstanding</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,480</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,568</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,480</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,579</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Effect of dilutive securities</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Weighted-average diluted shares outstanding</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,484</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,572</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,483</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,584</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Diluted earnings per share</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>0.49</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1.26</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2.14</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2.99</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div> 741000000 1983000000 3197000000 4766000000 8000000 10000000 17000000 22000000 733000000 1973000000 3180000000 4744000000 1480000000 1568000000 1480000000 1579000000 0.49 1.26 2.15 3.00 741000000 1983000000 3197000000 4766000000 8000000 10000000 17000000 22000000 733000000 1973000000 3180000000 4744000000 1480000000 1568000000 1480000000 1579000000 4000000 4000000 3000000 5000000 1484000000 1572000000 1483000000 1584000000 0.49 1.26 2.14 2.99 <span style="font-family:Calibri,sans-serif;font-size:12pt;color:#444867;font-weight:bold;">Licensing, Acquisitions and Other Arrangements</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"/></tr><tr><td style="width:100%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#444867;font-weight:bold;">Proposed Acquisition of Allergan plc</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">On June 25, 2019, AbbVie announced that it entered into a definitive transaction agreement under which AbbVie will acquire Allergan plc (Allergan) in a cash and stock transaction for a transaction equity value of approximately </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>$63 billion</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;">, based on the closing price of AbbVie’s common stock of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>$78.45</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> on June 24, 2019. Under the terms of the transaction agreement, Allergan shareholders will receive </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>0.8660</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> AbbVie shares and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>$120.30</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> in cash for each Allergan share.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">In connection with the proposed acquisition of Allergan, on June 25, 2019, AbbVie entered into a </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>$38.0 billion</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;text-align:right;"><span>364</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;">-day bridge credit agreement. On July 12, 2019, AbbVie entered into a term loan credit agreement with an aggregate principal amount of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>$6.0 billion</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> consisting of a </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>$1.5 billion</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>364</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;">-day term loan tranche, a </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>$2.5 billion</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">three</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">-year term loan tranche and a </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>$2.0 billion</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">five</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">-year term loan tranche, with the commitments under the bridge credit agreement to be reduced by such amount to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>$32.0 billion</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;">. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>No</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> amounts have been drawn under the bridge credit agreement or term loan credit agreement.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Allergan is a global pharmaceutical leader focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world. Allergan markets a portfolio of brands and products primarily focused on key therapeutic areas including medical aesthetics, eye care, neuroscience, gastroenterology and women's health.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">The transaction is expected to close in early 2020, subject to regulatory and Allergan shareholder approvals.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#444867;font-weight:bold;">Other Licensing &amp; Acquisitions Activity</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Cash outflows related to other acquisitions and investments totaled </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>$440 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">six months ended June 30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>$401 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">six months ended June 30, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">. AbbVie recorded acquired in-process research and development (IPR&amp;D) charges of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>$91 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">for the three months and</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>$246 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">six months ended June 30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">. AbbVie recorded </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>no</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> acquired IPR&amp;D charges for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">three months ended June 30, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> and recorded acquired IPR&amp;D charges of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>$69 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">six months ended June 30, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">Calico Life Sciences LLC </span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">In June 2018, AbbVie and Calico Life Sciences LLC (Calico) entered into an extension of a collaboration to discover, develop and bring to market new therapies for patients with age-related diseases, including neurodegeneration and cancer. Under the terms of the agreement, AbbVie and Calico will each contribute an additional </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>$500 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> to the collaboration and the term was extended for an additional </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>three years</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;">. Calico will be responsible for research and early development until 2022 and will advance collaboration projects through Phase 2a through 2027. Following completion of Phase 2a, AbbVie will have the option to exclusively license collaboration compounds. AbbVie will support Calico in its early research and development efforts and, upon exercise, would be responsible for late-stage development and commercial activities. Collaboration costs and profits will be shared equally by both parties post option exercise. During the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">six months ended June 30, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">, AbbVie recorded </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>$500 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> in other expense in the condensed consolidated statement of earnings related to its commitments under the agreement.</span></div> 63000000000 78.45 0.8660 120.30 38000000000.0 P364D 6000000000.0 1500000000 P364D 2500000000 2000000000.0 32000000000.0 0 440000000 401000000 91000000 246000000 0 69000000 500000000 P3Y 500000000 <span style="font-family:Calibri,sans-serif;font-size:12pt;color:#444867;font-weight:bold;">Collaboration with Janssen Biotech, Inc.</span><span style="font-family:Calibri,sans-serif;font-size:12pt;color:#444867;font-weight:bold;"> </span><div style="line-height:120%;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"/></tr><tr><td style="width:100%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">In December 2011, Pharmacyclics, a wholly-owned subsidiary of AbbVie, entered into a worldwide collaboration and license agreement with Janssen Biotech, Inc. and its affiliates (Janssen), one of the Janssen Pharmaceutical companies of Johnson &amp; Johnson, for the joint development and commercialization of IMBRUVICA, a novel, orally active, selective covalent inhibitor of Bruton's tyrosine kinase (BTK) and certain compounds structurally related to IMBRUVICA, for oncology and other indications, excluding all immune and inflammatory mediated diseases or conditions and all psychiatric or psychological diseases or conditions, in the United States and outside the United States.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">The collaboration provides Janssen with an exclusive license to commercialize IMBRUVICA outside of the United States and co-exclusively with AbbVie in the United States. Both parties are responsible for the development, manufacturing and marketing of any products generated as a result of the collaboration. The collaboration has no set duration or specific expiration date and provides for potential future development, regulatory and approval milestone payments of up to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>$200 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> to AbbVie. The collaboration also includes a cost sharing arrangement for associated collaboration activities. Except in certain cases, Janssen is responsible for approximately </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>60%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> of collaboration development costs and AbbVie is responsible for the remaining </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>40%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> of collaboration development costs.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">In the United States, both parties have co-exclusive rights to commercialize the products; however, AbbVie is the principal in the end-customer product sales. AbbVie and Janssen share pre-tax profits and losses equally from the commercialization of products. Sales of IMBRUVICA are included in AbbVie's net revenues. Janssen's share of profits is included in AbbVie's cost of products sold. Other costs incurred under the collaboration are reported in their respective expense line items, net of Janssen's share.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Outside the United States, Janssen is responsible for and has exclusive rights to commercialize IMBRUVICA. AbbVie and Janssen share pre-tax profits and losses equally from the commercialization of products. AbbVie's share of profits is included in AbbVie's net revenues. Other costs incurred under the collaboration are reported in their respective expense line items, net of Janssen's share.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">The following table shows the profit and cost sharing relationship between Janssen and AbbVie:</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:60%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Three months ended<br/>June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Six months ended<br/>June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">(in millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">United States - Janssen's share of profits (included in cost of products sold)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>422</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>325</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>808</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>601</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">International - AbbVie's share of profits (included in net revenues)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>213</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>157</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>406</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>295</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Global - AbbVie's share of other costs (included in respective line items)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>77</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>80</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>149</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>151</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">AbbVie’s receivable from Janssen, included in accounts receivable, net, was </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>$230 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> at </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">June 30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>$177 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> at </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December 31, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">. AbbVie’s payable to Janssen, included in accounts payable and accrued liabilities, was </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>$405 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> at </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">June 30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>$376 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> at </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December 31, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">.</span></div> 200000000 0.60 0.40 <div style="line-height:120%;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">The following table shows the profit and cost sharing relationship between Janssen and AbbVie:</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:60%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Three months ended<br/>June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Six months ended<br/>June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">(in millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">United States - Janssen's share of profits (included in cost of products sold)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>422</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>325</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>808</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>601</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">International - AbbVie's share of profits (included in net revenues)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>213</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>157</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>406</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>295</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Global - AbbVie's share of other costs (included in respective line items)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>77</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>80</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>149</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>151</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div> 422000000 325000000 808000000 601000000 213000000 157000000 406000000 295000000 77000000 80000000 149000000 151000000 230000000 177000000 405000000 376000000 <span style="font-family:Calibri,sans-serif;font-size:12pt;color:#444867;font-weight:bold;">Goodwill and Intangible Assets</span><span style="font-family:Calibri,sans-serif;font-size:12pt;color:#444867;font-weight:bold;"> </span><div style="line-height:120%;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"/></tr><tr><td style="width:100%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#444867;font-weight:bold;">Goodwill</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">The following table summarizes the changes in the carrying amount of goodwill:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:88%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Balance as of December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>15,663</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Foreign currency translation adjustments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(21</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Balance as of June 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>15,642</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">The company performs its annual goodwill impairment assessment in the third quarter, or earlier if impairment indicators exist. As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">June 30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">, there were </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>no</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> accumulated goodwill impairment losses.</span></div><div style="line-height:120%;padding-top:13px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#444867;font-weight:bold;">Intangible Assets, Net</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">The following table summarizes intangible assets:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"/></tr><tr><td style="width:35%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">June 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Gross <br/>carrying <br/>amount</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Accumulated <br/>amortization</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Net <br/>carrying <br/>amount</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Gross <br/>carrying <br/>amount</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Accumulated <br/>amortization</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Net <br/>carrying <br/>amount</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Definite-lived intangible assets</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Developed product rights</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>19,611</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(5,963</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>13,648</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>15,872</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(5,614</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>10,258</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">License agreements</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>7,798</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(2,017</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>5,781</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>7,865</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(1,810</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6,055</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total definite-lived intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>27,409</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(7,980</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>19,429</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>23,737</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(7,424</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>16,313</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Indefinite-lived research and development</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,030</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,030</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,920</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,920</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total intangible assets, net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>28,439</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(7,980</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>20,459</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>28,657</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(7,424</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>21,233</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">Indefinite-Lived Intangible Assets</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Indefinite-lived intangible assets represent acquired IPR&amp;D associated with products that have not yet received regulatory approval. The company performs its annual impairment assessment of indefinite-lived intangible assets in the third quarter, or earlier if impairment indicators exist. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>No</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> indefinite-lived intangible asset impairment charges were recorded for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">six months ended June 30, 2019 and 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">In April 2019, the U.S. Food and Drug Administration (FDA) and the European Commission approved SKYRIZI (risankizumab) for the treatment of moderate to severe plaque psoriasis. As a result, AbbVie reclassified </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>$3.9 billion</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> of indefinite-lived intangible assets related to SKYRIZI to developed product rights definite-lived intangible assets. This amount will be amortized over its estimated useful life using the estimated pattern of economic benefit.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">In the fourth quarter of 2018, the company recorded an impairment charge of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>$5.1 billion</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> related to IPR&amp;D acquired as part of the 2016 Stemcentrx acquisition following the decision to stop enrollment in the TAHOE trial. AbbVie continues to evaluate information as it becomes available with respect to the Stemcentrx-related clinical development programs and will monitor the remaining </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>$1.0 billion</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> of IPR&amp;D assets for further impairment.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">Definite-Lived Intangible Assets</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Amortization expense was </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>$388 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">for the three months and</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>$773 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">six months ended June 30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>$324 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">for the three months and</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>$654 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">six months ended June 30, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">. Amortization expense was included in cost of products sold in the condensed consolidated statements of earnings. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>No</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> definite-lived intangible asset impairment charges were recorded for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">six months ended June 30, 2019 and 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">.</span></div> <div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">The following table summarizes the changes in the carrying amount of goodwill:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:88%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Balance as of December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>15,663</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Foreign currency translation adjustments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(21</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Balance as of June 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>15,642</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div> 15663000000 -21000000 15642000000 0 <div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">The following table summarizes intangible assets:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"/></tr><tr><td style="width:35%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">June 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Gross <br/>carrying <br/>amount</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Accumulated <br/>amortization</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Net <br/>carrying <br/>amount</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Gross <br/>carrying <br/>amount</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Accumulated <br/>amortization</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Net <br/>carrying <br/>amount</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Definite-lived intangible assets</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Developed product rights</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>19,611</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(5,963</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>13,648</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>15,872</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(5,614</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>10,258</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">License agreements</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>7,798</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(2,017</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>5,781</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>7,865</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(1,810</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6,055</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total definite-lived intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>27,409</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(7,980</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>19,429</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>23,737</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(7,424</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>16,313</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Indefinite-lived research and development</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,030</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,030</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,920</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,920</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total intangible assets, net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>28,439</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(7,980</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>20,459</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>28,657</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(7,424</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>21,233</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div> <div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">The following table summarizes intangible assets:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"/></tr><tr><td style="width:35%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">June 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Gross <br/>carrying <br/>amount</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Accumulated <br/>amortization</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Net <br/>carrying <br/>amount</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Gross <br/>carrying <br/>amount</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Accumulated <br/>amortization</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Net <br/>carrying <br/>amount</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Definite-lived intangible assets</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Developed product rights</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>19,611</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(5,963</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>13,648</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>15,872</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(5,614</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>10,258</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">License agreements</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>7,798</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(2,017</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>5,781</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>7,865</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(1,810</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6,055</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total definite-lived intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>27,409</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(7,980</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>19,429</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>23,737</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(7,424</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>16,313</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Indefinite-lived research and development</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,030</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,030</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,920</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,920</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total intangible assets, net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>28,439</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(7,980</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>20,459</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>28,657</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(7,424</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>21,233</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div> 19611000000 5963000000 13648000000 15872000000 5614000000 10258000000 7798000000 2017000000 5781000000 7865000000 1810000000 6055000000 27409000000 7980000000 19429000000 23737000000 7424000000 16313000000 1030000000 1030000000 4920000000 4920000000 28439000000 7980000000 20459000000 28657000000 7424000000 21233000000 0 -3900000000 5100000000 1000000000.0 388000000 773000000 324000000 654000000 0 <span style="font-family:Calibri,sans-serif;font-size:12pt;color:#444867;font-weight:bold;">Restructuring Plans</span><span style="font-family:Calibri,sans-serif;font-size:12pt;color:#444867;font-weight:bold;"> </span><div style="line-height:120%;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"/></tr><tr><td style="width:100%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">AbbVie recorded restructuring charges of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>$19 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">for the three months and</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>$186 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">six months ended June 30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>$1 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">for the three months and</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>$23 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">six months ended June 30, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">. Restructuring charges for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">three and six months ended June 30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> primarily related to severance costs.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">The following table summarizes the cash activity in the restructuring reserve for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">six months ended June 30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:88%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Accrued balance as of December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>99</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Restructuring charges</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>172</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Payments and other adjustments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(80</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Accrued balance as of June 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>191</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div> 19000000 186000000 1000000 23000000 <div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">The following table summarizes the cash activity in the restructuring reserve for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">six months ended June 30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:88%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Accrued balance as of December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>99</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Restructuring charges</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>172</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Payments and other adjustments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(80</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Accrued balance as of June 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>191</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div> 99000000 172000000 80000000 191000000 <span style="font-family:Calibri,sans-serif;font-size:12pt;color:#444867;font-weight:bold;">Leases</span><span style="font-family:Calibri,sans-serif;font-size:12pt;color:#444867;font-weight:bold;">    </span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"/></tr><tr><td style="width:100%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><div style="line-height:120%;padding-top:13px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">AbbVie's lease portfolio primarily consists of real estate properties, vehicles and equipment. Short-term leases with a term of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">12 months</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> or less are not recorded on the balance sheet. For leases commencing or modified in 2019 or later, AbbVie does not separate lease components from non-lease components.</span></div><div style="line-height:120%;padding-top:10px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">The company records lease liabilities based on the present value of lease payments over the lease term. AbbVie generally uses an incremental borrowing rate to discount its lease liabilities, as the rate implicit in the lease is typically not readily determinable. Certain lease agreements include renewal options that are under the company's control. AbbVie includes optional renewal periods in the lease term only when it is reasonably certain that AbbVie will exercise its option. </span></div><div style="line-height:120%;padding-top:10px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Variable lease payments include payments to lessors for taxes, maintenance, insurance and other operating costs as well as payments that are adjusted based on an index or rate. The company's lease agreements do not contain any significant residual value guarantees or restrictive covenants.</span></div><div style="line-height:120%;padding-top:10px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">The following table summarizes the amounts and location of operating and finance leases on the condensed consolidated balance sheet:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:23%;"/><td style="width:65%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">(in millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Balance sheet caption</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">June 30, <br/>2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Operating</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Other assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>380</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Finance</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Property and equipment, net</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>27</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total lease assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>407</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Operating</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Accounts payable and accrued liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>111</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Noncurrent</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Other long-term liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>290</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Finance</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Current</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Current portion of long-term debt and finance lease obligations</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Noncurrent</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Long-term debt and finance lease obligations</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>22</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total lease liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>432</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:10px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">The following table summarizes the lease costs recognized in the condensed consolidated statements of earnings:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:74%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Three months ended<br/>June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Six months ended<br/>June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">(in millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Operating lease cost</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>32</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>64</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Finance lease cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Amortization of right-of-use assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Interest on lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Short-term lease cost</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Variable lease cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>14</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>29</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total lease cost</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>57</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>112</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:10px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Sublease income was insignificant for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">three and six months ended June 30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:10px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">The following table presents the weighted-average remaining lease term and weighted-average discount rate for operating and finance leases:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"/></tr><tr><td style="width:88%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">June 30, <br/>2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Weighted-average remaining lease term (in years)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Operating</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Finance</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Weighted-average discount rate</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Operating</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Finance</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:10px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">The following table presents supplementary cash flow information regarding the company's operating and finance leases:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:88%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Six months ended<br/>June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Cash paid for amounts included in the measurement of lease liabilities</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Operating cash flows from operating leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>58</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Operating cash flows from finance leases</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Financing cash flows from finance leases</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Right-of-use assets obtained in exchange for new finance lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Right-of-use assets obtained in exchange for new operating lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">The following table summarizes the future maturities of AbbVie's operating and finance lease liabilities as of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">June 30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Operating</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">leases</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Finance</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">leases</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Total </span><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)(b)</sup></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>65</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>73</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2020</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>121</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>132</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>100</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>109</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>55</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>58</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>35</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>36</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>79</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>79</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total lease payments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>455</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>32</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>487</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Less: Interest</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>54</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>55</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Present value of lease liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>401</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>31</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>432</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:10px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">(a) Total lease payments exclude approximately </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>$350 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> of contractual minimum lease payments for leases executed but not yet commenced. These leases will commence between years </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">2020</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> with lease terms of approximately </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>11 years</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:10px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">(b) Lease payments recognized as part of lease liabilities for optional renewal periods are insignificant.</span></div> Short-term leases with a term of <span style="font-family:Calibri,sans-serif;font-size:10pt;">12 months</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> or less are not recorded on the balance sheet. For leases commencing or modified in 2019 or later, AbbVie does not separate lease components from non-lease components.</span><div style="line-height:120%;padding-top:10px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">The company records lease liabilities based on the present value of lease payments over the lease term. AbbVie generally uses an incremental borrowing rate to discount its lease liabilities, as the rate implicit in the lease is typically not readily determinable. Certain lease agreements include renewal options that are under the company's control. AbbVie includes optional renewal periods in the lease term only when it is reasonably certain that AbbVie will exercise its option. </span></div><div style="line-height:120%;padding-top:10px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Variable lease payments include payments to lessors for taxes, maintenance, insurance and other operating costs as well as payments that are adjusted based on an index or rate. The company's lease agreements do not contain any significant residual value guarantees or restrictive covenants.</span></div> Short-term leases with a term of <span style="font-family:Calibri,sans-serif;font-size:10pt;">12 months</span> or less are not recorded on the balance sheet. <div style="line-height:120%;padding-top:10px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">The following table summarizes the amounts and location of operating and finance leases on the condensed consolidated balance sheet:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:23%;"/><td style="width:65%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">(in millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Balance sheet caption</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">June 30, <br/>2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Operating</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Other assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>380</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Finance</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Property and equipment, net</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>27</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total lease assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>407</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Operating</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Accounts payable and accrued liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>111</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Noncurrent</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Other long-term liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>290</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Finance</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Current</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Current portion of long-term debt and finance lease obligations</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Noncurrent</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Long-term debt and finance lease obligations</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>22</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total lease liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>432</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div> 380000000 27000000 407000000 111000000 290000000 9000000 22000000 432000000 <div style="line-height:120%;padding-top:10px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">The following table summarizes the lease costs recognized in the condensed consolidated statements of earnings:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:74%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Three months ended<br/>June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Six months ended<br/>June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">(in millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Operating lease cost</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>32</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>64</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Finance lease cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Amortization of right-of-use assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Interest on lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Short-term lease cost</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Variable lease cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>14</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>29</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total lease cost</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>57</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>112</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div> 32000000 64000000 2000000 4000000 0 0 9000000 15000000 14000000 29000000 57000000 112000000 <div style="line-height:120%;padding-top:10px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">The following table presents the weighted-average remaining lease term and weighted-average discount rate for operating and finance leases:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"/></tr><tr><td style="width:88%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">June 30, <br/>2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Weighted-average remaining lease term (in years)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Operating</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Finance</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Weighted-average discount rate</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Operating</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Finance</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div> P6Y P3Y 0.040 0.044 <div style="line-height:120%;padding-top:10px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">The following table presents supplementary cash flow information regarding the company's operating and finance leases:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:88%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Six months ended<br/>June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Cash paid for amounts included in the measurement of lease liabilities</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Operating cash flows from operating leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>58</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Operating cash flows from finance leases</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Financing cash flows from finance leases</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Right-of-use assets obtained in exchange for new finance lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Right-of-use assets obtained in exchange for new operating lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div> 58000000 0 4000000 0 15000000 <div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">The following table summarizes the future maturities of AbbVie's operating and finance lease liabilities as of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">June 30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Operating</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">leases</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Finance</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">leases</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Total </span><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)(b)</sup></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>65</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>73</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2020</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>121</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>132</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>100</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>109</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>55</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>58</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>35</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>36</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>79</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>79</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total lease payments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>455</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>32</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>487</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Less: Interest</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>54</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>55</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Present value of lease liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>401</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>31</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>432</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div> <div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">The following table summarizes the future maturities of AbbVie's operating and finance lease liabilities as of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">June 30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Operating</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">leases</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Finance</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">leases</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Total </span><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)(b)</sup></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>65</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>73</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2020</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>121</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>132</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>100</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>109</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>55</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>58</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>35</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>36</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>79</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>79</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total lease payments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>455</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>32</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>487</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Less: Interest</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>54</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>55</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Present value of lease liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>401</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>31</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>432</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div> 65000000 8000000 73000000 121000000 11000000 132000000 100000000 9000000 109000000 55000000 3000000 58000000 35000000 1000000 36000000 79000000 0 79000000 455000000 32000000 487000000 54000000 1000000 55000000 401000000 31000000 432000000 350000000 P11Y <span style="font-family:Calibri,sans-serif;font-size:12pt;color:#444867;font-weight:bold;">Financial Instruments and Fair Value Measures</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"/></tr><tr><td style="width:100%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#444867;font-weight:bold;">Risk Management Policy</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">See Note 10 to the company's Annual Report on Form 10-K for the year ended </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">December 31, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> for a summary of AbbVie's risk management policy and use of derivative instruments.</span></div><div style="line-height:120%;padding-top:13px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#444867;font-weight:bold;">Financial Instruments</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Various AbbVie foreign subsidiaries enter into foreign currency forward exchange contracts to manage exposures to changes in foreign exchange rates for anticipated intercompany transactions denominated in a currency other than the functional currency of the local entity. These contracts, with notional amounts totaling </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>$503 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> at </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">June 30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>$1.4 billion</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> at </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">December 31, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">, are designated as cash flow hedges and are recorded at fair value. The durations of these forward exchange contracts were generally less than </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>18 months</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;">. Accumulated gains and losses as of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">June 30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> will be reclassified from AOCI and included in cost of products sold at the time the products are sold, generally not exceeding </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>six months</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> from the date of settlement.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">The company also enters into foreign currency forward exchange contracts to manage its exposure to foreign currency denominated trade payables and receivables and intercompany loans. These contracts are not designated as hedges and are recorded at fair value. Resulting gains or losses are reflected in net foreign exchange gain or loss in the consolidated statements of earnings and are generally offset by losses or gains on the foreign currency exposure being managed. These contracts had notional amounts totaling </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>$7.9 billion</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> at </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">June 30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>$8.6 billion</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> at </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">December 31, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:13px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">The company also uses foreign currency forward exchange contracts or foreign currency denominated debt to hedge its net investments in certain foreign subsidiaries and affiliates. The company continued to designate </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>€3.6 billion</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> aggregate principal amount of senior Euro notes as net investment hedges at </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">June 30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">December 31, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">. In addition, in the second quarter of 2019, the company entered into foreign currency forward exchange contracts with notional amounts totaling </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>€971 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>£204 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>CHF62 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> and designated the instruments as net investment hedges. The company uses the spot method of assessing hedge effectiveness for derivative instruments designated as net investment hedges. Realized and unrealized gains and losses from these hedges are included in AOCI and the initial fair value of hedge components excluded from the assessment of effectiveness is recognized in interest expense, net over the life of the hedging instrument.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">AbbVie is a party to interest rate hedge contracts designated as fair value hedges with notional amounts totaling </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>$10.8 billion</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> at </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">June 30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">December 31, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">. The effect of the hedge contracts is to change a fixed-rate interest obligation to a floating rate for that portion of the debt. AbbVie records the contracts at fair value and adjusts the carrying amount of the fixed-rate debt by an offsetting amount.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">No</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> amounts are excluded from the assessment of effectiveness for cash flow hedges or fair value hedges.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">The following table summarizes the amounts and location of AbbVie’s derivative instruments on the condensed consolidated balance sheets:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:29%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Fair value – <br/>Derivatives in asset position</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Fair value –<br/>Derivatives in liability position</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">(in millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Balance sheet caption</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">June 30,<br/>2019</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">December 31, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Balance sheet caption</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">June 30,<br/>2019</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Foreign currency forward exchange contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Designated as cash flow hedges</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Prepaid expenses and</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;">other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;"><span>22</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;"><span>113</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Accounts payable and accrued liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Designated as net investment hedges</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Prepaid expenses and<br/>other</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Accounts payable and accrued liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Not designated as hedges</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Prepaid expenses and</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;">other</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;"><span>40</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;"><span>19</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Accounts payable and accrued liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;"><span>38</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;"><span>26</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Interest rate swaps designated as fair value hedges</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Prepaid expenses and other</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Accounts payable and accrued liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Interest rate swaps designated as fair value hedges</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Other assets</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;"><span>24</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Other long-term liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;"><span>117</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;"><span>466</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Total derivatives</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;"><span>97</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;"><span>132</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;"><span>164</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;"><span>492</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">While certain derivatives are subject to netting arrangements with the company’s counterparties, the company does not offset derivative assets and liabilities within the condensed consolidated balance sheets.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">The following table presents the pre-tax amounts of gains (losses) from derivative instruments recognized in other comprehensive income (loss):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:60%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Three months ended<br/>June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Six months ended<br/>June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">(in millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Foreign currency forward exchange contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Designated as cash flow hedges</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>169</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>121</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Designated as net investment hedges</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Assuming market rates remain constant through contract maturities, the company expects to reclass pre-tax gains of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>$90 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> into cost of products sold for foreign currency cash flow hedges during the next 12 months.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Related to AbbVie’s non-derivative, foreign currency denominated debt designated as net investment hedges, the company recognized in other comprehensive income (loss) a pre-tax </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">loss</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>$49 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">for the three months and</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> a pre-tax </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">gain</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>$35 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">six months ended June 30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> and recognized pre-tax gains of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>$270 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">for the three months and</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>$136 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">six months ended June 30, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:13px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">The following table summarizes the pre-tax amounts and location of derivative instrument net gains (losses) recognized in the condensed consolidated statements of earnings, including the net gains (losses) reclassified out of AOCI into net earnings. See </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">Note 11</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> for the amount of net gains (losses) reclassified out of AOCI.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18"/></tr><tr><td style="width:40%;"/><td style="width:20%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Three months ended<br/>June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Six months ended<br/>June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">(in millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Statement of earnings caption</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Foreign currency forward exchange contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Designated as cash flow hedges</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Cost of products sold</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>37</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(46</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>77</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(90</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Designated as net investment hedges</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Interest expense, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Not designated as hedges</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net foreign exchange loss</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(25</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>128</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(40</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>69</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Interest rate swaps designated as fair value hedges</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Interest expense, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>253</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(59</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>365</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(243</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Debt designated as hedged item in fair value hedges</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Interest expense, net</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(253</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>59</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(365</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>243</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#444867;font-weight:bold;">Fair Value Measures</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">The fair value hierarchy consists of the following three levels:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:17px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Level 1 – Valuations based on unadjusted quoted prices in active markets for identical assets that the company has the ability to access;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:17px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Level 2 – Valuations based on quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuations in which all significant inputs are observable in the market; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:17px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Level 3 – Valuations using significant inputs that are unobservable in the market and include the use of judgment by the company’s management about the assumptions market participants would use in pricing the asset or liability.</span></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">The following table summarizes the bases used to measure certain assets and liabilities carried at fair value on a recurring basis on the condensed consolidated balance sheet as of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">June 30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Basis of fair value measurement</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Quoted prices in active markets for</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">identical assets <br/>(Level 1)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Significant other</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">observable <br/>inputs <br/>(Level 2)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Significant <br/>unobservable <br/>inputs <br/>(Level 3)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Assets</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Cash and equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>5,172</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,388</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3,784</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,573</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,573</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Equity securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>79</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>79</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Interest rate hedges</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>24</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>24</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Foreign currency contracts</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>73</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>73</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6,921</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,467</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>5,454</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Liabilities</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Interest rate hedges</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>125</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>125</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Foreign currency contracts</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>39</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>39</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Contingent consideration</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6,789</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6,789</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6,953</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>164</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6,789</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:10px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">The following table summarizes the bases used to measure certain assets and liabilities carried at fair value on a recurring basis on the condensed consolidated balance sheet as of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">December 31, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Basis of fair value measurement</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Quoted prices in active markets for</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">identical assets <br/>(Level 1)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Significant other</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">observable <br/>inputs <br/>(Level 2)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Significant <br/>unobservable <br/>inputs <br/>(Level 3)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Assets</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Cash and equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>7,289</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,209</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6,080</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Time deposits</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>568</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>568</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,536</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,536</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Equity securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Foreign currency contracts</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>132</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>132</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>9,529</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,213</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>8,316</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Liabilities</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Interest rate hedges</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>466</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>466</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Foreign currency contracts</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>26</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>26</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Contingent consideration</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,483</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,483</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,975</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>492</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,483</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">The fair values of time deposits approximate their amortized cost due to the short maturities of these instruments. The fair values of available-for-sale debt securities were determined based on prices obtained from commercial pricing services. Equity securities consist of investments for which the fair values were determined by using the published market price per unit multiplied by the number of units held, without consideration of transaction costs. The derivatives entered into by the company were valued using published spot curves for interest rate hedges and published forward curves for foreign currency contracts. The fair value measurements of the contingent consideration liabilities were determined based on significant unobservable inputs, including the discount rate, estimated probabilities and timing of achieving specified development, regulatory and commercial milestones and the estimated amount of future sales of the acquired products. Changes to the fair value of the contingent consideration liabilities can result from changes to one or a number of inputs, including discount rates, the probabilities of achieving the milestones, the time required to achieve the milestones and estimated future sales. Significant judgment is employed in determining the appropriateness of these inputs. Changes to the inputs described above could have a material impact on the company's financial position and results of operations in any given period. At </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">June 30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">, a </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>50 basis point</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> increase/decrease in the assumed discount rate would have decreased/increased the value of the contingent consideration liabilities by approximately </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>$270 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;">. Additionally, at </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">June 30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">, a </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>five</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> percentage point increase/decrease in the assumed probability of success across all potential indications still in development would have increased/decreased the value of the contingent consideration liabilities by approximately </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>$210 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">There have been </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>no</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> transfers of assets or liabilities between the fair value measurement levels. The following table presents the changes in fair value of contingent consideration liabilities which are measured using Level 3 inputs:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:74%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Six months ended<br/>June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">(in millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Beginning balance</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,483</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,534</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Change in fair value recognized in net earnings</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,473</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>337</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Milestone payments</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(167</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(50</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Ending balance</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6,789</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,821</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">The change in fair value recognized in net earnings is recorded in other expense, net in the condensed consolidated statements of earnings. During the second quarter of 2019, the company recorded a </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>$2.3 billion</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> increase in the SKYRIZI contingent consideration liability due to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">higher probabilities of success, higher estimated future sales and declining interest rates. The higher probabilities of success resulted from the April 2019 regulatory approvals of SKYRIZI for the treatment of moderate to severe plaque psoriasis.</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> </span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Certain financial instruments are carried at historical cost or some basis other than fair value. The book values, approximate fair values and bases used to measure the approximate fair values of certain financial instruments as of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">June 30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> are shown in the table below:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="19"/></tr><tr><td style="width:42%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Basis of fair value measurement</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Book value</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Approximate fair value</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Quoted prices</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">in active markets for </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">identical assets <br/>(Level 1)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Significant <br/>other </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">observable <br/>inputs <br/>(Level 2)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Significant <br/>unobservable <br/>inputs <br/>(Level 3)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Liabilities</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;text-indent:-19px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Short-term borrowings</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>306</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>306</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>306</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Current portion of long-term debt and finance lease obligations, excluding fair value hedges</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>5,343</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>5,357</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>5,348</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Long-term debt and finance lease obligations, excluding fair value hedges</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>31,712</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>32,753</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>32,731</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>22</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>37,361</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>38,416</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>38,079</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>337</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">The book values, approximate fair values and bases used to measure the approximate fair values of certain financial instruments as of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">December 31, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> are shown in the table below:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="19"/></tr><tr><td style="width:42%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Basis of fair value measurement</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Book value</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Approximate fair value</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Quoted prices</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">in active markets for </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">identical assets <br/>(Level 1)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Significant <br/>other </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">observable <br/>inputs <br/>(Level 2)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Significant <br/>unobservable <br/>inputs <br/>(Level 3)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Liabilities</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Short-term borrowings</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3,699</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3,693</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3,693</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Current portion of long-term debt and finance lease obligations, excluding fair value hedges</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,609</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,617</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,609</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Long-term debt and finance lease obligations, excluding fair value hedges</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>35,468</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>34,052</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>34,024</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>28</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>40,776</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>39,362</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>35,633</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3,729</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">AbbVie also holds investments in equity securities that do not have readily determinable fair values. The company records these investments at cost and remeasures them to fair value based on certain observable price changes or impairment events as they occur. The carrying amount of these investments was </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>$65 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> as of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">June 30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>$84 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> as of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">December 31, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">No</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> significant cumulative upward or downward adjustments have been recorded for these investments as of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">June 30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#444867;font-weight:bold;">Available-for-sale Securities</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Substantially all of the company’s investments in debt securities were classified as available-for-sale with changes in fair value recognized in other comprehensive income. Debt securities classified as short-term were </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>$244 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> as of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">June 30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>$204 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> as of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">December 31, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">. Long-term debt securities mature primarily within </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>five years</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;">. Estimated fair values of available-for-sale debt securities were generally determined based on prices obtained from commercial pricing services.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">The following table summarizes available-for-sale securities by type as of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">June 30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">:</span></div><div style="line-height:120%;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Amortized cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Gross unrealized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Fair value</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">(in millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Gains</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Losses</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Asset backed securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>375</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>374</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,095</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,097</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Other debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>102</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>102</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,572</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,573</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">The following table summarizes available-for-sale securities by type as of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">December 31, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Amortized cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Gross unrealized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Fair value</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">(in millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Gains</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Losses</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Asset backed securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>423</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>421</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,042</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,034</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Other debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>81</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>81</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,546</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(11</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,536</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">AbbVie had </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>no</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> other-than-temporary impairments as of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">June 30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">. Net realized gains and losses were </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">insignificant</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> for both the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">three and six months ended June 30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#444867;font-weight:bold;">Concentrations of Risk</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Of total net accounts receivable, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>three</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> U.S. wholesalers accounted for </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>66%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> as of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">June 30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>63%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> as of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">December 31, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">, and substantially all of AbbVie’s net revenues in the United States were to these </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>three</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> wholesalers. </span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">HUMIRA (adalimumab) is AbbVie’s single largest product and accounted for approximately </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>58%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> of AbbVie’s total net revenues for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">six months ended June 30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>61%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">six months ended June 30, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#444867;font-weight:bold;">Debt and Credit Facilities</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">Short-Term Borrowings</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Short-term borrowings included commercial paper borrowings of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>$306 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> as of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">June 30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>$699 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> as of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">December 31, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">. The weighted-average interest rate on commercial paper borrowings was </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2.7%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">six months ended June 30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1.9%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">six months ended June 30, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">In March 2019, AbbVie repaid its </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>$3.0 billion</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>364</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;">-day </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">term loan credit agreement that was scheduled to mature in June 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">.</span></div><span style="font-family:Calibri,sans-serif;font-size:10pt;">In connection with the proposed acquisition of Allergan, on June 25, 2019, AbbVie entered into a </span><span style="font-family:Calibri,sans-serif;font-size:10pt;text-align:right;"><span>364</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;">-day bridge credit agreement and on July 12, 2019, AbbVie entered into a term loan credit agreement.</span> See Note 4 for additional information. 503000000 1400000000 P18M P6M 7900000000 8600000000 3600000000 971000000 204000000 62000000 10800000000 <div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">The following table summarizes the amounts and location of AbbVie’s derivative instruments on the condensed consolidated balance sheets:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:29%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Fair value – <br/>Derivatives in asset position</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Fair value –<br/>Derivatives in liability position</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">(in millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Balance sheet caption</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">June 30,<br/>2019</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">December 31, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Balance sheet caption</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">June 30,<br/>2019</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Foreign currency forward exchange contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Designated as cash flow hedges</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Prepaid expenses and</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;">other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;"><span>22</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;"><span>113</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Accounts payable and accrued liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Designated as net investment hedges</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Prepaid expenses and<br/>other</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Accounts payable and accrued liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Not designated as hedges</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Prepaid expenses and</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;">other</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;"><span>40</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;"><span>19</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Accounts payable and accrued liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;"><span>38</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;"><span>26</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Interest rate swaps designated as fair value hedges</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Prepaid expenses and other</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Accounts payable and accrued liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Interest rate swaps designated as fair value hedges</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Other assets</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;"><span>24</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Other long-term liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;"><span>117</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;"><span>466</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Total derivatives</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;"><span>97</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;"><span>132</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;"><span>164</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;"><span>492</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div> 22000000 113000000 0 0 11000000 0 1000000 0 40000000 19000000 38000000 26000000 0 0 8000000 0 24000000 0 117000000 466000000 97000000 132000000 164000000 492000000 <div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">The following table presents the pre-tax amounts of gains (losses) from derivative instruments recognized in other comprehensive income (loss):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:60%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Three months ended<br/>June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Six months ended<br/>June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">(in millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Foreign currency forward exchange contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Designated as cash flow hedges</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>169</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>121</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Designated as net investment hedges</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div> 2000000 169000000 5000000 121000000 10000000 0 10000000 0 90000000 49000000 -35000000 -270000000 -136000000 <div style="line-height:120%;padding-top:13px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">The following table summarizes the pre-tax amounts and location of derivative instrument net gains (losses) recognized in the condensed consolidated statements of earnings, including the net gains (losses) reclassified out of AOCI into net earnings. See </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">Note 11</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> for the amount of net gains (losses) reclassified out of AOCI.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18"/></tr><tr><td style="width:40%;"/><td style="width:20%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Three months ended<br/>June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Six months ended<br/>June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">(in millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Statement of earnings caption</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Foreign currency forward exchange contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Designated as cash flow hedges</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Cost of products sold</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>37</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(46</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>77</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(90</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Designated as net investment hedges</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Interest expense, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:18px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Not designated as hedges</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net foreign exchange loss</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(25</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>128</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(40</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>69</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Interest rate swaps designated as fair value hedges</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Interest expense, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>253</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(59</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>365</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(243</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Debt designated as hedged item in fair value hedges</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Interest expense, net</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(253</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>59</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(365</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>243</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div> 37000000 -46000000 77000000 -90000000 9000000 0 9000000 0 -25000000 128000000 -40000000 69000000 253000000 -59000000 365000000 -243000000 -253000000 59000000 -365000000 243000000 <div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">The following table summarizes the bases used to measure certain assets and liabilities carried at fair value on a recurring basis on the condensed consolidated balance sheet as of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">June 30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Basis of fair value measurement</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Quoted prices in active markets for</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">identical assets <br/>(Level 1)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Significant other</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">observable <br/>inputs <br/>(Level 2)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Significant <br/>unobservable <br/>inputs <br/>(Level 3)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Assets</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Cash and equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>5,172</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,388</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3,784</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,573</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,573</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Equity securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>79</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>79</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Interest rate hedges</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>24</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>24</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Foreign currency contracts</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>73</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>73</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6,921</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,467</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>5,454</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Liabilities</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Interest rate hedges</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>125</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>125</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Foreign currency contracts</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>39</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>39</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Contingent consideration</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6,789</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6,789</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6,953</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>164</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6,789</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:10px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">The following table summarizes the bases used to measure certain assets and liabilities carried at fair value on a recurring basis on the condensed consolidated balance sheet as of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">December 31, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Basis of fair value measurement</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Quoted prices in active markets for</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">identical assets <br/>(Level 1)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Significant other</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">observable <br/>inputs <br/>(Level 2)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Significant <br/>unobservable <br/>inputs <br/>(Level 3)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Assets</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Cash and equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>7,289</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,209</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6,080</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Time deposits</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>568</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>568</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,536</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,536</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Equity securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Foreign currency contracts</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>132</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>132</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>9,529</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,213</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>8,316</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Liabilities</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Interest rate hedges</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>466</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>466</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Foreign currency contracts</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>26</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>26</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Contingent consideration</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,483</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,483</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,975</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>492</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,483</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div> 5172000000 1388000000 3784000000 0 1573000000 0 1573000000 0 79000000 79000000 0 0 24000000 0 24000000 0 73000000 0 73000000 0 6921000000 1467000000 5454000000 0 125000000 0 125000000 0 39000000 0 39000000 0 6789000000 0 0 6789000000 6953000000 0 164000000 6789000000 7289000000 1209000000 6080000000 0 568000000 0 568000000 0 1536000000 0 1536000000 0 4000000 4000000 0 0 132000000 0 132000000 0 9529000000 1213000000 8316000000 0 466000000 0 466000000 0 26000000 0 26000000 0 4483000000 0 0 4483000000 4975000000 0 492000000 4483000000 0.50 270000000 0.05 210000000 0 The following table presents the changes in fair value of contingent consideration liabilities which are measured using Level 3 inputs:<div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:74%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Six months ended<br/>June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">(in millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Beginning balance</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,483</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,534</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Change in fair value recognized in net earnings</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,473</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>337</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Milestone payments</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(167</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(50</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Ending balance</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6,789</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,821</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div> 4483000000 4534000000 2473000000 337000000 167000000 50000000 6789000000 4821000000 2300000000 The book values, approximate fair values and bases used to measure the approximate fair values of certain financial instruments as of <span style="font-family:Calibri,sans-serif;font-size:10pt;">June 30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> are shown in the table below:</span><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="19"/></tr><tr><td style="width:42%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Basis of fair value measurement</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Book value</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Approximate fair value</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Quoted prices</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">in active markets for </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">identical assets <br/>(Level 1)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Significant <br/>other </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">observable <br/>inputs <br/>(Level 2)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Significant <br/>unobservable <br/>inputs <br/>(Level 3)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Liabilities</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;text-indent:-19px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Short-term borrowings</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>306</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>306</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>306</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Current portion of long-term debt and finance lease obligations, excluding fair value hedges</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>5,343</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>5,357</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>5,348</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Long-term debt and finance lease obligations, excluding fair value hedges</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>31,712</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>32,753</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>32,731</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>22</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>37,361</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>38,416</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>38,079</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>337</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">The book values, approximate fair values and bases used to measure the approximate fair values of certain financial instruments as of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">December 31, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> are shown in the table below:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="19"/></tr><tr><td style="width:42%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Basis of fair value measurement</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Book value</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Approximate fair value</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Quoted prices</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">in active markets for </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">identical assets <br/>(Level 1)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Significant <br/>other </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">observable <br/>inputs <br/>(Level 2)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Significant <br/>unobservable <br/>inputs <br/>(Level 3)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Liabilities</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Short-term borrowings</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3,699</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3,693</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3,693</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Current portion of long-term debt and finance lease obligations, excluding fair value hedges</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,609</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,617</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,609</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Long-term debt and finance lease obligations, excluding fair value hedges</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>35,468</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>34,052</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>34,024</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>28</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>40,776</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>39,362</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>35,633</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3,729</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div> 306000000 306000000 0 306000000 0 5343000000 5357000000 5348000000 9000000 0 31712000000 32753000000 32731000000 22000000 0 37361000000 38416000000 38079000000 337000000 0 3699000000 3693000000 0 3693000000 0 1609000000 1617000000 1609000000 8000000 0 35468000000 34052000000 34024000000 28000000 0 40776000000 39362000000 35633000000 3729000000 0 65000000 84000000 244000000 204000000 P5Y <div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">The following table summarizes available-for-sale securities by type as of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">June 30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">:</span></div><div style="line-height:120%;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Amortized cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Gross unrealized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Fair value</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">(in millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Gains</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Losses</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Asset backed securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>375</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>374</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,095</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,097</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Other debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>102</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>102</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,572</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,573</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">The following table summarizes available-for-sale securities by type as of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">December 31, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Amortized cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Gross unrealized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Fair value</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">(in millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Gains</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Losses</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Asset backed securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>423</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>421</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,042</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,034</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Other debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>81</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>81</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,546</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(11</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,536</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div> 375000000 0 1000000 374000000 1095000000 4000000 2000000 1097000000 102000000 0 0 102000000 1572000000 4000000 3000000 1573000000 423000000 0 2000000 421000000 1042000000 1000000 9000000 1034000000 81000000 0 0 81000000 1546000000 1000000 11000000 1536000000 0 3 0.66 0.63 3 0.58 0.61 306000000 699000000 0.027 0.019 3000000000.0 P364D P364D <span style="font-family:Calibri,sans-serif;font-size:12pt;color:#444867;font-weight:bold;">Post-Employment Benefits</span><span style="font-family:Calibri,sans-serif;font-size:12pt;color:#444867;font-weight:bold;"> </span><div style="line-height:120%;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"/></tr><tr><td style="width:100%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">The following table summarizes net periodic benefit cost relating to the company’s defined benefit and other post-employment plans:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="32"/></tr><tr><td style="width:37%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Defined <br/>benefit plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Other post- <br/>employment plans</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Three months ended<br/>June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Six months ended<br/>June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Three months ended<br/>June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Six months ended<br/>June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Service cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>68</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>72</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>135</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>144</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Interest cost</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>66</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>57</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>130</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>114</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Expected return on plan assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(119</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(110</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(238</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(221</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Amortization of actuarial losses and prior service cost (credit)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>29</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>39</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>55</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>76</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net periodic benefit cost</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>44</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>58</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>82</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>113</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>17</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>28</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>26</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:10px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">The components of net periodic benefit cost other than service cost are included in other expense, net in the condensed consolidated statements of earnings.</span></div> <div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">The following table summarizes net periodic benefit cost relating to the company’s defined benefit and other post-employment plans:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="32"/></tr><tr><td style="width:37%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Defined <br/>benefit plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Other post- <br/>employment plans</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Three months ended<br/>June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Six months ended<br/>June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Three months ended<br/>June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Six months ended<br/>June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Service cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>68</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>72</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>135</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>144</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Interest cost</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>66</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>57</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>130</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>114</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Expected return on plan assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(119</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(110</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(238</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(221</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Amortization of actuarial losses and prior service cost (credit)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>29</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>39</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>55</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>76</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net periodic benefit cost</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>44</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>58</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>82</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>113</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>17</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>28</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>26</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div> 68000000 72000000 135000000 144000000 7000000 5000000 13000000 13000000 66000000 57000000 130000000 114000000 9000000 4000000 15000000 12000000 119000000 110000000 238000000 221000000 0 0 0 0 -29000000 -39000000 -55000000 -76000000 -1000000 3000000 0 -1000000 44000000 58000000 82000000 113000000 17000000 6000000 28000000 26000000 <span style="font-family:Calibri,sans-serif;font-size:12pt;color:#444867;font-weight:bold;">Equity</span><span style="font-family:Calibri,sans-serif;font-size:12pt;color:#444867;font-weight:bold;"> </span><div style="line-height:120%;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"/></tr><tr><td style="width:100%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#444867;font-weight:bold;">Stock-Based Compensation</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Stock-based compensation expense is principally related to awards issued pursuant to the AbbVie 2013 Incentive Stock Program and is summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:48%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Three months ended<br/>June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Six months ended<br/>June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">(in millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Cost of products sold</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>20</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>16</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Research and development</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>33</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>35</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>105</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>107</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Selling, general and administrative</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>49</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>38</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>151</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>153</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Pre-tax compensation expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>87</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>85</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>276</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>276</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Tax benefit</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>16</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>19</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>49</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>48</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">After-tax compensation expense</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>71</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>66</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>227</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>228</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">Stock Options</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">During the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">six months ended June 30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">, primarily in connection with the company's annual grant, AbbVie granted </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1.0 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> stock options with a weighted-average grant-date fair value of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>$12.54</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;">. As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">June 30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>$8.5 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> of unrecognized compensation cost related to stock options is expected to be recognized as expense over approximately the next </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>two years</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;">. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">RSUs and Performance Shares</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">During the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">six months ended June 30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">, primarily in connection with the company's annual grant, AbbVie granted </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>5.4 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> RSUs and performance shares with a weighted-average grant-date fair value of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>$78.68</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;">. As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">June 30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>$434 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> of unrecognized compensation cost related to RSUs and performance shares is expected to be recognized as expense over approximately the next </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>two years</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#444867;font-weight:bold;">Cash Dividends</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">The following table summarizes quarterly cash dividends declared during </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"/></tr><tr><td style="width:15%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Date Declared</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Payment Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Dividend Per Share</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Date Declared</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Payment Date</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Dividend Per Share</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#2d2926;">06/20/19</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#2d2926;">08/15/19</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1.07</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#2d2926;">11/02/18</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#2d2926;">02/15/19</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1.07</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#2d2926;">02/21/19</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#2d2926;">05/15/19</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1.07</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#2d2926;">09/07/18</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#2d2926;">11/15/18</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>0.96</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#2d2926;">06/14/18</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#2d2926;">08/15/18</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>0.96</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#2d2926;">02/15/18</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#2d2926;">05/15/18</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>0.96</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#444867;font-weight:bold;">Stock Repurchase Program</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">The company's stock repurchase authorization permits purchases of AbbVie shares from time to time in open-market or private transactions at management's discretion. The program has no time limit and can be discontinued at any time.</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> Shares repurchased under these programs are recorded at acquisition cost, including related expenses, and are available for general corporate purposes.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">AbbVie repurchased </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> shares for </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>$300 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> during the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">six months ended June 30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>84 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> shares for </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>$8.8 billion</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> during the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">six months ended June 30, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">. AbbVie's remaining stock repurchase authorization was approximately </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>$4.0 billion</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> as of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">June 30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#444867;font-weight:bold;">Accumulated Other Comprehensive Loss</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">The following table summarizes the changes in each component of accumulated other comprehensive loss, net of tax, for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">six months ended June 30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Foreign currency <br/>translation adjustments</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Net investment</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">hedging activities</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Pension </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">and post- <br/>employment <br/>benefits</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Marketable</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">security activities</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Cash flow hedging <br/>activities</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Balance as of December 31, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(830</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(65</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(1,722</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(10</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>147</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(2,480</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Other comprehensive income (loss) before reclassifications</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(32</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>35</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>7</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>22</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net losses (gains) reclassified from accumulated other comprehensive loss</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>43</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(70</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(33</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net current-period other comprehensive income (loss)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(32</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>28</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>45</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(63</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(11</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Balance as of June 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(862</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(37</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(1,677</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>84</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(2,491</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Other comprehensive loss for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">six months ended June 30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> included foreign currency translation adjustments totaling a loss of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>$32 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;">, which was principally due to the weakening of the Euro in the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">six months ended June 30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> on the translation of the company’s assets denominated in the Euro.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">The following table summarizes the changes in each component of accumulated other comprehensive loss, net of tax, for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">six months ended June 30, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Foreign currency <br/>translation adjustments</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Net investment</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">hedging activities</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Pension </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">and post- <br/>employment <br/>benefits</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Marketable</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"> security activities</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Cash flow hedging <br/>activities</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Balance as of December 31, 2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(439</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(203</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(1,919</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(166</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(2,727</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Other comprehensive income (loss) before reclassifications</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(280</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>105</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>110</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(62</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net losses reclassified from accumulated other comprehensive loss</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>62</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>84</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>150</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net current-period other comprehensive income (loss)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(280</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>105</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>71</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>194</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>88</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Balance as of June 30, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(719</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(98</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(1,848</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>28</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(2,639</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Other comprehensive income for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">six months ended June 30, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> included foreign currency translation adjustments totaling a loss of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>$280 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;">, which was principally due to the weakening of the Euro in the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">six months ended June 30, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> on the translation of the company’s assets denominated in the Euro.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">The following table presents the impact on AbbVie’s condensed consolidated statements of earnings for significant amounts reclassified out of each component of accumulated other comprehensive loss:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Three months ended<br/>June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Six months ended<br/>June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">(in millions) (brackets denote gains)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Pension and post-employment benefits</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Amortization of actuarial losses and other</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>30</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>36</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>55</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>77</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Tax benefit</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(12</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(15</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total reclassifications, net of tax</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>23</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>29</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>43</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>62</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Cash flow hedging activities</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Losses (gains) on designated cash flow hedges</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(37</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>46</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(77</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>90</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Tax expense (benefit)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total reclassifications, net of tax</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(35</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>42</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(70</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>84</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Net investment hedging activities</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Gains on derivative amount excluded from effectiveness testing</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Tax expense</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total reclassifications, net of tax</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">(a) Amounts are included in the computation of net periodic benefit cost (see </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">Note 10</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">).</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">(b) Amounts are included in cost of products sold (see </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">Note 9</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">).</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">(c) Amounts are included in interest expense, net (see </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">Note 9</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">).</span></div> <div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Stock-based compensation expense is principally related to awards issued pursuant to the AbbVie 2013 Incentive Stock Program and is summarized as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:48%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Three months ended<br/>June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Six months ended<br/>June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">(in millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Cost of products sold</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>20</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>16</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Research and development</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>33</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>35</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>105</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>107</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Selling, general and administrative</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>49</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>38</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>151</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>153</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Pre-tax compensation expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>87</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>85</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>276</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>276</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Tax benefit</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>16</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>19</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>49</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>48</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">After-tax compensation expense</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>71</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>66</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>227</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>228</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div> 5000000 12000000 20000000 16000000 33000000 35000000 105000000 107000000 49000000 38000000 151000000 153000000 87000000 85000000 276000000 276000000 16000000 19000000 49000000 48000000 71000000 66000000 227000000 228000000 1000000.0 12.54 8500000 P2Y 5400000 78.68 434000000 P2Y <div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">The following table summarizes quarterly cash dividends declared during </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"/></tr><tr><td style="width:15%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Date Declared</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Payment Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Dividend Per Share</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Date Declared</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Payment Date</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Dividend Per Share</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#2d2926;">06/20/19</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#2d2926;">08/15/19</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1.07</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#2d2926;">11/02/18</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#2d2926;">02/15/19</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1.07</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#2d2926;">02/21/19</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#2d2926;">05/15/19</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1.07</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#2d2926;">09/07/18</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#2d2926;">11/15/18</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>0.96</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#2d2926;">06/14/18</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#2d2926;">08/15/18</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>0.96</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#2d2926;">02/15/18</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#2d2926;">05/15/18</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>0.96</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div> 1.07 1.07 1.07 0.96 0.96 0.96 4000000 300000000 84000000 8800000000 4000000000.0 -830000000 -65000000 -1722000000 -10000000 147000000 -2480000000 -32000000 35000000 2000000 10000000 7000000 22000000 0 7000000 -43000000 -1000000 70000000 33000000 -32000000 28000000 45000000 11000000 -63000000 -11000000 -862000000 -37000000 -1677000000 1000000 84000000 -2491000000 -32000000 <div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">The following table summarizes the changes in each component of accumulated other comprehensive loss, net of tax, for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">six months ended June 30, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Foreign currency <br/>translation adjustments</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Net investment</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">hedging activities</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Pension </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">and post- <br/>employment <br/>benefits</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Marketable</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;"> security activities</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Cash flow hedging <br/>activities</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Balance as of December 31, 2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(439</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(203</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(1,919</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(166</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(2,727</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Other comprehensive income (loss) before reclassifications</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(280</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>105</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>110</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(62</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net losses reclassified from accumulated other comprehensive loss</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>62</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>84</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>150</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net current-period other comprehensive income (loss)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(280</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>105</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>71</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>194</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>88</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Balance as of June 30, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(719</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(98</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(1,848</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>28</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(2,639</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">The following table summarizes the changes in each component of accumulated other comprehensive loss, net of tax, for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">six months ended June 30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Foreign currency <br/>translation adjustments</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Net investment</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">hedging activities</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Pension </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">and post- <br/>employment <br/>benefits</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Marketable</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">security activities</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Cash flow hedging <br/>activities</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Balance as of December 31, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(830</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(65</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(1,722</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(10</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>147</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(2,480</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Other comprehensive income (loss) before reclassifications</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(32</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>35</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>7</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>22</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net losses (gains) reclassified from accumulated other comprehensive loss</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>43</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(70</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(33</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net current-period other comprehensive income (loss)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(32</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>28</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>45</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(63</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(11</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Balance as of June 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(862</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(37</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(1,677</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>84</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(2,491</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div> -439000000 -203000000 -1919000000 0 -166000000 -2727000000 -280000000 105000000 9000000 -6000000 110000000 -62000000 0 0 -62000000 -4000000 -84000000 -150000000 -280000000 105000000 71000000 -2000000 194000000 88000000 -719000000 -98000000 -1848000000 -2000000 28000000 -2639000000 -280000000 <div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">The following table presents the impact on AbbVie’s condensed consolidated statements of earnings for significant amounts reclassified out of each component of accumulated other comprehensive loss:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Three months ended<br/>June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Six months ended<br/>June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">(in millions) (brackets denote gains)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Pension and post-employment benefits</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Amortization of actuarial losses and other</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>30</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>36</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>55</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>77</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Tax benefit</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(12</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(15</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total reclassifications, net of tax</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>23</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>29</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>43</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>62</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Cash flow hedging activities</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Losses (gains) on designated cash flow hedges</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(37</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>46</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(77</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>90</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Tax expense (benefit)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total reclassifications, net of tax</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(35</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>42</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(70</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>84</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Net investment hedging activities</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Gains on derivative amount excluded from effectiveness testing</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Tax expense</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total reclassifications, net of tax</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">(a) Amounts are included in the computation of net periodic benefit cost (see </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">Note 10</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">).</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">(b) Amounts are included in cost of products sold (see </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">Note 9</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">).</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">(c) Amounts are included in interest expense, net (see </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">Note 9</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">).</span></div> 30000000 36000000 55000000 77000000 7000000 7000000 12000000 15000000 23000000 29000000 43000000 62000000 -37000000 46000000 -77000000 90000000 2000000 -4000000 7000000 -6000000 35000000 -42000000 70000000 -84000000 9000000 0 9000000 0 2000000 0 2000000 0 7000000 0 7000000 0 <span style="font-family:Calibri,sans-serif;font-size:12pt;color:#444867;font-weight:bold;">Income Taxes</span><span style="font-family:Calibri,sans-serif;font-size:12pt;color:#444867;font-weight:bold;"> </span><div style="line-height:120%;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"/></tr><tr><td style="width:100%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">The effective tax rate was </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>8%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">for the three months and</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>5%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">six months ended June 30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">for the three months and</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">six months ended June 30, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">. The effective tax rate in each period differed from the U.S. statutory tax rate of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>21%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> principally due to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">the benefit from foreign operations which reflects the impact of lower income tax rates in locations outside the United States, tax incentives in Puerto Rico and other foreign tax jurisdictions and business development activities.</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> The </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">increase</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> in the effective tax rate for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">three and six months ended June 30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">over the prior year was principally due to the beneficial impact of the timing of provisions of the</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> Act </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">related to earnings from certain foreign subsidiaries in prior year and changes in the jurisdictional mix of earnings, including a change in fair value of contingent consideration liabilities. These increases were partially offset by the favorable resolution of various tax positions in the current year.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Due to the potential for resolution of federal, state and foreign examinations and the expiration of various statutes of limitations, it is reasonably possible that the company’s gross unrecognized tax benefits balance may change within the next </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">twelve months</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> by up to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>$41 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;">.</span></div> 0.08 0.05 0.02 0.01 0.21 41000000 <span style="font-family:Calibri,sans-serif;font-size:12pt;color:#444867;font-weight:bold;">Legal Proceedings and Contingencies</span><div style="line-height:120%;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"/></tr><tr><td style="width:100%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">AbbVie is subject to contingencies, such as various claims, legal proceedings and investigations regarding product liability, intellectual property, commercial, securities and other matters that arise in the normal course of business. Loss contingency provisions are recorded for probable losses at management’s best estimate of a loss, or when a best estimate cannot be made, a minimum loss contingency amount within a probable range is recorded. The recorded accrual balance for litigation was approximately </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>$330 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> as of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">June 30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>$350 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> as of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">December 31, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">. Initiation of new legal proceedings or a change in the status of existing proceedings may result in a change in the estimated loss accrued by AbbVie. While it is not feasible to predict the outcome of all proceedings and exposures with certainty, management believes that their ultimate disposition should not have a material adverse effect on AbbVie’s consolidated financial position, results of operations or cash flows.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Subject to certain exceptions specified in the separation agreement by and between Abbott and AbbVie, AbbVie assumed the liability for, and control of, all pending and threatened legal matters related to its business, including liabilities for any claims or legal proceedings related to products that had been part of its business, but were discontinued prior to the distribution, as well as assumed or retained liabilities, and will indemnify Abbott for any liability arising out of or resulting from such assumed legal matters.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Four lawsuits against Unimed Pharmaceuticals, Inc., Solvay Pharmaceuticals, Inc. (a company Abbott acquired in February 2010 and now known as AbbVie Products LLC) and others are consolidated for pre-trial purposes in the United States District Court for the Northern District of Georgia under the Multi-District Litigation (MDL) Rules as </span><span style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">In re: AndroGel Antitrust Litigation</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">, MDL No. 2084. These cases, brought by direct AndroGel purchasers, generally allege Solvay's 2006 patent litigation settlement agreements and related agreements with </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>three</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> generic companies violate federal antitrust laws. Plaintiffs seek monetary damages and attorneys' fees.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Lawsuits are pending against AbbVie and others generally alleging that the 2005 patent litigation settlement involving Niaspan entered into between Kos Pharmaceuticals, Inc. (a company acquired by Abbott in 2006 and presently a subsidiary of AbbVie) and a generic company violates federal and state antitrust laws and state unfair and deceptive trade practices and unjust enrichment laws. Plaintiffs generally seek monetary damages and/or injunctive relief and attorneys' fees. The lawsuits consist of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>four</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> individual plaintiff lawsuits and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>two</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> consolidated purported class actions: </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>one</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> brought by Niaspan direct purchasers and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>one</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> brought by Niaspan end-payers. The cases are pending in the United States District Court for the Eastern District of Pennsylvania for coordinated or consolidated pre-trial proceedings under the MDL Rules as </span><span style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">In re: Niaspan Antitrust Litigation</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">, MDL No. 2460. In October 2016, the Orange County, California District Attorney’s Office filed a lawsuit on behalf of the State of California regarding the Niaspan patent litigation settlement in Orange County Superior Court, asserting a claim under the unfair competition provision of the California Business and Professions Code seeking injunctive relief, restitution, civil penalties and attorneys’ fees. In May 2018, the California Court of Appeal ruled that the District Attorney’s Office may not bring monetary claims beyond the scope of Orange County, which the District Attorney’s Office is appealing.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">In September 2014, the FTC filed a lawsuit against AbbVie and others in the United States District Court for the Eastern District of Pennsylvania, alleging that the 2011 patent litigation with </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>two</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> generic companies regarding AndroGel was sham litigation and the settlements of that litigation violated federal antitrust law. In May 2015, the court dismissed the FTC’s settlement-related claim. In June 2018, following a bench trial, the court found for the FTC on its sham litigation claim and ordered a disgorgement remedy of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>$448 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;">, plus prejudgment interest. The court denied the FTC’s request for injunctive relief. AbbVie is appealing the court’s liability and disgorgement rulings and, based on an assessment of the merits of that appeal, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>no</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> liability has been accrued for this matter. The FTC is also appealing aspects of the court’s trial ruling and the dismissal of its settlement-related claim. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">One</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> purported class action on behalf of direct AndroGel purchasers based on the trial court’s ruling in the FTC’s case is also pending in the United States District Court for the Eastern District of Pennsylvania and is stayed pending the appeals in the FTC’s case.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">In January and February 2019, two shareholder derivative lawsuits, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">Brown v. Gonzalez, et al., </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">Elfers v. Gonzalez, et al.</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">, were filed in the United States District Court for the Northern District of Illinois, alleging that certain AbbVie directors and officers breached their fiduciary duties in connection with HUMIRA patient and reimbursement support services and other services and items of value, as alleged in the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">State of California</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> case discussed below.</span></div><div style="line-height:120%;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Between March and May 2019, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">12</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> putative class action lawsuits were filed in the United States District Court for the Northern District of Illinois by indirect HUMIRA purchasers, alleging that AbbVie’s settlements with biosimilar manufacturers and AbbVie’s HUMIRA patent portfolio violate state and federal antitrust laws.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">In November 2014, a putative class action lawsuit, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">Medical Mutual of Ohio v. AbbVie Inc., et al.</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">, was filed against several manufacturers of testosterone replacement therapies (TRTs), including AbbVie, in the United States District Court for the Northern District of Illinois on behalf of all insurance companies, health benefit providers, and other third party payers who paid for TRTs, including AndroGel. The claims asserted include violations of the federal RICO Act and state consumer fraud and deceptive trade practices laws. The complaint seeks monetary damages and injunctive relief. In July 2018, the court denied the plaintiff’s motion for class certification. In February 2019, the court granted the defendants’ summary judgment motion.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">In September 2018, the Commissioner of the California Department of Insurance intervened in a </span><span style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">qui tam</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> lawsuit, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">State of California and Lazaro Suarez v. AbbVie Inc., et al.</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">, brought under the California Insurance Frauds Prevention Act, in California Superior Court for Alameda County. The Department of Insurance’s complaint alleges that, through patient and reimbursement support services and other services and items of value provided in connection with HUMIRA, AbbVie caused the submission of fraudulent commercial insurance claims for HUMIRA in violation of the California statute. The complaint seeks injunctive relief, an assessment of up to three times the amount of the claims at issue, and civil penalties. In addition, a federal securities lawsuit (</span><span style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">Holwill v. AbbVie Inc., et al</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">.) is </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">pending in the United States District Court for the Northern District of Illinois) against AbbVie, its chief executive officer and former chief financial officer, alleging that reasons stated for HUMIRA sales growth in financial filings between 2013 and 2017 were misleading because they omitted the conduct alleged in the Department of Insurance’s complaint.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">In November 2014, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>five</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> individuals filed a putative class action lawsuit, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">Rubinstein, et al. v Gonzalez, et al.,</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> on behalf of purchasers and sellers of certain Shire plc (Shire) securities between June 20 and October 14, 2014, against AbbVie and its chief executive officer in the United States District Court for the Northern District of Illinois alleging that the defendants made and/or are responsible for material misstatements in violation of federal securities laws in connection with AbbVie's proposed transaction with Shire. In July 2019, the court granted preliminary approval to the parties’ settlement agreement.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">In June 2016, a lawsuit, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">Elliott Associates, L.P., et al. v. AbbVie Inc.</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">, was filed by </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>five</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> investment funds against AbbVie in the Cook County, Illinois Circuit Court alleging that AbbVie made misrepresentations and omissions in connec</span><span style="font-family:Calibri,sans-serif;font-size:10pt;background-color:#ffffff;">tion with its proposed t</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">ransaction with Shire. Similar lawsuits were filed between July 2017 and October 2018 against AbbVie and in some instances its chief executive officer in the same court by additional investment funds. Plaintiffs seek compensatory and punitive damages.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Product liability cases were filed in which plaintiffs generally allege that AbbVie and other manufacturers of TRTs did not adequately warn about risks of certain injuries, primarily heart attacks, strokes and blood clots. Approximately </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3,900</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> claims against AbbVie are consolidated for pre-trial purposes in the United States District Court for the Northern District of Illinois under the MDL Rules as </span><span style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">In re: Testosterone Replacement Therapy Products Liability Litigation</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">, MDL No. 2545. Approximately </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>200</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> claims against AbbVie are pending in various state courts. Plaintiffs generally seek compensatory and punitive damages. In November 2018, AbbVie entered into a Master Settlement Agreement with the Plaintiffs’ Steering Committee in the MDL encompassing existing claims in all courts. All proceedings in pending cases are effectively stayed during the settlement administration process.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Product liability cases are pending in which plaintiffs generally allege that AbbVie did not adequately warn about risk of certain injuries, primarily various birth defects, arising from use of Depakote. Approximately </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>150</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> cases are pending in the United States District Court for the Southern District of Illinois, and approximately </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">six</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> others are pending in various state courts. Plaintiffs generally seek compensatory and punitive damages. Approximately </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>ninety percent</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> of these pending cases, plus other unfiled claims, are subject to confidential settlement agreements and are expected to be dismissed with prejudice. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Beginning in May 2016, the Patent Trial &amp; Appeal Board of the U.S. Patent &amp; Trademark Office (PTO) instituted </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">five</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> inter partes review proceedings brought by Coherus Biosciences and Boehringer Ingelheim related to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">three</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> AbbVie patents covering methods of treatment of rheumatoid arthritis using adalimumab. In these proceedings, the PTO reviewed the validity of the patents and issued decisions of invalidity in May, June and July of 2017. AbbVie’s appeal of the decisions is pending in the Court of Appeals for the Federal Circuit.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">In March 2017, AbbVie filed a lawsuit, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">AbbVie Inc. v. Novartis Vaccines and Diagnostics, Inc. and Grifols Worldwide Operations Ltd., </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">in the United States District Court for the Northern District of California against Novartis Vaccines and Grifols Worldwide seeking a declaratory judgment that </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>11</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> HCV-related patents licensed to AbbVie in 2002 are invalid.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">AbbVie is seeking to enforce certain patent rights related to adalimumab (a drug AbbVie sells under the trademark HUMIRA®). In a case filed in United States District Court for the District of Delaware in August 2017, AbbVie alleges that Boehringer Ingelheim International GmbH’s, Boehringer Ingelheim Pharmaceutical, Inc.’s, and Boehringer Ingelheim Fremont, Inc.’s proposed biosimilar adalimumab product infringes certain AbbVie patents. AbbVie seeks declaratory and injunctive relief. In May 2019, the parties settled this case and it was dismissed without prejudice.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Pharmacyclics LLC, a wholly owned subsidiary of AbbVie, is seeking to enforce its patent rights relating to ibrutinib capsules (a drug Pharmacyclics sells under the trademark IMBRUVICA®). In February 2018, cases were filed in the United States District Court for the District of Delaware against the following defendants: Fresenius Kabi USA, LLC, Fresenius Kabi USA, Inc., and Fresenius Kabi Oncology Limited; Sun Pharma Global FZE and Sun Pharmaceutical Industries Ltd.; Cipla Limited and Cipla USA Inc.; and Zydus Worldwide DMCC, Cadila Healthcare Limited, Sandoz Inc., and Lek Pharmaceuticals D.D. In each case, Pharmacyclics alleges the defendant’s proposed generic ibrutinib product infringes certain Pharmacyclics patents and seeks declaratory and injunctive relief. Janssen Biotech, Inc. which is in a global collaboration with Pharmacyclics concerning the development and marketing of IMBRUVICA, is the co-plaintiff in these suits.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Pharmacyclics LLC, a wholly owned subsidiary of AbbVie, is seeking to enforce its patent rights relating to ibrutinib tablets (a drug Pharmacyclics sells under the trademark IMBRUVICA®). In a case filed in the United States District Court for the District of Delaware in March 2019, Pharmacyclics alleges that Alvogen Pine Brook LLC’s and Natco Pharma Ltd.’s proposed generic ibrutinib tablet </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">product infringes certain Pharmacyclics patents. Pharmacyclics seeks declaratory and injunctive relief. Janssen Biotech, Inc. which is in a global collaboration with Pharmacyclics concerning the development and marketing of IMBRUVICA, is the co-plaintiff in this suit.</span></div> 330000000 350000000 3 4 2 1 1 2 448000000 0 5 5 3900 200 150 0.90 11 <span style="font-family:Calibri,sans-serif;font-size:12pt;color:#444867;font-weight:bold;">Segment Information</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"/></tr><tr><td style="width:100%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">AbbVie operates in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>one</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> business segment—pharmaceutical products. The following table details AbbVie’s worldwide net revenues:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18"/></tr><tr><td style="width:11%;"/><td style="width:17%;"/><td style="width:21%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Three months ended<br/>June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Six months ended<br/>June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">(in millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;font-weight:bold;">Immunology</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">HUMIRA</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">United States</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>3,793</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>3,521</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>7,008</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>6,524</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>1,077</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>1,664</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>2,308</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>3,370</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>4,870</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>5,185</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>9,316</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>9,894</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">SKYRIZI</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>42</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>42</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">International</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>48</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>48</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;font-weight:bold;">Hematologic Oncology</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">IMBRUVICA</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>886</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>693</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>1,715</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>1,317</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">Collaboration revenues</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>213</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>157</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>406</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>295</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>1,099</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>850</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>2,121</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>1,612</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">VENCLEXTA</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">United States</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>117</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>47</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>222</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>88</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>52</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>18</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>98</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>36</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>169</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>65</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>320</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>124</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;font-weight:bold;">HCV</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">MAVYRET</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">United States</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>396</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>422</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>799</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>762</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>384</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>510</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>771</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>1,018</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>780</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>932</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>1,570</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>1,780</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">VIEKIRA</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">International</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>41</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>29</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>109</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>41</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>29</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>112</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;font-weight:bold;">Other Key Products</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">Creon</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">United States</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>257</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>219</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>484</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>428</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">Lupron</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">United States</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>168</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>180</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>359</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>357</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>41</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>43</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>79</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>85</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>209</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>223</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>438</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>442</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">Synthroid</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>203</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>193</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>385</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>375</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">Synagis</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">International</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>38</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>44</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>325</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>365</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">Duodopa</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>24</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>20</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>46</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>38</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">International</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>91</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>88</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>180</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>173</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>115</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>108</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>226</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>211</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">Sevoflurane</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">United States</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>18</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>19</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>35</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>36</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>73</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>94</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>148</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>183</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>91</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>113</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>183</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>219</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">Kaletra</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>23</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>26</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">International</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>67</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>78</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>132</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>138</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>77</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>91</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>155</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>164</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">AndroGel</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">United States</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>22</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>128</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>96</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>258</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">ORILISSA</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>18</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>31</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">International</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>19</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>32</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">All other</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>254</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>86</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>355</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>228</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">Total net revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>8,255</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>8,278</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>16,083</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>16,212</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div> <div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">AbbVie operates in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>one</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> business segment—pharmaceutical products. The following table details AbbVie’s worldwide net revenues:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18"/></tr><tr><td style="width:11%;"/><td style="width:17%;"/><td style="width:21%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Three months ended<br/>June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Six months ended<br/>June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">(in millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;font-weight:bold;">Immunology</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">HUMIRA</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">United States</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>3,793</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>3,521</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>7,008</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>6,524</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>1,077</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>1,664</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>2,308</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>3,370</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>4,870</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>5,185</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>9,316</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>9,894</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">SKYRIZI</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>42</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>42</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">International</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>48</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>48</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;font-weight:bold;">Hematologic Oncology</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">IMBRUVICA</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>886</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>693</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>1,715</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>1,317</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">Collaboration revenues</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>213</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>157</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>406</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>295</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>1,099</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>850</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>2,121</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>1,612</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">VENCLEXTA</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">United States</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>117</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>47</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>222</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>88</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>52</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>18</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>98</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>36</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>169</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>65</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>320</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>124</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;font-weight:bold;">HCV</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">MAVYRET</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">United States</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>396</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>422</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>799</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>762</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>384</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>510</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>771</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>1,018</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>780</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>932</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>1,570</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>1,780</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">VIEKIRA</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">International</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>41</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>29</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>109</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>41</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>29</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>112</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;font-weight:bold;">Other Key Products</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">Creon</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">United States</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>257</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>219</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>484</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>428</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">Lupron</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">United States</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>168</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>180</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>359</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>357</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>41</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>43</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>79</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>85</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>209</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>223</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>438</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>442</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">Synthroid</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>203</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>193</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>385</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>375</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">Synagis</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">International</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>38</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>44</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>325</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>365</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">Duodopa</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>24</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>20</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>46</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>38</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">International</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>91</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>88</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>180</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>173</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>115</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>108</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>226</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>211</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">Sevoflurane</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">United States</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>18</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>19</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>35</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>36</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>73</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>94</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>148</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>183</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>91</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>113</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>183</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>219</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">Kaletra</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>23</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>26</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">International</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>67</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>78</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>132</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>138</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>77</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>91</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>155</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>164</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">AndroGel</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">United States</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>22</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>128</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>96</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>258</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">ORILISSA</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>18</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>31</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">International</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>19</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>32</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">All other</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>254</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>86</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>355</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>228</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">Total net revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>8,255</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>8,278</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>16,083</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><span>16,212</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div> 1 3793000000 3521000000 7008000000 6524000000 1077000000 1664000000 2308000000 3370000000 4870000000 5185000000 9316000000 9894000000 42000000 0 42000000 0 6000000 0 6000000 0 48000000 0 48000000 0 886000000 693000000 1715000000 1317000000 213000000 157000000 406000000 295000000 1099000000 850000000 2121000000 1612000000 117000000 47000000 222000000 88000000 52000000 18000000 98000000 36000000 169000000 65000000 320000000 124000000 396000000 422000000 799000000 762000000 384000000 510000000 771000000 1018000000 780000000 932000000 1570000000 1780000000 0 0 0 3000000 4000000 41000000 29000000 109000000 4000000 41000000 29000000 112000000 257000000 219000000 484000000 428000000 168000000 180000000 359000000 357000000 41000000 43000000 79000000 85000000 209000000 223000000 438000000 442000000 203000000 193000000 385000000 375000000 38000000 44000000 325000000 365000000 24000000 20000000 46000000 38000000 91000000 88000000 180000000 173000000 115000000 108000000 226000000 211000000 18000000 19000000 35000000 36000000 73000000 94000000 148000000 183000000 91000000 113000000 183000000 219000000 10000000 13000000 23000000 26000000 67000000 78000000 132000000 138000000 77000000 91000000 155000000 164000000 22000000 128000000 96000000 258000000 18000000 0 31000000 0 1000000 0 1000000 0 19000000 0 32000000 0 254000000 86000000 355000000 228000000 8255000000 8278000000 16083000000 16212000000 Total lease payments exclude approximately $350 million of contractual minimum lease payments for leases executed but not yet commenced. These leases will commence between years 2019 and 2020 with lease terms of approximately 11 years. Lease payments recognized as part of lease liabilities for optional renewal periods are insignificant. Amounts are included in cost of products sold (see Note 9). Amounts are included in the computation of net periodic benefit cost (see Note 10). Amounts are included in interest expense, net (see Note 9). XML 16 R1.htm IDEA: XBRL DOCUMENT v3.19.2
Document and Entity Information - shares
 6 Months Ended
Jun. 30, 2019
Jul. 29, 2019
Entity Information    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Jun. 30, 2019  
Document Transition Report false  
Entity File Number 001-35565  
Entity Registrant Name AbbVie Inc.  
Entity Central Index Key 0001551152  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2019  
Document Fiscal Period Focus Q2  
Amendment Flag false  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 32-0375147  
Entity Address, Address Line One 1 North Waukegan Road  
Entity Address, City or Town North Chicago  
Entity Address, State or Province IL  
Entity Address, Postal Zip Code 60064  
City Area Code 847  
Local Phone Number 932-7900  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   1,478,483,838
Common Stock [Member] | NEW YORK STOCK EXCHANGE, INC. [Member]    
Entity Information    
Title of 12(b) Security Common Stock, par value $0.01 per share  
Trading Symbol ABBV  
Security Exchange Name NYSE  
Common Stock [Member] | CHICAGO STOCK EXCHANGE, INC [Member]    
Entity Information    
Title of 12(b) Security Common Stock, par value $0.01 per share  
Trading Symbol ABBV  
Security Exchange Name CHX  
XML 17 R2.htm IDEA: XBRL DOCUMENT v3.19.2
Condensed Consolidated Statements of Earnings (Unaudited) - USD ($)
shares in Millions, $ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2019
Jun. 30, 2018
Income Statement [Abstract]        
Net revenues $ 8,255 $ 8,278 $ 16,083 $ 16,212
Cost of products sold 1,819 1,934 3,513 3,861
Selling, general and administrative 1,654 1,760 3,334 3,551
Research and development 1,291 1,322 2,580 2,566
Acquired in-process research and development 91 0 246 69
Other expense 0 500 0 500
Total operating costs and expenses 4,855 5,516 9,673 10,547
Operating earnings 3,400 2,762 6,410 5,665
Interest expense, net 309 272 634 523
Net foreign exchange loss 6 8 12 16
Other expense, net 2,278 470 2,413 317
Earnings before income tax expense 807 2,012 3,351 4,809
Income tax expense 66 29 154 43
Net earnings $ 741 $ 1,983 $ 3,197 $ 4,766
Per share data        
Basic earnings per share (in dollars per share) $ 0.49 $ 1.26 $ 2.15 $ 3.00
Diluted earnings per share (in dollars per share) $ 0.49 $ 1.26 $ 2.14 $ 2.99
Weighted-average basic shares outstanding (in shares) 1,480 1,568 1,480 1,579
Weighted-average diluted shares outstanding (in shares) 1,484 1,572 1,483 1,584
XML 18 R3.htm IDEA: XBRL DOCUMENT v3.19.2
Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2019
Jun. 30, 2018
Statement of Comprehensive Income [Abstract]        
Net earnings $ 741 $ 1,983 $ 3,197 $ 4,766
Foreign currency translation adjustments, net of tax expense (benefit) of $5 for the three months and $6 for the six months ended June 30, 2019 and $(16) for the three months and $(19) for the six months ended June 30, 2018 71 (469) (32) (280)
Net investment hedging activities, net of tax expense (benefit) of $(11) for the three months and $8 for the six months ended June 30, 2019 and $61 for the three months and $31 for the six months ended June 30, 2018 (37) 209 28 105
Pension and post-employment benefits, net of tax expense (benefit) of $6 for the three months and $12 for the six months ended June 30, 2019 and $7 for the three months and $16 for the six months ended June 30, 2018 20 49 45 71
Marketable security activities, net of tax expense (benefit) of $— for the three months and $— for the six months ended June 30, 2019 and $— for the three months and $— for the six months ended June 30, 2018 4 5 11 (2)
Cash flow hedging activities, net of tax expense (benefit) of $(2) for the three months and $(9) for the six months ended June 30, 2019 and $18 for the three months and $17 for the six months ended June 30, 2018 (33) 197 (63) 194
Other comprehensive income (loss) 25 (9) (11) 88
Comprehensive income $ 766 $ 1,974 $ 3,186 $ 4,854
XML 19 R4.htm IDEA: XBRL DOCUMENT v3.19.2
Condensed Consolidated Statements of Comprehensive Income (Parenthetical) (Unaudited) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2019
Jun. 30, 2018
Statement of Comprehensive Income [Abstract]        
Foreign currency translation adjustments, tax expense (benefit) $ 5 $ (16) $ 6 $ (19)
Net investment hedging activities, tax expense (benefit) (11) 61 8 31
Pension and post-employment benefits, tax expense (benefit) 6 7 12 16
Marketable security activities, tax expense (benefit) 0 0 0 0
Cash flow hedging activities, tax expense (benefit) $ (2) $ 18 $ (9) $ 17
XML 20 R5.htm IDEA: XBRL DOCUMENT v3.19.2
Condensed Consolidated Balance Sheets - USD ($)
$ in Millions
Jun. 30, 2019
Dec. 31, 2018
Current assets    
Cash and equivalents $ 5,172 $ 7,289
Short-term investments 244 772
Accounts receivable, net 5,482 5,384
Inventories 1,895 1,605
Prepaid expenses and other 2,307 1,895
Total current assets 15,100 16,945
Investments 1,473 1,420
Property and equipment, net 2,879 2,883
Intangible assets, net 20,459 21,233
Goodwill 15,642 15,663
Other assets 1,589 1,208
Total assets 57,142 59,352
Current liabilities    
Short-term borrowings 306 3,699
Current portion of long-term debt and finance lease obligations 5,335 1,609
Accounts payable and accrued liabilities 11,300 11,931
Total current liabilities 16,941 17,239
Long-term debt and finance lease obligations 31,619 35,002
Deferred income taxes 1,148 1,067
Other long-term liabilities 16,000 14,490
Commitments and contingencies
Stockholders’ equity (deficit)    
Common stock, $0.01 par value, 4,000,000,000 shares authorized, 1,781,055,877 shares issued as of June 30, 2019 and 1,776,510,871 as of December 31, 2018 18 18
Common stock held in treasury, at cost, 302,685,326 shares as of June 30, 2019 and 297,686,473 as of December 31, 2018 (24,505) (24,108)
Additional paid-in capital 15,028 14,756
Retained earnings 3,384 3,368
Accumulated other comprehensive loss (2,491) (2,480)
Total stockholders’ equity (deficit) (8,566) (8,446)
Total liabilities and equity $ 57,142 $ 59,352
XML 21 R6.htm IDEA: XBRL DOCUMENT v3.19.2
Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares
Jun. 30, 2019
Dec. 31, 2018
Statement of Financial Position [Abstract]    
Common stock, par value (in dollars per share) $ 0.01 $ 0.01
Common stock, authorized (in shares) 4,000,000,000 4,000,000,000
Common stock, issued (in shares) 1,781,055,877 1,776,510,871
Common stock held in treasury, at cost (in shares) 302,685,326 297,686,473
XML 22 R7.htm IDEA: XBRL DOCUMENT v3.19.2
Condensed Consolidated Statements of Equity (Unaudited) - USD ($)
shares in Millions, $ in Millions
Total
Common stock
Treasury stock
Additional paid-in capital
Retained earnings
Accumulated other comprehensive loss
Beginning balance at Dec. 31, 2017 $ 5,097 $ 18 $ (11,923) $ 14,270 $ 5,459 $ (2,727)
Beginning balance (in shares) at Dec. 31, 2017   1,592        
Increase (Decrease) in Stockholders' Equity            
Net earnings 4,766 $ 0 0 0 4,766 0
Other comprehensive income, net of tax 88 0 0 0 0 88
Dividends declared (2,997) 0 0 0 (2,997) 0
Purchases of treasury stock (8,947) $ 0 (8,947) 0 0 0
Purchases of treasury stock (in shares)   (85)        
Stock-based compensation plans and other 351 $ 0 25 326 0 0
Stock-based compensation plans and other (in shares)   7        
Ending balance at Jun. 30, 2018 (3,375) $ 18 (20,845) 14,596 5,495 (2,639)
Ending balance (in shares) at Jun. 30, 2018   1,514        
Beginning balance at Mar. 31, 2018 3,553 $ 18 (13,331) 14,519 4,977 (2,630)
Beginning balance (in shares) at Mar. 31, 2018   1,587        
Increase (Decrease) in Stockholders' Equity            
Net earnings 1,983 $ 0 0 0 1,983 0
Other comprehensive income, net of tax (9) 0 0 0 0 (9)
Dividends declared (1,465) 0 0 0 (1,465) 0
Purchases of treasury stock (7,516) $ 0 (7,516) 0 0 0
Purchases of treasury stock (in shares)   (73)        
Stock-based compensation plans and other 79 $ 0 2 77 0 0
Stock-based compensation plans and other (in shares)   0        
Ending balance at Jun. 30, 2018 (3,375) $ 18 (20,845) 14,596 5,495 (2,639)
Ending balance (in shares) at Jun. 30, 2018   1,514        
Beginning balance at Dec. 31, 2018 (8,446) $ 18 (24,108) 14,756 3,368 (2,480)
Beginning balance (in shares) at Dec. 31, 2018   1,479        
Increase (Decrease) in Stockholders' Equity            
Net earnings 3,197 $ 0 0 0 3,197 0
Other comprehensive income, net of tax (11) 0 0 0 0 (11)
Dividends declared (3,181) 0 0 0 (3,181) 0
Purchases of treasury stock (422) $ 0 (422) 0 0 0
Purchases of treasury stock (in shares)   (5)        
Stock-based compensation plans and other 297 $ 0 25 272 0 0
Stock-based compensation plans and other (in shares)   4        
Ending balance at Jun. 30, 2019 (8,566) $ 18 (24,505) 15,028 3,384 (2,491)
Ending balance (in shares) at Jun. 30, 2019   1,478        
Beginning balance at Mar. 31, 2019 (7,826) $ 18 (24,502) 14,940 4,234 (2,516)
Beginning balance (in shares) at Mar. 31, 2019   1,478        
Increase (Decrease) in Stockholders' Equity            
Net earnings 741 $ 0 0 0 741 0
Other comprehensive income, net of tax 25 0 0 0 0 25
Dividends declared (1,591) 0 0 0 (1,591) 0
Purchases of treasury stock (3) $ 0 (3) 0 0 0
Purchases of treasury stock (in shares)   0        
Stock-based compensation plans and other 88 $ 0 0 88 0 0
Stock-based compensation plans and other (in shares)   0        
Ending balance at Jun. 30, 2019 $ (8,566) $ 18 $ (24,505) $ 15,028 $ 3,384 $ (2,491)
Ending balance (in shares) at Jun. 30, 2019   1,478        
XML 23 R8.htm IDEA: XBRL DOCUMENT v3.19.2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Millions
 6 Months Ended
Jun. 30, 2019
Jun. 30, 2018
Cash flows from operating activities    
Net earnings $ 3,197 $ 4,766
Adjustments to reconcile net earnings to net cash from operating activities:    
Depreciation 232 234
Amortization of intangible assets 773 654
Change in fair value of contingent consideration liabilities 2,473 337
Stock-based compensation 276 276
Upfront costs and milestones related to collaborations 321 656
Other, net (10) 118
Changes in operating assets and liabilities:    
Accounts receivable (96) (805)
Inventories (288) (191)
Prepaid expenses and other assets (97) (546)
Accounts payable and other liabilities (1,287) 12
Cash flows from operating activities 5,494 5,511
Cash flows from investing activities    
Acquisitions and investments (440) (401)
Acquisitions of property and equipment (235) (233)
Purchases of investment securities (558) (637)
Sales and maturities of investment securities 1,066 1,511
Cash flows from investing activities (167) 240
Cash flows from financing activities    
Net change in commercial paper borrowings (393) 111
Proceeds from issuance of other short-term borrowings 0 3,000
Repayments of other short-term borrowings (3,000) 0
Repayments of long-term debt and finance lease obligations (4) (3,013)
Debt issuance costs (171) 0
Dividends paid (3,180) (2,668)
Purchases of treasury stock (623) (8,947)
Proceeds from the exercise of stock options 5 64
Payments of contingent consideration liabilities (108) (39)
Other, net 21 5
Cash flows from financing activities (7,453) (11,487)
Effect of exchange rate changes on cash and equivalents 9 (20)
Net change in cash and equivalents (2,117) (5,756)
Cash and equivalents, beginning of period 7,289 9,303
Cash and equivalents, end of period $ 5,172 $ 3,547
XML 24 R9.htm IDEA: XBRL DOCUMENT v3.19.2
Basis of Presentation
 6 Months Ended
Jun. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis of Presentation Basis of Presentation
 

Basis of Historical Presentation
The unaudited interim condensed consolidated financial statements of AbbVie Inc. (AbbVie or the company) have been prepared pursuant to the rules and regulations of the U.S. Securities and Exchange Commission. Accordingly, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP) have been omitted. These unaudited interim condensed consolidated financial statements should be read in conjunction with the company’s audited consolidated financial statements and notes included in the company’s Annual Report on Form 10-K for the year ended December 31, 2018.
It is management’s opinion that these financial statements include all normal and recurring adjustments necessary for a fair presentation of the company’s financial position and operating results. Net revenues and net earnings for any interim period are not necessarily indicative of future or annual results. Certain reclassifications were made to conform the prior period interim condensed consolidated financial statements to the current period presentation.
Recent Accounting Pronouncements
Recently Adopted Accounting Pronouncements
ASU No. 2016-02
In February 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2016-02, Leases (Topic 842). The standard outlined a comprehensive lease accounting model that superseded the previous lease guidance and required lessees to recognize lease liabilities and corresponding right-of-use assets for all leases with lease terms greater than 12 months. The guidance also changed the definition of a lease and expanded the disclosure requirements of lease arrangements. AbbVie adopted the standard in the first quarter of 2019 using the modified retrospective method. Results for reporting periods beginning after December 31, 2018 have been presented in accordance with the standard, while results for prior periods have not been adjusted and continue to be reported in accordance with AbbVie's historical accounting. The cumulative effect of initially applying the new leases standard was recognized as an adjustment to the opening condensed consolidated balance sheet as of January 1, 2019.
The company elected a package of practical expedients for leases that commenced prior to January 1, 2019 and did not reassess historical conclusions on: (i) whether any expired or existing contracts are or contain leases; (ii) lease classification for any expired or existing leases; and (iii) initial direct costs capitalization for any existing leases.
Under the new standard, on January 1, 2019, the company recognized a cumulative-effect adjustment to its condensed consolidated balance sheet primarily related to the recognition of liabilities and corresponding right-of-use assets for operating leases. The adjustment to the condensed consolidated balance sheet included: (i) a $405 million increase to other assets; (ii) a $115 million increase to accounts payable and accrued liabilities; and (iii) a $290 million increase to other long-term liabilities. Other cumulative-effect adjustments to the condensed consolidated balance sheet were insignificant.
Adoption of the standard did not have a significant impact on AbbVie's condensed consolidated statements of earnings for the three and six months ended June 30, 2019.
ASU No. 2018-02
In February 2018, the FASB issued ASU No. 2018-02, Income Statement - Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income, which allowed a reclassification from accumulated other comprehensive income (AOCI) to retained earnings for stranded tax effects related to adjustments to deferred taxes resulting from the December 2017 enactment of the Tax Cuts and Jobs Act (the Act). AbbVie adopted the standard in the first quarter of 2019. Upon adoption, the company made an election to not reclassify the income tax effects of the Act from AOCI to retained earnings. Therefore, the adoption of the standard had no impact on AbbVie's consolidated financial statements.
Recent Accounting Pronouncements Not Yet Adopted
ASU No. 2016-13
In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326). The standard changes how credit losses are measured for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other financial instruments, the standard requires the use of a new forward-looking "expected credit loss" model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, the standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. Additionally, the standard requires new disclosures and will be effective for AbbVie starting with the first quarter of 2020. With certain exceptions, adjustments are to be applied using a modified-retrospective approach by reflecting adjustments through a cumulative-effect impact to retained earnings as of the beginning of the fiscal year of adoption. AbbVie is currently assessing the impact of adopting this guidance on its consolidated financial statements.
XML 25 R10.htm IDEA: XBRL DOCUMENT v3.19.2
Supplemental Financial Information
 6 Months Ended
Jun. 30, 2019
Supplemental Financial Information  
Supplemental Financial Information Supplemental Financial Information
 

Interest Expense, Net
 
 
Three months ended
June 30,
 
Six months ended
June 30,
(in millions)
 
2019
 
2018
 
2019
 
2018
Interest expense
 
$
358

 
$
320

 
$
745

 
$
629

Interest income
 
(49
)
 
(48
)
 
(111
)
 
(106
)
Interest expense, net
 
$
309

 
$
272

 
$
634

 
$
523


Inventories
(in millions)
June 30, 2019
 
December 31, 2018
Finished goods
$
638

 
$
473

Work-in-process
969

 
862

Raw materials
288

 
270

Inventories
$
1,895

 
$
1,605


Property and Equipment
(in millions)
June 30, 2019
 
December 31, 2018
Property and equipment, gross
$
8,443

 
$
8,396

Accumulated depreciation
(5,564
)
 
(5,513
)
Property and equipment, net
$
2,879

 
$
2,883


Depreciation expense was $114 million for the three months and $232 million for the six months ended June 30, 2019 and $119 million for the three months and $234 million for the six months ended June 30, 2018.
XML 26 R11.htm IDEA: XBRL DOCUMENT v3.19.2
Earnings Per Share
 6 Months Ended
Jun. 30, 2019
Earnings Per Share [Abstract]  
Earnings Per Share Earnings Per Share
 

AbbVie grants certain restricted stock units (RSUs) that are considered to be participating securities. Due to the presence of participating securities, AbbVie calculates earnings per share (EPS) using the more dilutive of the treasury stock or the two-class method. For all periods presented, the two-class method was more dilutive.

The following table summarizes the impact of the two-class method:

 
 
Three months ended
June 30,
 
Six months ended
June 30,
(in millions, except per share data)
 
2019
 
2018
 
2019
 
2018
Basic EPS
 
 
 
 
 
 
 
 
Net earnings
 
$
741

 
$
1,983

 
$
3,197

 
$
4,766

Earnings allocated to participating securities
 
8

 
10

 
17

 
22

Earnings available to common shareholders
 
$
733

 
$
1,973

 
$
3,180

 
$
4,744

Weighted-average basic shares outstanding
 
1,480

 
1,568

 
1,480

 
1,579

Basic earnings per share
 
$
0.49

 
$
1.26

 
$
2.15

 
$
3.00

 
 
 
 
 
 
 
 
 
Diluted EPS
 
 
 
 
 
 
 
 
Net earnings
 
$
741

 
$
1,983

 
$
3,197

 
$
4,766

Earnings allocated to participating securities
 
8

 
10

 
17

 
22

Earnings available to common shareholders
 
$
733

 
$
1,973

 
$
3,180

 
$
4,744

Weighted-average shares of common stock outstanding
 
1,480

 
1,568

 
1,480

 
1,579

Effect of dilutive securities
 
4

 
4

 
3

 
5

Weighted-average diluted shares outstanding
 
1,484

 
1,572

 
1,483

 
1,584

Diluted earnings per share
 
$
0.49

 
$
1.26

 
$
2.14

 
$
2.99



Certain shares issuable under stock-based compensation plans were excluded from the computation of EPS because the effect would have been antidilutive. The number of common shares excluded was insignificant for all periods presented.
XML 27 R12.htm IDEA: XBRL DOCUMENT v3.19.2
Licensing, Acquisitions, and Other Arrangements
 6 Months Ended
Jun. 30, 2019
Licensing, Acquisitions, and Other Arrangements  
Licensing, Acquisitions, and Other Arrangements Licensing, Acquisitions and Other Arrangements
 

Proposed Acquisition of Allergan plc
On June 25, 2019, AbbVie announced that it entered into a definitive transaction agreement under which AbbVie will acquire Allergan plc (Allergan) in a cash and stock transaction for a transaction equity value of approximately $63 billion, based on the closing price of AbbVie’s common stock of $78.45 on June 24, 2019. Under the terms of the transaction agreement, Allergan shareholders will receive 0.8660 AbbVie shares and $120.30 in cash for each Allergan share.
In connection with the proposed acquisition of Allergan, on June 25, 2019, AbbVie entered into a $38.0 billion 364-day bridge credit agreement. On July 12, 2019, AbbVie entered into a term loan credit agreement with an aggregate principal amount of $6.0 billion consisting of a $1.5 billion 364-day term loan tranche, a $2.5 billion three-year term loan tranche and a $2.0 billion five-year term loan tranche, with the commitments under the bridge credit agreement to be reduced by such amount to $32.0 billion. No amounts have been drawn under the bridge credit agreement or term loan credit agreement.
Allergan is a global pharmaceutical leader focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world. Allergan markets a portfolio of brands and products primarily focused on key therapeutic areas including medical aesthetics, eye care, neuroscience, gastroenterology and women's health.
The transaction is expected to close in early 2020, subject to regulatory and Allergan shareholder approvals.
Other Licensing & Acquisitions Activity
Cash outflows related to other acquisitions and investments totaled $440 million for the six months ended June 30, 2019 and $401 million for the six months ended June 30, 2018. AbbVie recorded acquired in-process research and development (IPR&D) charges of $91 million for the three months and $246 million for the six months ended June 30, 2019. AbbVie recorded no acquired IPR&D charges for the three months ended June 30, 2018 and recorded acquired IPR&D charges of $69 million for the six months ended June 30, 2018.
Calico Life Sciences LLC
In June 2018, AbbVie and Calico Life Sciences LLC (Calico) entered into an extension of a collaboration to discover, develop and bring to market new therapies for patients with age-related diseases, including neurodegeneration and cancer. Under the terms of the agreement, AbbVie and Calico will each contribute an additional $500 million to the collaboration and the term was extended for an additional three years. Calico will be responsible for research and early development until 2022 and will advance collaboration projects through Phase 2a through 2027. Following completion of Phase 2a, AbbVie will have the option to exclusively license collaboration compounds. AbbVie will support Calico in its early research and development efforts and, upon exercise, would be responsible for late-stage development and commercial activities. Collaboration costs and profits will be shared equally by both parties post option exercise. During the six months ended June 30, 2018, AbbVie recorded $500 million in other expense in the condensed consolidated statement of earnings related to its commitments under the agreement.
XML 28 R13.htm IDEA: XBRL DOCUMENT v3.19.2
Collaboration with Janssen Biotech, Inc.
 6 Months Ended
Jun. 30, 2019
Collaboration with Janssen Biotech, Inc.  
Collaboration with Janssen Biotech, Inc. Collaboration with Janssen Biotech, Inc.
 

In December 2011, Pharmacyclics, a wholly-owned subsidiary of AbbVie, entered into a worldwide collaboration and license agreement with Janssen Biotech, Inc. and its affiliates (Janssen), one of the Janssen Pharmaceutical companies of Johnson & Johnson, for the joint development and commercialization of IMBRUVICA, a novel, orally active, selective covalent inhibitor of Bruton's tyrosine kinase (BTK) and certain compounds structurally related to IMBRUVICA, for oncology and other indications, excluding all immune and inflammatory mediated diseases or conditions and all psychiatric or psychological diseases or conditions, in the United States and outside the United States.

The collaboration provides Janssen with an exclusive license to commercialize IMBRUVICA outside of the United States and co-exclusively with AbbVie in the United States. Both parties are responsible for the development, manufacturing and marketing of any products generated as a result of the collaboration. The collaboration has no set duration or specific expiration date and provides for potential future development, regulatory and approval milestone payments of up to $200 million to AbbVie. The collaboration also includes a cost sharing arrangement for associated collaboration activities. Except in certain cases, Janssen is responsible for approximately 60% of collaboration development costs and AbbVie is responsible for the remaining 40% of collaboration development costs.

In the United States, both parties have co-exclusive rights to commercialize the products; however, AbbVie is the principal in the end-customer product sales. AbbVie and Janssen share pre-tax profits and losses equally from the commercialization of products. Sales of IMBRUVICA are included in AbbVie's net revenues. Janssen's share of profits is included in AbbVie's cost of products sold. Other costs incurred under the collaboration are reported in their respective expense line items, net of Janssen's share.

Outside the United States, Janssen is responsible for and has exclusive rights to commercialize IMBRUVICA. AbbVie and Janssen share pre-tax profits and losses equally from the commercialization of products. AbbVie's share of profits is included in AbbVie's net revenues. Other costs incurred under the collaboration are reported in their respective expense line items, net of Janssen's share.

The following table shows the profit and cost sharing relationship between Janssen and AbbVie:

 
 
Three months ended
June 30,
 
Six months ended
June 30,
(in millions)
 
2019
 
2018
 
2019
 
2018
United States - Janssen's share of profits (included in cost of products sold)
 
$
422

 
$
325

 
$
808

 
$
601

International - AbbVie's share of profits (included in net revenues)
 
213

 
157

 
406

 
295

Global - AbbVie's share of other costs (included in respective line items)
 
77

 
80

 
149

 
151



AbbVie’s receivable from Janssen, included in accounts receivable, net, was $230 million at June 30, 2019 and $177 million at December 31, 2018. AbbVie’s payable to Janssen, included in accounts payable and accrued liabilities, was $405 million at June 30, 2019 and $376 million at December 31, 2018.
XML 29 R14.htm IDEA: XBRL DOCUMENT v3.19.2
Goodwill and Intangible Assets
 6 Months Ended
Jun. 30, 2019
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and Intangible Assets Goodwill and Intangible Assets
 

Goodwill

The following table summarizes the changes in the carrying amount of goodwill:
(in millions)
 
Balance as of December 31, 2018
$
15,663

Foreign currency translation adjustments
(21
)
Balance as of June 30, 2019
$
15,642



The company performs its annual goodwill impairment assessment in the third quarter, or earlier if impairment indicators exist. As of June 30, 2019, there were no accumulated goodwill impairment losses.
Intangible Assets, Net

The following table summarizes intangible assets:
 
June 30, 2019
 
December 31, 2018
(in millions)
Gross
carrying
amount
 
Accumulated
amortization
 
Net
carrying
amount
 
Gross
carrying
amount
 
Accumulated
amortization
 
Net
carrying
amount
Definite-lived intangible assets
 
 
 
 
 
 
 
 
 
 
 
Developed product rights
$
19,611

 
$
(5,963
)
 
$
13,648

 
$
15,872

 
$
(5,614
)
 
$
10,258

License agreements
7,798

 
(2,017
)
 
5,781

 
7,865

 
(1,810
)
 
6,055

Total definite-lived intangible assets
27,409

 
(7,980
)
 
19,429

 
23,737

 
(7,424
)
 
16,313

Indefinite-lived research and development
1,030

 
—

 
1,030

 
4,920

 
—

 
4,920

Total intangible assets, net
$
28,439

 
$
(7,980
)
 
$
20,459

 
$
28,657

 
$
(7,424
)
 
$
21,233


Indefinite-Lived Intangible Assets
Indefinite-lived intangible assets represent acquired IPR&D associated with products that have not yet received regulatory approval. The company performs its annual impairment assessment of indefinite-lived intangible assets in the third quarter, or earlier if impairment indicators exist. No indefinite-lived intangible asset impairment charges were recorded for the six months ended June 30, 2019 and 2018.
In April 2019, the U.S. Food and Drug Administration (FDA) and the European Commission approved SKYRIZI (risankizumab) for the treatment of moderate to severe plaque psoriasis. As a result, AbbVie reclassified $3.9 billion of indefinite-lived intangible assets related to SKYRIZI to developed product rights definite-lived intangible assets. This amount will be amortized over its estimated useful life using the estimated pattern of economic benefit.
In the fourth quarter of 2018, the company recorded an impairment charge of $5.1 billion related to IPR&D acquired as part of the 2016 Stemcentrx acquisition following the decision to stop enrollment in the TAHOE trial. AbbVie continues to evaluate information as it becomes available with respect to the Stemcentrx-related clinical development programs and will monitor the remaining $1.0 billion of IPR&D assets for further impairment.
Definite-Lived Intangible Assets
Amortization expense was $388 million for the three months and $773 million for the six months ended June 30, 2019 and $324 million for the three months and $654 million for the six months ended June 30, 2018. Amortization expense was included in cost of products sold in the condensed consolidated statements of earnings. No definite-lived intangible asset impairment charges were recorded for the six months ended June 30, 2019 and 2018.
XML 30 R15.htm IDEA: XBRL DOCUMENT v3.19.2
Restructuring Plans
 6 Months Ended
Jun. 30, 2019
Restructuring and Related Activities [Abstract]  
Restructuring Plans Restructuring Plans
 

AbbVie recorded restructuring charges of $19 million for the three months and $186 million for the six months ended June 30, 2019 and $1 million for the three months and $23 million for the six months ended June 30, 2018. Restructuring charges for the three and six months ended June 30, 2019 primarily related to severance costs.

The following table summarizes the cash activity in the restructuring reserve for the six months ended June 30, 2019:
(in millions)
 
Accrued balance as of December 31, 2018
$
99

Restructuring charges
172

Payments and other adjustments
(80
)
Accrued balance as of June 30, 2019
$
191
XML 31 R16.htm IDEA: XBRL DOCUMENT v3.19.2
Leases
 6 Months Ended
Jun. 30, 2019
Leases [Abstract]  
Leases Leases    
 
AbbVie's lease portfolio primarily consists of real estate properties, vehicles and equipment. Short-term leases with a term of 12 months or less are not recorded on the balance sheet. For leases commencing or modified in 2019 or later, AbbVie does not separate lease components from non-lease components.
The company records lease liabilities based on the present value of lease payments over the lease term. AbbVie generally uses an incremental borrowing rate to discount its lease liabilities, as the rate implicit in the lease is typically not readily determinable. Certain lease agreements include renewal options that are under the company's control. AbbVie includes optional renewal periods in the lease term only when it is reasonably certain that AbbVie will exercise its option.
Variable lease payments include payments to lessors for taxes, maintenance, insurance and other operating costs as well as payments that are adjusted based on an index or rate. The company's lease agreements do not contain any significant residual value guarantees or restrictive covenants.
The following table summarizes the amounts and location of operating and finance leases on the condensed consolidated balance sheet:
(in millions)
Balance sheet caption
June 30,
2019
Assets
 
 
Operating
Other assets
$
380

Finance
Property and equipment, net
27

Total lease assets
 
$
407

Liabilities
 
 
Operating
 
 
Current
Accounts payable and accrued liabilities
$
111

Noncurrent
Other long-term liabilities
290

Finance
 
 
Current
Current portion of long-term debt and finance lease obligations
9

Noncurrent
Long-term debt and finance lease obligations
22

Total lease liabilities
 
$
432


The following table summarizes the lease costs recognized in the condensed consolidated statements of earnings:
 
 
Three months ended
June 30,
 
Six months ended
June 30,
(in millions)
 
2019
 
2019
Operating lease cost
 
$
32

 
$
64

Finance lease cost
 
 
 
 
Amortization of right-of-use assets
 
2

 
4

Interest on lease liabilities
 
—

 
—

Short-term lease cost
 
9

 
15

Variable lease cost
 
14

 
29

Total lease cost
 
$
57

 
$
112


Sublease income was insignificant for the three and six months ended June 30, 2019.
The following table presents the weighted-average remaining lease term and weighted-average discount rate for operating and finance leases:
 
June 30,
2019
Weighted-average remaining lease term (in years)
 
Operating
6

Finance
3

Weighted-average discount rate
 
Operating
4.0
%
Finance
4.4
%

The following table presents supplementary cash flow information regarding the company's operating and finance leases:
 
Six months ended
June 30,
(in millions)
2019
Cash paid for amounts included in the measurement of lease liabilities
 
Operating cash flows from operating leases
$
58

Operating cash flows from finance leases
—

Financing cash flows from finance leases
4

Right-of-use assets obtained in exchange for new finance lease liabilities
—

Right-of-use assets obtained in exchange for new operating lease liabilities
15


The following table summarizes the future maturities of AbbVie's operating and finance lease liabilities as of June 30, 2019:
(in millions)
Operating
leases
 
Finance
leases
 
Total (a)(b)
2019
$
65

 
$
8

 
$
73

2020
121

 
11

 
132

2021
100

 
9

 
109

2022
55

 
3

 
58

2023
35

 
1

 
36

Thereafter
79

 
—

 
79

Total lease payments
455

 
32

 
487

Less: Interest
54

 
1

 
55

Present value of lease liabilities
$
401

 
$
31

 
$
432


(a) Total lease payments exclude approximately $350 million of contractual minimum lease payments for leases executed but not yet commenced. These leases will commence between years 2019 and 2020 with lease terms of approximately 11 years.
(b) Lease payments recognized as part of lease liabilities for optional renewal periods are insignificant.
XML 32 R17.htm IDEA: XBRL DOCUMENT v3.19.2
Financial Instruments and Fair Value Measures
 6 Months Ended
Jun. 30, 2019
Fair Value Disclosures [Abstract]  
Financial Instruments and Fair Value Measures Financial Instruments and Fair Value Measures
 

Risk Management Policy

See Note 10 to the company's Annual Report on Form 10-K for the year ended December 31, 2018 for a summary of AbbVie's risk management policy and use of derivative instruments.
Financial Instruments

Various AbbVie foreign subsidiaries enter into foreign currency forward exchange contracts to manage exposures to changes in foreign exchange rates for anticipated intercompany transactions denominated in a currency other than the functional currency of the local entity. These contracts, with notional amounts totaling $503 million at June 30, 2019 and $1.4 billion at December 31, 2018, are designated as cash flow hedges and are recorded at fair value. The durations of these forward exchange contracts were generally less than 18 months. Accumulated gains and losses as of June 30, 2019 will be reclassified from AOCI and included in cost of products sold at the time the products are sold, generally not exceeding six months from the date of settlement.

The company also enters into foreign currency forward exchange contracts to manage its exposure to foreign currency denominated trade payables and receivables and intercompany loans. These contracts are not designated as hedges and are recorded at fair value. Resulting gains or losses are reflected in net foreign exchange gain or loss in the consolidated statements of earnings and are generally offset by losses or gains on the foreign currency exposure being managed. These contracts had notional amounts totaling $7.9 billion at June 30, 2019 and $8.6 billion at December 31, 2018.
The company also uses foreign currency forward exchange contracts or foreign currency denominated debt to hedge its net investments in certain foreign subsidiaries and affiliates. The company continued to designate €3.6 billion aggregate principal amount of senior Euro notes as net investment hedges at June 30, 2019 and December 31, 2018. In addition, in the second quarter of 2019, the company entered into foreign currency forward exchange contracts with notional amounts totaling €971 million, £204 million and CHF62 million and designated the instruments as net investment hedges. The company uses the spot method of assessing hedge effectiveness for derivative instruments designated as net investment hedges. Realized and unrealized gains and losses from these hedges are included in AOCI and the initial fair value of hedge components excluded from the assessment of effectiveness is recognized in interest expense, net over the life of the hedging instrument.

AbbVie is a party to interest rate hedge contracts designated as fair value hedges with notional amounts totaling $10.8 billion at June 30, 2019 and December 31, 2018. The effect of the hedge contracts is to change a fixed-rate interest obligation to a floating rate for that portion of the debt. AbbVie records the contracts at fair value and adjusts the carrying amount of the fixed-rate debt by an offsetting amount.

No amounts are excluded from the assessment of effectiveness for cash flow hedges or fair value hedges.

The following table summarizes the amounts and location of AbbVie’s derivative instruments on the condensed consolidated balance sheets:
 
Fair value –
Derivatives in asset position
 
Fair value –
Derivatives in liability position
(in millions)
Balance sheet caption
June 30,
2019
December 31, 2018
 
Balance sheet caption
June 30,
2019
December 31, 2018
Foreign currency forward exchange contracts
 
 
 
 
 
 
 
Designated as cash flow hedges
Prepaid expenses and
other
$
22

$
113

 
Accounts payable and accrued liabilities
$
—

$
—

Designated as net investment hedges
Prepaid expenses and
other
11

—

 
Accounts payable and accrued liabilities
1

—

Not designated as hedges
Prepaid expenses and
other
40

19

 
Accounts payable and accrued liabilities
38

26

Interest rate swaps designated as fair value hedges
Prepaid expenses and other
—

—

 
Accounts payable and accrued liabilities
8

—

Interest rate swaps designated as fair value hedges
Other assets
24

—

 
Other long-term liabilities
117

466

Total derivatives
 
$
97

$
132

 
 
$
164

$
492


While certain derivatives are subject to netting arrangements with the company’s counterparties, the company does not offset derivative assets and liabilities within the condensed consolidated balance sheets.

The following table presents the pre-tax amounts of gains (losses) from derivative instruments recognized in other comprehensive income (loss):
 
 
Three months ended
June 30,
 
Six months ended
June 30,
(in millions)
 
2019
 
2018
 
2019
 
2018
Foreign currency forward exchange contracts
 
 
 
 
 
 
 
 
Designated as cash flow hedges
 
$
2

 
$
169

 
$
5

 
$
121

Designated as net investment hedges
 
10

 
—

 
10

 
—



Assuming market rates remain constant through contract maturities, the company expects to reclass pre-tax gains of $90 million into cost of products sold for foreign currency cash flow hedges during the next 12 months.

Related to AbbVie’s non-derivative, foreign currency denominated debt designated as net investment hedges, the company recognized in other comprehensive income (loss) a pre-tax loss of $49 million for the three months and a pre-tax gain of $35 million for the six months ended June 30, 2019 and recognized pre-tax gains of $270 million for the three months and $136 million for the six months ended June 30, 2018.
The following table summarizes the pre-tax amounts and location of derivative instrument net gains (losses) recognized in the condensed consolidated statements of earnings, including the net gains (losses) reclassified out of AOCI into net earnings. See Note 11 for the amount of net gains (losses) reclassified out of AOCI.

 
 
 
Three months ended
June 30,
 
Six months ended
June 30,
(in millions)
Statement of earnings caption
 
2019
 
2018
 
2019
 
2018
Foreign currency forward exchange contracts
 
 
 
 
 
 
 
 
 
Designated as cash flow hedges
Cost of products sold
 
$
37

 
$
(46
)
 
$
77

 
$
(90
)
Designated as net investment hedges
Interest expense, net
 
9

 
—

 
9

 
—

Not designated as hedges
Net foreign exchange loss
 
(25
)
 
128

 
(40
)
 
69

Interest rate swaps designated as fair value hedges
Interest expense, net
 
253

 
(59
)
 
365

 
(243
)
Debt designated as hedged item in fair value hedges
Interest expense, net
 
(253
)
 
59

 
(365
)
 
243



Fair Value Measures

The fair value hierarchy consists of the following three levels:

•
Level 1 – Valuations based on unadjusted quoted prices in active markets for identical assets that the company has the ability to access;
•
Level 2 – Valuations based on quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuations in which all significant inputs are observable in the market; and
•
Level 3 – Valuations using significant inputs that are unobservable in the market and include the use of judgment by the company’s management about the assumptions market participants would use in pricing the asset or liability.

The following table summarizes the bases used to measure certain assets and liabilities carried at fair value on a recurring basis on the condensed consolidated balance sheet as of June 30, 2019:
 
 
 
Basis of fair value measurement
(in millions)
Total
 
Quoted prices in active markets for
identical assets
(Level 1)
 
Significant other
observable
inputs
(Level 2)
 
Significant
unobservable
inputs
(Level 3)
Assets
 
 
 
 
 
 
 
Cash and equivalents
$
5,172

 
$
1,388

 
$
3,784

 
$
—

Debt securities
1,573

 
—

 
1,573

 
—

Equity securities
79

 
79

 
—

 
—

Interest rate hedges
24

 
—

 
24

 
—

Foreign currency contracts
73

 
—

 
73

 
—

Total assets
$
6,921

 
$
1,467

 
$
5,454

 
$
—

Liabilities
 
 
 
 
 
 
 
Interest rate hedges
$
125

 
$
—

 
$
125

 
$
—

Foreign currency contracts
39

 
—

 
39

 
—

Contingent consideration
6,789

 
—

 
—

 
6,789

Total liabilities
$
6,953

 
$
—

 
$
164

 
$
6,789

The following table summarizes the bases used to measure certain assets and liabilities carried at fair value on a recurring basis on the condensed consolidated balance sheet as of December 31, 2018:
 
 
 
Basis of fair value measurement
(in millions)
Total
 
Quoted prices in active markets for
identical assets
(Level 1)
 
Significant other
observable
inputs
(Level 2)
 
Significant
unobservable
inputs
(Level 3)
Assets
 
 
 
 
 
 
 
Cash and equivalents
$
7,289

 
$
1,209

 
$
6,080

 
$
—

Time deposits
568

 
—

 
568

 
—

Debt securities
1,536

 
—

 
1,536

 
—

Equity securities
4

 
4

 
—

 
—

Foreign currency contracts
132

 
—

 
132

 
—

Total assets
$
9,529

 
$
1,213

 
$
8,316

 
$
—

Liabilities
 
 
 
 
 
 
 
Interest rate hedges
$
466

 
$
—

 
$
466

 
$
—

Foreign currency contracts
26

 
—

 
26

 
—

Contingent consideration
4,483

 
—

 
—

 
4,483

Total liabilities
$
4,975

 
$
—

 
$
492

 
$
4,483


The fair values of time deposits approximate their amortized cost due to the short maturities of these instruments. The fair values of available-for-sale debt securities were determined based on prices obtained from commercial pricing services. Equity securities consist of investments for which the fair values were determined by using the published market price per unit multiplied by the number of units held, without consideration of transaction costs. The derivatives entered into by the company were valued using published spot curves for interest rate hedges and published forward curves for foreign currency contracts. The fair value measurements of the contingent consideration liabilities were determined based on significant unobservable inputs, including the discount rate, estimated probabilities and timing of achieving specified development, regulatory and commercial milestones and the estimated amount of future sales of the acquired products. Changes to the fair value of the contingent consideration liabilities can result from changes to one or a number of inputs, including discount rates, the probabilities of achieving the milestones, the time required to achieve the milestones and estimated future sales. Significant judgment is employed in determining the appropriateness of these inputs. Changes to the inputs described above could have a material impact on the company's financial position and results of operations in any given period. At June 30, 2019, a 50 basis point increase/decrease in the assumed discount rate would have decreased/increased the value of the contingent consideration liabilities by approximately $270 million. Additionally, at June 30, 2019, a five percentage point increase/decrease in the assumed probability of success across all potential indications still in development would have increased/decreased the value of the contingent consideration liabilities by approximately $210 million.
There have been no transfers of assets or liabilities between the fair value measurement levels. The following table presents the changes in fair value of contingent consideration liabilities which are measured using Level 3 inputs:
 
 
Six months ended
June 30,
(in millions)
 
2019
 
2018
Beginning balance
 
$
4,483

 
$
4,534

Change in fair value recognized in net earnings
 
2,473

 
337

Milestone payments
 
(167
)
 
(50
)
Ending balance
 
$
6,789

 
$
4,821


The change in fair value recognized in net earnings is recorded in other expense, net in the condensed consolidated statements of earnings. During the second quarter of 2019, the company recorded a $2.3 billion increase in the SKYRIZI contingent consideration liability due to higher probabilities of success, higher estimated future sales and declining interest rates. The higher probabilities of success resulted from the April 2019 regulatory approvals of SKYRIZI for the treatment of moderate to severe plaque psoriasis.
Certain financial instruments are carried at historical cost or some basis other than fair value. The book values, approximate fair values and bases used to measure the approximate fair values of certain financial instruments as of June 30, 2019 are shown in the table below:
 
 
 
 
Basis of fair value measurement
(in millions)
Book value
Approximate fair value
 
Quoted prices
in active markets for
identical assets
(Level 1)
 
Significant
other 
observable
inputs
(Level 2)
 
Significant
unobservable
inputs
(Level 3)
Liabilities
 
 
 
 
 
 
 
 
Short-term borrowings
$
306

$
306

 
$
—

 
$
306

 
$
—

Current portion of long-term debt and finance lease obligations, excluding fair value hedges
5,343

5,357

 
5,348

 
9

 
—

Long-term debt and finance lease obligations, excluding fair value hedges
31,712

32,753

 
32,731

 
22

 
—

Total liabilities
$
37,361

$
38,416

 
$
38,079

 
$
337

 
$
—


The book values, approximate fair values and bases used to measure the approximate fair values of certain financial instruments as of December 31, 2018 are shown in the table below:
 
 
 
 
Basis of fair value measurement
(in millions)
Book value
Approximate fair value
 
Quoted prices
in active markets for
identical assets
(Level 1)
 
Significant
other 
observable
inputs
(Level 2)
 
Significant
unobservable
inputs
(Level 3)
Liabilities
 
 
 
 
 
 
 
 
Short-term borrowings
$
3,699

$
3,693

 
$
—

 
$
3,693

 
$
—

Current portion of long-term debt and finance lease obligations, excluding fair value hedges
1,609

1,617

 
1,609

 
8

 
—

Long-term debt and finance lease obligations, excluding fair value hedges
35,468

34,052

 
34,024

 
28

 
—

Total liabilities
$
40,776

$
39,362

 
$
35,633

 
$
3,729

 
$
—


AbbVie also holds investments in equity securities that do not have readily determinable fair values. The company records these investments at cost and remeasures them to fair value based on certain observable price changes or impairment events as they occur. The carrying amount of these investments was $65 million as of June 30, 2019 and $84 million as of December 31, 2018. No significant cumulative upward or downward adjustments have been recorded for these investments as of June 30, 2019.
Available-for-sale Securities
Substantially all of the company’s investments in debt securities were classified as available-for-sale with changes in fair value recognized in other comprehensive income. Debt securities classified as short-term were $244 million as of June 30, 2019 and $204 million as of December 31, 2018. Long-term debt securities mature primarily within five years. Estimated fair values of available-for-sale debt securities were generally determined based on prices obtained from commercial pricing services.
The following table summarizes available-for-sale securities by type as of June 30, 2019:
 
Amortized cost
 
Gross unrealized
 
Fair value
(in millions)
 
Gains
 
Losses
 
Asset backed securities
$
375

 
$
—

 
$
(1
)
 
$
374

Corporate debt securities
1,095

 
4

 
(2
)
 
1,097

Other debt securities
102

 
—

 
—

 
102

Total
$
1,572

 
$
4

 
$
(3
)
 
$
1,573


The following table summarizes available-for-sale securities by type as of December 31, 2018:
 
Amortized cost
 
Gross unrealized
 
Fair value
(in millions)
 
Gains
 
Losses
 
Asset backed securities
$
423

 
$
—

 
$
(2
)
 
$
421

Corporate debt securities
1,042

 
1

 
(9
)
 
1,034

Other debt securities
81

 
—

 
—

 
81

Total
$
1,546

 
$
1

 
$
(11
)
 
$
1,536


AbbVie had no other-than-temporary impairments as of June 30, 2019. Net realized gains and losses were insignificant for both the three and six months ended June 30, 2019 and 2018.
Concentrations of Risk
Of total net accounts receivable, three U.S. wholesalers accounted for 66% as of June 30, 2019 and 63% as of December 31, 2018, and substantially all of AbbVie’s net revenues in the United States were to these three wholesalers.
HUMIRA (adalimumab) is AbbVie’s single largest product and accounted for approximately 58% of AbbVie’s total net revenues for the six months ended June 30, 2019 and 61% for the six months ended June 30, 2018.
Debt and Credit Facilities
Short-Term Borrowings
Short-term borrowings included commercial paper borrowings of $306 million as of June 30, 2019 and $699 million as of December 31, 2018. The weighted-average interest rate on commercial paper borrowings was 2.7% for the six months ended June 30, 2019 and 1.9% for the six months ended June 30, 2018.
In March 2019, AbbVie repaid its $3.0 billion 364-day term loan credit agreement that was scheduled to mature in June 2019.
In connection with the proposed acquisition of Allergan, on June 25, 2019, AbbVie entered into a 364-day bridge credit agreement and on July 12, 2019, AbbVie entered into a term loan credit agreement. See Note 4 for additional information.
XML 33 R18.htm IDEA: XBRL DOCUMENT v3.19.2
Post-Employment Benefits
 6 Months Ended
Jun. 30, 2019
Postemployment Benefits [Abstract]  
Post-Employment Benefits Post-Employment Benefits
 

The following table summarizes net periodic benefit cost relating to the company’s defined benefit and other post-employment plans:
 
Defined
benefit plans
 
Other post-
employment plans
 
Three months ended
June 30,
 
Six months ended
June 30,
 
Three months ended
June 30,
 
Six months ended
June 30,
(in millions)
2019
 
2018
 
2019
 
2018
 
2019
 
2018
 
2019
 
2018
Service cost
$
68

 
$
72

 
$
135

 
$
144

 
$
7

 
$
5

 
$
13

 
$
13

Interest cost
66

 
57

 
130

 
114

 
9

 
4

 
15

 
12

Expected return on plan assets
(119
)
 
(110
)
 
(238
)
 
(221
)
 
—

 
—

 
—

 
—

Amortization of actuarial losses and prior service cost (credit)
29

 
39

 
55

 
76

 
1

 
(3
)
 
—

 
1

Net periodic benefit cost
$
44

 
$
58

 
$
82

 
$
113

 
$
17

 
$
6

 
$
28

 
$
26


The components of net periodic benefit cost other than service cost are included in other expense, net in the condensed consolidated statements of earnings.
XML 34 R19.htm IDEA: XBRL DOCUMENT v3.19.2
Equity
 6 Months Ended
Jun. 30, 2019
Stockholders' Equity Note [Abstract]  
Equity Equity
 

Stock-Based Compensation

Stock-based compensation expense is principally related to awards issued pursuant to the AbbVie 2013 Incentive Stock Program and is summarized as follows:
 
 
Three months ended
June 30,
 
Six months ended
June 30,
(in millions)
 
2019
 
2018
 
2019
 
2018
Cost of products sold
 
$
5

 
$
12

 
$
20

 
$
16

Research and development
 
33

 
35

 
105

 
107

Selling, general and administrative
 
49

 
38

 
151

 
153

Pre-tax compensation expense
 
87

 
85

 
276

 
276

Tax benefit
 
16

 
19

 
49

 
48

After-tax compensation expense
 
$
71

 
$
66

 
$
227

 
$
228



Stock Options

During the six months ended June 30, 2019, primarily in connection with the company's annual grant, AbbVie granted 1.0 million stock options with a weighted-average grant-date fair value of $12.54. As of June 30, 2019, $8.5 million of unrecognized compensation cost related to stock options is expected to be recognized as expense over approximately the next two years.

RSUs and Performance Shares

During the six months ended June 30, 2019, primarily in connection with the company's annual grant, AbbVie granted 5.4 million RSUs and performance shares with a weighted-average grant-date fair value of $78.68. As of June 30, 2019, $434 million of unrecognized compensation cost related to RSUs and performance shares is expected to be recognized as expense over approximately the next two years.

Cash Dividends

The following table summarizes quarterly cash dividends declared during 2019 and 2018:
2019
 
2018
Date Declared
 
Payment Date
 
Dividend Per Share
 
Date Declared
 
Payment Date
 
Dividend Per Share
06/20/19
 
08/15/19
 
$
1.07

 
11/02/18
 
02/15/19
 
$
1.07

02/21/19
 
05/15/19
 
$
1.07

 
09/07/18
 
11/15/18
 
$
0.96


 

 


 
06/14/18
 
08/15/18
 
$
0.96


 

 


 
02/15/18
 
05/15/18
 
$
0.96


Stock Repurchase Program
The company's stock repurchase authorization permits purchases of AbbVie shares from time to time in open-market or private transactions at management's discretion. The program has no time limit and can be discontinued at any time. Shares repurchased under these programs are recorded at acquisition cost, including related expenses, and are available for general corporate purposes.
AbbVie repurchased 4 million shares for $300 million during the six months ended June 30, 2019 and 84 million shares for $8.8 billion during the six months ended June 30, 2018. AbbVie's remaining stock repurchase authorization was approximately $4.0 billion as of June 30, 2019.
Accumulated Other Comprehensive Loss
The following table summarizes the changes in each component of accumulated other comprehensive loss, net of tax, for the six months ended June 30, 2019:
(in millions)
Foreign currency
translation adjustments
 
Net investment
hedging activities
 
Pension 
and post-
employment
benefits
 
Marketable
security activities
 
Cash flow hedging
activities
 
Total
Balance as of December 31, 2018
$
(830
)
 
$
(65
)
 
$
(1,722
)
 
$
(10
)
 
$
147

 
$
(2,480
)
Other comprehensive income (loss) before reclassifications
(32
)
 
35

 
2

 
10

 
7

 
22

Net losses (gains) reclassified from accumulated other comprehensive loss
—

 
(7
)
 
43

 
1

 
(70
)
 
(33
)
Net current-period other comprehensive income (loss)
(32
)
 
28

 
45

 
11

 
(63
)
 
(11
)
Balance as of June 30, 2019
$
(862
)
 
$
(37
)
 
$
(1,677
)
 
$
1

 
$
84

 
$
(2,491
)


Other comprehensive loss for the six months ended June 30, 2019 included foreign currency translation adjustments totaling a loss of $32 million, which was principally due to the weakening of the Euro in the six months ended June 30, 2019 on the translation of the company’s assets denominated in the Euro.

The following table summarizes the changes in each component of accumulated other comprehensive loss, net of tax, for the six months ended June 30, 2018:
(in millions)
Foreign currency
translation adjustments
 
Net investment
hedging activities
 
Pension 
and post-
employment
benefits
 
Marketable
 security activities
 
Cash flow hedging
activities
 
Total
Balance as of December 31, 2017
$
(439
)
 
$
(203
)
 
$
(1,919
)
 
$
—

 
$
(166
)
 
$
(2,727
)
Other comprehensive income (loss) before reclassifications
(280
)
 
105

 
9

 
(6
)
 
110

 
(62
)
Net losses reclassified from accumulated other comprehensive loss
—

 
—

 
62

 
4

 
84

 
150

Net current-period other comprehensive income (loss)
(280
)
 
105

 
71

 
(2
)
 
194

 
88

Balance as of June 30, 2018
$
(719
)
 
$
(98
)
 
$
(1,848
)
 
$
(2
)
 
$
28

 
$
(2,639
)


Other comprehensive income for the six months ended June 30, 2018 included foreign currency translation adjustments totaling a loss of $280 million, which was principally due to the weakening of the Euro in the six months ended June 30, 2018 on the translation of the company’s assets denominated in the Euro.

The following table presents the impact on AbbVie’s condensed consolidated statements of earnings for significant amounts reclassified out of each component of accumulated other comprehensive loss:
 
Three months ended
June 30,
 
Six months ended
June 30,
(in millions) (brackets denote gains)
2019
 
2018
 
2019
 
2018
Pension and post-employment benefits
 
 
 
 
 
 
 
Amortization of actuarial losses and other(a)
$
30

 
$
36

 
$
55

 
$
77

Tax benefit
(7
)
 
(7
)
 
(12
)
 
(15
)
Total reclassifications, net of tax
$
23

 
$
29

 
$
43

 
$
62

Cash flow hedging activities
 
 
 
 
 
 
 
Losses (gains) on designated cash flow hedges(b)
$
(37
)
 
$
46

 
$
(77
)
 
$
90

Tax expense (benefit)
2

 
(4
)
 
7

 
(6
)
Total reclassifications, net of tax
$
(35
)
 
$
42

 
$
(70
)
 
$
84

Net investment hedging activities
 
 
 
 
 
 
 
Gains on derivative amount excluded from effectiveness testing(c)
$
(9
)
 
$
—

 
$
(9
)
 
$
—

Tax expense
2

 
—

 
2

 
—

Total reclassifications, net of tax
$
(7
)
 
$
—

 
$
(7
)
 
$
—


(a) Amounts are included in the computation of net periodic benefit cost (see Note 10).
(b) Amounts are included in cost of products sold (see Note 9).
(c) Amounts are included in interest expense, net (see Note 9).
XML 35 R20.htm IDEA: XBRL DOCUMENT v3.19.2
Income Taxes
 6 Months Ended
Jun. 30, 2019
Income Tax Disclosure [Abstract]  
Income Taxes Income Taxes
 

The effective tax rate was 8% for the three months and 5% for the six months ended June 30, 2019 and 2% for the three months and 1% for the six months ended June 30, 2018. The effective tax rate in each period differed from the U.S. statutory tax rate of 21% principally due to the benefit from foreign operations which reflects the impact of lower income tax rates in locations outside the United States, tax incentives in Puerto Rico and other foreign tax jurisdictions and business development activities. The increase in the effective tax rate for the three and six months ended June 30, 2019 over the prior year was principally due to the beneficial impact of the timing of provisions of the Act related to earnings from certain foreign subsidiaries in prior year and changes in the jurisdictional mix of earnings, including a change in fair value of contingent consideration liabilities. These increases were partially offset by the favorable resolution of various tax positions in the current year.

Due to the potential for resolution of federal, state and foreign examinations and the expiration of various statutes of limitations, it is reasonably possible that the company’s gross unrecognized tax benefits balance may change within the next twelve months by up to $41 million.
XML 36 R21.htm IDEA: XBRL DOCUMENT v3.19.2
Legal Proceedings and Contingencies
 6 Months Ended
Jun. 30, 2019
Commitments and Contingencies Disclosure [Abstract]  
Legal Proceedings and Contingencies Legal Proceedings and Contingencies
 

AbbVie is subject to contingencies, such as various claims, legal proceedings and investigations regarding product liability, intellectual property, commercial, securities and other matters that arise in the normal course of business. Loss contingency provisions are recorded for probable losses at management’s best estimate of a loss, or when a best estimate cannot be made, a minimum loss contingency amount within a probable range is recorded. The recorded accrual balance for litigation was approximately $330 million as of June 30, 2019 and $350 million as of December 31, 2018. Initiation of new legal proceedings or a change in the status of existing proceedings may result in a change in the estimated loss accrued by AbbVie. While it is not feasible to predict the outcome of all proceedings and exposures with certainty, management believes that their ultimate disposition should not have a material adverse effect on AbbVie’s consolidated financial position, results of operations or cash flows.

Subject to certain exceptions specified in the separation agreement by and between Abbott and AbbVie, AbbVie assumed the liability for, and control of, all pending and threatened legal matters related to its business, including liabilities for any claims or legal proceedings related to products that had been part of its business, but were discontinued prior to the distribution, as well as assumed or retained liabilities, and will indemnify Abbott for any liability arising out of or resulting from such assumed legal matters.

Four lawsuits against Unimed Pharmaceuticals, Inc., Solvay Pharmaceuticals, Inc. (a company Abbott acquired in February 2010 and now known as AbbVie Products LLC) and others are consolidated for pre-trial purposes in the United States District Court for the Northern District of Georgia under the Multi-District Litigation (MDL) Rules as In re: AndroGel Antitrust Litigation, MDL No. 2084. These cases, brought by direct AndroGel purchasers, generally allege Solvay's 2006 patent litigation settlement agreements and related agreements with three generic companies violate federal antitrust laws. Plaintiffs seek monetary damages and attorneys' fees.

Lawsuits are pending against AbbVie and others generally alleging that the 2005 patent litigation settlement involving Niaspan entered into between Kos Pharmaceuticals, Inc. (a company acquired by Abbott in 2006 and presently a subsidiary of AbbVie) and a generic company violates federal and state antitrust laws and state unfair and deceptive trade practices and unjust enrichment laws. Plaintiffs generally seek monetary damages and/or injunctive relief and attorneys' fees. The lawsuits consist of four individual plaintiff lawsuits and two consolidated purported class actions: one brought by Niaspan direct purchasers and one brought by Niaspan end-payers. The cases are pending in the United States District Court for the Eastern District of Pennsylvania for coordinated or consolidated pre-trial proceedings under the MDL Rules as In re: Niaspan Antitrust Litigation, MDL No. 2460. In October 2016, the Orange County, California District Attorney’s Office filed a lawsuit on behalf of the State of California regarding the Niaspan patent litigation settlement in Orange County Superior Court, asserting a claim under the unfair competition provision of the California Business and Professions Code seeking injunctive relief, restitution, civil penalties and attorneys’ fees. In May 2018, the California Court of Appeal ruled that the District Attorney’s Office may not bring monetary claims beyond the scope of Orange County, which the District Attorney’s Office is appealing.

In September 2014, the FTC filed a lawsuit against AbbVie and others in the United States District Court for the Eastern District of Pennsylvania, alleging that the 2011 patent litigation with two generic companies regarding AndroGel was sham litigation and the settlements of that litigation violated federal antitrust law. In May 2015, the court dismissed the FTC’s settlement-related claim. In June 2018, following a bench trial, the court found for the FTC on its sham litigation claim and ordered a disgorgement remedy of $448 million, plus prejudgment interest. The court denied the FTC’s request for injunctive relief. AbbVie is appealing the court’s liability and disgorgement rulings and, based on an assessment of the merits of that appeal, no liability has been accrued for this matter. The FTC is also appealing aspects of the court’s trial ruling and the dismissal of its settlement-related claim. One purported class action on behalf of direct AndroGel purchasers based on the trial court’s ruling in the FTC’s case is also pending in the United States District Court for the Eastern District of Pennsylvania and is stayed pending the appeals in the FTC’s case.

In January and February 2019, two shareholder derivative lawsuits, Brown v. Gonzalez, et al., and Elfers v. Gonzalez, et al., were filed in the United States District Court for the Northern District of Illinois, alleging that certain AbbVie directors and officers breached their fiduciary duties in connection with HUMIRA patient and reimbursement support services and other services and items of value, as alleged in the State of California case discussed below.

Between March and May 2019, 12 putative class action lawsuits were filed in the United States District Court for the Northern District of Illinois by indirect HUMIRA purchasers, alleging that AbbVie’s settlements with biosimilar manufacturers and AbbVie’s HUMIRA patent portfolio violate state and federal antitrust laws.

In November 2014, a putative class action lawsuit, Medical Mutual of Ohio v. AbbVie Inc., et al., was filed against several manufacturers of testosterone replacement therapies (TRTs), including AbbVie, in the United States District Court for the Northern District of Illinois on behalf of all insurance companies, health benefit providers, and other third party payers who paid for TRTs, including AndroGel. The claims asserted include violations of the federal RICO Act and state consumer fraud and deceptive trade practices laws. The complaint seeks monetary damages and injunctive relief. In July 2018, the court denied the plaintiff’s motion for class certification. In February 2019, the court granted the defendants’ summary judgment motion.

In September 2018, the Commissioner of the California Department of Insurance intervened in a qui tam lawsuit, State of California and Lazaro Suarez v. AbbVie Inc., et al., brought under the California Insurance Frauds Prevention Act, in California Superior Court for Alameda County. The Department of Insurance’s complaint alleges that, through patient and reimbursement support services and other services and items of value provided in connection with HUMIRA, AbbVie caused the submission of fraudulent commercial insurance claims for HUMIRA in violation of the California statute. The complaint seeks injunctive relief, an assessment of up to three times the amount of the claims at issue, and civil penalties. In addition, a federal securities lawsuit (Holwill v. AbbVie Inc., et al.) is
pending in the United States District Court for the Northern District of Illinois) against AbbVie, its chief executive officer and former chief financial officer, alleging that reasons stated for HUMIRA sales growth in financial filings between 2013 and 2017 were misleading because they omitted the conduct alleged in the Department of Insurance’s complaint.

In November 2014, five individuals filed a putative class action lawsuit, Rubinstein, et al. v Gonzalez, et al., on behalf of purchasers and sellers of certain Shire plc (Shire) securities between June 20 and October 14, 2014, against AbbVie and its chief executive officer in the United States District Court for the Northern District of Illinois alleging that the defendants made and/or are responsible for material misstatements in violation of federal securities laws in connection with AbbVie's proposed transaction with Shire. In July 2019, the court granted preliminary approval to the parties’ settlement agreement.

In June 2016, a lawsuit, Elliott Associates, L.P., et al. v. AbbVie Inc., was filed by five investment funds against AbbVie in the Cook County, Illinois Circuit Court alleging that AbbVie made misrepresentations and omissions in connection with its proposed transaction with Shire. Similar lawsuits were filed between July 2017 and October 2018 against AbbVie and in some instances its chief executive officer in the same court by additional investment funds. Plaintiffs seek compensatory and punitive damages.

Product liability cases were filed in which plaintiffs generally allege that AbbVie and other manufacturers of TRTs did not adequately warn about risks of certain injuries, primarily heart attacks, strokes and blood clots. Approximately 3,900 claims against AbbVie are consolidated for pre-trial purposes in the United States District Court for the Northern District of Illinois under the MDL Rules as In re: Testosterone Replacement Therapy Products Liability Litigation, MDL No. 2545. Approximately 200 claims against AbbVie are pending in various state courts. Plaintiffs generally seek compensatory and punitive damages. In November 2018, AbbVie entered into a Master Settlement Agreement with the Plaintiffs’ Steering Committee in the MDL encompassing existing claims in all courts. All proceedings in pending cases are effectively stayed during the settlement administration process.

Product liability cases are pending in which plaintiffs generally allege that AbbVie did not adequately warn about risk of certain injuries, primarily various birth defects, arising from use of Depakote. Approximately 150 cases are pending in the United States District Court for the Southern District of Illinois, and approximately six others are pending in various state courts. Plaintiffs generally seek compensatory and punitive damages. Approximately ninety percent of these pending cases, plus other unfiled claims, are subject to confidential settlement agreements and are expected to be dismissed with prejudice.

Beginning in May 2016, the Patent Trial & Appeal Board of the U.S. Patent & Trademark Office (PTO) instituted five inter partes review proceedings brought by Coherus Biosciences and Boehringer Ingelheim related to three AbbVie patents covering methods of treatment of rheumatoid arthritis using adalimumab. In these proceedings, the PTO reviewed the validity of the patents and issued decisions of invalidity in May, June and July of 2017. AbbVie’s appeal of the decisions is pending in the Court of Appeals for the Federal Circuit.

In March 2017, AbbVie filed a lawsuit, AbbVie Inc. v. Novartis Vaccines and Diagnostics, Inc. and Grifols Worldwide Operations Ltd., in the United States District Court for the Northern District of California against Novartis Vaccines and Grifols Worldwide seeking a declaratory judgment that 11 HCV-related patents licensed to AbbVie in 2002 are invalid.

AbbVie is seeking to enforce certain patent rights related to adalimumab (a drug AbbVie sells under the trademark HUMIRA®). In a case filed in United States District Court for the District of Delaware in August 2017, AbbVie alleges that Boehringer Ingelheim International GmbH’s, Boehringer Ingelheim Pharmaceutical, Inc.’s, and Boehringer Ingelheim Fremont, Inc.’s proposed biosimilar adalimumab product infringes certain AbbVie patents. AbbVie seeks declaratory and injunctive relief. In May 2019, the parties settled this case and it was dismissed without prejudice.

Pharmacyclics LLC, a wholly owned subsidiary of AbbVie, is seeking to enforce its patent rights relating to ibrutinib capsules (a drug Pharmacyclics sells under the trademark IMBRUVICA®). In February 2018, cases were filed in the United States District Court for the District of Delaware against the following defendants: Fresenius Kabi USA, LLC, Fresenius Kabi USA, Inc., and Fresenius Kabi Oncology Limited; Sun Pharma Global FZE and Sun Pharmaceutical Industries Ltd.; Cipla Limited and Cipla USA Inc.; and Zydus Worldwide DMCC, Cadila Healthcare Limited, Sandoz Inc., and Lek Pharmaceuticals D.D. In each case, Pharmacyclics alleges the defendant’s proposed generic ibrutinib product infringes certain Pharmacyclics patents and seeks declaratory and injunctive relief. Janssen Biotech, Inc. which is in a global collaboration with Pharmacyclics concerning the development and marketing of IMBRUVICA, is the co-plaintiff in these suits.

Pharmacyclics LLC, a wholly owned subsidiary of AbbVie, is seeking to enforce its patent rights relating to ibrutinib tablets (a drug Pharmacyclics sells under the trademark IMBRUVICA®). In a case filed in the United States District Court for the District of Delaware in March 2019, Pharmacyclics alleges that Alvogen Pine Brook LLC’s and Natco Pharma Ltd.’s proposed generic ibrutinib tablet
product infringes certain Pharmacyclics patents. Pharmacyclics seeks declaratory and injunctive relief. Janssen Biotech, Inc. which is in a global collaboration with Pharmacyclics concerning the development and marketing of IMBRUVICA, is the co-plaintiff in this suit.
XML 37 R22.htm IDEA: XBRL DOCUMENT v3.19.2
Segment Information
 6 Months Ended
Jun. 30, 2019
Segment Reporting [Abstract]  
Segment Information Segment Information
 

AbbVie operates in one business segment—pharmaceutical products. The following table details AbbVie’s worldwide net revenues:
 
 
 
Three months ended
June 30,
 
Six months ended
June 30,
 
 
 
 
(in millions)
 
 
2019
 
2018
 
2019
 
2018
Immunology
 
 
 
 
 
 
 
 
HUMIRA
United States
 
$
3,793

 
$
3,521

 
$
7,008

 
$
6,524

 
International
 
1,077

 
1,664

 
2,308

 
3,370

 
Total
 
$
4,870

 
$
5,185

 
$
9,316

 
$
9,894

SKYRIZI
United States
 
$
42

 
$
—

 
$
42

 
$
—

 
International
 
6

 
—

 
6

 
—

 
Total
 
$
48

 
$
—

 
$
48

 
$
—

Hematologic Oncology
 
 
 
 
 
 
 
 
IMBRUVICA
United States
 
$
886

 
$
693

 
$
1,715

 
$
1,317

 
Collaboration revenues
 
213

 
157

 
406

 
295

 
Total
 
$
1,099

 
$
850

 
$
2,121

 
$
1,612

VENCLEXTA
United States
 
$
117

 
$
47

 
$
222

 
$
88

 
International
 
52

 
18

 
98

 
36

 
Total
 
$
169

 
$
65

 
$
320

 
$
124

HCV
 
 
 
 
 
 
 
 
MAVYRET
United States
 
$
396

 
$
422

 
$
799

 
$
762

 
International
 
384

 
510

 
771

 
1,018

 
Total
 
$
780

 
$
932

 
$
1,570

 
$
1,780

VIEKIRA
United States
 
$
—

 
$
—

 
$
—

 
$
3

 
International
 
4

 
41

 
29

 
109

 
Total
 
$
4

 
$
41

 
$
29

 
$
112

Other Key Products
 
 
 
 
 
 
 
 
Creon
United States
 
$
257

 
$
219

 
$
484

 
$
428

Lupron
United States
 
$
168

 
$
180

 
$
359

 
$
357

 
International
 
41

 
43

 
79

 
85

 
Total
 
$
209

 
$
223

 
$
438

 
$
442

Synthroid
United States
 
$
203

 
$
193

 
$
385

 
$
375

Synagis
International
 
$
38

 
$
44

 
$
325

 
$
365

Duodopa
United States
 
$
24

 
$
20

 
$
46

 
$
38

 
International
 
91

 
88

 
180

 
173

 
Total
 
$
115

 
$
108

 
$
226

 
$
211

Sevoflurane
United States
 
$
18

 
$
19

 
$
35

 
$
36

 
International
 
73

 
94

 
148

 
183

 
Total
 
$
91

 
$
113

 
$
183

 
$
219

Kaletra
United States
 
$
10

 
$
13

 
$
23

 
$
26

 
International
 
67

 
78

 
132

 
138

 
Total
 
$
77

 
$
91

 
$
155

 
$
164

AndroGel
United States
 
$
22

 
$
128

 
$
96

 
$
258

ORILISSA
United States
 
$
18

 
$
—

 
$
31

 
$
—

 
International
 
1

 
—

 
1

 
—

 
Total
 
$
19

 
$
—

 
$
32

 
$
—

All other
 
 
$
254

 
$
86

 
$
355

 
$
228

Total net revenues
 
$
8,255

 
$
8,278

 
$
16,083

 
$
16,212
XML 38 R23.htm IDEA: XBRL DOCUMENT v3.19.2
Basis of Presentation (Policies)
 6 Months Ended
Jun. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Recent Accounting Pronouncements
Recent Accounting Pronouncements
Recently Adopted Accounting Pronouncements
ASU No. 2016-02
In February 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2016-02, Leases (Topic 842). The standard outlined a comprehensive lease accounting model that superseded the previous lease guidance and required lessees to recognize lease liabilities and corresponding right-of-use assets for all leases with lease terms greater than 12 months. The guidance also changed the definition of a lease and expanded the disclosure requirements of lease arrangements. AbbVie adopted the standard in the first quarter of 2019 using the modified retrospective method. Results for reporting periods beginning after December 31, 2018 have been presented in accordance with the standard, while results for prior periods have not been adjusted and continue to be reported in accordance with AbbVie's historical accounting. The cumulative effect of initially applying the new leases standard was recognized as an adjustment to the opening condensed consolidated balance sheet as of January 1, 2019.
The company elected a package of practical expedients for leases that commenced prior to January 1, 2019 and did not reassess historical conclusions on: (i) whether any expired or existing contracts are or contain leases; (ii) lease classification for any expired or existing leases; and (iii) initial direct costs capitalization for any existing leases.
Under the new standard, on January 1, 2019, the company recognized a cumulative-effect adjustment to its condensed consolidated balance sheet primarily related to the recognition of liabilities and corresponding right-of-use assets for operating leases. The adjustment to the condensed consolidated balance sheet included: (i) a $405 million increase to other assets; (ii) a $115 million increase to accounts payable and accrued liabilities; and (iii) a $290 million increase to other long-term liabilities. Other cumulative-effect adjustments to the condensed consolidated balance sheet were insignificant.
Adoption of the standard did not have a significant impact on AbbVie's condensed consolidated statements of earnings for the three and six months ended June 30, 2019.
ASU No. 2018-02
In February 2018, the FASB issued ASU No. 2018-02, Income Statement - Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income, which allowed a reclassification from accumulated other comprehensive income (AOCI) to retained earnings for stranded tax effects related to adjustments to deferred taxes resulting from the December 2017 enactment of the Tax Cuts and Jobs Act (the Act). AbbVie adopted the standard in the first quarter of 2019. Upon adoption, the company made an election to not reclassify the income tax effects of the Act from AOCI to retained earnings. Therefore, the adoption of the standard had no impact on AbbVie's consolidated financial statements.
Recent Accounting Pronouncements Not Yet Adopted
ASU No. 2016-13
In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326). The standard changes how credit losses are measured for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other financial instruments, the standard requires the use of a new forward-looking "expected credit loss" model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, the standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. Additionally, the standard requires new disclosures and will be effective for AbbVie starting with the first quarter of 2020. With certain exceptions, adjustments are to be applied using a modified-retrospective approach by reflecting adjustments through a cumulative-effect impact to retained earnings as of the beginning of the fiscal year of adoption. AbbVie is currently assessing the impact of adopting this guidance on its consolidated financial statements.
XML 39 R24.htm IDEA: XBRL DOCUMENT v3.19.2
Leases (Policies)
 6 Months Ended
Jun. 30, 2019
Leases [Abstract]  
Leases Short-term leases with a term of 12 months or less are not recorded on the balance sheet. For leases commencing or modified in 2019 or later, AbbVie does not separate lease components from non-lease components.
The company records lease liabilities based on the present value of lease payments over the lease term. AbbVie generally uses an incremental borrowing rate to discount its lease liabilities, as the rate implicit in the lease is typically not readily determinable. Certain lease agreements include renewal options that are under the company's control. AbbVie includes optional renewal periods in the lease term only when it is reasonably certain that AbbVie will exercise its option.
Variable lease payments include payments to lessors for taxes, maintenance, insurance and other operating costs as well as payments that are adjusted based on an index or rate. The company's lease agreements do not contain any significant residual value guarantees or restrictive covenants.
Short-Term Leases Short-term leases with a term of 12 months or less are not recorded on the balance sheet.
XML 40 R25.htm IDEA: XBRL DOCUMENT v3.19.2
Supplemental Financial Information (Tables)
 6 Months Ended
Jun. 30, 2019
Supplemental Financial Information  
Schedule of interest expense, net

Interest Expense, Net
 
 
Three months ended
June 30,
 
Six months ended
June 30,
(in millions)
 
2019
 
2018
 
2019
 
2018
Interest expense
 
$
358

 
$
320

 
$
745

 
$
629

Interest income
 
(49
)
 
(48
)
 
(111
)
 
(106
)
Interest expense, net
 
$
309

 
$
272

 
$
634

 
$
523
Schedule of inventories
Inventories
(in millions)
June 30, 2019
 
December 31, 2018
Finished goods
$
638

 
$
473

Work-in-process
969

 
862

Raw materials
288

 
270

Inventories
$
1,895

 
$
1,605
Schedule of property and equipment
Property and Equipment
(in millions)
June 30, 2019
 
December 31, 2018
Property and equipment, gross
$
8,443

 
$
8,396

Accumulated depreciation
(5,564
)
 
(5,513
)
Property and equipment, net
$
2,879

 
$
2,883
XML 41 R26.htm IDEA: XBRL DOCUMENT v3.19.2
Earnings Per Share (Tables)
 6 Months Ended
Jun. 30, 2019
Earnings Per Share [Abstract]  
Schedule of diluted earnings per share, impact of two-class method
The following table summarizes the impact of the two-class method:

 
 
Three months ended
June 30,
 
Six months ended
June 30,
(in millions, except per share data)
 
2019
 
2018
 
2019
 
2018
Basic EPS
 
 
 
 
 
 
 
 
Net earnings
 
$
741

 
$
1,983

 
$
3,197

 
$
4,766

Earnings allocated to participating securities
 
8

 
10

 
17

 
22

Earnings available to common shareholders
 
$
733

 
$
1,973

 
$
3,180

 
$
4,744

Weighted-average basic shares outstanding
 
1,480

 
1,568

 
1,480

 
1,579

Basic earnings per share
 
$
0.49

 
$
1.26

 
$
2.15

 
$
3.00

 
 
 
 
 
 
 
 
 
Diluted EPS
 
 
 
 
 
 
 
 
Net earnings
 
$
741

 
$
1,983

 
$
3,197

 
$
4,766

Earnings allocated to participating securities
 
8

 
10

 
17

 
22

Earnings available to common shareholders
 
$
733

 
$
1,973

 
$
3,180

 
$
4,744

Weighted-average shares of common stock outstanding
 
1,480

 
1,568

 
1,480

 
1,579

Effect of dilutive securities
 
4

 
4

 
3

 
5

Weighted-average diluted shares outstanding
 
1,484

 
1,572

 
1,483

 
1,584

Diluted earnings per share
 
$
0.49

 
$
1.26

 
$
2.14

 
$
2.99
XML 42 R27.htm IDEA: XBRL DOCUMENT v3.19.2
Collaboration with Janssen Biotech, Inc. (Tables)
 6 Months Ended
Jun. 30, 2019
Collaboration with Janssen Biotech, Inc.  
Schedule of profit and cost sharing relationship
The following table shows the profit and cost sharing relationship between Janssen and AbbVie:

 
 
Three months ended
June 30,
 
Six months ended
June 30,
(in millions)
 
2019
 
2018
 
2019
 
2018
United States - Janssen's share of profits (included in cost of products sold)
 
$
422

 
$
325

 
$
808

 
$
601

International - AbbVie's share of profits (included in net revenues)
 
213

 
157

 
406

 
295

Global - AbbVie's share of other costs (included in respective line items)
 
77

 
80

 
149

 
151
XML 43 R28.htm IDEA: XBRL DOCUMENT v3.19.2
Goodwill and Intangible Assets (Tables)
 6 Months Ended
Jun. 30, 2019
Goodwill and Intangible Assets Disclosure [Abstract]  
Summary of changes in the carrying amount of goodwill
The following table summarizes the changes in the carrying amount of goodwill:
(in millions)
 
Balance as of December 31, 2018
$
15,663

Foreign currency translation adjustments
(21
)
Balance as of June 30, 2019
$
15,642
Summary of definite-lived intangible assets
The following table summarizes intangible assets:
 
June 30, 2019
 
December 31, 2018
(in millions)
Gross
carrying
amount
 
Accumulated
amortization
 
Net
carrying
amount
 
Gross
carrying
amount
 
Accumulated
amortization
 
Net
carrying
amount
Definite-lived intangible assets
 
 
 
 
 
 
 
 
 
 
 
Developed product rights
$
19,611

 
$
(5,963
)
 
$
13,648

 
$
15,872

 
$
(5,614
)
 
$
10,258

License agreements
7,798

 
(2,017
)
 
5,781

 
7,865

 
(1,810
)
 
6,055

Total definite-lived intangible assets
27,409

 
(7,980
)
 
19,429

 
23,737

 
(7,424
)
 
16,313

Indefinite-lived research and development
1,030

 
—

 
1,030

 
4,920

 
—

 
4,920

Total intangible assets, net
$
28,439

 
$
(7,980
)
 
$
20,459

 
$
28,657

 
$
(7,424
)
 
$
21,233
Summary of indefinite-lived intangible assets
The following table summarizes intangible assets:
 
June 30, 2019
 
December 31, 2018
(in millions)
Gross
carrying
amount
 
Accumulated
amortization
 
Net
carrying
amount
 
Gross
carrying
amount
 
Accumulated
amortization
 
Net
carrying
amount
Definite-lived intangible assets
 
 
 
 
 
 
 
 
 
 
 
Developed product rights
$
19,611

 
$
(5,963
)
 
$
13,648

 
$
15,872

 
$
(5,614
)
 
$
10,258

License agreements
7,798

 
(2,017
)
 
5,781

 
7,865

 
(1,810
)
 
6,055

Total definite-lived intangible assets
27,409

 
(7,980
)
 
19,429

 
23,737

 
(7,424
)
 
16,313

Indefinite-lived research and development
1,030

 
—

 
1,030

 
4,920

 
—

 
4,920

Total intangible assets, net
$
28,439

 
$
(7,980
)
 
$
20,459

 
$
28,657

 
$
(7,424
)
 
$
21,233
XML 44 R29.htm IDEA: XBRL DOCUMENT v3.19.2
Restructuring Plans (Tables)
 6 Months Ended
Jun. 30, 2019
Restructuring and Related Activities [Abstract]  
Summary of the cash activity in the restructuring reserve
The following table summarizes the cash activity in the restructuring reserve for the six months ended June 30, 2019:
(in millions)
 
Accrued balance as of December 31, 2018
$
99

Restructuring charges
172

Payments and other adjustments
(80
)
Accrued balance as of June 30, 2019
$
191
XML 45 R30.htm IDEA: XBRL DOCUMENT v3.19.2
Leases (Tables)
 6 Months Ended
Jun. 30, 2019
Leases [Abstract]  
Summary of amounts and location of operating and finance leases on the condensed consolidated balance sheet
The following table summarizes the amounts and location of operating and finance leases on the condensed consolidated balance sheet:
(in millions)
Balance sheet caption
June 30,
2019
Assets
 
 
Operating
Other assets
$
380

Finance
Property and equipment, net
27

Total lease assets
 
$
407

Liabilities
 
 
Operating
 
 
Current
Accounts payable and accrued liabilities
$
111

Noncurrent
Other long-term liabilities
290

Finance
 
 
Current
Current portion of long-term debt and finance lease obligations
9

Noncurrent
Long-term debt and finance lease obligations
22

Total lease liabilities
 
$
432
Summary of lease costs recognized in the condensed consolidated statement of earnings
The following table summarizes the lease costs recognized in the condensed consolidated statements of earnings:
 
 
Three months ended
June 30,
 
Six months ended
June 30,
(in millions)
 
2019
 
2019
Operating lease cost
 
$
32

 
$
64

Finance lease cost
 
 
 
 
Amortization of right-of-use assets
 
2

 
4

Interest on lease liabilities
 
—

 
—

Short-term lease cost
 
9

 
15

Variable lease cost
 
14

 
29

Total lease cost
 
$
57

 
$
112
Schedule of weighted-average remaining lease term and weighted-average discount rate for operating and finance leases
The following table presents the weighted-average remaining lease term and weighted-average discount rate for operating and finance leases:
 
June 30,
2019
Weighted-average remaining lease term (in years)
 
Operating
6

Finance
3

Weighted-average discount rate
 
Operating
4.0
%
Finance
4.4
%
Schedule of supplementary cash flow information regarding the company's operating and finance leases
The following table presents supplementary cash flow information regarding the company's operating and finance leases:
 
Six months ended
June 30,
(in millions)
2019
Cash paid for amounts included in the measurement of lease liabilities
 
Operating cash flows from operating leases
$
58

Operating cash flows from finance leases
—

Financing cash flows from finance leases
4

Right-of-use assets obtained in exchange for new finance lease liabilities
—

Right-of-use assets obtained in exchange for new operating lease liabilities
15
Summary of future maturities of AbbVie's operating lease liabilities
The following table summarizes the future maturities of AbbVie's operating and finance lease liabilities as of June 30, 2019:
(in millions)
Operating
leases
 
Finance
leases
 
Total (a)(b)
2019
$
65

 
$
8

 
$
73

2020
121

 
11

 
132

2021
100

 
9

 
109

2022
55

 
3

 
58

2023
35

 
1

 
36

Thereafter
79

 
—

 
79

Total lease payments
455

 
32

 
487

Less: Interest
54

 
1

 
55

Present value of lease liabilities
$
401

 
$
31

 
$
432
Summary of future maturities of AbbVie's finance lease liabilities
The following table summarizes the future maturities of AbbVie's operating and finance lease liabilities as of June 30, 2019:
(in millions)
Operating
leases
 
Finance
leases
 
Total (a)(b)
2019
$
65

 
$
8

 
$
73

2020
121

 
11

 
132

2021
100

 
9

 
109

2022
55

 
3

 
58

2023
35

 
1

 
36

Thereafter
79

 
—

 
79

Total lease payments
455

 
32

 
487

Less: Interest
54

 
1

 
55

Present value of lease liabilities
$
401

 
$
31

 
$
432
XML 46 R31.htm IDEA: XBRL DOCUMENT v3.19.2
Financial Instruments and Fair Value Measures (Tables)
 6 Months Ended
Jun. 30, 2019
Fair Value Disclosures [Abstract]  
Summary of amounts and location of derivatives on the condensed consolidated balance sheets
The following table summarizes the amounts and location of AbbVie’s derivative instruments on the condensed consolidated balance sheets:
 
Fair value –
Derivatives in asset position
 
Fair value –
Derivatives in liability position
(in millions)
Balance sheet caption
June 30,
2019
December 31, 2018
 
Balance sheet caption
June 30,
2019
December 31, 2018
Foreign currency forward exchange contracts
 
 
 
 
 
 
 
Designated as cash flow hedges
Prepaid expenses and
other
$
22

$
113

 
Accounts payable and accrued liabilities
$
—

$
—

Designated as net investment hedges
Prepaid expenses and
other
11

—

 
Accounts payable and accrued liabilities
1

—

Not designated as hedges
Prepaid expenses and
other
40

19

 
Accounts payable and accrued liabilities
38

26

Interest rate swaps designated as fair value hedges
Prepaid expenses and other
—

—

 
Accounts payable and accrued liabilities
8

—

Interest rate swaps designated as fair value hedges
Other assets
24

—

 
Other long-term liabilities
117

466

Total derivatives
 
$
97

$
132

 
 
$
164

$
492
Schedule of pre-tax amounts of derivatives recognized in other comprehensive income (loss)
The following table presents the pre-tax amounts of gains (losses) from derivative instruments recognized in other comprehensive income (loss):
 
 
Three months ended
June 30,
 
Six months ended
June 30,
(in millions)
 
2019
 
2018
 
2019
 
2018
Foreign currency forward exchange contracts
 
 
 
 
 
 
 
 
Designated as cash flow hedges
 
$
2

 
$
169

 
$
5

 
$
121

Designated as net investment hedges
 
10

 
—

 
10

 
—
Summary of pre-tax amounts and location of derivatives recognized in the condensed consolidated statements of earnings
The following table summarizes the pre-tax amounts and location of derivative instrument net gains (losses) recognized in the condensed consolidated statements of earnings, including the net gains (losses) reclassified out of AOCI into net earnings. See Note 11 for the amount of net gains (losses) reclassified out of AOCI.

 
 
 
Three months ended
June 30,
 
Six months ended
June 30,
(in millions)
Statement of earnings caption
 
2019
 
2018
 
2019
 
2018
Foreign currency forward exchange contracts
 
 
 
 
 
 
 
 
 
Designated as cash flow hedges
Cost of products sold
 
$
37

 
$
(46
)
 
$
77

 
$
(90
)
Designated as net investment hedges
Interest expense, net
 
9

 
—

 
9

 
—

Not designated as hedges
Net foreign exchange loss
 
(25
)
 
128

 
(40
)
 
69

Interest rate swaps designated as fair value hedges
Interest expense, net
 
253

 
(59
)
 
365

 
(243
)
Debt designated as hedged item in fair value hedges
Interest expense, net
 
(253
)
 
59

 
(365
)
 
243
Summary of bases used to measure assets and liabilities carried at fair value on a recurring basis
The following table summarizes the bases used to measure certain assets and liabilities carried at fair value on a recurring basis on the condensed consolidated balance sheet as of June 30, 2019:
 
 
 
Basis of fair value measurement
(in millions)
Total
 
Quoted prices in active markets for
identical assets
(Level 1)
 
Significant other
observable
inputs
(Level 2)
 
Significant
unobservable
inputs
(Level 3)
Assets
 
 
 
 
 
 
 
Cash and equivalents
$
5,172

 
$
1,388

 
$
3,784

 
$
—

Debt securities
1,573

 
—

 
1,573

 
—

Equity securities
79

 
79

 
—

 
—

Interest rate hedges
24

 
—

 
24

 
—

Foreign currency contracts
73

 
—

 
73

 
—

Total assets
$
6,921

 
$
1,467

 
$
5,454

 
$
—

Liabilities
 
 
 
 
 
 
 
Interest rate hedges
$
125

 
$
—

 
$
125

 
$
—

Foreign currency contracts
39

 
—

 
39

 
—

Contingent consideration
6,789

 
—

 
—

 
6,789

Total liabilities
$
6,953

 
$
—

 
$
164

 
$
6,789

The following table summarizes the bases used to measure certain assets and liabilities carried at fair value on a recurring basis on the condensed consolidated balance sheet as of December 31, 2018:
 
 
 
Basis of fair value measurement
(in millions)
Total
 
Quoted prices in active markets for
identical assets
(Level 1)
 
Significant other
observable
inputs
(Level 2)
 
Significant
unobservable
inputs
(Level 3)
Assets
 
 
 
 
 
 
 
Cash and equivalents
$
7,289

 
$
1,209

 
$
6,080

 
$
—

Time deposits
568

 
—

 
568

 
—

Debt securities
1,536

 
—

 
1,536

 
—

Equity securities
4

 
4

 
—

 
—

Foreign currency contracts
132

 
—

 
132

 
—

Total assets
$
9,529

 
$
1,213

 
$
8,316

 
$
—

Liabilities
 
 
 
 
 
 
 
Interest rate hedges
$
466

 
$
—

 
$
466

 
$
—

Foreign currency contracts
26

 
—

 
26

 
—

Contingent consideration
4,483

 
—

 
—

 
4,483

Total liabilities
$
4,975

 
$
—

 
$
492

 
$
4,483
Schedule of changes in fair value of Level 3 inputs The following table presents the changes in fair value of contingent consideration liabilities which are measured using Level 3 inputs:
 
 
Six months ended
June 30,
(in millions)
 
2019
 
2018
Beginning balance
 
$
4,483

 
$
4,534

Change in fair value recognized in net earnings
 
2,473

 
337

Milestone payments
 
(167
)
 
(50
)
Ending balance
 
$
6,789

 
$
4,821
Schedule of book values, approximate fair values and bases used to measure certain financial instruments The book values, approximate fair values and bases used to measure the approximate fair values of certain financial instruments as of June 30, 2019 are shown in the table below:
 
 
 
 
Basis of fair value measurement
(in millions)
Book value
Approximate fair value
 
Quoted prices
in active markets for
identical assets
(Level 1)
 
Significant
other 
observable
inputs
(Level 2)
 
Significant
unobservable
inputs
(Level 3)
Liabilities
 
 
 
 
 
 
 
 
Short-term borrowings
$
306

$
306

 
$
—

 
$
306

 
$
—

Current portion of long-term debt and finance lease obligations, excluding fair value hedges
5,343

5,357

 
5,348

 
9

 
—

Long-term debt and finance lease obligations, excluding fair value hedges
31,712

32,753

 
32,731

 
22

 
—

Total liabilities
$
37,361

$
38,416

 
$
38,079

 
$
337

 
$
—


The book values, approximate fair values and bases used to measure the approximate fair values of certain financial instruments as of December 31, 2018 are shown in the table below:
 
 
 
 
Basis of fair value measurement
(in millions)
Book value
Approximate fair value
 
Quoted prices
in active markets for
identical assets
(Level 1)
 
Significant
other 
observable
inputs
(Level 2)
 
Significant
unobservable
inputs
(Level 3)
Liabilities
 
 
 
 
 
 
 
 
Short-term borrowings
$
3,699

$
3,693

 
$
—

 
$
3,693

 
$
—

Current portion of long-term debt and finance lease obligations, excluding fair value hedges
1,609

1,617

 
1,609

 
8

 
—

Long-term debt and finance lease obligations, excluding fair value hedges
35,468

34,052

 
34,024

 
28

 
—

Total liabilities
$
40,776

$
39,362

 
$
35,633

 
$
3,729

 
$
—
Summary of available-for-sale securities by type
The following table summarizes available-for-sale securities by type as of June 30, 2019:
 
Amortized cost
 
Gross unrealized
 
Fair value
(in millions)
 
Gains
 
Losses
 
Asset backed securities
$
375

 
$
—

 
$
(1
)
 
$
374

Corporate debt securities
1,095

 
4

 
(2
)
 
1,097

Other debt securities
102

 
—

 
—

 
102

Total
$
1,572

 
$
4

 
$
(3
)
 
$
1,573


The following table summarizes available-for-sale securities by type as of December 31, 2018:
 
Amortized cost
 
Gross unrealized
 
Fair value
(in millions)
 
Gains
 
Losses
 
Asset backed securities
$
423

 
$
—

 
$
(2
)
 
$
421

Corporate debt securities
1,042

 
1

 
(9
)
 
1,034

Other debt securities
81

 
—

 
—

 
81

Total
$
1,546

 
$
1

 
$
(11
)
 
$
1,536
XML 47 R32.htm IDEA: XBRL DOCUMENT v3.19.2
Post-Employment Benefits (Tables)
 6 Months Ended
Jun. 30, 2019
Postemployment Benefits [Abstract]  
Summary of net periodic benefit costs
The following table summarizes net periodic benefit cost relating to the company’s defined benefit and other post-employment plans:
 
Defined
benefit plans
 
Other post-
employment plans
 
Three months ended
June 30,
 
Six months ended
June 30,
 
Three months ended
June 30,
 
Six months ended
June 30,
(in millions)
2019
 
2018
 
2019
 
2018
 
2019
 
2018
 
2019
 
2018
Service cost
$
68

 
$
72

 
$
135

 
$
144

 
$
7

 
$
5

 
$
13

 
$
13

Interest cost
66

 
57

 
130

 
114

 
9

 
4

 
15

 
12

Expected return on plan assets
(119
)
 
(110
)
 
(238
)
 
(221
)
 
—

 
—

 
—

 
—

Amortization of actuarial losses and prior service cost (credit)
29

 
39

 
55

 
76

 
1

 
(3
)
 
—

 
1

Net periodic benefit cost
$
44

 
$
58

 
$
82

 
$
113

 
$
17

 
$
6

 
$
28

 
$
26
XML 48 R33.htm IDEA: XBRL DOCUMENT v3.19.2
Equity (Tables)
 6 Months Ended
Jun. 30, 2019
Stockholders' Equity Note [Abstract]  
Summary of share-based compensation expense
Stock-based compensation expense is principally related to awards issued pursuant to the AbbVie 2013 Incentive Stock Program and is summarized as follows:
 
 
Three months ended
June 30,
 
Six months ended
June 30,
(in millions)
 
2019
 
2018
 
2019
 
2018
Cost of products sold
 
$
5

 
$
12

 
$
20

 
$
16

Research and development
 
33

 
35

 
105

 
107

Selling, general and administrative
 
49

 
38

 
151

 
153

Pre-tax compensation expense
 
87

 
85

 
276

 
276

Tax benefit
 
16

 
19

 
49

 
48

After-tax compensation expense
 
$
71

 
$
66

 
$
227

 
$
228
Summary of quarterly cash dividends
The following table summarizes quarterly cash dividends declared during 2019 and 2018:
2019
 
2018
Date Declared
 
Payment Date
 
Dividend Per Share
 
Date Declared
 
Payment Date
 
Dividend Per Share
06/20/19
 
08/15/19
 
$
1.07

 
11/02/18
 
02/15/19
 
$
1.07

02/21/19
 
05/15/19
 
$
1.07

 
09/07/18
 
11/15/18
 
$
0.96


 

 


 
06/14/18
 
08/15/18
 
$
0.96


 

 


 
02/15/18
 
05/15/18
 
$
0.96
Summary of changes in balances of each component of accumulated other comprehensive loss
The following table summarizes the changes in each component of accumulated other comprehensive loss, net of tax, for the six months ended June 30, 2018:
(in millions)
Foreign currency
translation adjustments
 
Net investment
hedging activities
 
Pension 
and post-
employment
benefits
 
Marketable
 security activities
 
Cash flow hedging
activities
 
Total
Balance as of December 31, 2017
$
(439
)
 
$
(203
)
 
$
(1,919
)
 
$
—

 
$
(166
)
 
$
(2,727
)
Other comprehensive income (loss) before reclassifications
(280
)
 
105

 
9

 
(6
)
 
110

 
(62
)
Net losses reclassified from accumulated other comprehensive loss
—

 
—

 
62

 
4

 
84

 
150

Net current-period other comprehensive income (loss)
(280
)
 
105

 
71

 
(2
)
 
194

 
88

Balance as of June 30, 2018
$
(719
)
 
$
(98
)
 
$
(1,848
)
 
$
(2
)
 
$
28

 
$
(2,639
)

The following table summarizes the changes in each component of accumulated other comprehensive loss, net of tax, for the six months ended June 30, 2019:
(in millions)
Foreign currency
translation adjustments
 
Net investment
hedging activities
 
Pension 
and post-
employment
benefits
 
Marketable
security activities
 
Cash flow hedging
activities
 
Total
Balance as of December 31, 2018
$
(830
)
 
$
(65
)
 
$
(1,722
)
 
$
(10
)
 
$
147

 
$
(2,480
)
Other comprehensive income (loss) before reclassifications
(32
)
 
35

 
2

 
10

 
7

 
22

Net losses (gains) reclassified from accumulated other comprehensive loss
—

 
(7
)
 
43

 
1

 
(70
)
 
(33
)
Net current-period other comprehensive income (loss)
(32
)
 
28

 
45

 
11

 
(63
)
 
(11
)
Balance as of June 30, 2019
$
(862
)
 
$
(37
)
 
$
(1,677
)
 
$
1

 
$
84

 
$
(2,491
)
Schedule of the significant amounts reclassified out of each component of accumulated other comprehensive loss
The following table presents the impact on AbbVie’s condensed consolidated statements of earnings for significant amounts reclassified out of each component of accumulated other comprehensive loss:
 
Three months ended
June 30,
 
Six months ended
June 30,
(in millions) (brackets denote gains)
2019
 
2018
 
2019
 
2018
Pension and post-employment benefits
 
 
 
 
 
 
 
Amortization of actuarial losses and other(a)
$
30

 
$
36

 
$
55

 
$
77

Tax benefit
(7
)
 
(7
)
 
(12
)
 
(15
)
Total reclassifications, net of tax
$
23

 
$
29

 
$
43

 
$
62

Cash flow hedging activities
 
 
 
 
 
 
 
Losses (gains) on designated cash flow hedges(b)
$
(37
)
 
$
46

 
$
(77
)
 
$
90

Tax expense (benefit)
2

 
(4
)
 
7

 
(6
)
Total reclassifications, net of tax
$
(35
)
 
$
42

 
$
(70
)
 
$
84

Net investment hedging activities
 
 
 
 
 
 
 
Gains on derivative amount excluded from effectiveness testing(c)
$
(9
)
 
$
—

 
$
(9
)
 
$
—

Tax expense
2

 
—

 
2

 
—

Total reclassifications, net of tax
$
(7
)
 
$
—

 
$
(7
)
 
$
—


(a) Amounts are included in the computation of net periodic benefit cost (see Note 10).
(b) Amounts are included in cost of products sold (see Note 9).
(c) Amounts are included in interest expense, net (see Note 9).
XML 49 R34.htm IDEA: XBRL DOCUMENT v3.19.2
Segment Information (Tables)
 6 Months Ended
Jun. 30, 2019
Segment Reporting [Abstract]  
Schedule of worldwide net revenues

AbbVie operates in one business segment—pharmaceutical products. The following table details AbbVie’s worldwide net revenues:
 
 
 
Three months ended
June 30,
 
Six months ended
June 30,
 
 
 
 
(in millions)
 
 
2019
 
2018
 
2019
 
2018
Immunology
 
 
 
 
 
 
 
 
HUMIRA
United States
 
$
3,793

 
$
3,521

 
$
7,008

 
$
6,524

 
International
 
1,077

 
1,664

 
2,308

 
3,370

 
Total
 
$
4,870

 
$
5,185

 
$
9,316

 
$
9,894

SKYRIZI
United States
 
$
42

 
$
—

 
$
42

 
$
—

 
International
 
6

 
—

 
6

 
—

 
Total
 
$
48

 
$
—

 
$
48

 
$
—

Hematologic Oncology
 
 
 
 
 
 
 
 
IMBRUVICA
United States
 
$
886

 
$
693

 
$
1,715

 
$
1,317

 
Collaboration revenues
 
213

 
157

 
406

 
295

 
Total
 
$
1,099

 
$
850

 
$
2,121

 
$
1,612

VENCLEXTA
United States
 
$
117

 
$
47

 
$
222

 
$
88

 
International
 
52

 
18

 
98

 
36

 
Total
 
$
169

 
$
65

 
$
320

 
$
124

HCV
 
 
 
 
 
 
 
 
MAVYRET
United States
 
$
396

 
$
422

 
$
799

 
$
762

 
International
 
384

 
510

 
771

 
1,018

 
Total
 
$
780

 
$
932

 
$
1,570

 
$
1,780

VIEKIRA
United States
 
$
—

 
$
—

 
$
—

 
$
3

 
International
 
4

 
41

 
29

 
109

 
Total
 
$
4

 
$
41

 
$
29

 
$
112

Other Key Products
 
 
 
 
 
 
 
 
Creon
United States
 
$
257

 
$
219

 
$
484

 
$
428

Lupron
United States
 
$
168

 
$
180

 
$
359

 
$
357

 
International
 
41

 
43

 
79

 
85

 
Total
 
$
209

 
$
223

 
$
438

 
$
442

Synthroid
United States
 
$
203

 
$
193

 
$
385

 
$
375

Synagis
International
 
$
38

 
$
44

 
$
325

 
$
365

Duodopa
United States
 
$
24

 
$
20

 
$
46

 
$
38

 
International
 
91

 
88

 
180

 
173

 
Total
 
$
115

 
$
108

 
$
226

 
$
211

Sevoflurane
United States
 
$
18

 
$
19

 
$
35

 
$
36

 
International
 
73

 
94

 
148

 
183

 
Total
 
$
91

 
$
113

 
$
183

 
$
219

Kaletra
United States
 
$
10

 
$
13

 
$
23

 
$
26

 
International
 
67

 
78

 
132

 
138

 
Total
 
$
77

 
$
91

 
$
155

 
$
164

AndroGel
United States
 
$
22

 
$
128

 
$
96

 
$
258

ORILISSA
United States
 
$
18

 
$
—

 
$
31

 
$
—

 
International
 
1

 
—

 
1

 
—

 
Total
 
$
19

 
$
—

 
$
32

 
$
—

All other
 
 
$
254

 
$
86

 
$
355

 
$
228

Total net revenues
 
$
8,255

 
$
8,278

 
$
16,083

 
$
16,212
XML 50 R35.htm IDEA: XBRL DOCUMENT v3.19.2
Basis of Presentation (Details) - USD ($)
$ in Millions
Jun. 30, 2019
Jan. 01, 2019
Dec. 31, 2018
New Accounting Pronouncements or Change in Accounting Principle      
Other assets $ 1,589   $ 1,208
Accounts payable and accrued liabilities 11,300   11,931
Other long-term liabilities $ 16,000   $ 14,490
Accounting Standards Update 2016-02      
New Accounting Pronouncements or Change in Accounting Principle      
Other assets   $ 405  
Accounts payable and accrued liabilities   115  
Other long-term liabilities   $ 290  
XML 51 R36.htm IDEA: XBRL DOCUMENT v3.19.2
Supplemental Financial Information (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2019
Jun. 30, 2018
Dec. 31, 2018
Interest Expense, Net          
Interest expense $ 358 $ 320 $ 745 $ 629  
Interest income (49) (48) (111) (106)  
Interest expense, net 309 272 634 523  
Inventories          
Finished goods 638   638   $ 473
Work-in-process 969   969   862
Raw materials 288   288   270
Inventories 1,895   1,895   1,605
Property and Equipment          
Property and equipment, gross 8,443   8,443   8,396
Accumulated depreciation (5,564)   (5,564)   (5,513)
Property and equipment, net 2,879   2,879   $ 2,883
Depreciation expense $ 114 $ 119 $ 232 $ 234  
XML 52 R37.htm IDEA: XBRL DOCUMENT v3.19.2
Earnings Per Share (Details) - USD ($)
$ / shares in Units, shares in Millions, $ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2019
Jun. 30, 2018
Basic EPS        
Net earnings $ 741 $ 1,983 $ 3,197 $ 4,766
Earnings allocated to participating securities 8 10 17 22
Earnings available to common shareholders $ 733 $ 1,973 $ 3,180 $ 4,744
Weighted-average basic shares outstanding (in shares) 1,480 1,568 1,480 1,579
Basic earnings per share (in dollars per share) $ 0.49 $ 1.26 $ 2.15 $ 3.00
Diluted EPS        
Net earnings $ 741 $ 1,983 $ 3,197 $ 4,766
Earnings allocated to participating securities 8 10 17 22
Earnings available to common shareholders $ 733 $ 1,973 $ 3,180 $ 4,744
Weighted-average basic shares outstanding (in shares) 1,480 1,568 1,480 1,579
Effect of dilutive securities (in shares) 4 4 3 5
Weighted-average diluted shares outstanding (in shares) 1,484 1,572 1,483 1,584
Diluted earnings per share (in dollars per share) $ 0.49 $ 1.26 $ 2.14 $ 2.99
XML 53 R38.htm IDEA: XBRL DOCUMENT v3.19.2
Licensing, Acquisitions, and Other Arrangements - Proposed Acquisition of Allergan plc (Details) - USD ($)
 3 Months Ended 6 Months Ended
Jul. 12, 2019
Jun. 25, 2019
Mar. 31, 2020
Jun. 30, 2019
Jan. 01, 2020
Jun. 24, 2019
Business Acquisition            
Closing price of AbbVie's common stock           $ 78.45
June 2019 bridge credit agreement | Bridge credit agreement            
Business Acquisition            
Bridge credit agreement maximum borrowing capacity   $ 38,000,000,000.0        
Credit agreement term   364 days        
Amount drawn under credit agreement       $ 0    
June 2019 bridge credit agreement | Bridge credit agreement | Subsequent event            
Business Acquisition            
Bridge credit agreement maximum borrowing capacity $ 32,000,000,000.0          
July 2019 term loan agreement | Subsequent event | Term loan agreement            
Business Acquisition            
Principal amount of term loan 6,000,000,000.0          
Amount drawn under credit agreement $ 0          
July 2019 364-day term loan tranche | Term loan agreement | Subsequent event            
Business Acquisition            
Credit agreement term 364 days          
Principal amount of term loan $ 1,500,000,000          
July 2019 three-year term loan tranche | Subsequent event | Term loan agreement            
Business Acquisition            
Credit agreement term 3 years          
Principal amount of term loan $ 2,500,000,000          
July 2019 five-year term loan tranche | Subsequent event | Term loan agreement            
Business Acquisition            
Credit agreement term 5 years          
Principal amount of term loan $ 2,000,000,000.0          
Allergan plc | Scenario, forecast            
Business Acquisition            
Total consideration     $ 63,000,000,000      
Shares of AbbVie stock received by Allergan shareholders         0.8660  
Cash per share received by Allergan shareholders         $ 120.30  
XML 54 R39.htm IDEA: XBRL DOCUMENT v3.19.2
Licensing, Acquisitions, and Other Arrangements - Other Licensing & Acquisitions Activity (Details) - USD ($)
$ in Millions
 1 Months Ended 3 Months Ended 6 Months Ended
Jun. 30, 2018
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2019
Jun. 30, 2018
Collaborative and license agreements          
Cash outflows related to acquisitions and investments       $ 440 $ 401
Acquired in-process research and development   $ 91 $ 0 246 69
Other expense   $ 0 $ 500 $ 0 500
Collaborative arrangement          
Collaborative and license agreements          
Additional contribution to collaboration $ 500        
Calico Life Sciences Llc | Collaborative arrangement          
Collaborative and license agreements          
Additional contribution to collaboration by partner $ 500        
Term by which the agreement was extended 3 years        
Other expense         $ 500
XML 55 R40.htm IDEA: XBRL DOCUMENT v3.19.2
Collaboration with Janssen Biotech, Inc. (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2019
Jun. 30, 2018
Dec. 31, 2018
Collaborative and license agreements          
Accounts receivable, net $ 5,482   $ 5,482   $ 5,384
Accounts payable and accrued liabilities 11,300   $ 11,300   11,931
Collaborative arrangement          
Collaborative and license agreements          
Share of collaboration development costs responsible by the entity (as a percent)     40.00%    
Global - AbbVie's share of other costs (included in respective line items) 77 $ 80 $ 149 $ 151  
Collaborative arrangement | International          
Collaborative and license agreements          
International - AbbVie's share of profits (included in net revenues) 213 157 406 295  
Janssen Biotech Inc | Collaborative arrangement          
Collaborative and license agreements          
Milestone payments 200   $ 200    
Share of collaboration development costs responsible by Janssen (as a percent)     60.00%    
Accounts receivable, net 230   $ 230   177
Accounts payable and accrued liabilities 405   405   $ 376
Janssen Biotech Inc | Collaborative arrangement | United States          
Collaborative and license agreements          
United States - Janssen's share of profits (included in cost of products sold) $ 422 $ 325 $ 808 $ 601  
XML 56 R41.htm IDEA: XBRL DOCUMENT v3.19.2
Goodwill and Intangible Assets - Goodwill (Details)
 6 Months Ended
Jun. 30, 2019
USD ($)
Changes in the carrying amount of goodwill  
Balance at the beginning of the period $ 15,663,000,000
Foreign currency translation adjustments (21,000,000)
Balance at the end of the period 15,642,000,000
Accumulated goodwill impairment losses  
Accumulated goodwill impairment losses $ 0
XML 57 R42.htm IDEA: XBRL DOCUMENT v3.19.2
Goodwill and Intangible Assets - Summary of Intangible Assets, Net (Details) - USD ($)
$ in Millions
Jun. 30, 2019
Dec. 31, 2018
Finite-Lived Intangible Assets    
Gross carrying amount $ 27,409 $ 23,737
Accumulated amortization (7,980) (7,424)
Net carrying amount 19,429 16,313
Indefinite-lived research and development 1,030 4,920
Total intangible assets gross carrying amount 28,439 28,657
Total intangible assets, net 20,459 21,233
Developed product rights    
Finite-Lived Intangible Assets    
Gross carrying amount 19,611 15,872
Accumulated amortization (5,963) (5,614)
Net carrying amount 13,648 10,258
License agreements    
Finite-Lived Intangible Assets    
Gross carrying amount 7,798 7,865
Accumulated amortization (2,017) (1,810)
Net carrying amount $ 5,781 $ 6,055
XML 58 R43.htm IDEA: XBRL DOCUMENT v3.19.2
Goodwill and Intangible Assets - Indefinite-Lived Intangible Assets (Details) - USD ($)
 1 Months Ended 3 Months Ended 6 Months Ended
Apr. 30, 2019
Jun. 30, 2019
Dec. 31, 2018
Jun. 30, 2018
Jun. 30, 2019
Jun. 30, 2018
Indefinite-lived Intangible Assets            
Indefinite-lived intangible asset impairment charges   $ 0   $ 0 $ 0 $ 0
Indefinite-lived research and development assets   $ 1,030,000,000 $ 4,920,000,000   $ 1,030,000,000  
In-Process Research and Development | Stemcentrx Inc.            
Indefinite-lived Intangible Assets            
Indefinite-lived intangible asset impairment charges     5,100,000,000      
Indefinite-lived research and development assets     $ 1,000,000,000.0      
SKYRIZI            
Indefinite-lived Intangible Assets            
Reclassification from indefinite-lived intangible assets $ (3,900,000,000)          
XML 59 R44.htm IDEA: XBRL DOCUMENT v3.19.2
Goodwill and Intangible Assets - Definite-Lived Intangible Assets (Details) - USD ($)
 1 Months Ended 3 Months Ended 6 Months Ended
Apr. 30, 2019
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2019
Jun. 30, 2018
Finite-Lived Intangible Assets          
Amortization of intangible assets   $ 388,000,000 $ 324,000,000 $ 773,000,000 $ 654,000,000
Definite-lived intangible assets impairment charges   $ 0 $ 0 $ 0 $ 0
SKYRIZI | Developed product rights          
Finite-Lived Intangible Assets          
Reclassification to definite-lived intangible assets $ 3,900,000,000        
XML 60 R45.htm IDEA: XBRL DOCUMENT v3.19.2
Restructuring Plans (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2019
Jun. 30, 2018
Restructuring and Related Activities [Abstract]        
Restructuring charges $ 19 $ 1 $ 186 $ 23
Restructuring reserve activity        
Accrued balance beginning of the period     99  
Restructuring charges     172  
Payments and other adjustments     (80)  
Accrued balance end of the period $ 191   $ 191  
XML 61 R46.htm IDEA: XBRL DOCUMENT v3.19.2
Leases - Balance Sheet Disclosure (Details)
$ in Millions
Jun. 30, 2019
USD ($)
Assets  
Total lease assets $ 407
Liabilities  
Total lease liabilities 432 [1],[2]
Other assets  
Assets  
Operating lease assets 380
Property and equipment, net  
Assets  
Finance lease assets 27
Accounts payable and accrued liabilities  
Liabilities  
Current operating lease liabilities 111
Other long-term liabilities  
Liabilities  
Noncurrent operating lease liabilities 290
Current portion of long-term debt and finance lease obligations  
Liabilities  
Current finance lease liabilities 9
Long-term debt and finance lease obligations  
Liabilities  
Noncurrent finance lease liabilities $ 22
[1] Lease payments recognized as part of lease liabilities for optional renewal periods are insignificant.
[2] Total lease payments exclude approximately $350 million of contractual minimum lease payments for leases executed but not yet commenced. These leases will commence between years 2019 and 2020 with lease terms of approximately 11 years.
XML 62 R47.htm IDEA: XBRL DOCUMENT v3.19.2
Leases - Cost (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2019
Jun. 30, 2019
Leases [Abstract]    
Operating lease cost $ 32 $ 64
Finance lease amortization of right-of-use assets 2 4
Finance lease interest on lease liabilities 0 0
Short-term lease cost 9 15
Variable lease cost 14 29
Total lease cost $ 57 $ 112
XML 63 R48.htm IDEA: XBRL DOCUMENT v3.19.2
Leases - Weighted-Average Remaining Lease Term and Discount Rate (Details)
Jun. 30, 2019
Leases [Abstract]  
Weighted-average remaining lease term for operating leases 6 years
Weighted-average remaining lease term for finance leases 3 years
Weighted-average discount rate for operating leases 4.00%
Weighted-average discount rate for finance leases 4.40%
XML 64 R49.htm IDEA: XBRL DOCUMENT v3.19.2
Leases - Cash Flow Disclosure (Details)
$ in Millions
 6 Months Ended
Jun. 30, 2019
USD ($)
Leases [Abstract]  
Operating cash flows from operating leases $ 58
Operating cash flows from finance leases 0
Financing cash flows from finance leases 4
Right-of-use assets obtained in exchange for new finance lease liabilities 0
Right-of-use assets obtained in exchange for new operating lease liabilities $ 15
XML 65 R50.htm IDEA: XBRL DOCUMENT v3.19.2
Leases - Maturities of Lease Liabilities (Details)
$ in Millions
 6 Months Ended
Jun. 30, 2019
USD ($)
Operating leases  
2019 $ 65
2020 121
2021 100
2022 55
2023 35
Thereafter 79
Total lease payments 455
Less: Interest 54
Present value of lease liabilities 401
Finance leases  
2019 8
2020 11
2021 9
2022 3
2023 1
Thereafter 0
Total lease payments 32
Less: Interest 1
Present value of lease liabilities 31
Total  
2019 73 [1],[2]
2020 132 [1],[2]
2021 109 [1],[2]
2022 58 [1],[2]
2023 36 [1],[2]
Thereafter 79 [1],[2]
Total lease payments 487 [1],[2]
Less: Interest 55 [1],[2]
Present value of lease liabilities 432 [1],[2]
Contractual minimum lease payments for leases executed but not yet commenced $ 350
Lease term for leases executed but not yet commenced 11 years
[1] Lease payments recognized as part of lease liabilities for optional renewal periods are insignificant.
[2] Total lease payments exclude approximately $350 million of contractual minimum lease payments for leases executed but not yet commenced. These leases will commence between years 2019 and 2020 with lease terms of approximately 11 years.
XML 66 R51.htm IDEA: XBRL DOCUMENT v3.19.2
Financial Instruments and Fair Value Measures - Financial Instruments (Details)
 6 Months Ended
Jun. 30, 2019
USD ($)
Jun. 30, 2019
GBP (£)
Jun. 30, 2019
EUR (€)
Jun. 30, 2019
CHF (SFr)
Dec. 31, 2018
USD ($)
Dec. 31, 2018
EUR (€)
Derivative instruments, notional amount and fair value            
Foreign currency contracts in asset position $ 97,000,000       $ 132,000,000  
Foreign currency contracts in liability position $ 164,000,000       492,000,000  
Designated as hedging instrument | Net investment hedges | Senior notes            
Derivative instruments, notional amount and fair value            
Principal amount of unsecured senior notes | €     € 3,600,000,000     € 3,600,000,000
Designated as hedging instrument | Foreign currency forward exchange contracts            
Derivative instruments, notional amount and fair value            
Duration of forward exchange contracts 18 months          
Designated as hedging instrument | Foreign currency forward exchange contracts | Cash flow hedges            
Derivative instruments, notional amount and fair value            
Notional amount of derivative instruments $ 503,000,000       1,400,000,000  
Approximate length of time over which accumulated gains and losses will be recognized in Cost of products sold 6 months          
Designated as hedging instrument | Foreign currency forward exchange contracts | Cash flow hedges | Prepaid expenses and other            
Derivative instruments, notional amount and fair value            
Foreign currency contracts in asset position $ 22,000,000       113,000,000  
Designated as hedging instrument | Foreign currency forward exchange contracts | Cash flow hedges | Accounts payable and accrued liabilities            
Derivative instruments, notional amount and fair value            
Foreign currency contracts in liability position 0       0  
Designated as hedging instrument | Foreign currency forward exchange contracts | Net investment hedges            
Derivative instruments, notional amount and fair value            
Notional amount of derivative instruments   £ 204,000,000 € 971,000,000 SFr 62,000,000    
Designated as hedging instrument | Foreign currency forward exchange contracts | Net investment hedges | Prepaid expenses and other            
Derivative instruments, notional amount and fair value            
Foreign currency contracts in asset position 11,000,000       0  
Designated as hedging instrument | Foreign currency forward exchange contracts | Net investment hedges | Accounts payable and accrued liabilities            
Derivative instruments, notional amount and fair value            
Foreign currency contracts in liability position 1,000,000       0  
Designated as hedging instrument | Interest rate contracts | Fair value hedges            
Derivative instruments, notional amount and fair value            
Notional amount of derivative instruments 10,800,000,000       10,800,000,000.0  
Designated as hedging instrument | Interest rate contracts | Fair value hedges | Prepaid expenses and other            
Derivative instruments, notional amount and fair value            
Foreign currency contracts in asset position 0       0  
Designated as hedging instrument | Interest rate contracts | Fair value hedges | Accounts payable and accrued liabilities            
Derivative instruments, notional amount and fair value            
Foreign currency contracts in liability position 8,000,000       0  
Designated as hedging instrument | Interest rate contracts | Fair value hedges | Other assets            
Derivative instruments, notional amount and fair value            
Foreign currency contracts in asset position 24,000,000       0  
Designated as hedging instrument | Interest rate contracts | Fair value hedges | Other long-term liabilities            
Derivative instruments, notional amount and fair value            
Foreign currency contracts in liability position 117,000,000       466,000,000  
Not designated as hedging instrument | Foreign currency forward exchange contracts            
Derivative instruments, notional amount and fair value            
Notional amount of derivative instruments 7,900,000,000       8,600,000,000  
Not designated as hedging instrument | Foreign currency forward exchange contracts | Prepaid expenses and other            
Derivative instruments, notional amount and fair value            
Foreign currency contracts in asset position 40,000,000       19,000,000  
Not designated as hedging instrument | Foreign currency forward exchange contracts | Accounts payable and accrued liabilities            
Derivative instruments, notional amount and fair value            
Foreign currency contracts in liability position $ 38,000,000       $ 26,000,000  
XML 67 R52.htm IDEA: XBRL DOCUMENT v3.19.2
Financial Instruments and Fair Value Measures - Amount Of Gain/(Loss) Recognized For Derivative Instruments (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2019
Jun. 30, 2018
Gain (loss) on derivatives        
Foreign currency cash flow hedge gain expected to be reclassified during next 12 months $ 90   $ 90  
Fair value hedges | Interest expense, net        
Gain (loss) on derivatives        
Debt designated as hedged item in fair value hedges gain (loss) (253) $ 59 (365) $ 243
Foreign currency forward exchange contracts | Designated as hedging instrument        
Gain (loss) on derivatives        
Pre-tax gains (losses) from derivative instruments designated as cash flow hedges recognized in other comprehensive income 2 169 5 121
Pre-tax gains (losses) from net investment hedge instruments recognized in other comprehensive income 10 0 10 0
Foreign currency forward exchange contracts | Not designated as hedges | Net foreign exchange loss        
Gain (loss) on derivatives        
Derivative gain (loss), net (25) 128 (40) 69
Foreign currency forward exchange contracts | Cash flow hedges | Designated as hedging instrument | Cost of products sold        
Gain (loss) on derivatives        
Derivative gain (loss), net 37 (46) 77 (90)
Foreign currency forward exchange contracts | Net investment hedges | Designated as hedging instrument | Interest expense, net        
Gain (loss) on derivatives        
Derivative gain (loss), net 9 0 9 0
Interest rate swaps designated as fair value hedges | Fair value hedges | Designated as hedging instrument | Interest expense, net        
Gain (loss) on derivatives        
Derivative gain (loss), net 253 (59) 365 (243)
Senior notes | Designated as hedging instrument        
Gain (loss) on derivatives        
Pre-tax gains (losses) from net investment hedge instruments recognized in other comprehensive income $ 49 $ (270) $ (35) $ (136)
XML 68 R53.htm IDEA: XBRL DOCUMENT v3.19.2
Financial Instruments and Fair Value Measures - Fair Value Measures (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2019
Jun. 30, 2019
Jun. 30, 2018
Dec. 31, 2018
Assets        
Foreign currency contracts $ 97 $ 97   $ 132
Liabilities        
Foreign currency contracts 164 164   492
Change in fair value recognized in net earnings   $ 2,473 $ 337  
Changes Measurement | Change in assumed discount rate        
Liabilities        
Discount rate change   50.00%    
Contingent consideration liability change   $ 270    
Changes Measurement | Change in assumed probability rate        
Liabilities        
Contingent consideration liability change   $ 210    
Assumed probability rate change   5.00%    
Quoted prices in active markets for identical assets (Level 1)        
Liabilities        
Total liabilities 38,079 $ 38,079   35,633
Significant other observable inputs (Level 2)        
Liabilities        
Total liabilities 337 337   3,729
Significant unobservable inputs (Level 3)        
Liabilities        
Total liabilities 0 0   0
Recurring        
Assets        
Cash and equivalents 5,172 5,172   7,289
Debt securities 1,573 1,573   1,536
Equity securities 79 79   4
Interest rate hedges 24 24    
Total assets 6,921 6,921   9,529
Liabilities        
Interest rate hedges 125 125   466
Contingent consideration 6,789 6,789   4,483
Total liabilities 6,953 6,953   4,975
Recurring | Foreign currency contracts        
Assets        
Foreign currency contracts 73 73   132
Liabilities        
Foreign currency contracts 39 39   26
Recurring | Time deposits        
Assets        
Time deposits       568
Recurring | Quoted prices in active markets for identical assets (Level 1)        
Assets        
Cash and equivalents 1,388 1,388   1,209
Debt securities 0 0   0
Equity securities 79 79   4
Interest rate hedges 0 0    
Total assets 1,467 1,467   1,213
Liabilities        
Interest rate hedges 0 0   0
Contingent consideration 0 0   0
Total liabilities 0 0   0
Recurring | Quoted prices in active markets for identical assets (Level 1) | Foreign currency contracts        
Assets        
Foreign currency contracts 0 0   0
Liabilities        
Foreign currency contracts 0 0   0
Recurring | Quoted prices in active markets for identical assets (Level 1) | Time deposits        
Assets        
Time deposits       0
Recurring | Significant other observable inputs (Level 2)        
Assets        
Cash and equivalents 3,784 3,784   6,080
Debt securities 1,573 1,573   1,536
Equity securities 0 0   0
Interest rate hedges 24 24    
Total assets 5,454 5,454   8,316
Liabilities        
Interest rate hedges 125 125   466
Contingent consideration 0 0   0
Total liabilities 164 164   492
Recurring | Significant other observable inputs (Level 2) | Foreign currency contracts        
Assets        
Foreign currency contracts 73 73   132
Liabilities        
Foreign currency contracts 39 39   26
Recurring | Significant other observable inputs (Level 2) | Time deposits        
Assets        
Time deposits       568
Recurring | Significant unobservable inputs (Level 3)        
Assets        
Cash and equivalents 0 0   0
Debt securities 0 0   0
Equity securities 0 0   0
Interest rate hedges 0 0    
Total assets 0 0   0
Liabilities        
Interest rate hedges 0 0   0
Contingent consideration 6,789 6,789   4,483
Total liabilities 6,789 6,789   4,483
Recurring | Significant unobservable inputs (Level 3) | Foreign currency contracts        
Assets        
Foreign currency contracts 0 0   0
Liabilities        
Foreign currency contracts 0 $ 0   0
Recurring | Significant unobservable inputs (Level 3) | Time deposits        
Assets        
Time deposits       $ 0
SKYRIZI        
Liabilities        
Change in fair value recognized in net earnings $ 2,300      
XML 69 R54.htm IDEA: XBRL DOCUMENT v3.19.2
Financial Instruments and Fair Value Measures - Transfers of Assets or Liabilities Between The Fair Value Measurement Levels (Details)
 6 Months Ended
Jun. 30, 2019
USD ($)
Jun. 30, 2018
USD ($)
Transfers of assets or liabilities between the fair value measurement levels    
Transfer of assets from level 1 to level 2 $ 0  
Transfer of assets from level 2 to level 1 0  
Transfer of liabilities from level 1 to level 2 0  
Transfer of liabilities from level 2 to level 1 0  
Reconciliation of the fair value measurements that use significant unobservable inputs (Level 3)    
Beginning balance 4,483,000,000 $ 4,534,000,000
Change in fair value recognized in net earnings 2,473,000,000 337,000,000
Milestone payments (167,000,000) (50,000,000)
Ending balance $ 6,789,000,000 $ 4,821,000,000
XML 70 R55.htm IDEA: XBRL DOCUMENT v3.19.2
Financial Instruments and Fair Value Measures - Bases Used To Measure The Approximate Fair Values Of Financial Instruments (Details) - USD ($)
$ in Millions
Jun. 30, 2019
Dec. 31, 2018
Liabilities    
Carrying amount of investments in equity securities that do not have readily determinable fair values $ 65 $ 84
Quoted prices in active markets for identical assets (Level 1)    
Liabilities    
Short-term borrowings 0 0
Current portion of long-term debt and finance lease obligations, excluding fair value hedges 5,348 1,609
Long-term debt and finance lease obligations, excluding fair value hedges 32,731 34,024
Total liabilities 38,079 35,633
Significant other observable inputs (Level 2)    
Liabilities    
Short-term borrowings 306 3,693
Current portion of long-term debt and finance lease obligations, excluding fair value hedges 9 8
Long-term debt and finance lease obligations, excluding fair value hedges 22 28
Total liabilities 337 3,729
Significant unobservable inputs (Level 3)    
Liabilities    
Short-term borrowings 0 0
Current portion of long-term debt and finance lease obligations, excluding fair value hedges 0 0
Long-term debt and finance lease obligations, excluding fair value hedges 0 0
Total liabilities 0 0
Book value    
Liabilities    
Short-term borrowings 306 3,699
Current portion of long-term debt and finance lease obligations, excluding fair value hedges 5,343 1,609
Long-term debt and finance lease obligations, excluding fair value hedges 31,712 35,468
Total liabilities 37,361 40,776
Approximate fair value    
Liabilities    
Short-term borrowings 306 3,693
Current portion of long-term debt and finance lease obligations, excluding fair value hedges 5,357 1,617
Long-term debt and finance lease obligations, excluding fair value hedges 32,753 34,052
Total liabilities $ 38,416 $ 39,362
XML 71 R56.htm IDEA: XBRL DOCUMENT v3.19.2
Financial Instruments and Fair Value Measures - Available-for-sale Securities (Details) - USD ($)
Jun. 30, 2019
Dec. 31, 2018
Available-for-sale Securities    
Maximum maturity period of long-term debt securities (in years) 5 years  
Amortized cost $ 1,572,000,000 $ 1,546,000,000
Gross unrealized, Gains 4,000,000 1,000,000
Gross unrealized, Losses (3,000,000) (11,000,000)
Fair value 1,573,000,000 1,536,000,000
Other-than-temporary impairments 0  
Short-term investments    
Available-for-sale Securities    
Debt securities 244,000,000 204,000,000
Asset backed securities    
Available-for-sale Securities    
Amortized cost 375,000,000 423,000,000
Gross unrealized, Gains 0 0
Gross unrealized, Losses (1,000,000) (2,000,000)
Fair value 374,000,000 421,000,000
Corporate debt securities    
Available-for-sale Securities    
Amortized cost 1,095,000,000 1,042,000,000
Gross unrealized, Gains 4,000,000 1,000,000
Gross unrealized, Losses (2,000,000) (9,000,000)
Fair value 1,097,000,000 1,034,000,000
Other debt securities    
Available-for-sale Securities    
Amortized cost 102,000,000 81,000,000
Gross unrealized, Gains 0 0
Gross unrealized, Losses 0 0
Fair value $ 102,000,000 $ 81,000,000
XML 72 R57.htm IDEA: XBRL DOCUMENT v3.19.2
Financial Instruments and Fair Value Measures - Concentrations of Risk (Details) - wholesaler
 6 Months Ended
Jun. 30, 2019
Jun. 30, 2018
Accounts receivable, net    
Concentration of Risk    
Number of principal customers 3  
Accounts receivable, net | Geographic Risk    
Concentration of Risk    
Concentrations risk (as a percent) 66.00% 63.00%
Total revenues | HUMIRA    
Concentration of Risk    
Concentrations risk (as a percent) 58.00% 61.00%
XML 73 R58.htm IDEA: XBRL DOCUMENT v3.19.2
Financial Instruments and Fair Value Measures - Debt and Credit Facilities (Details) - USD ($)
 1 Months Ended 6 Months Ended
Jun. 25, 2019
Mar. 31, 2019
May 31, 2018
Jun. 30, 2019
Jun. 30, 2018
Dec. 31, 2018
Short-Term Borrowings            
Short-term borrowings       $ 306,000,000   $ 3,699,000,000
Repayments of other short-term borrowings       3,000,000,000 $ 0  
Commercial paper            
Short-Term Borrowings            
Short-term borrowings       $ 306,000,000   $ 699,000,000
Weighted-average interest rate on commercial paper (as a percent)       2.70% 1.90%  
Term loan facilities | May 2018 term loan credit agreement            
Short-Term Borrowings            
Repayments of other short-term borrowings   $ 3,000,000,000.0        
Credit agreement term     364 days      
Bridge credit agreement | June 2019 bridge credit agreement            
Short-Term Borrowings            
Credit agreement term 364 days          
XML 74 R59.htm IDEA: XBRL DOCUMENT v3.19.2
Post-Employment Benefits (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2019
Jun. 30, 2018
Defined benefit plans        
Defined benefit and other post-employment plans        
Service cost $ 68 $ 72 $ 135 $ 144
Interest cost 66 57 130 114
Expected return on plan assets (119) (110) (238) (221)
Amortization of actuarial losses and prior service cost (credit) 29 39 55 76
Net periodic benefit cost 44 58 82 113
Other post-employment plans        
Defined benefit and other post-employment plans        
Service cost 7 5 13 13
Interest cost 9 4 15 12
Expected return on plan assets 0 0 0 0
Amortization of actuarial losses and prior service cost (credit) 1 (3) 0 1
Net periodic benefit cost $ 17 $ 6 $ 28 $ 26
XML 75 R60.htm IDEA: XBRL DOCUMENT v3.19.2
Equity - Stock-Based Compensation (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2019
Jun. 30, 2018
Share-based Compensation Arrangement by Share-based Payment Award        
Pre-tax compensation expense $ 87 $ 85 $ 276 $ 276
Tax benefit 16 19 49 48
After-tax compensation expense 71 66 227 228
Cost of products sold        
Share-based Compensation Arrangement by Share-based Payment Award        
Pre-tax compensation expense 5 12 20 16
Research and development        
Share-based Compensation Arrangement by Share-based Payment Award        
Pre-tax compensation expense 33 35 105 107
Selling, general and administrative        
Share-based Compensation Arrangement by Share-based Payment Award        
Pre-tax compensation expense $ 49 $ 38 $ 151 $ 153
XML 76 R61.htm IDEA: XBRL DOCUMENT v3.19.2
Equity - Stock Options (Details) - Stock Options
$ / shares in Units, shares in Millions, $ in Millions
 6 Months Ended
Jun. 30, 2019
USD ($)
$ / shares
shares
Share-based Compensation Arrangement by Share-based Payment Award  
Stock options granted (in shares) | shares 1.0
Weighted-average grant-date fair value of the stock options granted (in dollars per share) | $ / shares $ 12.54
Unrecognized compensation cost | $ $ 8.5
Period for recognition of unrecognized compensation cost 2 years
XML 77 R62.htm IDEA: XBRL DOCUMENT v3.19.2
Equity - RSUs and Performance Shares (Details) - RSUs and Performance Shares
$ / shares in Units, shares in Millions, $ in Millions
 6 Months Ended
Jun. 30, 2019
USD ($)
$ / shares
shares
Share-based Compensation Arrangement by Share-based Payment Award  
Shares granted (in shares) | shares 5.4
Fair market value of awards vested (in dollars per share) | $ / shares $ 78.68
Unrecognized compensation cost | $ $ 434
Period for recognition of unrecognized compensation cost 2 years
XML 78 R63.htm IDEA: XBRL DOCUMENT v3.19.2
Equity - Cash Dividends (Details) - $ / shares
Jun. 20, 2019
Feb. 21, 2019
Nov. 02, 2018
Sep. 07, 2018
Jun. 14, 2018
Feb. 15, 2018
Stockholders' Equity Note [Abstract]            
Cash dividends declared per common share (in dollars per share) $ 1.07 $ 1.07 $ 1.07 $ 0.96 $ 0.96 $ 0.96
XML 79 R64.htm IDEA: XBRL DOCUMENT v3.19.2
Equity - Stock Repurchase Program (Details) - USD ($)
shares in Millions, $ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2019
Jun. 30, 2018
Equity, Class of Treasury Stock        
Payment for shares repurchased $ 3 $ 7,516 $ 422 $ 8,947
Remaining share repurchase authorization amount $ 4,000   $ 4,000  
December 2018 Stock Repurchase Authorization        
Equity, Class of Treasury Stock        
Shares repurchased (in shares)     4  
Payment for shares repurchased     $ 300  
February 2017 Stock Repurchase Program        
Equity, Class of Treasury Stock        
Shares repurchased (in shares)       84
Payment for shares repurchased       $ 8,800
XML 80 R65.htm IDEA: XBRL DOCUMENT v3.19.2
Equity - Accumulated Other Comprehensive Loss (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2019
Jun. 30, 2018
AOCI Attributable to Parent, Net of Tax        
Beginning balance $ (7,826) $ 3,553 $ (8,446) $ 5,097
Other comprehensive income (loss) 25 (9) (11) 88
Ending balance (8,566) (3,375) (8,566) (3,375)
Accumulated other comprehensive loss        
AOCI Attributable to Parent, Net of Tax        
Beginning balance (2,516) (2,630) (2,480) (2,727)
Other comprehensive income (loss) before reclassifications     22 (62)
Net losses (gains) reclassified from accumulated other comprehensive loss     (33) 150
Other comprehensive income (loss) 25 (9) (11) 88
Ending balance (2,491) (2,639) (2,491) (2,639)
Foreign currency translation adjustments        
AOCI Attributable to Parent, Net of Tax        
Beginning balance     (830) (439)
Other comprehensive income (loss) before reclassifications     (32) (280)
Net losses (gains) reclassified from accumulated other comprehensive loss     0 0
Other comprehensive income (loss)     (32) (280)
Ending balance (862) (719) (862) (719)
Net investment hedging activities        
AOCI Attributable to Parent, Net of Tax        
Beginning balance     (65) (203)
Other comprehensive income (loss) before reclassifications     35 105
Net losses (gains) reclassified from accumulated other comprehensive loss     (7) 0
Other comprehensive income (loss)     28 105
Ending balance (37) (98) (37) (98)
Pension and post-employment benefits        
AOCI Attributable to Parent, Net of Tax        
Beginning balance     (1,722) (1,919)
Other comprehensive income (loss) before reclassifications     2 9
Net losses (gains) reclassified from accumulated other comprehensive loss     43 62
Other comprehensive income (loss)     45 71
Ending balance (1,677) (1,848) (1,677) (1,848)
Marketable security activities        
AOCI Attributable to Parent, Net of Tax        
Beginning balance     (10) 0
Other comprehensive income (loss) before reclassifications     10 (6)
Net losses (gains) reclassified from accumulated other comprehensive loss     1 4
Other comprehensive income (loss)     11 (2)
Ending balance 1 (2) 1 (2)
Cash flow hedging activities        
AOCI Attributable to Parent, Net of Tax        
Beginning balance     147 (166)
Other comprehensive income (loss) before reclassifications     7 110
Net losses (gains) reclassified from accumulated other comprehensive loss     (70) 84
Other comprehensive income (loss)     (63) 194
Ending balance $ 84 $ 28 $ 84 $ 28
XML 81 R66.htm IDEA: XBRL DOCUMENT v3.19.2
Equity - Amounts Reclassified Out Of Accumulated Other Comprehensive Income (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2019
Jun. 30, 2018
Significant amounts reclassified out of each component of AOCI        
Losses (gains) on designated cash flow hedges $ 1,819 $ 1,934 $ 3,513 $ 3,861
Gains on derivative amount excluded from effectiveness testing 309 272 634 523
Tax expense (benefit) 66 29 154 43
Total reclassifications, net of tax (741) (1,983) (3,197) (4,766)
Pension and post-employment benefits        
Significant amounts reclassified out of each component of AOCI        
Amortization of actuarial losses and other [1] 30 36 55 77
Tax benefit (7) (7) (12) (15)
Total reclassifications, net of tax 23 29 43 62
Reclassification out of accumulated other comprehensive income | Cash flow hedging activities        
Significant amounts reclassified out of each component of AOCI        
Losses (gains) on designated cash flow hedges [2] (37) 46 (77) 90
Tax expense (benefit) 2 (4) 7 (6)
Total reclassifications, net of tax (35) 42 (70) 84
Net investment hedging activity | Reclassification out of accumulated other comprehensive income | AOCI, Derivative Qualifying as Hedge, Excluded Component, Parent [Member]        
Significant amounts reclassified out of each component of AOCI        
Gains on derivative amount excluded from effectiveness testing [3] (9) 0 (9) 0
Tax expense (benefit) 2 0 2 0
Total reclassifications, net of tax $ (7) $ 0 $ (7) $ 0
[1] Amounts are included in the computation of net periodic benefit cost (see Note 10).
[2] Amounts are included in cost of products sold (see Note 9).
[3] Amounts are included in interest expense, net (see Note 9).
XML 82 R67.htm IDEA: XBRL DOCUMENT v3.19.2
Income Taxes (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2019
Jun. 30, 2018
Income Tax Disclosure [Abstract]        
Effective tax rate 8.00% 2.00% 5.00% 1.00%
U.S. statutory tax rate     21.00% 21.00%
Potential change in unrecognized tax benefits $ 41   $ 41  
XML 83 R68.htm IDEA: XBRL DOCUMENT v3.19.2
Legal Proceedings and Contingencies (Details)
 1 Months Ended 6 Months Ended
Jun. 30, 2018
USD ($)
Mar. 31, 2017
Jun. 30, 2016
investment_fund
Nov. 30, 2014
individual
Sep. 30, 2014
company
Jun. 30, 2019
USD ($)
claim
Jun. 30, 2019
USD ($)
company
claim
Jun. 30, 2019
USD ($)
direct_purchaser
claim
Jun. 30, 2019
USD ($)
lawsuit
claim
Jun. 30, 2019
USD ($)
claim
class_action
Jun. 30, 2019
USD ($)
claim
end_payor_purchaser
Dec. 31, 2018
USD ($)
Legal Proceedings and Contingencies                        
Recorded accrual balance for litigation | $           $ 330,000,000 $ 330,000,000 $ 330,000,000 $ 330,000,000 $ 330,000,000 $ 330,000,000 $ 350,000,000
Number of individual putative class action lawsuit | individual       5                
Percentage of claims subject to settlement agreements           90.00%            
Depakote                        
Legal Proceedings and Contingencies                        
Number of claims pending | claim           150 150 150 150 150 150  
AndroGel Antitrust Litigation                        
Legal Proceedings and Contingencies                        
Recorded accrual balance for litigation | $           $ 0 $ 0 $ 0 $ 0 $ 0 $ 0  
Number of generic companies with whom certain litigation related agreements were entered into | company         2   3          
AndroGel Antitrust Litigation | Disgorgement remedy                        
Legal Proceedings and Contingencies                        
Damages awarded against company | $ $ 448,000,000                      
Niaspan                        
Legal Proceedings and Contingencies                        
Number of individual plaintiff lawsuits | lawsuit                 4      
Number of purported class actions | class_action                   2    
Number of healthcare benefit providers who filed lawsuits               1     1  
Elliott Associates, L.P.                        
Legal Proceedings and Contingencies                        
Number of parties to lawsuit (in investment funds) | investment_fund     5                  
Testosterone Replacement Therapy Products Liability Litigation                        
Legal Proceedings and Contingencies                        
Numbers of claims consolidated for pre-trial purposes | claim           3,900 3,900 3,900 3,900 3,900 3,900  
Number of claims pending | claim           200 200 200 200 200 200  
Novartis Vaccines and Diagnostics Inc and Grifols Worldwide Operations Ltd [Member]                        
Legal Proceedings and Contingencies                        
HCV-related patents   11                    
XML 84 R69.htm IDEA: XBRL DOCUMENT v3.19.2
Segment Information - Additional Information (Details)
 6 Months Ended
Jun. 30, 2019
segment
Segment Reporting [Abstract]  
Number of operating segments 1
XML 85 R70.htm IDEA: XBRL DOCUMENT v3.19.2
Segment Information - Disaggregation of Revenue (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2019
Jun. 30, 2018
Disaggregation of Revenue        
Total net revenues $ 8,255 $ 8,278 $ 16,083 $ 16,212
All other        
Disaggregation of Revenue        
Net revenues 254 86 355 228
Immunology | HUMIRA        
Disaggregation of Revenue        
Net revenues 4,870 5,185 9,316 9,894
Immunology | HUMIRA | United States        
Disaggregation of Revenue        
Net revenues 3,793 3,521 7,008 6,524
Immunology | HUMIRA | International        
Disaggregation of Revenue        
Net revenues 1,077 1,664 2,308 3,370
Immunology | SKYRIZI        
Disaggregation of Revenue        
Net revenues 48 0 48 0
Immunology | SKYRIZI | United States        
Disaggregation of Revenue        
Net revenues 42 0 42 0
Immunology | SKYRIZI | International        
Disaggregation of Revenue        
Net revenues 6 0 6 0
Hematologic Oncology | IMBRUVICA        
Disaggregation of Revenue        
Net revenues 1,099 850 2,121 1,612
Hematologic Oncology | IMBRUVICA | United States        
Disaggregation of Revenue        
Net revenues 886 693 1,715 1,317
Hematologic Oncology | IMBRUVICA | International        
Disaggregation of Revenue        
Collaboration revenues 213 157 406 295
Hematologic Oncology | VENCLEXTA        
Disaggregation of Revenue        
Net revenues 169 65 320 124
Hematologic Oncology | VENCLEXTA | United States        
Disaggregation of Revenue        
Net revenues 117 47 222 88
Hematologic Oncology | VENCLEXTA | International        
Disaggregation of Revenue        
Net revenues 52 18 98 36
HCV | MAVYRET        
Disaggregation of Revenue        
Net revenues 780 932 1,570 1,780
HCV | MAVYRET | United States        
Disaggregation of Revenue        
Net revenues 396 422 799 762
HCV | MAVYRET | International        
Disaggregation of Revenue        
Net revenues 384 510 771 1,018
HCV | VIEKIRA        
Disaggregation of Revenue        
Net revenues 4 41 29 112
HCV | VIEKIRA | United States        
Disaggregation of Revenue        
Net revenues 0 0 0 3
HCV | VIEKIRA | International        
Disaggregation of Revenue        
Net revenues 4 41 29 109
Other Key Products | Creon | United States        
Disaggregation of Revenue        
Net revenues 257 219 484 428
Other Key Products | Lupron        
Disaggregation of Revenue        
Net revenues 209 223 438 442
Other Key Products | Lupron | United States        
Disaggregation of Revenue        
Net revenues 168 180 359 357
Other Key Products | Lupron | International        
Disaggregation of Revenue        
Net revenues 41 43 79 85
Other Key Products | Synthroid | United States        
Disaggregation of Revenue        
Net revenues 203 193 385 375
Other Key Products | Synagis | International        
Disaggregation of Revenue        
Net revenues 38 44 325 365
Other Key Products | Duodopa        
Disaggregation of Revenue        
Net revenues 115 108 226 211
Other Key Products | Duodopa | United States        
Disaggregation of Revenue        
Net revenues 24 20 46 38
Other Key Products | Duodopa | International        
Disaggregation of Revenue        
Net revenues 91 88 180 173
Other Key Products | Sevoflurane        
Disaggregation of Revenue        
Net revenues 91 113 183 219
Other Key Products | Sevoflurane | United States        
Disaggregation of Revenue        
Net revenues 18 19 35 36
Other Key Products | Sevoflurane | International        
Disaggregation of Revenue        
Net revenues 73 94 148 183
Other Key Products | Kaletra        
Disaggregation of Revenue        
Net revenues 77 91 155 164
Other Key Products | Kaletra | United States        
Disaggregation of Revenue        
Net revenues 10 13 23 26
Other Key Products | Kaletra | International        
Disaggregation of Revenue        
Net revenues 67 78 132 138
Other Key Products | AndroGel | United States        
Disaggregation of Revenue        
Net revenues 22 128 96 258
Other Key Products | ORILISSA        
Disaggregation of Revenue        
Net revenues 19 0 32 0
Other Key Products | ORILISSA | United States        
Disaggregation of Revenue        
Net revenues 18 0 31 0
Other Key Products | ORILISSA | International        
Disaggregation of Revenue        
Net revenues $ 1 $ 0 $ 1 $ 0
XML 86 R9999.htm IDEA: XBRL DOCUMENT v3.19.2
Label Element Value
Cumulative Effect of New Accounting Principle in Period of Adoption us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption $ (1,733,000,000)
Common Stock [Member]  
Cumulative Effect of New Accounting Principle in Period of Adoption us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption 0
Additional Paid-in Capital [Member]  
Cumulative Effect of New Accounting Principle in Period of Adoption us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption 0
Retained Earnings [Member]  
Cumulative Effect of New Accounting Principle in Period of Adoption us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption (1,733,000,000)
Treasury Stock [Member]  
Cumulative Effect of New Accounting Principle in Period of Adoption us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption 0
AOCI Attributable to Parent [Member]  
Cumulative Effect of New Accounting Principle in Period of Adoption us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption $ 0
EXCEL 87 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 89 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 90 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.2 html 460 416 1 true 111 0 false 17 false false R1.htm 0001000 - Document - Document and Entity Information Sheet http://www.abbvie.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 1001000 - Statement - Condensed Consolidated Statements of Earnings (Unaudited) Sheet http://www.abbvie.com/role/CondensedConsolidatedStatementsOfEarningsUnaudited Condensed Consolidated Statements of Earnings (Unaudited) Statements 2 false false R3.htm 1002000 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited) Sheet http://www.abbvie.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited Condensed Consolidated Statements of Comprehensive Income (Unaudited) Statements 3 false false R4.htm 1002501 - Statement - Condensed Consolidated Statements of Comprehensive Income (Parenthetical) (Unaudited) Sheet http://www.abbvie.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeParentheticalUnaudited Condensed Consolidated Statements of Comprehensive Income (Parenthetical) (Unaudited) Statements 4 false false R5.htm 1003000 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 5 false false R6.htm 1003501 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.abbvie.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 6 false false R7.htm 1004000 - Statement - Condensed Consolidated Statements of Equity (Unaudited) Sheet http://www.abbvie.com/role/CondensedConsolidatedStatementsOfEquityUnaudited Condensed Consolidated Statements of Equity (Unaudited) Statements 7 false false R8.htm 1005000 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.abbvie.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 8 false false R9.htm 2101100 - Disclosure - Basis of Presentation Sheet http://www.abbvie.com/role/BasisOfPresentation Basis of Presentation Notes 9 false false R10.htm 2103100 - Disclosure - Supplemental Financial Information Sheet http://www.abbvie.com/role/SupplementalFinancialInformation Supplemental Financial Information Notes 10 false false R11.htm 2104100 - Disclosure - Earnings Per Share Sheet http://www.abbvie.com/role/EarningsPerShare Earnings Per Share Notes 11 false false R12.htm 2105100 - Disclosure - Licensing, Acquisitions, and Other Arrangements Sheet http://www.abbvie.com/role/LicensingAcquisitionsAndOtherArrangements Licensing, Acquisitions, and Other Arrangements Notes 12 false false R13.htm 2106100 - Disclosure - Collaboration with Janssen Biotech, Inc. Sheet http://www.abbvie.com/role/CollaborationWithJanssenBiotechInc Collaboration with Janssen Biotech, Inc. Notes 13 false false R14.htm 2107100 - Disclosure - Goodwill and Intangible Assets Sheet http://www.abbvie.com/role/GoodwillAndIntangibleAssets Goodwill and Intangible Assets Notes 14 false false R15.htm 2108100 - Disclosure - Restructuring Plans Sheet http://www.abbvie.com/role/RestructuringPlans Restructuring Plans Notes 15 false false R16.htm 2109100 - Disclosure - Leases Sheet http://www.abbvie.com/role/Leases Leases Notes 16 false false R17.htm 2110100 - Disclosure - Financial Instruments and Fair Value Measures Sheet http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasures Financial Instruments and Fair Value Measures Notes 17 false false R18.htm 2111100 - Disclosure - Post-Employment Benefits Sheet http://www.abbvie.com/role/PostEmploymentBenefits Post-Employment Benefits Notes 18 false false R19.htm 2112100 - Disclosure - Equity Sheet http://www.abbvie.com/role/Equity Equity Notes 19 false false R20.htm 2113100 - Disclosure - Income Taxes Sheet http://www.abbvie.com/role/IncomeTaxes Income Taxes Notes 20 false false R21.htm 2114100 - Disclosure - Legal Proceedings and Contingencies Sheet http://www.abbvie.com/role/LegalProceedingsAndContingencies Legal Proceedings and Contingencies Notes 21 false false R22.htm 2115100 - Disclosure - Segment Information Sheet http://www.abbvie.com/role/SegmentInformation Segment Information Notes 22 false false R23.htm 2201201 - Disclosure - Basis of Presentation (Policies) Sheet http://www.abbvie.com/role/BasisOfPresentationPolicies Basis of Presentation (Policies) Policies 23 false false R24.htm 2209201 - Disclosure - Leases (Policies) Sheet http://www.abbvie.com/role/LeasesPolicies Leases (Policies) Policies 24 false false R25.htm 2303301 - Disclosure - Supplemental Financial Information (Tables) Sheet http://www.abbvie.com/role/SupplementalFinancialInformationTables Supplemental Financial Information (Tables) Tables http://www.abbvie.com/role/SupplementalFinancialInformation 25 false false R26.htm 2304301 - Disclosure - Earnings Per Share (Tables) Sheet http://www.abbvie.com/role/EarningsPerShareTables Earnings Per Share (Tables) Tables http://www.abbvie.com/role/EarningsPerShare 26 false false R27.htm 2306301 - Disclosure - Collaboration with Janssen Biotech, Inc. (Tables) Sheet http://www.abbvie.com/role/CollaborationWithJanssenBiotechIncTables Collaboration with Janssen Biotech, Inc. (Tables) Tables http://www.abbvie.com/role/CollaborationWithJanssenBiotechInc 27 false false R28.htm 2307301 - Disclosure - Goodwill and Intangible Assets (Tables) Sheet http://www.abbvie.com/role/GoodwillAndIntangibleAssetsTables Goodwill and Intangible Assets (Tables) Tables http://www.abbvie.com/role/GoodwillAndIntangibleAssets 28 false false R29.htm 2308301 - Disclosure - Restructuring Plans (Tables) Sheet http://www.abbvie.com/role/RestructuringPlansTables Restructuring Plans (Tables) Tables http://www.abbvie.com/role/RestructuringPlans 29 false false R30.htm 2309302 - Disclosure - Leases (Tables) Sheet http://www.abbvie.com/role/LeasesTables Leases (Tables) Tables http://www.abbvie.com/role/Leases 30 false false R31.htm 2310301 - Disclosure - Financial Instruments and Fair Value Measures (Tables) Sheet http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresTables Financial Instruments and Fair Value Measures (Tables) Tables http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasures 31 false false R32.htm 2311301 - Disclosure - Post-Employment Benefits (Tables) Sheet http://www.abbvie.com/role/PostEmploymentBenefitsTables Post-Employment Benefits (Tables) Tables http://www.abbvie.com/role/PostEmploymentBenefits 32 false false R33.htm 2312301 - Disclosure - Equity (Tables) Sheet http://www.abbvie.com/role/EquityTables Equity (Tables) Tables http://www.abbvie.com/role/Equity 33 false false R34.htm 2315301 - Disclosure - Segment Information (Tables) Sheet http://www.abbvie.com/role/SegmentInformationTables Segment Information (Tables) Tables http://www.abbvie.com/role/SegmentInformation 34 false false R35.htm 2401402 - Disclosure - Basis of Presentation (Details) Sheet http://www.abbvie.com/role/BasisOfPresentationDetails Basis of Presentation (Details) Details http://www.abbvie.com/role/BasisOfPresentationPolicies 35 false false R36.htm 2403402 - Disclosure - Supplemental Financial Information (Details) Sheet http://www.abbvie.com/role/SupplementalFinancialInformationDetails Supplemental Financial Information (Details) Details http://www.abbvie.com/role/SupplementalFinancialInformationTables 36 false false R37.htm 2404402 - Disclosure - Earnings Per Share (Details) Sheet http://www.abbvie.com/role/EarningsPerShareDetails Earnings Per Share (Details) Details http://www.abbvie.com/role/EarningsPerShareTables 37 false false R38.htm 2405401 - Disclosure - Licensing, Acquisitions, and Other Arrangements - Proposed Acquisition of Allergan plc (Details) Sheet http://www.abbvie.com/role/LicensingAcquisitionsAndOtherArrangementsProposedAcquisitionOfAllerganPlcDetails Licensing, Acquisitions, and Other Arrangements - Proposed Acquisition of Allergan plc (Details) Details 38 false false R39.htm 2405402 - Disclosure - Licensing, Acquisitions, and Other Arrangements - Other Licensing & Acquisitions Activity (Details) Sheet http://www.abbvie.com/role/LicensingAcquisitionsAndOtherArrangementsOtherLicensingAcquisitionsActivityDetails Licensing, Acquisitions, and Other Arrangements - Other Licensing & Acquisitions Activity (Details) Details 39 false false R40.htm 2406402 - Disclosure - Collaboration with Janssen Biotech, Inc. (Details) Sheet http://www.abbvie.com/role/CollaborationWithJanssenBiotechIncDetails Collaboration with Janssen Biotech, Inc. (Details) Details http://www.abbvie.com/role/CollaborationWithJanssenBiotechIncTables 40 false false R41.htm 2407402 - Disclosure - Goodwill and Intangible Assets - Goodwill (Details) Sheet http://www.abbvie.com/role/GoodwillAndIntangibleAssetsGoodwillDetails Goodwill and Intangible Assets - Goodwill (Details) Details 41 false false R42.htm 2407403 - Disclosure - Goodwill and Intangible Assets - Summary of Intangible Assets, Net (Details) Sheet http://www.abbvie.com/role/GoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsNetDetails Goodwill and Intangible Assets - Summary of Intangible Assets, Net (Details) Details 42 false false R43.htm 2407404 - Disclosure - Goodwill and Intangible Assets - Indefinite-Lived Intangible Assets (Details) Sheet http://www.abbvie.com/role/GoodwillAndIntangibleAssetsIndefiniteLivedIntangibleAssetsDetails Goodwill and Intangible Assets - Indefinite-Lived Intangible Assets (Details) Details 43 false false R44.htm 2407405 - Disclosure - Goodwill and Intangible Assets - Definite-Lived Intangible Assets (Details) Sheet http://www.abbvie.com/role/GoodwillAndIntangibleAssetsDefiniteLivedIntangibleAssetsDetails Goodwill and Intangible Assets - Definite-Lived Intangible Assets (Details) Details 44 false false R45.htm 2408402 - Disclosure - Restructuring Plans (Details) Sheet http://www.abbvie.com/role/RestructuringPlansDetails Restructuring Plans (Details) Details http://www.abbvie.com/role/RestructuringPlansTables 45 false false R46.htm 2409403 - Disclosure - Leases - Balance Sheet Disclosure (Details) Sheet http://www.abbvie.com/role/LeasesBalanceSheetDisclosureDetails Leases - Balance Sheet Disclosure (Details) Details 46 false false R47.htm 2409404 - Disclosure - Leases - Cost (Details) Sheet http://www.abbvie.com/role/LeasesCostDetails Leases - Cost (Details) Details 47 false false R48.htm 2409405 - Disclosure - Leases - Weighted-Average Remaining Lease Term and Discount Rate (Details) Sheet http://www.abbvie.com/role/LeasesWeightedAverageRemainingLeaseTermAndDiscountRateDetails Leases - Weighted-Average Remaining Lease Term and Discount Rate (Details) Details 48 false false R49.htm 2409406 - Disclosure - Leases - Cash Flow Disclosure (Details) Sheet http://www.abbvie.com/role/LeasesCashFlowDisclosureDetails Leases - Cash Flow Disclosure (Details) Details 49 false false R50.htm 2409407 - Disclosure - Leases - Maturities of Lease Liabilities (Details) Sheet http://www.abbvie.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetails Leases - Maturities of Lease Liabilities (Details) Details 50 false false R51.htm 2410402 - Disclosure - Financial Instruments and Fair Value Measures - Financial Instruments (Details) Sheet http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresFinancialInstrumentsDetails Financial Instruments and Fair Value Measures - Financial Instruments (Details) Details 51 false false R52.htm 2410403 - Disclosure - Financial Instruments and Fair Value Measures - Amount Of Gain/(Loss) Recognized For Derivative Instruments (Details) Sheet http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails Financial Instruments and Fair Value Measures - Amount Of Gain/(Loss) Recognized For Derivative Instruments (Details) Details 52 false false R53.htm 2410404 - Disclosure - Financial Instruments and Fair Value Measures - Fair Value Measures (Details) Sheet http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresFairValueMeasuresDetails Financial Instruments and Fair Value Measures - Fair Value Measures (Details) Details 53 false false R54.htm 2410405 - Disclosure - Financial Instruments and Fair Value Measures - Transfers of Assets or Liabilities Between The Fair Value Measurement Levels (Details) Sheet http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresTransfersOfAssetsOrLiabilitiesBetweenFairValueMeasurementLevelsDetails Financial Instruments and Fair Value Measures - Transfers of Assets or Liabilities Between The Fair Value Measurement Levels (Details) Details 54 false false R55.htm 2410406 - Disclosure - Financial Instruments and Fair Value Measures - Bases Used To Measure The Approximate Fair Values Of Financial Instruments (Details) Sheet http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresBasesUsedToMeasureApproximateFairValuesOfFinancialInstrumentsDetails Financial Instruments and Fair Value Measures - Bases Used To Measure The Approximate Fair Values Of Financial Instruments (Details) Details 55 false false R56.htm 2410407 - Disclosure - Financial Instruments and Fair Value Measures - Available-for-sale Securities (Details) Sheet http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresAvailableForSaleSecuritiesDetails Financial Instruments and Fair Value Measures - Available-for-sale Securities (Details) Details 56 false false R57.htm 2410408 - Disclosure - Financial Instruments and Fair Value Measures - Concentrations of Risk (Details) Sheet http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresConcentrationsOfRiskDetails Financial Instruments and Fair Value Measures - Concentrations of Risk (Details) Details 57 false false R58.htm 2410409 - Disclosure - Financial Instruments and Fair Value Measures - Debt and Credit Facilities (Details) Sheet http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresDebtAndCreditFacilitiesDetails Financial Instruments and Fair Value Measures - Debt and Credit Facilities (Details) Details 58 false false R59.htm 2411402 - Disclosure - Post-Employment Benefits (Details) Sheet http://www.abbvie.com/role/PostEmploymentBenefitsDetails Post-Employment Benefits (Details) Details http://www.abbvie.com/role/PostEmploymentBenefitsTables 59 false false R60.htm 2412402 - Disclosure - Equity - Stock-Based Compensation (Details) Sheet http://www.abbvie.com/role/EquityStockBasedCompensationDetails Equity - Stock-Based Compensation (Details) Details 60 false false R61.htm 2412403 - Disclosure - Equity - Stock Options (Details) Sheet http://www.abbvie.com/role/EquityStockOptionsDetails Equity - Stock Options (Details) Details 61 false false R62.htm 2412404 - Disclosure - Equity - RSUs and Performance Shares (Details) Sheet http://www.abbvie.com/role/EquityRsusAndPerformanceSharesDetails Equity - RSUs and Performance Shares (Details) Details 62 false false R63.htm 2412405 - Disclosure - Equity - Cash Dividends (Details) Sheet http://www.abbvie.com/role/EquityCashDividendsDetails Equity - Cash Dividends (Details) Details 63 false false R64.htm 2412406 - Disclosure - Equity - Stock Repurchase Program (Details) Sheet http://www.abbvie.com/role/EquityStockRepurchaseProgramDetails Equity - Stock Repurchase Program (Details) Details 64 false false R65.htm 2412407 - Disclosure - Equity - Accumulated Other Comprehensive Loss (Details) Sheet http://www.abbvie.com/role/EquityAccumulatedOtherComprehensiveLossDetails Equity - Accumulated Other Comprehensive Loss (Details) Details 65 false false R66.htm 2412408 - Disclosure - Equity - Amounts Reclassified Out Of Accumulated Other Comprehensive Income (Details) Sheet http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveIncomeDetails Equity - Amounts Reclassified Out Of Accumulated Other Comprehensive Income (Details) Details 66 false false R67.htm 2413401 - Disclosure - Income Taxes (Details) Sheet http://www.abbvie.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://www.abbvie.com/role/IncomeTaxes 67 false false R68.htm 2414401 - Disclosure - Legal Proceedings and Contingencies (Details) Sheet http://www.abbvie.com/role/LegalProceedingsAndContingenciesDetails Legal Proceedings and Contingencies (Details) Details http://www.abbvie.com/role/LegalProceedingsAndContingencies 68 false false R69.htm 2415402 - Disclosure - Segment Information - Additional Information (Details) Sheet http://www.abbvie.com/role/SegmentInformationAdditionalInformationDetails Segment Information - Additional Information (Details) Details 69 false false R70.htm 2415403 - Disclosure - Segment Information - Disaggregation of Revenue (Details) Sheet http://www.abbvie.com/role/SegmentInformationDisaggregationOfRevenueDetails Segment Information - Disaggregation of Revenue (Details) Details 70 false false R9999.htm Uncategorized Items - abbv-20190630x10q.htm Sheet http://xbrl.sec.gov/role/uncategorizedFacts Uncategorized Items - abbv-20190630x10q.htm Cover 71 false false All Reports Book All Reports abbv-20190630x10q.htm abbv-20190630.xsd abbv-20190630_cal.xml abbv-20190630_def.xml abbv-20190630_lab.xml abbv-20190630_pre.xml abbv-20190630xex102.htm abbv-20190630xex105.htm abbv-20190630xex311.htm abbv-20190630xex312.htm abbv-20190630xex321.htm abbv-20190630xex322.htm abbvieimage1a25.jpg abbvieimage2a12.gif http://fasb.org/srt/2018-01-31 http://xbrl.sec.gov/exch/2018-01-31 http://xbrl.sec.gov/country/2017-01-31 http://xbrl.sec.gov/dei/2019-01-31 http://fasb.org/us-gaap/2018-01-31 http://xbrl.sec.gov/invest/2013-01-31 true true JSON 93 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "abbv-20190630x10q.htm": { "axisCustom": 2, "axisStandard": 34, "contextCount": 460, "dts": { "calculationLink": { "local": [ "abbv-20190630_cal.xml" ] }, "definitionLink": { "local": [ "abbv-20190630_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-eedm-def-2018-01-31.xml", "http://xbrl.fasb.org/srt/2018/elts/srt-eedm1-def-2018-01-31.xml" ] }, "inline": { "local": [ "abbv-20190630x10q.htm" ] }, "labelLink": { "local": [ "abbv-20190630_lab.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-doc-2018-01-31.xml", "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml", "http://xbrl.sec.gov/invest/2013/invest-doc-2013-01-31.xml" ] }, "presentationLink": { "local": [ "abbv-20190630_pre.xml" ] }, "referenceLink": { "remote": [ "http://xbrl.sec.gov/invest/2013/invest-ref-2013-01-31.xml", "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-ref-2018-01-31.xml", "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "abbv-20190630.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2018/elts/srt-types-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2018/elts/us-roles-2018-01-31.xsd", "http://xbrl.fasb.org/srt/2018/elts/srt-roles-2018-01-31.xsd", "http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2018/elts/us-types-2018-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "https://xbrl.sec.gov/exch/2018/exch-2018-01-31.xsd", "http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd", "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2018/elts/us-parts-codification-2018-01-31.xsd" ] } }, "elementCount": 623, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2018-01-31": 39, "http://www.abbvie.com/20190630": 5, "http://xbrl.sec.gov/dei/2019-01-31": 7, "http://xbrl.sec.gov/invest/2013-01-31": 1, "total": 52 }, "keyCustom": 44, "keyStandard": 372, "memberCustom": 45, "memberStandard": 64, "nsprefix": "abbv", "nsuri": "http://www.abbvie.com/20190630", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001000 - Document - Document and Entity Information", "role": "http://www.abbvie.com/role/DocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2103100 - Disclosure - Supplemental Financial Information", "role": "http://www.abbvie.com/role/SupplementalFinancialInformation", "shortName": "Supplemental Financial Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2104100 - Disclosure - Earnings Per Share", "role": "http://www.abbvie.com/role/EarningsPerShare", "shortName": "Earnings Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "abbv:AcquisitionsCollaborationsAndOtherArrangementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2105100 - Disclosure - Licensing, Acquisitions, and Other Arrangements", "role": "http://www.abbvie.com/role/LicensingAcquisitionsAndOtherArrangements", "shortName": "Licensing, Acquisitions, and Other Arrangements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "abbv:AcquisitionsCollaborationsAndOtherArrangementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2106100 - Disclosure - Collaboration with Janssen Biotech, Inc.", "role": "http://www.abbvie.com/role/CollaborationWithJanssenBiotechInc", "shortName": "Collaboration with Janssen Biotech, Inc.", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2107100 - Disclosure - Goodwill and Intangible Assets", "role": "http://www.abbvie.com/role/GoodwillAndIntangibleAssets", "shortName": "Goodwill and Intangible Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2108100 - Disclosure - Restructuring Plans", "role": "http://www.abbvie.com/role/RestructuringPlans", "shortName": "Restructuring Plans", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2109100 - Disclosure - Leases", "role": "http://www.abbvie.com/role/Leases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativesAndFairValueTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2110100 - Disclosure - Financial Instruments and Fair Value Measures", "role": "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasures", "shortName": "Financial Instruments and Fair Value Measures", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativesAndFairValueTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PostemploymentBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2111100 - Disclosure - Post-Employment Benefits", "role": "http://www.abbvie.com/role/PostEmploymentBenefits", "shortName": "Post-Employment Benefits", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PostemploymentBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2112100 - Disclosure - Equity", "role": "http://www.abbvie.com/role/Equity", "shortName": "Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:DisaggregationOfRevenueTableTextBlock", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FD2019Q2QTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001000 - Statement - Condensed Consolidated Statements of Earnings (Unaudited)", "role": "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfEarningsUnaudited", "shortName": "Condensed Consolidated Statements of Earnings (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FD2019Q2QTD", "decimals": "-6", "lang": null, "name": "us-gaap:SellingGeneralAndAdministrativeExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2113100 - Disclosure - Income Taxes", "role": "http://www.abbvie.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LegalMattersAndContingenciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2114100 - Disclosure - Legal Proceedings and Contingencies", "role": "http://www.abbvie.com/role/LegalProceedingsAndContingencies", "shortName": "Legal Proceedings and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LegalMattersAndContingenciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2115100 - Disclosure - Segment Information", "role": "http://www.abbvie.com/role/SegmentInformation", "shortName": "Segment Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2201201 - Disclosure - Basis of Presentation (Policies)", "role": "http://www.abbvie.com/role/BasisOfPresentationPolicies", "shortName": "Basis of Presentation (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeLeasesPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2209201 - Disclosure - Leases (Policies)", "role": "http://www.abbvie.com/role/LeasesPolicies", "shortName": "Leases (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeLeasesPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2303301 - Disclosure - Supplemental Financial Information (Tables)", "role": "http://www.abbvie.com/role/SupplementalFinancialInformationTables", "shortName": "Supplemental Financial Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2304301 - Disclosure - Earnings Per Share (Tables)", "role": "http://www.abbvie.com/role/EarningsPerShareTables", "shortName": "Earnings Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2306301 - Disclosure - Collaboration with Janssen Biotech, Inc. (Tables)", "role": "http://www.abbvie.com/role/CollaborationWithJanssenBiotechIncTables", "shortName": "Collaboration with Janssen Biotech, Inc. (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2307301 - Disclosure - Goodwill and Intangible Assets (Tables)", "role": "http://www.abbvie.com/role/GoodwillAndIntangibleAssetsTables", "shortName": "Goodwill and Intangible Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2308301 - Disclosure - Restructuring Plans (Tables)", "role": "http://www.abbvie.com/role/RestructuringPlansTables", "shortName": "Restructuring Plans (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FD2019Q2QTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002000 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited)", "role": "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited", "shortName": "Condensed Consolidated Statements of Comprehensive Income (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FD2019Q2QTD", "decimals": "-6", "lang": null, "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "abbv:OperatingandFinanceLeaseBalanceSheetDisclosureTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2309302 - Disclosure - Leases (Tables)", "role": "http://www.abbvie.com/role/LeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "abbv:OperatingandFinanceLeaseBalanceSheetDisclosureTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2310301 - Disclosure - Financial Instruments and Fair Value Measures (Tables)", "role": "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresTables", "shortName": "Financial Instruments and Fair Value Measures (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2311301 - Disclosure - Post-Employment Benefits (Tables)", "role": "http://www.abbvie.com/role/PostEmploymentBenefitsTables", "shortName": "Post-Employment Benefits (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2312301 - Disclosure - Equity (Tables)", "role": "http://www.abbvie.com/role/EquityTables", "shortName": "Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2315301 - Disclosure - Segment Information (Tables)", "role": "http://www.abbvie.com/role/SegmentInformationTables", "shortName": "Segment Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FI2019Q2", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:OtherAssetsNoncurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401402 - Disclosure - Basis of Presentation (Details)", "role": "http://www.abbvie.com/role/BasisOfPresentationDetails", "shortName": "Basis of Presentation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "I2019Q1Jan1_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member", "decimals": "-6", "lang": null, "name": "us-gaap:OtherAssetsNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FD2019Q2QTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:InterestExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403402 - Disclosure - Supplemental Financial Information (Details)", "role": "http://www.abbvie.com/role/SupplementalFinancialInformationDetails", "shortName": "Supplemental Financial Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FD2019Q2QTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:InterestExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FD2019Q2QTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2404402 - Disclosure - Earnings Per Share (Details)", "role": "http://www.abbvie.com/role/EarningsPerShareDetails", "shortName": "Earnings Per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FD2019Q2QTD", "decimals": "-6", "lang": null, "name": "us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "I2019Q2June24", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:SharePrice", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405401 - Disclosure - Licensing, Acquisitions, and Other Arrangements - Proposed Acquisition of Allergan plc (Details)", "role": "http://www.abbvie.com/role/LicensingAcquisitionsAndOtherArrangementsProposedAcquisitionOfAllerganPlcDetails", "shortName": "Licensing, Acquisitions, and Other Arrangements - Proposed Acquisition of Allergan plc (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "I2019Q2June24", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:SharePrice", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FD2019Q2YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:PaymentsToAcquireOtherInvestments", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405402 - Disclosure - Licensing, Acquisitions, and Other Arrangements - Other Licensing & Acquisitions Activity (Details)", "role": "http://www.abbvie.com/role/LicensingAcquisitionsAndOtherArrangementsOtherLicensingAcquisitionsActivityDetails", "shortName": "Licensing, Acquisitions, and Other Arrangements - Other Licensing & Acquisitions Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "D2018Q2Jun01-Jun30_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember", "decimals": "-6", "lang": null, "name": "abbv:AdditionalContributionToCollaboration", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "1002501 - Statement - Condensed Consolidated Statements of Comprehensive Income (Parenthetical) (Unaudited)", "role": "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeParentheticalUnaudited", "shortName": "Condensed Consolidated Statements of Comprehensive Income (Parenthetical) (Unaudited)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R40": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FI2019Q2", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406402 - Disclosure - Collaboration with Janssen Biotech, Inc. (Details)", "role": "http://www.abbvie.com/role/CollaborationWithJanssenBiotechIncDetails", "shortName": "Collaboration with Janssen Biotech, Inc. (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FD2019Q2YTD_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember", "decimals": "2", "lang": null, "name": "abbv:CollaborativeArrangementsPercentageOfShareOfDevelopmentCosts", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FI2018Q4", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407402 - Disclosure - Goodwill and Intangible Assets - Goodwill (Details)", "role": "http://www.abbvie.com/role/GoodwillAndIntangibleAssetsGoodwillDetails", "shortName": "Goodwill and Intangible Assets - Goodwill (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FD2019Q2YTD", "decimals": "-6", "lang": null, "name": "us-gaap:GoodwillTranslationAndPurchaseAccountingAdjustments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FI2019Q2", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407403 - Disclosure - Goodwill and Intangible Assets - Summary of Intangible Assets, Net (Details)", "role": "http://www.abbvie.com/role/GoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsNetDetails", "shortName": "Goodwill and Intangible Assets - Summary of Intangible Assets, Net (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FI2019Q2", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FD2019Q2YTD", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407404 - Disclosure - Goodwill and Intangible Assets - Indefinite-Lived Intangible Assets (Details)", "role": "http://www.abbvie.com/role/GoodwillAndIntangibleAssetsIndefiniteLivedIntangibleAssetsDetails", "shortName": "Goodwill and Intangible Assets - Indefinite-Lived Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FD2019Q2YTD", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FD2019Q2QTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407405 - Disclosure - Goodwill and Intangible Assets - Definite-Lived Intangible Assets (Details)", "role": "http://www.abbvie.com/role/GoodwillAndIntangibleAssetsDefiniteLivedIntangibleAssetsDetails", "shortName": "Goodwill and Intangible Assets - Definite-Lived Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FD2019Q2QTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FD2019Q2QTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:RestructuringCharges", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408402 - Disclosure - Restructuring Plans (Details)", "role": "http://www.abbvie.com/role/RestructuringPlansDetails", "shortName": "Restructuring Plans (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FD2019Q2QTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:RestructuringCharges", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "abbv:OperatingandFinanceLeaseBalanceSheetDisclosureTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FI2019Q2", "decimals": "-6", "first": true, "lang": null, "name": "abbv:LeaseRightofUseAsset", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409403 - Disclosure - Leases - Balance Sheet Disclosure (Details)", "role": "http://www.abbvie.com/role/LeasesBalanceSheetDisclosureDetails", "shortName": "Leases - Balance Sheet Disclosure (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "abbv:OperatingandFinanceLeaseBalanceSheetDisclosureTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FI2019Q2", "decimals": "-6", "first": true, "lang": null, "name": "abbv:LeaseRightofUseAsset", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FD2019Q2QTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409404 - Disclosure - Leases - Cost (Details)", "role": "http://www.abbvie.com/role/LeasesCostDetails", "shortName": "Leases - Cost (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FD2019Q2QTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "abbv:OperatingandFinanceLeaseWeightedAverageRemainingLeaseTermandDiscountRateTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FI2019Q2", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409405 - Disclosure - Leases - Weighted-Average Remaining Lease Term and Discount Rate (Details)", "role": "http://www.abbvie.com/role/LeasesWeightedAverageRemainingLeaseTermAndDiscountRateDetails", "shortName": "Leases - Weighted-Average Remaining Lease Term and Discount Rate (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "abbv:OperatingandFinanceLeaseWeightedAverageRemainingLeaseTermandDiscountRateTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FI2019Q2", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "abbv:OperatingandFinanceLeaseCashFlowDisclosureTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FD2019Q2YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409406 - Disclosure - Leases - Cash Flow Disclosure (Details)", "role": "http://www.abbvie.com/role/LeasesCashFlowDisclosureDetails", "shortName": "Leases - Cash Flow Disclosure (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "abbv:OperatingandFinanceLeaseCashFlowDisclosureTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FD2019Q2YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FI2019Q2", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003000 - Statement - Condensed Consolidated Balance Sheets", "role": "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets", "shortName": "Condensed Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FI2019Q2", "decimals": "-6", "lang": null, "name": "us-gaap:ShortTermInvestments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FI2019Q2", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409407 - Disclosure - Leases - Maturities of Lease Liabilities (Details)", "role": "http://www.abbvie.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetails", "shortName": "Leases - Maturities of Lease Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FI2019Q2", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FI2019Q2", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410402 - Disclosure - Financial Instruments and Fair Value Measures - Financial Instruments (Details)", "role": "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresFinancialInstrumentsDetails", "shortName": "Financial Instruments and Fair Value Measures - Financial Instruments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FI2019Q2_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember", "decimals": "INF", "lang": null, "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FI2019Q2", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410403 - Disclosure - Financial Instruments and Fair Value Measures - Amount Of Gain/(Loss) Recognized For Derivative Instruments (Details)", "role": "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails", "shortName": "Financial Instruments and Fair Value Measures - Amount Of Gain/(Loss) Recognized For Derivative Instruments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FD2019Q2QTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_FairValueHedgingMember_us-gaap_IncomeStatementLocationAxis_us-gaap_InterestExpenseMember", "decimals": "-6", "lang": null, "name": "us-gaap:IncreaseDecreaseInFairValueOfHedgedItemInInterestRateFairValueHedge1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FI2019Q2", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410404 - Disclosure - Financial Instruments and Fair Value Measures - Fair Value Measures (Details)", "role": "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresFairValueMeasuresDetails", "shortName": "Financial Instruments and Fair Value Measures - Fair Value Measures (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FD2019Q2YTD_abbv_ContingentConsiderationChangeByTypeAxis_abbv_ChangeInAssumedDiscountRateMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_ChangeDuringPeriodFairValueDisclosureMember", "decimals": "INF", "lang": null, "name": "abbv:FairValueInputsDiscountRateChange", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FI2019Q2", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410405 - Disclosure - Financial Instruments and Fair Value Measures - Transfers of Assets or Liabilities Between The Fair Value Measurement Levels (Details)", "role": "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresTransfersOfAssetsOrLiabilitiesBetweenFairValueMeasurementLevelsDetails", "shortName": "Financial Instruments and Fair Value Measures - Transfers of Assets or Liabilities Between The Fair Value Measurement Levels (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FI2019Q2", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FI2019Q2", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410406 - Disclosure - Financial Instruments and Fair Value Measures - Bases Used To Measure The Approximate Fair Values Of Financial Instruments (Details)", "role": "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresBasesUsedToMeasureApproximateFairValuesOfFinancialInstrumentsDetails", "shortName": "Financial Instruments and Fair Value Measures - Bases Used To Measure The Approximate Fair Values Of Financial Instruments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FI2019Q2", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FI2019Q2", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410407 - Disclosure - Financial Instruments and Fair Value Measures - Available-for-sale Securities (Details)", "role": "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresAvailableForSaleSecuritiesDetails", "shortName": "Financial Instruments and Fair Value Measures - Available-for-sale Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FI2019Q2", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FD2019Q2YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember", "decimals": "INF", "first": true, "lang": null, "name": "abbv:NumberOfPrincipalUSCustomers", "reportCount": 1, "unique": true, "unitRef": "wholesaler", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410408 - Disclosure - Financial Instruments and Fair Value Measures - Concentrations of Risk (Details)", "role": "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresConcentrationsOfRiskDetails", "shortName": "Financial Instruments and Fair Value Measures - Concentrations of Risk (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FD2019Q2YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember", "decimals": "INF", "first": true, "lang": null, "name": "abbv:NumberOfPrincipalUSCustomers", "reportCount": 1, "unique": true, "unitRef": "wholesaler", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FI2019Q2", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:ShortTermBorrowings", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410409 - Disclosure - Financial Instruments and Fair Value Measures - Debt and Credit Facilities (Details)", "role": "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresDebtAndCreditFacilitiesDetails", "shortName": "Financial Instruments and Fair Value Measures - Debt and Credit Facilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FI2019Q2_us-gaap_ShortTermDebtTypeAxis_us-gaap_CommercialPaperMember", "decimals": "INF", "lang": null, "name": "us-gaap:ShortTermBorrowings", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FD2019Q2QTD_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:DefinedBenefitPlanServiceCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411402 - Disclosure - Post-Employment Benefits (Details)", "role": "http://www.abbvie.com/role/PostEmploymentBenefitsDetails", "shortName": "Post-Employment Benefits (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FD2019Q2QTD_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:DefinedBenefitPlanServiceCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "1003501 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "role": "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R60": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FD2019Q2QTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412402 - Disclosure - Equity - Stock-Based Compensation (Details)", "role": "http://www.abbvie.com/role/EquityStockBasedCompensationDetails", "shortName": "Equity - Stock-Based Compensation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FD2019Q2QTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412403 - Disclosure - Equity - Stock Options (Details)", "role": "http://www.abbvie.com/role/EquityStockOptionsDetails", "shortName": "Equity - Stock Options (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FD2019Q2YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FD2019Q2YTD_us-gaap_AwardTypeAxis_abbv_RestrictedStockUnitsAndPerformanceSharesMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412404 - Disclosure - Equity - RSUs and Performance Shares (Details)", "role": "http://www.abbvie.com/role/EquityRsusAndPerformanceSharesDetails", "shortName": "Equity - RSUs and Performance Shares (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FD2019Q2YTD_us-gaap_AwardTypeAxis_abbv_RestrictedStockUnitsAndPerformanceSharesMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfDividendsPayableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "D2019Q2Jun20", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:CommonStockDividendsPerShareDeclared", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412405 - Disclosure - Equity - Cash Dividends (Details)", "role": "http://www.abbvie.com/role/EquityCashDividendsDetails", "shortName": "Equity - Cash Dividends (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfDividendsPayableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "D2019Q2Jun20", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:CommonStockDividendsPerShareDeclared", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FD2019Q2QTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:TreasuryStockValueAcquiredCostMethod", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412406 - Disclosure - Equity - Stock Repurchase Program (Details)", "role": "http://www.abbvie.com/role/EquityStockRepurchaseProgramDetails", "shortName": "Equity - Stock Repurchase Program (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FD2019Q2YTD_us-gaap_ShareRepurchaseProgramAxis_abbv_December2018StockRepurchaseAuthorizationMember", "decimals": "-6", "lang": null, "name": "us-gaap:TreasuryStockSharesAcquired", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FI2019Q1", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412407 - Disclosure - Equity - Accumulated Other Comprehensive Loss (Details)", "role": "http://www.abbvie.com/role/EquityAccumulatedOtherComprehensiveLossDetails", "shortName": "Equity - Accumulated Other Comprehensive Loss (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FD2019Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember", "decimals": "-6", "lang": null, "name": "us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FD2019Q2QTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412408 - Disclosure - Equity - Amounts Reclassified Out Of Accumulated Other Comprehensive Income (Details)", "role": "http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveIncomeDetails", "shortName": "Equity - Amounts Reclassified Out Of Accumulated Other Comprehensive Income (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember", "decimals": "-6", "lang": null, "name": "us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FD2019Q2QTD", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413401 - Disclosure - Income Taxes (Details)", "role": "http://www.abbvie.com/role/IncomeTaxesDetails", "shortName": "Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FD2019Q2QTD", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FI2019Q2", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:LossContingencyAccrualAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414401 - Disclosure - Legal Proceedings and Contingencies (Details)", "role": "http://www.abbvie.com/role/LegalProceedingsAndContingenciesDetails", "shortName": "Legal Proceedings and Contingencies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FI2018Q4", "decimals": "-6", "lang": null, "name": "us-gaap:LossContingencyAccrualAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "us-gaap:DisaggregationOfRevenueTableTextBlock", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FD2019Q2YTD", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415402 - Disclosure - Segment Information - Additional Information (Details)", "role": "http://www.abbvie.com/role/SegmentInformationAdditionalInformationDetails", "shortName": "Segment Information - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "us-gaap:DisaggregationOfRevenueTableTextBlock", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FD2019Q2YTD", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FI2017Q4", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004000 - Statement - Condensed Consolidated Statements of Equity (Unaudited)", "role": "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfEquityUnaudited", "shortName": "Condensed Consolidated Statements of Equity (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember", "decimals": "-6", "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:DisaggregationOfRevenueTableTextBlock", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FD2019Q2QTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415403 - Disclosure - Segment Information - Disaggregation of Revenue (Details)", "role": "http://www.abbvie.com/role/SegmentInformationDisaggregationOfRevenueDetails", "shortName": "Segment Information - Disaggregation of Revenue (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:DisaggregationOfRevenueTableTextBlock", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FD2019Q2QTD_srt_ProductOrServiceAxis_abbv_OtherProductsMember", "decimals": "-6", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FD2019Q2YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005000 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "role": "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FD2019Q2YTD", "decimals": "-6", "lang": null, "name": "us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101100 - Disclosure - Basis of Presentation", "role": "http://www.abbvie.com/role/BasisOfPresentation", "shortName": "Basis of Presentation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "FD2019Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9999": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "abbv-20190630x10q.htm", "contextRef": "I2018Q1Jan1", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "", "isDefault": "false", "longName": "Uncategorized Items - abbv-20190630x10q.htm", "role": "http://xbrl.sec.gov/role/uncategorizedFacts", "shortName": "Uncategorized Items - abbv-20190630x10q.htm", "subGroupType": "", "uniqueAnchor": null } }, "segmentCount": 111, "tag": { "abbv_AccumulatedNetGainLossFromNetInvestmentHedgesAttributableToParentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Accumulated Net Gain (Loss) From Net Investment Hedges Attributable To Parent [Member]", "label": "Accumulated Net Gain (Loss) From Net Investment Hedges Attributable To Parent [Member]", "terseLabel": "Net investment hedging activities" } } }, "localname": "AccumulatedNetGainLossFromNetInvestmentHedgesAttributableToParentMember", "nsuri": "http://www.abbvie.com/20190630", "presentation": [ "http://www.abbvie.com/role/EquityAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "domainItemType" }, "abbv_AcquisitionsCollaborationsAndOtherArrangementsDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "", "label": "Licensing, Acquisitions, and Other Arrangements" } } }, "localname": "AcquisitionsCollaborationsAndOtherArrangementsDisclosureAbstract", "nsuri": "http://www.abbvie.com/20190630", "xbrltype": "stringItemType" }, "abbv_AcquisitionsCollaborationsAndOtherArrangementsDisclosureTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for acquisitions, collaborations and other arrangements of the entity.", "label": "Acquisitions Collaborations and Other Arrangements Disclosure [Text Block]", "terseLabel": "Licensing, Acquisitions, and Other Arrangements" } } }, "localname": "AcquisitionsCollaborationsAndOtherArrangementsDisclosureTextBlock", "nsuri": "http://www.abbvie.com/20190630", "presentation": [ "http://www.abbvie.com/role/LicensingAcquisitionsAndOtherArrangements" ], "xbrltype": "textBlockItemType" }, "abbv_AdditionalContributionToCollaboration": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the additional contribution amount to a collaboration.", "label": "Additional Contribution To Collaboration", "terseLabel": "Additional contribution to collaboration" } } }, "localname": "AdditionalContributionToCollaboration", "nsuri": "http://www.abbvie.com/20190630", "presentation": [ "http://www.abbvie.com/role/LicensingAcquisitionsAndOtherArrangementsOtherLicensingAcquisitionsActivityDetails" ], "xbrltype": "monetaryItemType" }, "abbv_AdditionalContributionToCollaborationByPartner": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the additional contribution amount to a collaboration by partner.", "label": "Additional Contribution To Collaboration By Partner", "terseLabel": "Additional contribution to collaboration by partner" } } }, "localname": "AdditionalContributionToCollaborationByPartner", "nsuri": "http://www.abbvie.com/20190630", "presentation": [ "http://www.abbvie.com/role/LicensingAcquisitionsAndOtherArrangementsOtherLicensingAcquisitionsActivityDetails" ], "xbrltype": "monetaryItemType" }, "abbv_AllerganplcMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the information pertaining to Allergan plc.", "label": "Allergan plc [Member]", "terseLabel": "Allergan plc" } } }, "localname": "AllerganplcMember", "nsuri": "http://www.abbvie.com/20190630", "presentation": [ "http://www.abbvie.com/role/LicensingAcquisitionsAndOtherArrangementsProposedAcquisitionOfAllerganPlcDetails" ], "xbrltype": "domainItemType" }, "abbv_AndroGelAntitrustLitigationMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents information pertaining to AndroGel Antitrust Litigation.", "label": "Andro Gel Antitrust Litigation [Member]", "terseLabel": "AndroGel Antitrust Litigation" } } }, "localname": "AndroGelAntitrustLitigationMember", "nsuri": "http://www.abbvie.com/20190630", "presentation": [ "http://www.abbvie.com/role/LegalProceedingsAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "abbv_AndroGelMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents information pertaining to AndroGel, a product of the entity.", "label": "Andro Gel [Member]", "terseLabel": "AndroGel" } } }, "localname": "AndroGelMember", "nsuri": "http://www.abbvie.com/20190630", "presentation": [ "http://www.abbvie.com/role/SegmentInformationDisaggregationOfRevenueDetails" ], "xbrltype": "domainItemType" }, "abbv_BusinessCombinationConsiderationTransferredNumberOfSharesIssuedPerOneShareOfAcquiredEntity": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the number of shares issued by the acquiring entity per one share of acquired entity.", "label": "Business Combination Consideration Transferred Number Of Shares Issued Per One Share Of Acquired Entity", "terseLabel": "Shares of AbbVie stock received by Allergan shareholders" } } }, "localname": "BusinessCombinationConsiderationTransferredNumberOfSharesIssuedPerOneShareOfAcquiredEntity", "nsuri": "http://www.abbvie.com/20190630", "presentation": [ "http://www.abbvie.com/role/LicensingAcquisitionsAndOtherArrangementsProposedAcquisitionOfAllerganPlcDetails" ], "xbrltype": "sharesItemType" }, "abbv_BusinessCombinationContingentConsiderationArrangementsPotentialChangeinAmountofContingentConsiderationLiability": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Business Combination, Contingent Consideration Arrangements, Potential Change in Amount of Contingent Consideration, Liability", "label": "Business Combination, Contingent Consideration Arrangements, Potential Change in Amount of Contingent Consideration, Liability", "terseLabel": "Contingent consideration liability change" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsPotentialChangeinAmountofContingentConsiderationLiability", "nsuri": "http://www.abbvie.com/20190630", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresFairValueMeasuresDetails" ], "xbrltype": "monetaryItemType" }, "abbv_CalicoLifeSciencesLlcMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents information pertaining to transactions with Calico Life Sciences LLC.", "label": "Calico Life Sciences Llc [Member]", "terseLabel": "Calico Life Sciences Llc" } } }, "localname": "CalicoLifeSciencesLlcMember", "nsuri": "http://www.abbvie.com/20190630", "presentation": [ "http://www.abbvie.com/role/LicensingAcquisitionsAndOtherArrangementsOtherLicensingAcquisitionsActivityDetails" ], "xbrltype": "domainItemType" }, "abbv_ChangeInAssumedDiscountRateMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Change In Assumed Discount Rate [Member]", "label": "Change In Assumed Discount Rate [Member]", "terseLabel": "Change in assumed discount rate" } } }, "localname": "ChangeInAssumedDiscountRateMember", "nsuri": "http://www.abbvie.com/20190630", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresFairValueMeasuresDetails" ], "xbrltype": "domainItemType" }, "abbv_ChangeInAssumedProbabilityRateMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Change In Assumed Probability Rate [Member]", "label": "Change In Assumed Probability Rate [Member]", "terseLabel": "Change in assumed probability rate" } } }, "localname": "ChangeInAssumedProbabilityRateMember", "nsuri": "http://www.abbvie.com/20190630", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresFairValueMeasuresDetails" ], "xbrltype": "domainItemType" }, "abbv_CollaborationsAndLicenseAgreementsDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "No definition available.", "label": "Collaboration with Janssen Biotech, Inc." } } }, "localname": "CollaborationsAndLicenseAgreementsDisclosureAbstract", "nsuri": "http://www.abbvie.com/20190630", "xbrltype": "stringItemType" }, "abbv_CollaborativeArrangementMilestoneMethodPaymentsReceivable": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The maximum milestone payments that may be received by the entity based on the achievement of specified events under a collaborative arrangement.", "label": "Collaborative Arrangement Milestone Method Payments Receivable", "terseLabel": "Milestone payments" } } }, "localname": "CollaborativeArrangementMilestoneMethodPaymentsReceivable", "nsuri": "http://www.abbvie.com/20190630", "presentation": [ "http://www.abbvie.com/role/CollaborationWithJanssenBiotechIncDetails" ], "xbrltype": "monetaryItemType" }, "abbv_CollaborativeArrangementsPaymentToOtherPartyAsShareOfProfitsBeforeIncomeTaxes": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Represents the amount paid or to be paid to other party as profit sharing in the contract which is recorded as expense for the company.", "label": "Collaborative Arrangements Payment To Other Party As Share Of Profits Before Income Taxes", "terseLabel": "United States - Janssen's share of profits (included in cost of products sold)" } } }, "localname": "CollaborativeArrangementsPaymentToOtherPartyAsShareOfProfitsBeforeIncomeTaxes", "nsuri": "http://www.abbvie.com/20190630", "presentation": [ "http://www.abbvie.com/role/CollaborationWithJanssenBiotechIncDetails" ], "xbrltype": "monetaryItemType" }, "abbv_CollaborativeArrangementsPercentageOfShareOfDevelopmentCosts": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the percentage of share in collaboration development costs responsible by the entity under cost sharing arrangement.", "label": "Collaborative Arrangements Percentage Of Share Of Development Costs", "terseLabel": "Share of collaboration development costs responsible by the entity (as a percent)" } } }, "localname": "CollaborativeArrangementsPercentageOfShareOfDevelopmentCosts", "nsuri": "http://www.abbvie.com/20190630", "presentation": [ "http://www.abbvie.com/role/CollaborationWithJanssenBiotechIncDetails" ], "xbrltype": "percentItemType" }, "abbv_CollaborativeArrangementsPercentageOfShareOfDevelopmentCostsResponsibleByThirdParty": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the percentage of share in collaboration development costs responsible by Janssen under cost sharing arrangement.", "label": "Collaborative Arrangements Percentage Of Share Of Development Costs Responsible By Third Party", "terseLabel": "Share of collaboration development costs responsible by Janssen (as a percent)" } } }, "localname": "CollaborativeArrangementsPercentageOfShareOfDevelopmentCostsResponsibleByThirdParty", "nsuri": "http://www.abbvie.com/20190630", "presentation": [ "http://www.abbvie.com/role/CollaborationWithJanssenBiotechIncDetails" ], "xbrltype": "percentItemType" }, "abbv_ContingentConsiderationChangeByTypeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Contingent Consideration Change, By Type [Axis]", "label": "Contingent Consideration Change, By Type [Axis]", "terseLabel": "Contingent Consideration Change, By Type [Axis]" } } }, "localname": "ContingentConsiderationChangeByTypeAxis", "nsuri": "http://www.abbvie.com/20190630", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresFairValueMeasuresDetails" ], "xbrltype": "stringItemType" }, "abbv_ContingentConsiderationChangeByTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Domain] for Contingent Consideration Change, By Type [Axis]", "label": "Contingent Consideration Change, By Type [Domain]", "terseLabel": "Contingent Consideration Change, By Type [Domain]" } } }, "localname": "ContingentConsiderationChangeByTypeDomain", "nsuri": "http://www.abbvie.com/20190630", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresFairValueMeasuresDetails" ], "xbrltype": "domainItemType" }, "abbv_CostSharingExpenses": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Represents cost sharing expenses.", "label": "Cost Sharing Expenses", "terseLabel": "Global - AbbVie's share of other costs (included in respective line items)" } } }, "localname": "CostSharingExpenses", "nsuri": "http://www.abbvie.com/20190630", "presentation": [ "http://www.abbvie.com/role/CollaborationWithJanssenBiotechIncDetails" ], "xbrltype": "monetaryItemType" }, "abbv_CreonMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents information pertaining to Creon, a product of the entity.", "label": "Creon [Member]", "terseLabel": "Creon" } } }, "localname": "CreonMember", "nsuri": "http://www.abbvie.com/20190630", "presentation": [ "http://www.abbvie.com/role/SegmentInformationDisaggregationOfRevenueDetails" ], "xbrltype": "domainItemType" }, "abbv_December2018StockRepurchaseAuthorizationMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "December 2018 Stock Repurchase Authorization", "label": "December 2018 Stock Repurchase Authorization [Member]", "terseLabel": "December 2018 Stock Repurchase Authorization" } } }, "localname": "December2018StockRepurchaseAuthorizationMember", "nsuri": "http://www.abbvie.com/20190630", "presentation": [ "http://www.abbvie.com/role/EquityStockRepurchaseProgramDetails" ], "xbrltype": "domainItemType" }, "abbv_DefinedBenefitPlanAmortizationOfActuarialGainLossPriorServiceCostCredit": { "auth_ref": [], "calculation": { "http://www.abbvie.com/role/PostEmploymentBenefitsDetails": { "order": 4.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount of amortization of actuarial losses and prior service costs included in the calculation of net periodic pension benefit cost.", "label": "Defined Benefit Plan, Amortization Of Actuarial Gain (Loss), Prior Service Cost (Credit)", "negatedLabel": "Amortization of actuarial losses and prior service cost (credit)" } } }, "localname": "DefinedBenefitPlanAmortizationOfActuarialGainLossPriorServiceCostCredit", "nsuri": "http://www.abbvie.com/20190630", "presentation": [ "http://www.abbvie.com/role/PostEmploymentBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "abbv_DepakoteMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents information concerning Depakote-related claims.", "label": "Depakote [Member]", "terseLabel": "Depakote" } } }, "localname": "DepakoteMember", "nsuri": "http://www.abbvie.com/20190630", "presentation": [ "http://www.abbvie.com/role/LegalProceedingsAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "abbv_DisgorgementRemedyMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disgorgement remedy", "label": "DisgorgementRemedy [Member]", "terseLabel": "Disgorgement remedy" } } }, "localname": "DisgorgementRemedyMember", "nsuri": "http://www.abbvie.com/20190630", "presentation": [ "http://www.abbvie.com/role/LegalProceedingsAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "abbv_DuodopaMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents information pertaining to Duodopa, a product of the entity.", "label": "Duodopa [Member]", "terseLabel": "Duodopa" } } }, "localname": "DuodopaMember", "nsuri": "http://www.abbvie.com/20190630", "presentation": [ "http://www.abbvie.com/role/SegmentInformationDisaggregationOfRevenueDetails" ], "xbrltype": "domainItemType" }, "abbv_ElliottAssociatesL.P.Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents information pertaining to Elliot Associates, LP.", "label": "Elliott Associates, L.P. [Member]", "terseLabel": "Elliott Associates, L.P." } } }, "localname": "ElliottAssociatesL.P.Member", "nsuri": "http://www.abbvie.com/20190630", "presentation": [ "http://www.abbvie.com/role/LegalProceedingsAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "abbv_FairValueInputsAssumedProbabilityRateChange": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fair Value Inputs, Assumed Probability Rate Change", "label": "Fair Value Inputs, Assumed Probability Rate Change", "terseLabel": "Assumed probability rate change" } } }, "localname": "FairValueInputsAssumedProbabilityRateChange", "nsuri": "http://www.abbvie.com/20190630", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresFairValueMeasuresDetails" ], "xbrltype": "percentItemType" }, "abbv_FairValueInputsDiscountRateChange": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fair Value Inputs, Assumed Discount Rate Change", "label": "Fair Value Inputs, Discount Rate Change", "terseLabel": "Discount rate change" } } }, "localname": "FairValueInputsDiscountRateChange", "nsuri": "http://www.abbvie.com/20190630", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresFairValueMeasuresDetails" ], "xbrltype": "percentItemType" }, "abbv_February2017StockRepurchaseProgramMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "February 2017 Stock Repurchase Program", "label": "February 2017 Stock Repurchase Program [Member]", "terseLabel": "February 2017 Stock Repurchase Program" } } }, "localname": "February2017StockRepurchaseProgramMember", "nsuri": "http://www.abbvie.com/20190630", "presentation": [ "http://www.abbvie.com/role/EquityStockRepurchaseProgramDetails" ], "xbrltype": "domainItemType" }, "abbv_HCVMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents information pertaining to HCV, a key product portfolio of the entity.", "label": "HCV [Member]", "terseLabel": "HCV" } } }, "localname": "HCVMember", "nsuri": "http://www.abbvie.com/20190630", "presentation": [ "http://www.abbvie.com/role/SegmentInformationDisaggregationOfRevenueDetails" ], "xbrltype": "domainItemType" }, "abbv_HUMIRAMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents information pertaining to HUMIRA, a product of the entity.", "label": "H U M I R A [Member]", "terseLabel": "HUMIRA" } } }, "localname": "HUMIRAMember", "nsuri": "http://www.abbvie.com/20190630", "presentation": [ "http://www.abbvie.com/role/SegmentInformationDisaggregationOfRevenueDetails" ], "xbrltype": "domainItemType" }, "abbv_HematologicOncologyMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents information pertaining to Hematologic Oncology, a key product portfolio of the entity.", "label": "Hematologic Oncology [Member]", "terseLabel": "Hematologic Oncology" } } }, "localname": "HematologicOncologyMember", "nsuri": "http://www.abbvie.com/20190630", "presentation": [ "http://www.abbvie.com/role/SegmentInformationDisaggregationOfRevenueDetails" ], "xbrltype": "domainItemType" }, "abbv_ImbruvicaMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents information pertaining to Imbruvica, a product of the entity.", "label": "Imbruvica [Member]", "terseLabel": "IMBRUVICA" } } }, "localname": "ImbruvicaMember", "nsuri": "http://www.abbvie.com/20190630", "presentation": [ "http://www.abbvie.com/role/SegmentInformationDisaggregationOfRevenueDetails" ], "xbrltype": "domainItemType" }, "abbv_ImmunologyMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents information pertaining to Immunology, a key product portfolio of the entity.", "label": "Immunology [Member]", "terseLabel": "Immunology" } } }, "localname": "ImmunologyMember", "nsuri": "http://www.abbvie.com/20190630", "presentation": [ "http://www.abbvie.com/role/SegmentInformationDisaggregationOfRevenueDetails" ], "xbrltype": "domainItemType" }, "abbv_JanssenBiotechIncMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the information pertains to the entity Janssen Biotech Inc.", "label": "Janssen Biotech Inc [Member]", "terseLabel": "Janssen Biotech Inc" } } }, "localname": "JanssenBiotechIncMember", "nsuri": "http://www.abbvie.com/20190630", "presentation": [ "http://www.abbvie.com/role/CollaborationWithJanssenBiotechIncDetails" ], "xbrltype": "domainItemType" }, "abbv_July2019364DayTermLoanTrancheMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "July 2019 364-Day Term Loan Tranche", "label": "July 2019 364-Day Term Loan Tranche [Member]", "terseLabel": "July 2019 364-day term loan tranche" } } }, "localname": "July2019364DayTermLoanTrancheMember", "nsuri": "http://www.abbvie.com/20190630", "presentation": [ "http://www.abbvie.com/role/LicensingAcquisitionsAndOtherArrangementsProposedAcquisitionOfAllerganPlcDetails" ], "xbrltype": "domainItemType" }, "abbv_July2019FiveYearTermLoanTrancheMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "July 2019 Five-Year Term Loan Tranche", "label": "July 2019 Five-Year Term Loan Tranche [Member]", "terseLabel": "July 2019 five-year term loan tranche" } } }, "localname": "July2019FiveYearTermLoanTrancheMember", "nsuri": "http://www.abbvie.com/20190630", "presentation": [ "http://www.abbvie.com/role/LicensingAcquisitionsAndOtherArrangementsProposedAcquisitionOfAllerganPlcDetails" ], "xbrltype": "domainItemType" }, "abbv_July2019TermLoanCreditAgreementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "July 2019 Term Loan Credit Agreement", "label": "July 2019 Term Loan Credit Agreement [Member]", "terseLabel": "July 2019 term loan agreement" } } }, "localname": "July2019TermLoanCreditAgreementMember", "nsuri": "http://www.abbvie.com/20190630", "presentation": [ "http://www.abbvie.com/role/LicensingAcquisitionsAndOtherArrangementsProposedAcquisitionOfAllerganPlcDetails" ], "xbrltype": "domainItemType" }, "abbv_July2019ThreeYearTermLoanTrancheMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "July 2019 Three-Year Term Loan Tranche", "label": "July 2019 Three-Year Term Loan Tranche [Member]", "terseLabel": "July 2019 three-year term loan tranche" } } }, "localname": "July2019ThreeYearTermLoanTrancheMember", "nsuri": "http://www.abbvie.com/20190630", "presentation": [ "http://www.abbvie.com/role/LicensingAcquisitionsAndOtherArrangementsProposedAcquisitionOfAllerganPlcDetails" ], "xbrltype": "domainItemType" }, "abbv_June2019BridgeCreditFacilityMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "June 2019 Bridge Credit Facility", "label": "June 2019 Bridge Credit Facility [Member]", "terseLabel": "June 2019 bridge credit agreement" } } }, "localname": "June2019BridgeCreditFacilityMember", "nsuri": "http://www.abbvie.com/20190630", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresDebtAndCreditFacilitiesDetails", "http://www.abbvie.com/role/LicensingAcquisitionsAndOtherArrangementsProposedAcquisitionOfAllerganPlcDetails" ], "xbrltype": "domainItemType" }, "abbv_KaletraMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents information pertaining to Kaletra, a product of the entity.", "label": "Kaletra [Member]", "terseLabel": "Kaletra" } } }, "localname": "KaletraMember", "nsuri": "http://www.abbvie.com/20190630", "presentation": [ "http://www.abbvie.com/role/SegmentInformationDisaggregationOfRevenueDetails" ], "xbrltype": "domainItemType" }, "abbv_KeyProductPortfolioAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information concerning the company's portfolios of key products.", "label": "Key Product Portfolio [Axis]", "terseLabel": "Key Product Portfolio [Axis]" } } }, "localname": "KeyProductPortfolioAxis", "nsuri": "http://www.abbvie.com/20190630", "presentation": [ "http://www.abbvie.com/role/SegmentInformationDisaggregationOfRevenueDetails" ], "xbrltype": "stringItemType" }, "abbv_KeyProductPortfolioDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Domain] for Information concerning the company's portfolios of key products.", "label": "Key Product Portfolio [Domain]", "terseLabel": "Key Product Portfolio [Domain]" } } }, "localname": "KeyProductPortfolioDomain", "nsuri": "http://www.abbvie.com/20190630", "presentation": [ "http://www.abbvie.com/role/SegmentInformationDisaggregationOfRevenueDetails" ], "xbrltype": "domainItemType" }, "abbv_LeaseLiability": { "auth_ref": [], "calculation": { "http://www.abbvie.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetailsCalc2": { "order": 2.0, "parentTag": "abbv_LeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating and finance leases.", "label": "Lease, Liability", "terseLabel": "Total lease liabilities", "verboseLabel": "Present value of lease liabilities" } } }, "localname": "LeaseLiability", "nsuri": "http://www.abbvie.com/20190630", "presentation": [ "http://www.abbvie.com/role/LeasesBalanceSheetDisclosureDetails", "http://www.abbvie.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "abbv_LeaseLiabilityPaymentsDue": { "auth_ref": [], "calculation": { "http://www.abbvie.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.abbvie.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetailsCalc2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating and finance leases.", "label": "Lease, Liability, Payments, Due", "totalLabel": "Total lease payments" } } }, "localname": "LeaseLiabilityPaymentsDue", "nsuri": "http://www.abbvie.com/20190630", "presentation": [ "http://www.abbvie.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "abbv_LeaseLiabilityPaymentsDueYearFive": { "auth_ref": [], "calculation": { "http://www.abbvie.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetails": { "order": 5.0, "parentTag": "abbv_LeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating and finance leases, due in fifth fiscal year following latest fiscal year.", "label": "Lease, Liability, Payments, Due Year Five", "terseLabel": "2023" } } }, "localname": "LeaseLiabilityPaymentsDueYearFive", "nsuri": "http://www.abbvie.com/20190630", "presentation": [ "http://www.abbvie.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "abbv_LeaseLiabilityPaymentsDueYearFour": { "auth_ref": [], "calculation": { "http://www.abbvie.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetails": { "order": 4.0, "parentTag": "abbv_LeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating and finance leases, due in fourth fiscal year following latest fiscal year.", "label": "Lease, Liability, Payments, Due Year Four", "terseLabel": "2022" } } }, "localname": "LeaseLiabilityPaymentsDueYearFour", "nsuri": "http://www.abbvie.com/20190630", "presentation": [ "http://www.abbvie.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "abbv_LeaseLiabilityPaymentsDueYearThree": { "auth_ref": [], "calculation": { "http://www.abbvie.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetails": { "order": 3.0, "parentTag": "abbv_LeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating and finance leases, due in third fiscal year following latest fiscal year.", "label": "Lease, Liability, Payments, Due Year Three", "terseLabel": "2021" } } }, "localname": "LeaseLiabilityPaymentsDueYearThree", "nsuri": "http://www.abbvie.com/20190630", "presentation": [ "http://www.abbvie.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "abbv_LeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [], "calculation": { "http://www.abbvie.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetails": { "order": 2.0, "parentTag": "abbv_LeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating and finance leases, due in second fiscal year following latest fiscal year.", "label": "Lease, Liability, Payments, Due Year Two", "terseLabel": "2020" } } }, "localname": "LeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://www.abbvie.com/20190630", "presentation": [ "http://www.abbvie.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "abbv_LeaseLiabilityPaymentsDueafterYearFive": { "auth_ref": [], "calculation": { "http://www.abbvie.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetails": { "order": 6.0, "parentTag": "abbv_LeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating and finance leases, due after fifth fiscal year following latest fiscal year.", "label": "Lease, Liability, Payments, Due after Year Five", "terseLabel": "Thereafter" } } }, "localname": "LeaseLiabilityPaymentsDueafterYearFive", "nsuri": "http://www.abbvie.com/20190630", "presentation": [ "http://www.abbvie.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "abbv_LeaseLiabilityPaymentsRemainderofFiscalYear": { "auth_ref": [], "calculation": { "http://www.abbvie.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetails": { "order": 1.0, "parentTag": "abbv_LeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating and finance leases having an initial or remaining lease term in excess of one year due in remainder of fiscal year following latest fiscal year.", "label": "Lease, Liability, Payments, Remainder of Fiscal Year", "terseLabel": "2019" } } }, "localname": "LeaseLiabilityPaymentsRemainderofFiscalYear", "nsuri": "http://www.abbvie.com/20190630", "presentation": [ "http://www.abbvie.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "abbv_LeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [], "calculation": { "http://www.abbvie.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetailsCalc2": { "order": 1.0, "parentTag": "abbv_LeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating and finance leases.", "label": "Lease, Liability, Undiscounted Excess Amount", "terseLabel": "Less: Interest" } } }, "localname": "LeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://www.abbvie.com/20190630", "presentation": [ "http://www.abbvie.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "abbv_LeaseLiabiltiiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lease Liabilities, Payments, Due", "label": "Lease Liabiltiies, Payments, Due [Abstract]", "terseLabel": "Total" } } }, "localname": "LeaseLiabiltiiesPaymentsDueAbstract", "nsuri": "http://www.abbvie.com/20190630", "presentation": [ "http://www.abbvie.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "abbv_LeaseRightofUseAsset": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating and finance leases.", "label": "Lease, Right-of-Use Asset", "terseLabel": "Total lease assets" } } }, "localname": "LeaseRightofUseAsset", "nsuri": "http://www.abbvie.com/20190630", "presentation": [ "http://www.abbvie.com/role/LeasesBalanceSheetDisclosureDetails" ], "xbrltype": "monetaryItemType" }, "abbv_LesseeLeaseLeaseNotyetCommencedContractualMinimumPayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's contractual minimum lease payments for operating and finance leases that have not yet commenced.", "label": "Lessee, Lease, Lease Not yet Commenced, Contractual Minimum Payments", "terseLabel": "Contractual minimum lease payments for leases executed but not yet commenced" } } }, "localname": "LesseeLeaseLeaseNotyetCommencedContractualMinimumPayments", "nsuri": "http://www.abbvie.com/20190630", "presentation": [ "http://www.abbvie.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "abbv_LesseeLeaseLeaseNotyetCommencedTermofContract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lessee, Lease, Lease Not yet Commenced, Term of Contract", "label": "Lessee, Lease, Lease Not yet Commenced, Term of Contract", "terseLabel": "Lease term for leases executed but not yet commenced" } } }, "localname": "LesseeLeaseLeaseNotyetCommencedTermofContract", "nsuri": "http://www.abbvie.com/20190630", "presentation": [ "http://www.abbvie.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetails" ], "xbrltype": "durationItemType" }, "abbv_LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresBasesUsedToMeasureApproximateFairValuesOfFinancialInstrumentsDetails": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the fair value amount of obligation related to long-term debt (excluding convertible debt) and capital leases, the portion which is due in one year or less in the future.", "label": "Long Term Debt and Capital Lease Obligations Current Fair Value Disclosure", "verboseLabel": "Current portion of long-term debt and finance lease obligations, excluding fair value hedges" } } }, "localname": "LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure", "nsuri": "http://www.abbvie.com/20190630", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresBasesUsedToMeasureApproximateFairValuesOfFinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "abbv_LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresBasesUsedToMeasureApproximateFairValuesOfFinancialInstrumentsDetails": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the fair value amount of as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year from the balance sheet date or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer plus capital lease obligations due to be paid more than one year after the balance sheet date.", "label": "Long Term Debt and Capital Lease Obligations Fair Value Disclosure", "verboseLabel": "Long-term debt and finance lease obligations, excluding fair value hedges" } } }, "localname": "LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure", "nsuri": "http://www.abbvie.com/20190630", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresBasesUsedToMeasureApproximateFairValuesOfFinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "abbv_LongTermDebtandFinanceLeaseObligationsCurrentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Refers to long-term debt and finance lease obligations due within one year or the normal operating cycle, if longer.", "label": "LongTermDebtandFinanceLeaseObligationsCurrent [Member]", "terseLabel": "Current portion of long-term debt and finance lease obligations" } } }, "localname": "LongTermDebtandFinanceLeaseObligationsCurrentMember", "nsuri": "http://www.abbvie.com/20190630", "presentation": [ "http://www.abbvie.com/role/LeasesBalanceSheetDisclosureDetails" ], "xbrltype": "domainItemType" }, "abbv_LongTermDebtandFinanceLeaseObligationsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Refers to long-term debt and finance lease obligations due after one year or beyond the normal operating cycle, if longer.", "label": "LongTermDebtandFinanceLeaseObligations [Member]", "terseLabel": "Long-term debt and finance lease obligations" } } }, "localname": "LongTermDebtandFinanceLeaseObligationsMember", "nsuri": "http://www.abbvie.com/20190630", "presentation": [ "http://www.abbvie.com/role/LeasesBalanceSheetDisclosureDetails" ], "xbrltype": "domainItemType" }, "abbv_LossContingencyIndividualPlaintiffLawsuitsNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the number of individual plaintiff lawsuits filed, pertaining to a loss contingency during the period.", "label": "Loss Contingency Individual Plaintiff Lawsuits Number", "terseLabel": "Number of individual plaintiff lawsuits" } } }, "localname": "LossContingencyIndividualPlaintiffLawsuitsNumber", "nsuri": "http://www.abbvie.com/20190630", "presentation": [ "http://www.abbvie.com/role/LegalProceedingsAndContingenciesDetails" ], "xbrltype": "integerItemType" }, "abbv_LossContingencyNumberOfGenericCompaniesAsCounterpartyOfLitigationRelatedAgreementsViolatedCertainLaws": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the number of generic companies with whom certain litigation related agreements are entered into that violated federal and state antitrust laws and state consumer protection and unjust enrichment laws.", "label": "Loss Contingency Number of Generic Companies as Counterparty of Litigation Related Agreements Violated Certain Laws", "terseLabel": "Number of generic companies with whom certain litigation related agreements were entered into" } } }, "localname": "LossContingencyNumberOfGenericCompaniesAsCounterpartyOfLitigationRelatedAgreementsViolatedCertainLaws", "nsuri": "http://www.abbvie.com/20190630", "presentation": [ "http://www.abbvie.com/role/LegalProceedingsAndContingenciesDetails" ], "xbrltype": "integerItemType" }, "abbv_LossContingencyPurportedClassActionsNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the number of purported class actions filed, pertaining to a loss contingency during the period.", "label": "Loss Contingency Purported Class Actions Number", "terseLabel": "Number of purported class actions" } } }, "localname": "LossContingencyPurportedClassActionsNumber", "nsuri": "http://www.abbvie.com/20190630", "presentation": [ "http://www.abbvie.com/role/LegalProceedingsAndContingenciesDetails" ], "xbrltype": "integerItemType" }, "abbv_LupronMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents information pertaining to Lupron, a product of the entity.", "label": "Lupron [Member]", "terseLabel": "Lupron" } } }, "localname": "LupronMember", "nsuri": "http://www.abbvie.com/20190630", "presentation": [ "http://www.abbvie.com/role/SegmentInformationDisaggregationOfRevenueDetails" ], "xbrltype": "domainItemType" }, "abbv_MAVYRETMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents information pertaining to MAVYRET, a product of the entity.", "label": "MAVYRET [Member]", "terseLabel": "MAVYRET" } } }, "localname": "MAVYRETMember", "nsuri": "http://www.abbvie.com/20190630", "presentation": [ "http://www.abbvie.com/role/SegmentInformationDisaggregationOfRevenueDetails" ], "xbrltype": "domainItemType" }, "abbv_May2018TermLoanCreditAgreementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "May 2018 Term Loan Credit Agreement", "label": "May 2018 Term Loan Credit Agreement [Member]", "terseLabel": "May 2018 term loan credit agreement" } } }, "localname": "May2018TermLoanCreditAgreementMember", "nsuri": "http://www.abbvie.com/20190630", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresDebtAndCreditFacilitiesDetails" ], "xbrltype": "domainItemType" }, "abbv_NiaspanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents information pertaining to Niaspan, a product of the entity.", "label": "Niaspan [Member]", "terseLabel": "Niaspan" } } }, "localname": "NiaspanMember", "nsuri": "http://www.abbvie.com/20190630", "presentation": [ "http://www.abbvie.com/role/LegalProceedingsAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "abbv_NovartisVaccinesandDiagnosticsIncandGrifolsWorldwideOperationsLtdMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Novartis Vaccines and Diagnostics, Inc. and Grifols Worldwide Operations Ltd.", "label": "Novartis Vaccines and Diagnostics Inc and Grifols Worldwide Operations Ltd [Member]", "terseLabel": "Novartis Vaccines and Diagnostics Inc and Grifols Worldwide Operations Ltd [Member]" } } }, "localname": "NovartisVaccinesandDiagnosticsIncandGrifolsWorldwideOperationsLtdMember", "nsuri": "http://www.abbvie.com/20190630", "presentation": [ "http://www.abbvie.com/role/LegalProceedingsAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "abbv_NumberOfClaimsConsolidatedForPreTrialPurposes": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Numbers of claims are consolidated for pre-trial purposes.", "label": "Number Of Claims Consolidated For Pre-Trial Purposes", "terseLabel": "Numbers of claims consolidated for pre-trial purposes" } } }, "localname": "NumberOfClaimsConsolidatedForPreTrialPurposes", "nsuri": "http://www.abbvie.com/20190630", "presentation": [ "http://www.abbvie.com/role/LegalProceedingsAndContingenciesDetails" ], "xbrltype": "integerItemType" }, "abbv_NumberOfPrincipalUSCustomers": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the number of principal U.S. customers of the entity.", "label": "Number of Principal US Customers", "terseLabel": "Number of principal customers" } } }, "localname": "NumberOfPrincipalUSCustomers", "nsuri": "http://www.abbvie.com/20190630", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresConcentrationsOfRiskDetails" ], "xbrltype": "integerItemType" }, "abbv_ORILISSAMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents information pertaining to ORILISSA, a product of the entity.", "label": "ORILISSA [Member]", "terseLabel": "ORILISSA" } } }, "localname": "ORILISSAMember", "nsuri": "http://www.abbvie.com/20190630", "presentation": [ "http://www.abbvie.com/role/SegmentInformationDisaggregationOfRevenueDetails" ], "xbrltype": "domainItemType" }, "abbv_OperatingandFinanceLeaseBalanceSheetDisclosureTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Operating and Finance Lease Balance Sheet Disclosure [Table Text Block]", "label": "Operating and Finance Lease Balance Sheet Disclosure [Table Text Block]", "terseLabel": "Summary of amounts and location of operating and finance leases on the condensed consolidated balance sheet" } } }, "localname": "OperatingandFinanceLeaseBalanceSheetDisclosureTableTextBlock", "nsuri": "http://www.abbvie.com/20190630", "presentation": [ "http://www.abbvie.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "abbv_OperatingandFinanceLeaseCashFlowDisclosureTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Operating and Finance Lease Cash Flow Disclosure [Table Text Block]", "label": "Operating and Finance Lease Cash Flow Disclosure [Table Text Block]", "terseLabel": "Schedule of supplementary cash flow information regarding the company's operating and finance leases" } } }, "localname": "OperatingandFinanceLeaseCashFlowDisclosureTableTextBlock", "nsuri": "http://www.abbvie.com/20190630", "presentation": [ "http://www.abbvie.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "abbv_OperatingandFinanceLeaseWeightedAverageRemainingLeaseTermandDiscountRateTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Operating and Finance Lease Weighted-Average Remaining Lease Term and Discount Rate [Table Text Block]", "label": "Operating and Finance Lease Weighted-Average Remaining Lease Term and Discount Rate [Table Text Block]", "terseLabel": "Schedule of weighted-average remaining lease term and weighted-average discount rate for operating and finance leases" } } }, "localname": "OperatingandFinanceLeaseWeightedAverageRemainingLeaseTermandDiscountRateTableTextBlock", "nsuri": "http://www.abbvie.com/20190630", "presentation": [ "http://www.abbvie.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "abbv_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossAfterReclassificationandTaxPortionAttributabletoParent": { "auth_ref": [], "calculation": { "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instruments and nonderivative instruments designated and qualifying as net investment hedge, attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), After Reclassification and Tax, Portion Attributable to Parent", "terseLabel": "Net investment hedging activities, net of tax expense (benefit) of $(11) for the three months and $8 for the six months ended June 30, 2019 and $61 for the three months and $31 for the six months ended June 30, 2018" } } }, "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossAfterReclassificationandTaxPortionAttributabletoParent", "nsuri": "http://www.abbvie.com/20190630", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "abbv_OtherComprehensiveIncomeLossNetInvestmentHedgeTaxPortionAttributabletoParent": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on derivative instruments and nonderivative instruments designated and qualifying as net investment hedge, attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Tax, Portion Attributable to Parent", "terseLabel": "Net investment hedging activities, tax expense (benefit)" } } }, "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeTaxPortionAttributabletoParent", "nsuri": "http://www.abbvie.com/20190630", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeParentheticalUnaudited" ], "xbrltype": "monetaryItemType" }, "abbv_OtherKeyProductsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents information pertaining to other key products of the entity.", "label": "Other Key Products [Member]", "terseLabel": "Other Key Products" } } }, "localname": "OtherKeyProductsMember", "nsuri": "http://www.abbvie.com/20190630", "presentation": [ "http://www.abbvie.com/role/SegmentInformationDisaggregationOfRevenueDetails" ], "xbrltype": "domainItemType" }, "abbv_OtherProductsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents information pertaining to other products of the entity not specified anywhere.", "label": "Other Products [Member]", "terseLabel": "All other" } } }, "localname": "OtherProductsMember", "nsuri": "http://www.abbvie.com/20190630", "presentation": [ "http://www.abbvie.com/role/SegmentInformationDisaggregationOfRevenueDetails" ], "xbrltype": "domainItemType" }, "abbv_PercentageofClaimsSubjecttoSettlementAgreements": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage of claims subject to settlement agreements", "label": "Percentage of Claims Subject to Settlement Agreements", "terseLabel": "Percentage of claims subject to settlement agreements" } } }, "localname": "PercentageofClaimsSubjecttoSettlementAgreements", "nsuri": "http://www.abbvie.com/20190630", "presentation": [ "http://www.abbvie.com/role/LegalProceedingsAndContingenciesDetails" ], "xbrltype": "percentItemType" }, "abbv_PutativeClassActionLawsuitIndividualNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents number of the number of individual putative class action lawsuit.", "label": "Putative Class Action Lawsuit Individual Number", "terseLabel": "Number of individual putative class action lawsuit" } } }, "localname": "PutativeClassActionLawsuitIndividualNumber", "nsuri": "http://www.abbvie.com/20190630", "presentation": [ "http://www.abbvie.com/role/LegalProceedingsAndContingenciesDetails" ], "xbrltype": "integerItemType" }, "abbv_RestrictedStockUnitsAndPerformanceSharesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Restricted Stock Units And Performance Shares [Member]", "label": "Restricted Stock Units And Performance Shares [Member]", "terseLabel": "RSUs and Performance Shares" } } }, "localname": "RestrictedStockUnitsAndPerformanceSharesMember", "nsuri": "http://www.abbvie.com/20190630", "presentation": [ "http://www.abbvie.com/role/EquityRsusAndPerformanceSharesDetails" ], "xbrltype": "domainItemType" }, "abbv_RestructuringReserveCashSettledRestructuringCharges": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The change in the restructuring reserve related to the amount of restructuring charges during the period that are expected to be cash settled.", "label": "Restructuring Reserve Cash Settled Restructuring Charges", "terseLabel": "Restructuring charges" } } }, "localname": "RestructuringReserveCashSettledRestructuringCharges", "nsuri": "http://www.abbvie.com/20190630", "presentation": [ "http://www.abbvie.com/role/RestructuringPlansDetails" ], "xbrltype": "monetaryItemType" }, "abbv_RestructuringReservePeriodCashSettledAndOtherAdjustments": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The change in the restructuring reserve related to the amount of cash paid and other adjustments during the period.", "label": "Restructuring Reserve Period Cash Settled and Other Adjustments", "negatedLabel": "Payments and other adjustments" } } }, "localname": "RestructuringReservePeriodCashSettledAndOtherAdjustments", "nsuri": "http://www.abbvie.com/20190630", "presentation": [ "http://www.abbvie.com/role/RestructuringPlansDetails" ], "xbrltype": "monetaryItemType" }, "abbv_RevenuefromCollaborativeArrangementExcludingRevenuefromContractwithCustomer": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.", "label": "Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer", "terseLabel": "Collaboration revenues", "verboseLabel": "International - AbbVie's share of profits (included in net revenues)" } } }, "localname": "RevenuefromCollaborativeArrangementExcludingRevenuefromContractwithCustomer", "nsuri": "http://www.abbvie.com/20190630", "presentation": [ "http://www.abbvie.com/role/CollaborationWithJanssenBiotechIncDetails", "http://www.abbvie.com/role/SegmentInformationDisaggregationOfRevenueDetails" ], "xbrltype": "monetaryItemType" }, "abbv_SKYRIZIMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents information pertaining to SKYRIZI, a product of the entity.", "label": "SKYRIZI [Member]", "terseLabel": "SKYRIZI" } } }, "localname": "SKYRIZIMember", "nsuri": "http://www.abbvie.com/20190630", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresFairValueMeasuresDetails", "http://www.abbvie.com/role/GoodwillAndIntangibleAssetsDefiniteLivedIntangibleAssetsDetails", "http://www.abbvie.com/role/GoodwillAndIntangibleAssetsIndefiniteLivedIntangibleAssetsDetails", "http://www.abbvie.com/role/SegmentInformationDisaggregationOfRevenueDetails" ], "xbrltype": "domainItemType" }, "abbv_SevofluraneMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents information pertaining to Sevoflurane, a product of the entity.", "label": "Sevoflurane [Member]", "terseLabel": "Sevoflurane" } } }, "localname": "SevofluraneMember", "nsuri": "http://www.abbvie.com/20190630", "presentation": [ "http://www.abbvie.com/role/SegmentInformationDisaggregationOfRevenueDetails" ], "xbrltype": "domainItemType" }, "abbv_StemcentrxInc.Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the information pertaining to acquisition of Stemcentrx, Inc.", "label": "Stemcentrx Inc. [Member]", "terseLabel": "Stemcentrx Inc." } } }, "localname": "StemcentrxInc.Member", "nsuri": "http://www.abbvie.com/20190630", "presentation": [ "http://www.abbvie.com/role/GoodwillAndIntangibleAssetsIndefiniteLivedIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "abbv_SupplementalFinancialInformationDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "", "label": "Supplemental Financial Information" } } }, "localname": "SupplementalFinancialInformationDisclosureAbstract", "nsuri": "http://www.abbvie.com/20190630", "xbrltype": "stringItemType" }, "abbv_SynagisMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents information pertaining to Synagis, a product of the entity.", "label": "Synagis [Member]", "terseLabel": "Synagis" } } }, "localname": "SynagisMember", "nsuri": "http://www.abbvie.com/20190630", "presentation": [ "http://www.abbvie.com/role/SegmentInformationDisaggregationOfRevenueDetails" ], "xbrltype": "domainItemType" }, "abbv_SynthroidMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents information pertaining to Synthroid, a product of the entity.", "label": "Synthroid [Member]", "terseLabel": "Synthroid" } } }, "localname": "SynthroidMember", "nsuri": "http://www.abbvie.com/20190630", "presentation": [ "http://www.abbvie.com/role/SegmentInformationDisaggregationOfRevenueDetails" ], "xbrltype": "domainItemType" }, "abbv_TermByWhichTheAgreementWasExtended": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the term by which the agreement was extended.", "label": "Term By Which The Agreement Was Extended", "terseLabel": "Term by which the agreement was extended" } } }, "localname": "TermByWhichTheAgreementWasExtended", "nsuri": "http://www.abbvie.com/20190630", "presentation": [ "http://www.abbvie.com/role/LicensingAcquisitionsAndOtherArrangementsOtherLicensingAcquisitionsActivityDetails" ], "xbrltype": "durationItemType" }, "abbv_TestosteroneReplacementTherapyProductsLiabilityLitigationMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information relating to Testosterone Replacement Therapy Products Liability Litigation.", "label": "Testosterone Replacement Therapy Products Liability Litigation [Member]", "terseLabel": "Testosterone Replacement Therapy Products Liability Litigation" } } }, "localname": "TestosteroneReplacementTherapyProductsLiabilityLitigationMember", "nsuri": "http://www.abbvie.com/20190630", "presentation": [ "http://www.abbvie.com/role/LegalProceedingsAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "abbv_UpfrontCostsRelatedToCollaborations": { "auth_ref": [], "calculation": { "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Represents the amount of upfront costs related to collaborations reported in the statement of cash flows.", "label": "Upfront Costs Related To Collaborations", "terseLabel": "Upfront costs and milestones related to collaborations" } } }, "localname": "UpfrontCostsRelatedToCollaborations", "nsuri": "http://www.abbvie.com/20190630", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "abbv_VENCLEXTAMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents information pertaining to VENCLEXTA, a product of the entity.", "label": "VENCLEXTA [Member]", "terseLabel": "VENCLEXTA" } } }, "localname": "VENCLEXTAMember", "nsuri": "http://www.abbvie.com/20190630", "presentation": [ "http://www.abbvie.com/role/SegmentInformationDisaggregationOfRevenueDetails" ], "xbrltype": "domainItemType" }, "abbv_VIEKIRAMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents information pertaining to VIEKIRA, a product of the entity.", "label": "VIEKIRA [Member]", "terseLabel": "VIEKIRA" } } }, "localname": "VIEKIRAMember", "nsuri": "http://www.abbvie.com/20190630", "presentation": [ "http://www.abbvie.com/role/SegmentInformationDisaggregationOfRevenueDetails" ], "xbrltype": "domainItemType" }, "country_US": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "UNITED STATES", "terseLabel": "United States" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2017-01-31", "presentation": [ "http://www.abbvie.com/role/CollaborationWithJanssenBiotechIncDetails", "http://www.abbvie.com/role/SegmentInformationDisaggregationOfRevenueDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abbvie.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abbvie.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abbvie.com/role/DocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abbvie.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abbvie.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abbvie.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r419" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abbvie.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r420" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abbvie.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abbvie.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntitiesTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Container to assemble all relevant information about each entity associated with the document instance", "label": "Entities [Table]", "terseLabel": "Entities [Table]" } } }, "localname": "EntitiesTable", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abbvie.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abbvie.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abbvie.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abbvie.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abbvie.com/role/DocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r421" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abbvie.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abbvie.com/role/DocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abbvie.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r421" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abbvie.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abbvie.com/role/DocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r421" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abbvie.com/role/DocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abbvie.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInformationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Entity Information [Line Items]", "terseLabel": "Entity Information" } } }, "localname": "EntityInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abbvie.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r422" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abbvie.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityListingsExchangeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.", "label": "Entity Listings, Exchange [Axis]", "terseLabel": "Entity Listings, Exchange [Axis]" } } }, "localname": "EntityListingsExchangeAxis", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abbvie.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r421" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abbvie.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r421" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abbvie.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r421" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abbvie.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r421" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abbvie.com/role/DocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_ExchangeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383.", "label": "Exchange [Domain]", "terseLabel": "Exchange [Domain]" } } }, "localname": "ExchangeDomain", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abbvie.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abbvie.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r417" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abbvie.com/role/DocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r418" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abbvie.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abbvie.com/role/DocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "exch_XCHI": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "CHICAGO STOCK EXCHANGE, INC [Member]", "terseLabel": "CHICAGO STOCK EXCHANGE, INC [Member]" } } }, "localname": "XCHI", "nsuri": "http://xbrl.sec.gov/exch/2018-01-31", "presentation": [ "http://www.abbvie.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "exch_XNYS": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "NEW YORK STOCK EXCHANGE, INC. [Member]", "terseLabel": "NEW YORK STOCK EXCHANGE, INC. [Member]" } } }, "localname": "XNYS", "nsuri": "http://xbrl.sec.gov/exch/2018-01-31", "presentation": [ "http://www.abbvie.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "invest_DerivativeNotionalAmount": { "auth_ref": [ "r423" ], "lang": { "en-US": { "role": { "documentation": "Aggregate notional amount specified by the derivative(s). Expressed as an absolute value.", "label": "Derivative, Notional Amount", "terseLabel": "Notional amount of derivative instruments" } } }, "localname": "DerivativeNotionalAmount", "nsuri": "http://xbrl.sec.gov/invest/2013-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresFinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r48", "r102" ], "lang": { "en-US": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CollaborationWithJanssenBiotechIncDetails", "http://www.abbvie.com/role/LicensingAcquisitionsAndOtherArrangementsOtherLicensingAcquisitionsActivityDetails" ], "xbrltype": "stringItemType" }, "srt_LitigationCaseAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Litigation Case [Axis]", "terseLabel": "Litigation Case [Axis]" } } }, "localname": "LitigationCaseAxis", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.abbvie.com/role/LegalProceedingsAndContingenciesDetails" ], "xbrltype": "stringItemType" }, "srt_LitigationCaseTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Litigation Case [Domain]", "terseLabel": "Litigation Case Type [Domain]" } } }, "localname": "LitigationCaseTypeDomain", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.abbvie.com/role/LegalProceedingsAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r136", "r218", "r220", "r408" ], "lang": { "en-US": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresFairValueMeasuresDetails", "http://www.abbvie.com/role/GoodwillAndIntangibleAssetsDefiniteLivedIntangibleAssetsDetails", "http://www.abbvie.com/role/GoodwillAndIntangibleAssetsIndefiniteLivedIntangibleAssetsDetails", "http://www.abbvie.com/role/SegmentInformationDisaggregationOfRevenueDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresFairValueMeasuresDetails", "http://www.abbvie.com/role/GoodwillAndIntangibleAssetsDefiniteLivedIntangibleAssetsDetails", "http://www.abbvie.com/role/GoodwillAndIntangibleAssetsIndefiniteLivedIntangibleAssetsDetails", "http://www.abbvie.com/role/SegmentInformationDisaggregationOfRevenueDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CollaborationWithJanssenBiotechIncDetails", "http://www.abbvie.com/role/LicensingAcquisitionsAndOtherArrangementsOtherLicensingAcquisitionsActivityDetails" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CollaborationWithJanssenBiotechIncDetails", "http://www.abbvie.com/role/SegmentInformationDisaggregationOfRevenueDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r137", "r218", "r221", "r415", "r416" ], "lang": { "en-US": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CollaborationWithJanssenBiotechIncDetails", "http://www.abbvie.com/role/SegmentInformationDisaggregationOfRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AOCIAttributableToParentNetOfTaxRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "AOCI Attributable to Parent, Net of Tax [Roll Forward]", "terseLabel": "AOCI Attributable to Parent, Net of Tax" } } }, "localname": "AOCIAttributableToParentNetOfTaxRollForward", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/EquityAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdate201602Member": { "auth_ref": [ "r353" ], "lang": { "en-US": { "role": { "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).", "label": "Accounting Standards Update 2016-02 [Member]", "terseLabel": "Accounting Standards Update 2016-02" } } }, "localname": "AccountingStandardsUpdate201602Member", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/BasisOfPresentationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r37" ], "calculation": { "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts Payable and Accrued Liabilities, Current", "terseLabel": "Accounts payable and accrued liabilities" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/BasisOfPresentationDetails", "http://www.abbvie.com/role/CollaborationWithJanssenBiotechIncDetails", "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing accounts payable and accrued liabilities.", "label": "Accounts Payable and Accrued Liabilities [Member]", "terseLabel": "Accounts payable and accrued liabilities" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresFinancialInstrumentsDetails", "http://www.abbvie.com/role/LeasesBalanceSheetDisclosureDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "label": "Accounts Receivable [Member]", "terseLabel": "Accounts receivable, net" } } }, "localname": "AccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresConcentrationsOfRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r16", "r219" ], "calculation": { "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.", "label": "Accounts Receivable, Net, Current", "terseLabel": "Accounts receivable, net" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CollaborationWithJanssenBiotechIncDetails", "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": { "auth_ref": [ "r55", "r61", "r63", "r233", "r287" ], "lang": { "en-US": { "role": { "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent.", "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]", "terseLabel": "Pension and post-employment benefits" } } }, "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/EquityAccumulatedOtherComprehensiveLossDetails", "http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r31", "r183" ], "calculation": { "http://www.abbvie.com/role/SupplementalFinancialInformationDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/SupplementalFinancialInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": { "auth_ref": [ "r61", "r70", "r286" ], "lang": { "en-US": { "role": { "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.", "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]", "terseLabel": "Cash flow hedging activities" } } }, "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/EquityAccumulatedOtherComprehensiveLossDetails", "http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": { "auth_ref": [ "r52", "r53", "r54", "r61", "r63" ], "lang": { "en-US": { "role": { "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.", "label": "Accumulated Net Investment Gain (Loss) Attributable to Parent [Member]", "terseLabel": "Marketable security activities" } } }, "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/EquityAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "terseLabel": "Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/EquityAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r58", "r60", "r61" ], "calculation": { "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossOtherThanTemporaryImpairmentNotCreditLossNetOfTaxAvailableforsaleDebtSecurities": { "auth_ref": [ "r61", "r142", "r144" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Accumulated other comprehensive loss related to portion of other than temporary impairment (OTTI) due to factors other than credit losses on debt securities categorized as available-for-sale that an entity does not intend to sell and which it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis of the debt security. The amount represented by this item is net of tax, as applicable.", "label": "Accumulated Other Comprehensive Income (Loss), Other than Temporary Impairment, Not Credit Loss, Net of Tax, Available-for-sale, Debt Securities", "terseLabel": "Other-than-temporary impairments" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossOtherThanTemporaryImpairmentNotCreditLossNetOfTaxAvailableforsaleDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresAvailableForSaleSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/EquityAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r57", "r61", "r63", "r287" ], "lang": { "en-US": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfEquityUnaudited", "http://www.abbvie.com/role/EquityAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "auth_ref": [ "r50", "r61", "r63", "r287" ], "lang": { "en-US": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "terseLabel": "Foreign currency translation adjustments" } } }, "localname": "AccumulatedTranslationAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/EquityAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalFinancialInformationDisclosureTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.", "label": "Additional Financial Information Disclosure [Text Block]", "terseLabel": "Supplemental Financial Information" } } }, "localname": "AdditionalFinancialInformationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/SupplementalFinancialInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r17" ], "calculation": { "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r107" ], "lang": { "en-US": { "role": { "documentation": "Information by new accounting pronouncement.", "label": "Adjustments for New Accounting Pronouncements [Axis]", "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/BasisOfPresentationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net earnings to net cash from operating activities:" } } }, "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r245", "r253", "r257" ], "calculation": { "http://www.abbvie.com/role/EquityStockBasedCompensationDetails": { "order": 1.0, "parentTag": "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.", "label": "Allocated Share-based Compensation Expense", "terseLabel": "Pre-tax compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/EquityStockBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax": { "auth_ref": [], "calculation": { "http://www.abbvie.com/role/EquityStockBasedCompensationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of expense, net of income tax, recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.", "label": "Allocated Share-based Compensation Expense, Net of Tax", "totalLabel": "After-tax compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpenseNetOfTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/EquityStockBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r96", "r167", "r175" ], "calculation": { "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "terseLabel": "Amortization of intangible assets" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://www.abbvie.com/role/GoodwillAndIntangibleAssetsDefiniteLivedIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentParentMember": { "auth_ref": [ "r61", "r321" ], "lang": { "en-US": { "role": { "documentation": "Accumulated other comprehensive income (loss) from increase (decrease) in value of excluded component of derivative hedge, attributable to parent.", "label": "AOCI, Derivative Qualifying as Hedge, Excluded Component, Parent [Member]", "terseLabel": "AOCI, Derivative Qualifying as Hedge, Excluded Component, Parent [Member]" } } }, "localname": "AociDerivativeQualifyingAsHedgeExcludedComponentParentMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This item is to be populated with the collective of (i) types (categories) of arrangements of the entity applicable to its revenue-generating activities or operations and non-arrangement transactions, including but not limited to, for instance, sales of product manufactured by the entity, if such comparison of arrangements as a component of all transactions is provided by the entity.", "label": "Arrangements and Non-arrangement Transactions [Domain]", "terseLabel": "Arrangements and Non-arrangement Transactions [Domain]" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CollaborationWithJanssenBiotechIncDetails", "http://www.abbvie.com/role/LicensingAcquisitionsAndOtherArrangementsOtherLicensingAcquisitionsActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AssetBackedSecuritiesMember": { "auth_ref": [ "r148", "r227" ], "lang": { "en-US": { "role": { "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.", "label": "Asset-backed Securities [Member]", "terseLabel": "Asset backed securities" } } }, "localname": "AssetBackedSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresAvailableForSaleSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r134", "r383", "r399" ], "calculation": { "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets", "http://www.abbvie.com/role/LeasesBalanceSheetDisclosureDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r3", "r4", "r46" ], "calculation": { "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r324" ], "calculation": { "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresFairValueMeasuresDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "totalLabel": "Total assets" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresFairValueMeasuresDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets, Fair Value Disclosure [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresFairValueMeasuresDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleSecurities": { "auth_ref": [], "calculation": { "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresAvailableForSaleSecuritiesDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesAmortizedCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.", "label": "Available-for-sale Securities", "verboseLabel": "Fair value" } } }, "localname": "AvailableForSaleSecurities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresAvailableForSaleSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r145" ], "calculation": { "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresAvailableForSaleSecuritiesDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesAmortizedCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax of unrealized gain in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.", "label": "Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Gross unrealized, Gains" } } }, "localname": "AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresAvailableForSaleSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [], "calculation": { "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresAvailableForSaleSecuritiesDetails": { "order": 3.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesAmortizedCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before tax of unrealized loss in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.", "label": "Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax", "negatedTerseLabel": "Gross unrealized, Losses" } } }, "localname": "AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresAvailableForSaleSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesAmortizedCost": { "auth_ref": [], "calculation": { "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresAvailableForSaleSecuritiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.", "label": "Available-for-sale Securities, Amortized Cost Basis", "totalLabel": "Amortized cost" } } }, "localname": "AvailableForSaleSecuritiesAmortizedCost", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresAvailableForSaleSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r140", "r143" ], "calculation": { "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresFairValueMeasuresDetails": { "order": 2.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale", "terseLabel": "Debt securities" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresAvailableForSaleSecuritiesDetails", "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresFairValueMeasuresDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesEquitySecurities": { "auth_ref": [], "calculation": { "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresFairValueMeasuresDetails": { "order": 3.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of equity securities categorized neither as held-to-maturity nor as trading.", "label": "Available-for-sale Securities, Equity Securities", "verboseLabel": "Equity securities" } } }, "localname": "AvailableForSaleSecuritiesEquitySecurities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresFairValueMeasuresDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.", "label": "Available-for-sale Securities [Table Text Block]", "terseLabel": "Summary of available-for-sale securities by type" } } }, "localname": "AvailableForSaleSecuritiesTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r247", "r255" ], "lang": { "en-US": { "role": { "documentation": "Information by award type pertaining to equity-based compensation.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/EquityRsusAndPerformanceSharesDetails", "http://www.abbvie.com/role/EquityStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresFinancialInstrumentsDetails", "http://www.abbvie.com/role/LeasesBalanceSheetDisclosureDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r297", "r303" ], "lang": { "en-US": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresFinancialInstrumentsDetails", "http://www.abbvie.com/role/LeasesBalanceSheetDisclosureDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BankTimeDepositsMember": { "auth_ref": [ "r394" ], "lang": { "en-US": { "role": { "documentation": "Certificates of deposit (CD) or savings accounts with a fixed term or understanding the customer can only withdraw by giving advanced notice with a bank or other financial institution. A CD is a short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest.", "label": "Bank Time Deposits [Member]", "terseLabel": "Time deposits" } } }, "localname": "BankTimeDepositsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresFairValueMeasuresDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BridgeLoanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Financing which is expected to be replaced by a medium to long-term loan. The loan \"bridges\" the gap in time when otherwise no financing would be in place.", "label": "Bridge Loan [Member]", "terseLabel": "Bridge credit agreement" } } }, "localname": "BridgeLoanMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresDebtAndCreditFacilitiesDetails", "http://www.abbvie.com/role/LicensingAcquisitionsAndOtherArrangementsProposedAcquisitionOfAllerganPlcDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/GoodwillAndIntangibleAssetsIndefiniteLivedIntangibleAssetsDetails", "http://www.abbvie.com/role/LicensingAcquisitionsAndOtherArrangementsProposedAcquisitionOfAllerganPlcDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r271", "r272" ], "lang": { "en-US": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/GoodwillAndIntangibleAssetsIndefiniteLivedIntangibleAssetsDetails", "http://www.abbvie.com/role/LicensingAcquisitionsAndOtherArrangementsProposedAcquisitionOfAllerganPlcDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]", "terseLabel": "Business Acquisition" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/LicensingAcquisitionsAndOtherArrangementsProposedAcquisitionOfAllerganPlcDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionSharePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.", "label": "Business Acquisition, Share Price", "terseLabel": "Cash per share received by Allergan shareholders" } } }, "localname": "BusinessAcquisitionSharePrice", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/LicensingAcquisitionsAndOtherArrangementsProposedAcquisitionOfAllerganPlcDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r276", "r277", "r279" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Business Combination, Consideration Transferred", "terseLabel": "Total consideration" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/LicensingAcquisitionsAndOtherArrangementsProposedAcquisitionOfAllerganPlcDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "auth_ref": [ "r95", "r281" ], "calculation": { "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "terseLabel": "Change in fair value of contingent consideration liabilities" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "auth_ref": [ "r275", "r278", "r280" ], "calculation": { "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresFairValueMeasuresDetails": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.", "label": "Business Combination, Contingent Consideration, Liability", "verboseLabel": "Contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationLiability", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresFairValueMeasuresDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Business Combinations [Abstract]" } } }, "localname": "BusinessCombinationsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_CarryingReportedAmountFairValueDisclosureMember": { "auth_ref": [ "r338", "r339" ], "lang": { "en-US": { "role": { "documentation": "Measured as reported on the statement of financial position (balance sheet).", "label": "Reported Value Measurement [Member]", "terseLabel": "Book value" } } }, "localname": "CarryingReportedAmountFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresBasesUsedToMeasureApproximateFairValuesOfFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r1", "r28", "r98" ], "calculation": { "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "periodEndLabel": "Cash and equivalents, end of period", "periodStartLabel": "Cash and equivalents, beginning of period", "terseLabel": "Cash and equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets", "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresFairValueMeasuresDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash and equivalents" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresFairValueMeasuresDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease": { "auth_ref": [], "calculation": { "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.", "label": "Cash and Cash Equivalents, Period Increase (Decrease)", "totalLabel": "Net change in cash and equivalents" } } }, "localname": "CashAndCashEquivalentsPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowHedgingMember": { "auth_ref": [ "r293" ], "lang": { "en-US": { "role": { "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.", "label": "Cash Flow Hedging [Member]", "verboseLabel": "Cash flow hedges" } } }, "localname": "CashFlowHedgingMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails", "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ChangeDuringPeriodFairValueDisclosureMember": { "auth_ref": [ "r343" ], "lang": { "en-US": { "role": { "documentation": "Measure of change in fair value.", "label": "Changes Measurement [Member]", "terseLabel": "Changes Measurement" } } }, "localname": "ChangeDuringPeriodFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresFairValueMeasuresDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfTreasuryStockTable": { "auth_ref": [ "r211", "r212", "r213", "r214" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.", "label": "Class of Treasury Stock [Table]", "terseLabel": "Class of Treasury Stock [Table]" } } }, "localname": "ClassOfTreasuryStockTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/EquityStockRepurchaseProgramDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "auth_ref": [ "r283" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.", "label": "Collaborative Arrangement Disclosure [Text Block]", "terseLabel": "Collaboration with Janssen Biotech, Inc." } } }, "localname": "CollaborativeArrangementDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CollaborationWithJanssenBiotechInc" ], "xbrltype": "textBlockItemType" }, "us-gaap_CollaborativeArrangementMember": { "auth_ref": [ "r282" ], "lang": { "en-US": { "role": { "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.", "label": "Collaborative Arrangement [Member]", "terseLabel": "Collaborative arrangement" } } }, "localname": "CollaborativeArrangementMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CollaborationWithJanssenBiotechIncDetails", "http://www.abbvie.com/role/LicensingAcquisitionsAndOtherArrangementsOtherLicensingAcquisitionsActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]", "terseLabel": "Collaborative and license agreements" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CollaborationWithJanssenBiotechIncDetails", "http://www.abbvie.com/role/LicensingAcquisitionsAndOtherArrangementsOtherLicensingAcquisitionsActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommercialPaperMember": { "auth_ref": [ "r207" ], "lang": { "en-US": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.", "label": "Commercial Paper [Member]", "terseLabel": "Commercial paper" } } }, "localname": "CommercialPaperMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresDebtAndCreditFacilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r42", "r195", "r390", "r404" ], "calculation": { "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommonStockDividendsPerShareDeclared": { "auth_ref": [ "r210" ], "lang": { "en-US": { "role": { "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.", "label": "Common Stock, Dividends, Per Share, Declared", "terseLabel": "Cash dividends declared per common share (in dollars per share)" } } }, "localname": "CommonStockDividendsPerShareDeclared", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/EquityCashDividendsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common stock", "verboseLabel": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfEquityUnaudited", "http://www.abbvie.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValueOutstanding": { "auth_ref": [ "r15" ], "calculation": { "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.", "label": "Common Stock, Value, Outstanding", "verboseLabel": "Common stock, $0.01 par value, 4,000,000,000 shares authorized, 1,781,055,877 shares issued as of June 30, 2019 and 1,776,510,871 as of December 31, 2018" } } }, "localname": "CommonStockValueOutstanding", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r66", "r68", "r69" ], "calculation": { "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive income" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r126", "r127", "r340", "r341" ], "lang": { "en-US": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresConcentrationsOfRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r126", "r127", "r340", "r341", "r410" ], "lang": { "en-US": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]", "terseLabel": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresConcentrationsOfRiskDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r126", "r127", "r340", "r341", "r410" ], "lang": { "en-US": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]", "terseLabel": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresConcentrationsOfRiskDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Concentration Risk [Line Items]", "terseLabel": "Concentration of Risk" } } }, "localname": "ConcentrationRiskLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresConcentrationsOfRiskDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r126", "r127", "r340", "r341" ], "lang": { "en-US": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk, Percentage", "terseLabel": "Concentrations risk (as a percent)" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresConcentrationsOfRiskDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTable": { "auth_ref": [ "r123", "r126", "r127", "r128", "r340", "r342" ], "lang": { "en-US": { "role": { "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Concentration Risk [Table]", "terseLabel": "Concentration Risk [Table]" } } }, "localname": "ConcentrationRiskTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresConcentrationsOfRiskDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r126", "r127", "r340", "r341" ], "lang": { "en-US": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresConcentrationsOfRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CorporateDebtSecuritiesMember": { "auth_ref": [ "r227", "r242" ], "lang": { "en-US": { "role": { "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.", "label": "Corporate Debt Securities [Member]", "terseLabel": "Corporate debt securities" } } }, "localname": "CorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresAvailableForSaleSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r76" ], "calculation": { "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfEarningsUnaudited": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 }, "http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveIncomeDetails": { "order": 3.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of products sold", "verboseLabel": "Losses (gains) on designated cash flow hedges" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfEarningsUnaudited", "http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost of Sales [Member]", "terseLabel": "Cost of products sold" } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/EquityStockBasedCompensationDetails", "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r74" ], "calculation": { "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfEarningsUnaudited": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "totalLabel": "Total operating costs and expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfEarningsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.", "label": "Cumulative Effect of New Accounting Principle in Period of Adoption", "terseLabel": "Adoption of new accounting standards" } } }, "localname": "CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r9", "r11", "r12", "r384", "r385", "r397" ], "lang": { "en-US": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresDebtAndCreditFacilitiesDetails", "http://www.abbvie.com/role/LicensingAcquisitionsAndOtherArrangementsProposedAcquisitionOfAllerganPlcDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r349", "r351" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "verboseLabel": "Principal amount of unsecured senior notes" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresFinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r41" ], "lang": { "en-US": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresDebtAndCreditFacilitiesDetails", "http://www.abbvie.com/role/LicensingAcquisitionsAndOtherArrangementsProposedAcquisitionOfAllerganPlcDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTerm": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Debt Instrument, Term", "terseLabel": "Credit agreement term", "verboseLabel": "Credit agreement term" } } }, "localname": "DebtInstrumentTerm", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresDebtAndCreditFacilitiesDetails", "http://www.abbvie.com/role/LicensingAcquisitionsAndOtherArrangementsProposedAcquisitionOfAllerganPlcDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount": { "auth_ref": [ "r40" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of unused borrowing capacity under the long-term financing arrangement that is available to the entity as of the balance sheet date.", "label": "Debt Instrument, Unused Borrowing Capacity, Amount", "terseLabel": "Principal amount of term loan" } } }, "localname": "DebtInstrumentUnusedBorrowingCapacityAmount", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/LicensingAcquisitionsAndOtherArrangementsProposedAcquisitionOfAllerganPlcDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTerm": { "auth_ref": [ "r327" ], "lang": { "en-US": { "role": { "documentation": "Period between issuance and maturity of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Debt Securities, Available-for-sale, Term", "terseLabel": "Maximum maturity period of long-term debt securities (in years)" } } }, "localname": "DebtSecuritiesAvailableForSaleTerm", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresAvailableForSaleSecuritiesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible": { "auth_ref": [ "r265" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.", "label": "Decrease in Unrecognized Tax Benefits is Reasonably Possible", "terseLabel": "Potential change in unrecognized tax benefits" } } }, "localname": "DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesNoncurrent": { "auth_ref": [ "r260", "r261", "r262" ], "calculation": { "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting and classified as noncurrent.", "label": "Deferred Tax Liabilities, Net, Noncurrent", "terseLabel": "Deferred income taxes" } } }, "localname": "DeferredTaxLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanDisclosureLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Defined Benefit Plan Disclosure [Line Items]", "terseLabel": "Defined benefit and other post-employment plans" } } }, "localname": "DefinedBenefitPlanDisclosureLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/PostEmploymentBenefitsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": { "auth_ref": [ "r232", "r241", "r242" ], "calculation": { "http://www.abbvie.com/role/PostEmploymentBenefitsDetails": { "order": 3.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.", "label": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets", "negatedLabel": "Expected return on plan assets" } } }, "localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/PostEmploymentBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanInterestCost": { "auth_ref": [ "r226", "r231", "r240", "r242" ], "calculation": { "http://www.abbvie.com/role/PostEmploymentBenefitsDetails": { "order": 2.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost recognized for passage of time related to defined benefit plan.", "label": "Defined Benefit Plan, Interest Cost", "terseLabel": "Interest cost" } } }, "localname": "DefinedBenefitPlanInterestCost", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/PostEmploymentBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": { "auth_ref": [ "r229", "r238", "r242" ], "calculation": { "http://www.abbvie.com/role/PostEmploymentBenefitsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan.", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)", "totalLabel": "Net periodic benefit cost" } } }, "localname": "DefinedBenefitPlanNetPeriodicBenefitCost", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/PostEmploymentBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanServiceCost": { "auth_ref": [ "r225", "r230", "r239", "r242" ], "calculation": { "http://www.abbvie.com/role/PostEmploymentBenefitsDetails": { "order": 1.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.", "label": "Defined Benefit Plan, Service Cost", "terseLabel": "Service cost" } } }, "localname": "DefinedBenefitPlanServiceCost", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/PostEmploymentBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r96", "r181" ], "calculation": { "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation", "verboseLabel": "Depreciation expense" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://www.abbvie.com/role/SupplementalFinancialInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]", "terseLabel": "Derivative Contract Type [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails", "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresFairValueMeasuresDetails", "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeFairValueOfDerivativeAsset": { "auth_ref": [ "r47", "r49", "r301", "r380" ], "calculation": { "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresFairValueMeasuresDetails": { "order": 5.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.", "label": "Derivative Asset, Fair Value, Gross Asset", "terseLabel": "Foreign currency contracts", "verboseLabel": "Foreign currency contracts in asset position" } } }, "localname": "DerivativeFairValueOfDerivativeAsset", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresFairValueMeasuresDetails", "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresFinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeFairValueOfDerivativeLiability": { "auth_ref": [ "r47", "r49", "r301", "r380" ], "calculation": { "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresFairValueMeasuresDetails": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.", "label": "Derivative Liability, Fair Value, Gross Liability", "terseLabel": "Foreign currency contracts", "verboseLabel": "Foreign currency contracts in liability position" } } }, "localname": "DerivativeFairValueOfDerivativeLiability", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresFairValueMeasuresDetails", "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresFinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeGainLossOnDerivativeNet": { "auth_ref": [ "r299" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.", "label": "Derivative, Gain (Loss) on Derivative, Net", "terseLabel": "Derivative gain (loss), net" } } }, "localname": "DerivativeGainLossOnDerivativeNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r298", "r302", "r307", "r312" ], "lang": { "en-US": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]", "terseLabel": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails", "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresFairValueMeasuresDetails", "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "auth_ref": [ "r295", "r298", "r307" ], "lang": { "en-US": { "role": { "documentation": "Information by type of hedging relationship.", "label": "Hedging Relationship [Axis]", "terseLabel": "Hedging Relationship [Axis]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveIncomeDetails", "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails", "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": { "auth_ref": [ "r295", "r298", "r307", "r312", "r313", "r316", "r318" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.", "label": "Derivative Instruments, Gain (Loss) [Table]", "terseLabel": "Derivative Instruments, Gain (Loss) [Table]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative Instruments, Gain (Loss) [Line Items]", "terseLabel": "Gain (loss) on derivatives" } } }, "localname": "DerivativeInstrumentsGainLossLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeTable": { "auth_ref": [ "r105", "r289", "r290", "r291", "r295", "r296", "r304", "r307", "r314", "r315", "r318" ], "lang": { "en-US": { "role": { "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.", "label": "Derivative [Table]", "terseLabel": "Derivative [Table]" } } }, "localname": "DerivativeTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeTermOfContract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Derivative, Term of Contract", "terseLabel": "Duration of forward exchange contracts" } } }, "localname": "DerivativeTermOfContract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresFinancialInstrumentsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DerivativesAndFairValueTextBlock": { "auth_ref": [ "r322", "r335" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for derivatives and fair value of assets and liabilities.", "label": "Derivatives and Fair Value [Text Block]", "terseLabel": "Financial Instruments and Fair Value Measures" } } }, "localname": "DerivativesAndFairValueTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasures" ], "xbrltype": "textBlockItemType" }, "us-gaap_DerivativesFairValueLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivatives, Fair Value [Line Items]", "terseLabel": "Derivative instruments, notional amount and fair value" } } }, "localname": "DerivativesFairValueLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "auth_ref": [ "r295" ], "lang": { "en-US": { "role": { "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Designated as Hedging Instrument [Member]", "terseLabel": "Designated as hedging instrument" } } }, "localname": "DesignatedAsHedgingInstrumentMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails", "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DevelopedTechnologyRightsMember": { "auth_ref": [ "r274" ], "lang": { "en-US": { "role": { "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.", "label": "Developed Technology Rights [Member]", "terseLabel": "Developed product rights" } } }, "localname": "DevelopedTechnologyRightsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/GoodwillAndIntangibleAssetsDefiniteLivedIntangibleAssetsDetails", "http://www.abbvie.com/role/GoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation of Revenue" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/SegmentInformationDisaggregationOfRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]", "terseLabel": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/SegmentInformationDisaggregationOfRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r218" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Schedule of worldwide net revenues" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/SegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r215", "r258" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.", "label": "Disclosure of Compensation Related Costs, Share-based Payments [Text Block]", "terseLabel": "Equity" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/Equity" ], "xbrltype": "textBlockItemType" }, "us-gaap_DividendsCommonStockCash": { "auth_ref": [ "r210" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.", "label": "Dividends, Common Stock, Cash", "negatedTerseLabel": "Dividends declared" } } }, "localname": "DividendsCommonStockCash", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r73", "r108", "r114", "r117", "r118", "r119", "r121", "r392", "r406" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic earnings per share (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfEarningsUnaudited", "http://www.abbvie.com/role/EarningsPerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAndDilutedAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share, Basic and Diluted [Abstract]", "terseLabel": "Per share data" } } }, "localname": "EarningsPerShareBasicAndDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfEarningsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasicTwoClassMethodAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share, Basic, Two Class Method [Abstract]", "terseLabel": "Basic EPS" } } }, "localname": "EarningsPerShareBasicTwoClassMethodAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/EarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r73", "r108", "r114", "r117", "r118", "r119", "r121", "r392", "r406" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted earnings per share (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfEarningsUnaudited", "http://www.abbvie.com/role/EarningsPerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDilutedTwoClassMethodAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share, Diluted, Two Class Method [Abstract]", "terseLabel": "Diluted EPS" } } }, "localname": "EarningsPerShareDilutedTwoClassMethodAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/EarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r122" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Earnings Per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/EarningsPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents": { "auth_ref": [ "r347" ], "calculation": { "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.", "label": "Effect of Exchange Rate on Cash and Cash Equivalents", "terseLabel": "Effect of exchange rate changes on cash and equivalents" } } }, "localname": "EffectOfExchangeRateOnCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r104", "r263", "r264" ], "lang": { "en-US": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Effective tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r263", "r264", "r266" ], "lang": { "en-US": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "terseLabel": "U.S. statutory tax rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r254" ], "lang": { "en-US": { "role": { "documentation": "Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition", "terseLabel": "Period for recognition of unrecognized compensation cost" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/EquityRsusAndPerformanceSharesDetails", "http://www.abbvie.com/role/EquityStockOptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "auth_ref": [ "r254" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Unrecognized cost of unvested share-based awards, other than options, awarded to employees as compensation.", "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options", "terseLabel": "Unrecognized compensation cost" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/EquityRsusAndPerformanceSharesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r254" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Unrecognized cost of unvested options awarded to employees as compensation.", "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options", "terseLabel": "Unrecognized compensation cost" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/EquityStockOptionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": { "auth_ref": [ "r253" ], "calculation": { "http://www.abbvie.com/role/EquityStockBasedCompensationDetails": { "order": 2.0, "parentTag": "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The total recognized tax benefit related to compensation cost for equity-based payment arrangements recognized in income during the period.", "label": "Employee Service Share-based Compensation, Tax Benefit from Compensation Expense", "terseLabel": "Tax benefit" } } }, "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/EquityStockBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "An arrangement whereby an employee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement. Although there are variations, normally, after vesting, when an option is exercised, the employee-holder pays the strike value in cash to the issuing employer-entity and receives equity shares. The equity shares can be sold into the market for cash at the current market price without restriction. Options may be used to attract, retain and incentivize employees, in addition to their regular salary and other benefits.", "label": "Employee Stock Option [Member]", "terseLabel": "Stock Options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/EquityStockOptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityClassOfTreasuryStockLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Equity, Class of Treasury Stock [Line Items]", "terseLabel": "Equity, Class of Treasury Stock" } } }, "localname": "EquityClassOfTreasuryStockLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/EquityStockRepurchaseProgramDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r209" ], "lang": { "en-US": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfEquityUnaudited", "http://www.abbvie.com/role/EquityAccumulatedOtherComprehensiveLossDetails", "http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": { "auth_ref": [ "r154" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in equity security without readily determinable fair value.", "label": "Equity Securities without Readily Determinable Fair Value, Amount", "terseLabel": "Carrying amount of investments in equity securities that do not have readily determinable fair values" } } }, "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresBasesUsedToMeasureApproximateFairValuesOfFinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EstimateOfFairValueFairValueDisclosureMember": { "auth_ref": [ "r337" ], "lang": { "en-US": { "role": { "documentation": "Measured as an estimate of fair value.", "label": "Estimate of Fair Value Measurement [Member]", "terseLabel": "Approximate fair value" } } }, "localname": "EstimateOfFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresBasesUsedToMeasureApproximateFairValuesOfFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair value, asset and liability measures", "verboseLabel": "Bases used to measure the approximate fair values of the financial instruments" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresBasesUsedToMeasureApproximateFairValuesOfFinancialInstrumentsDetails", "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresFairValueMeasuresDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r323", "r324", "r325", "r326", "r332", "r333" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.", "label": "Fair Value Measurements, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresBasesUsedToMeasureApproximateFairValuesOfFinancialInstrumentsDetails", "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresFairValueMeasuresDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount": { "auth_ref": [ "r326" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of transfers of assets measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.", "label": "Fair Value, Assets, Level 1 to Level 2 Transfers, Amount", "terseLabel": "Transfer of assets from level 1 to level 2" } } }, "localname": "FairValueAssetsLevel1ToLevel2TransfersAmount", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresTransfersOfAssetsOrLiabilitiesBetweenFairValueMeasurementLevelsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount": { "auth_ref": [ "r326" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of transfers of assets measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.", "label": "Fair Value, Assets, Level 2 to Level 1 Transfers, Amount", "terseLabel": "Transfer of assets from level 2 to level 1" } } }, "localname": "FairValueAssetsLevel2ToLevel1TransfersAmount", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresTransfersOfAssetsOrLiabilitiesBetweenFairValueMeasurementLevelsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueByBalanceSheetGroupingTextBlock": { "auth_ref": [ "r324", "r338" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.", "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]", "terseLabel": "Schedule of book values, approximate fair values and bases used to measure certain financial instruments" } } }, "localname": "FairValueByBalanceSheetGroupingTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r227", "r228", "r242", "r325", "r376" ], "lang": { "en-US": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresBasesUsedToMeasureApproximateFairValuesOfFinancialInstrumentsDetails", "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresFairValueMeasuresDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementBasisAxis": { "auth_ref": [ "r324", "r334" ], "lang": { "en-US": { "role": { "documentation": "Information by measurement basis.", "label": "Measurement Basis [Axis]", "terseLabel": "Measurement Basis [Axis]" } } }, "localname": "FairValueByMeasurementBasisAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresBasesUsedToMeasureApproximateFairValuesOfFinancialInstrumentsDetails", "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresFairValueMeasuresDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r323" ], "lang": { "en-US": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresFairValueMeasuresDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosureItemAmountsDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.", "label": "Fair Value Measurement [Domain]", "terseLabel": "Fair Value Measurement [Domain]" } } }, "localname": "FairValueDisclosureItemAmountsDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresBasesUsedToMeasureApproximateFairValuesOfFinancialInstrumentsDetails", "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresFairValueMeasuresDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueHedgingMember": { "auth_ref": [ "r292" ], "lang": { "en-US": { "role": { "documentation": "A hedge of the exposure to changes in the fair value of a recognized asset or liability, or of an unrecognized firm commitment, that are attributable to a particular risk.", "label": "Fair Value Hedging [Member]", "terseLabel": "Fair value hedges" } } }, "localname": "FairValueHedgingMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails", "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r227", "r228", "r242", "r325", "r377" ], "lang": { "en-US": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Quoted prices in active markets for identical assets (Level 1)" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresBasesUsedToMeasureApproximateFairValuesOfFinancialInstrumentsDetails", "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresFairValueMeasuresDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r227", "r228", "r242", "r325", "r378" ], "lang": { "en-US": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Significant other observable inputs (Level 2)" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresBasesUsedToMeasureApproximateFairValuesOfFinancialInstrumentsDetails", "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresFairValueMeasuresDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r227", "r228", "r242", "r325", "r379" ], "lang": { "en-US": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Significant unobservable inputs (Level 3)" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresBasesUsedToMeasureApproximateFairValuesOfFinancialInstrumentsDetails", "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresFairValueMeasuresDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount": { "auth_ref": [ "r326" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of transfers of liabilities measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.", "label": "Fair Value, Liabilities, Level 1 to Level 2 Transfers, Amount", "terseLabel": "Transfer of liabilities from level 1 to level 2" } } }, "localname": "FairValueLiabilitiesLevel1ToLevel2TransfersAmount", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresTransfersOfAssetsOrLiabilitiesBetweenFairValueMeasurementLevelsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount": { "auth_ref": [ "r326" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of transfers of liabilities measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.", "label": "Fair Value, Liabilities, Level 2 to Level 1 Transfers, Amount", "terseLabel": "Transfer of liabilities from level 2 to level 1" } } }, "localname": "FairValueLiabilitiesLevel2ToLevel1TransfersAmount", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresTransfersOfAssetsOrLiabilitiesBetweenFairValueMeasurementLevelsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "terseLabel": "Reconciliation of the fair value measurements that use significant unobservable inputs (Level 3)" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresTransfersOfAssetsOrLiabilitiesBetweenFairValueMeasurementLevelsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r328", "r333" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Schedule of changes in fair value of Level 3 inputs" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [ "r323", "r331" ], "lang": { "en-US": { "role": { "documentation": "Provides the general categories used to describe the frequency with which financial assets and liabilities (as defined) are measured at fair value (on a recurring or nonrecurring basis).", "label": "Fair Value, Measurement Frequency [Domain]", "terseLabel": "Fair Value Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresFairValueMeasuresDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "auth_ref": [ "r329" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) recognized on the income statement for financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings", "terseLabel": "Change in fair value recognized in net earnings" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresFairValueMeasuresDetails", "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresTransfersOfAssetsOrLiabilitiesBetweenFairValueMeasurementLevelsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": { "auth_ref": [ "r330" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements", "negatedTerseLabel": "Milestone payments" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresTransfersOfAssetsOrLiabilitiesBetweenFairValueMeasurementLevelsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "auth_ref": [ "r328" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresTransfersOfAssetsOrLiabilitiesBetweenFairValueMeasurementLevelsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Measurements Fair Value Hierarchy [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresBasesUsedToMeasureApproximateFairValuesOfFinancialInstrumentsDetails", "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresFairValueMeasuresDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r323", "r331" ], "lang": { "en-US": { "role": { "documentation": "This item represents a description of the frequency with which certain items are measured at fair value. Items measured at fair value on a recurring basis generally include those items for which measurement inputs are readily available and which are measured at fair value at successive reporting periods.", "label": "Fair Value, Measurements, Recurring [Member]", "terseLabel": "Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresFairValueMeasuresDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueTransfersBetweenLevel1AndLevel2DescriptionAndPolicyAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Fair Value, Transfers Between Level 1 and Level 2, Description and Policy [Abstract]", "terseLabel": "Transfers of assets or liabilities between the fair value measurement levels" } } }, "localname": "FairValueTransfersBetweenLevel1AndLevel2DescriptionAndPolicyAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresTransfersOfAssetsOrLiabilitiesBetweenFairValueMeasurementLevelsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinanceLeaseInterestExpense": { "auth_ref": [ "r357", "r363", "r373" ], "calculation": { "http://www.abbvie.com/role/LeasesCostDetails": { "order": 3.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of interest expense on finance lease liability.", "label": "Finance Lease, Interest Expense", "terseLabel": "Finance lease interest on lease liabilities" } } }, "localname": "FinanceLeaseInterestExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/LeasesCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseInterestPaymentOnLiability": { "auth_ref": [ "r359", "r367" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of interest paid on finance lease liability.", "label": "Finance Lease, Interest Payment on Liability", "terseLabel": "Operating cash flows from finance leases" } } }, "localname": "FinanceLeaseInterestPaymentOnLiability", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/LeasesCashFlowDisclosureDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Finance Lease Liabilities, Payments, Due [Abstract]", "terseLabel": "Finance leases" } } }, "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinanceLeaseLiability": { "auth_ref": [ "r356", "r372" ], "calculation": { "http://www.abbvie.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetailsCalc2": { "order": 2.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.", "label": "Finance Lease, Liability", "terseLabel": "Present value of lease liabilities" } } }, "localname": "FinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityCurrent": { "auth_ref": [ "r356" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.", "label": "Finance Lease, Liability, Current", "terseLabel": "Current finance lease liabilities" } } }, "localname": "FinanceLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/LeasesBalanceSheetDisclosureDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r372" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.", "label": "Finance Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Summary of future maturities of AbbVie's finance lease liabilities" } } }, "localname": "FinanceLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "auth_ref": [ "r356" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.", "label": "Finance Lease, Liability, Noncurrent", "terseLabel": "Noncurrent finance lease liabilities" } } }, "localname": "FinanceLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/LeasesBalanceSheetDisclosureDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDue": { "auth_ref": [ "r372" ], "calculation": { "http://www.abbvie.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.abbvie.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetailsCalc2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.", "label": "Finance Lease, Liability, Payments, Due", "totalLabel": "Total lease payments" } } }, "localname": "FinanceLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r372" ], "calculation": { "http://www.abbvie.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetails": { "order": 6.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due after fifth fiscal year following latest fiscal year.", "label": "Finance Lease, Liability, Payments, Due after Year Five", "terseLabel": "Thereafter" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r372" ], "calculation": { "http://www.abbvie.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in fifth fiscal year following latest fiscal year.", "label": "Finance Lease, Liability, Payments, Due Year Five", "terseLabel": "2023" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r372" ], "calculation": { "http://www.abbvie.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in fourth fiscal year following latest fiscal year.", "label": "Finance Lease, Liability, Payments, Due Year Four", "terseLabel": "2022" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r372" ], "calculation": { "http://www.abbvie.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in third fiscal year following latest fiscal year.", "label": "Finance Lease, Liability, Payments, Due Year Three", "terseLabel": "2021" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r372" ], "calculation": { "http://www.abbvie.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in second fiscal year following latest fiscal year.", "label": "Finance Lease, Liability, Payments, Due Year Two", "terseLabel": "2020" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r372" ], "calculation": { "http://www.abbvie.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in remainder of fiscal year following latest fiscal year ended.", "label": "Finance Lease, Liability, Payments, Remainder of Fiscal Year", "terseLabel": "2019" } } }, "localname": "FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r372" ], "calculation": { "http://www.abbvie.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetailsCalc2": { "order": 1.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.", "label": "Finance Lease, Liability, Undiscounted Excess Amount", "terseLabel": "Less: Interest" } } }, "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeasePrincipalPayments": { "auth_ref": [ "r358", "r367" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow for principal payment on finance lease.", "label": "Finance Lease, Principal Payments", "terseLabel": "Financing cash flows from finance leases" } } }, "localname": "FinanceLeasePrincipalPayments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/LeasesCashFlowDisclosureDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAsset": { "auth_ref": [ "r355" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's right to use underlying asset under finance lease.", "label": "Finance Lease, Right-of-Use Asset", "terseLabel": "Finance lease assets" } } }, "localname": "FinanceLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/LeasesBalanceSheetDisclosureDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAssetAmortization": { "auth_ref": [ "r357", "r363", "r373" ], "calculation": { "http://www.abbvie.com/role/LeasesCostDetails": { "order": 2.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.", "label": "Finance Lease, Right-of-Use Asset, Amortization", "terseLabel": "Finance lease amortization of right-of-use assets" } } }, "localname": "FinanceLeaseRightOfUseAssetAmortization", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/LeasesCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r370", "r373" ], "lang": { "en-US": { "role": { "documentation": "Weighted average discount rate for finance lease calculated at point in time.", "label": "Finance Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted-average discount rate for finance leases" } } }, "localname": "FinanceLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/LeasesWeightedAverageRemainingLeaseTermAndDiscountRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r369", "r373" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Finance Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted-average remaining lease term for finance leases" } } }, "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/LeasesWeightedAverageRemainingLeaseTermAndDiscountRateDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresAvailableForSaleSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r174" ], "calculation": { "http://www.abbvie.com/role/GoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsNetDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0 }, "http://www.abbvie.com/role/GoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsNetDetailsCalc2": { "order": 2.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedLabel": "Accumulated amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/GoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r168", "r171", "r174", "r177", "r382" ], "lang": { "en-US": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/GoodwillAndIntangibleAssetsDefiniteLivedIntangibleAssetsDetails", "http://www.abbvie.com/role/GoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r174", "r382" ], "calculation": { "http://www.abbvie.com/role/GoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsNetDetails": { "order": 2.0, "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Gross carrying amount" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/GoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Finite-Lived Intangible Assets" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/GoodwillAndIntangibleAssetsDefiniteLivedIntangibleAssetsDetails", "http://www.abbvie.com/role/GoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r168", "r173" ], "lang": { "en-US": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/GoodwillAndIntangibleAssetsDefiniteLivedIntangibleAssetsDetails", "http://www.abbvie.com/role/GoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r174" ], "calculation": { "http://www.abbvie.com/role/GoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsNetDetails": { "order": 2.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "totalLabel": "Net carrying amount" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/GoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in carrying value of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Period Increase (Decrease)", "terseLabel": "Reclassification to definite-lived intangible assets" } } }, "localname": "FiniteLivedIntangibleAssetsPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/GoodwillAndIntangibleAssetsDefiniteLivedIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months": { "auth_ref": [ "r319" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The estimated net amount of unrealized gains or losses on foreign currency cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months.", "label": "Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months", "terseLabel": "Foreign currency cash flow hedge gain expected to be reclassified during next 12 months" } } }, "localname": "ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyGainLossMember": { "auth_ref": [ "r311" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing foreign currency gain (loss).", "label": "Foreign Currency Gain (Loss) [Member]", "terseLabel": "Net foreign exchange loss" } } }, "localname": "ForeignCurrencyGainLossMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "auth_ref": [ "r344", "r345", "r346" ], "calculation": { "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfEarningsUnaudited": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.", "label": "Foreign Currency Transaction Gain (Loss), before Tax", "negatedLabel": "Net foreign exchange loss" } } }, "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfEarningsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignExchangeContractMember": { "auth_ref": [ "r227", "r310" ], "lang": { "en-US": { "role": { "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.", "label": "Foreign Exchange Contract [Member]", "terseLabel": "Foreign currency contracts" } } }, "localname": "ForeignExchangeContractMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresFairValueMeasuresDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignExchangeForwardMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Foreign exchange forward traded on an exchange (examples include but are not limited to the International Securities Exchange, Philadelphia Stock Exchange, or the Chicago Mercantile Exchange) for options or future contracts to buy or sell a certain currency, at a specified date, at a fixed exercise exchange rate.", "label": "Foreign Exchange Forward [Member]", "terseLabel": "Foreign currency forward exchange contracts" } } }, "localname": "ForeignExchangeForwardMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails", "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of entity's patents that another entity has allegedly infringed.", "label": "Gain Contingency, Patents Allegedly Infringed upon, Number", "terseLabel": "HCV-related patents" } } }, "localname": "GainContingencyPatentsAllegedlyInfringedUponNumber", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/LegalProceedingsAndContingenciesDetails" ], "xbrltype": "integerItemType" }, "us-gaap_GeographicConcentrationRiskMember": { "auth_ref": [ "r125" ], "lang": { "en-US": { "role": { "documentation": "Reflects the percentage that a specified dollar value on the balance sheet or income statement in the period from one or more specified geographic areas is to a corresponding consolidated, segment, or product line amount. Risk is the materially adverse effects of economic decline or antagonistic political actions resulting in loss of assets, sales volume, labor supply, or source of materials and supplies in a US state or a specified country, continent, or region such as EMEA (Europe, Middle East, Africa).", "label": "Geographic Concentration Risk [Member]", "terseLabel": "Geographic Risk" } } }, "localname": "GeographicConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresConcentrationsOfRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r158", "r159" ], "calculation": { "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "periodEndLabel": "Balance at the end of the period", "periodStartLabel": "Balance at the beginning of the period", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets", "http://www.abbvie.com/role/GoodwillAndIntangibleAssetsGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r180" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "terseLabel": "Goodwill and Intangible Assets" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/GoodwillAndIntangibleAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": { "auth_ref": [ "r160", "r163" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Impaired, Accumulated Impairment Loss", "terseLabel": "Accumulated goodwill impairment losses" } } }, "localname": "GoodwillImpairedAccumulatedImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/GoodwillAndIntangibleAssetsGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillImpairedAccumulatedImpairmentLossAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Goodwill, Impaired, Accumulated Impairment Loss [Abstract]", "terseLabel": "Accumulated goodwill impairment losses" } } }, "localname": "GoodwillImpairedAccumulatedImpairmentLossAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/GoodwillAndIntangibleAssetsGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GoodwillRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Goodwill [Roll Forward]", "terseLabel": "Changes in the carrying amount of goodwill" } } }, "localname": "GoodwillRollForward", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/GoodwillAndIntangibleAssetsGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GoodwillTranslationAndPurchaseAccountingAdjustments": { "auth_ref": [ "r161", "r162", "r270" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) from foreign currency translation adjustments and purchase accounting adjustments of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Translation and Purchase Accounting Adjustments", "verboseLabel": "Foreign currency translation adjustments" } } }, "localname": "GoodwillTranslationAndPurchaseAccountingAdjustments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/GoodwillAndIntangibleAssetsGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_HedgingDesignationAxis": { "auth_ref": [ "r295", "r313" ], "lang": { "en-US": { "role": { "documentation": "Information by designation of purpose of derivative instrument.", "label": "Hedging Designation [Axis]", "terseLabel": "Hedging Designation [Axis]" } } }, "localname": "HedgingDesignationAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails", "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_HedgingDesignationDomain": { "auth_ref": [ "r295" ], "lang": { "en-US": { "role": { "documentation": "Designation of purpose of derivative instrument.", "label": "Hedging Designation [Domain]", "terseLabel": "Hedging Designation [Domain]" } } }, "localname": "HedgingDesignationDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails", "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_HedgingRelationshipDomain": { "auth_ref": [ "r295" ], "lang": { "en-US": { "role": { "documentation": "Nature or intent of a hedge.", "label": "Hedging Relationship [Domain]", "terseLabel": "Hedging Relationship [Domain]" } } }, "localname": "HedgingRelationshipDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveIncomeDetails", "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails", "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": { "auth_ref": [ "r96", "r178" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.", "label": "Impairment of Intangible Assets, Finite-lived", "terseLabel": "Definite-lived intangible assets impairment charges" } } }, "localname": "ImpairmentOfIntangibleAssetsFinitelived", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/GoodwillAndIntangibleAssetsDefiniteLivedIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": { "auth_ref": [ "r96", "r178" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.", "label": "Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)", "terseLabel": "Indefinite-lived intangible asset impairment charges" } } }, "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/GoodwillAndIntangibleAssetsIndefiniteLivedIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InProcessResearchAndDevelopmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.", "label": "In Process Research and Development [Member]", "terseLabel": "In-Process Research and Development" } } }, "localname": "InProcessResearchAndDevelopmentMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/GoodwillAndIntangibleAssetsIndefiniteLivedIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r103" ], "calculation": { "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfEarningsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.", "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest", "totalLabel": "Earnings before income tax expense" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfEarningsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r185" ], "lang": { "en-US": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/EquityStockBasedCompensationDetails", "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/EquityStockBasedCompensationDetails", "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r269" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r101", "r133", "r268" ], "calculation": { "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfEarningsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 }, "http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveIncomeDetails": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Income tax expense", "verboseLabel": "Tax expense (benefit)" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfEarningsUnaudited", "http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r95" ], "calculation": { "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "terseLabel": "Accounts payable and other liabilities" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r95" ], "calculation": { "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInFairValueOfHedgedItemInInterestRateFairValueHedge1": { "auth_ref": [ "r298", "r305" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of unrealized gain (loss) included in earnings related to the fair value of the hedged item in an interest rate fair value hedge, offset by the gain (loss) on the hedging instrument to the extent that the fair value hedge is determined to be effective.", "label": "Increase (Decrease) in Fair Value of Hedged Item in Interest Rate Fair Value Hedge", "terseLabel": "Debt designated as hedged item in fair value hedges gain (loss)" } } }, "localname": "IncreaseDecreaseInFairValueOfHedgedItemInInterestRateFairValueHedge1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r95" ], "calculation": { "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r95" ], "calculation": { "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfEquityUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r115", "r120" ], "calculation": { "http://www.abbvie.com/role/EarningsPerShareDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements", "terseLabel": "Effect of dilutive securities (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/EarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r169", "r176" ], "lang": { "en-US": { "role": { "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets [Axis]", "terseLabel": "Indefinite-lived Intangible Assets [Axis]" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/GoodwillAndIntangibleAssetsIndefiniteLivedIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Indefinite-lived Intangible Assets [Line Items]", "terseLabel": "Indefinite-lived Intangible Assets" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/GoodwillAndIntangibleAssetsIndefiniteLivedIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "auth_ref": [ "r176" ], "calculation": { "http://www.abbvie.com/role/GoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsNetDetails": { "order": 1.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)", "terseLabel": "Indefinite-lived research and development", "verboseLabel": "Indefinite-lived research and development assets" } } }, "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/GoodwillAndIntangibleAssetsIndefiniteLivedIntangibleAssetsDetails", "http://www.abbvie.com/role/GoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r169", "r176" ], "lang": { "en-US": { "role": { "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.", "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/GoodwillAndIntangibleAssetsIndefiniteLivedIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease": { "auth_ref": [ "r176" ], "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets, Period Increase (Decrease)", "terseLabel": "Reclassification from indefinite-lived intangible assets" } } }, "localname": "IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/GoodwillAndIntangibleAssetsIndefiniteLivedIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsGrossExcludingGoodwill": { "auth_ref": [], "calculation": { "http://www.abbvie.com/role/GoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsNetDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.abbvie.com/role/GoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsNetDetailsCalc2": { "order": 1.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.", "label": "Intangible Assets, Gross (Excluding Goodwill)", "totalLabel": "Total intangible assets gross carrying amount" } } }, "localname": "IntangibleAssetsGrossExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/GoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r166", "r172" ], "calculation": { "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.abbvie.com/role/GoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsNetDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.abbvie.com/role/GoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsNetDetailsCalc2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Intangible assets, net", "totalLabel": "Total intangible assets, net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets", "http://www.abbvie.com/role/GoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r71", "r132", "r348", "r350", "r393" ], "calculation": { "http://www.abbvie.com/role/SupplementalFinancialInformationDetails": { "order": 1.0, "parentTag": "us-gaap_InterestIncomeExpenseNonoperatingNet", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "terseLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/SupplementalFinancialInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseMember": { "auth_ref": [ "r311" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing interest expense.", "label": "Interest Expense [Member]", "terseLabel": "Interest expense, net" } } }, "localname": "InterestExpenseMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities.", "label": "Interest Income and Interest Expense Disclosure [Table Text Block]", "terseLabel": "Schedule of interest expense, net" } } }, "localname": "InterestIncomeAndInterestExpenseDisclosureTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/SupplementalFinancialInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_InterestIncomeExpenseNonoperatingNet": { "auth_ref": [], "calculation": { "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfEarningsUnaudited": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 }, "http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveIncomeDetails": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 }, "http://www.abbvie.com/role/SupplementalFinancialInformationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net amount of nonoperating interest income (expense).", "label": "Interest Income (Expense), Nonoperating, Net", "negatedLabel": "Interest expense, net", "negatedTerseLabel": "Gains on derivative amount excluded from effectiveness testing", "negatedTotalLabel": "Interest expense, net" } } }, "localname": "InterestIncomeExpenseNonoperatingNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfEarningsUnaudited", "http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveIncomeDetails", "http://www.abbvie.com/role/SupplementalFinancialInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateDerivativeAssetsAtFairValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value as of the balance sheet date of interest rate derivative assets, which includes all such derivative instruments in hedging and nonhedging relationships that are recognized as assets.", "label": "Interest Rate Derivative Assets, at Fair Value", "terseLabel": "Interest rate hedges" } } }, "localname": "InterestRateDerivativeAssetsAtFairValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresFairValueMeasuresDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateDerivativeLiabilitiesAtFairValue": { "auth_ref": [], "calculation": { "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresFairValueMeasuresDetails": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value as of the balance sheet date of interest rate derivative liabilities, which includes all such derivative instruments in hedging and nonhedging relationships that are recognized as liabilities.", "label": "Interest Rate Derivative Liabilities, at Fair Value", "terseLabel": "Interest rate hedges" } } }, "localname": "InterestRateDerivativeLiabilitiesAtFairValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresFairValueMeasuresDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateSwapMember": { "auth_ref": [ "r309" ], "lang": { "en-US": { "role": { "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.", "label": "Interest Rate Swap [Member]", "terseLabel": "Interest rate contracts", "verboseLabel": "Interest rate swaps designated as fair value hedges" } } }, "localname": "InterestRateSwapMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails", "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InterestRevenueOrExpenseNetAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Interest Revenue (Expense), Net [Abstract]", "verboseLabel": "Interest Expense, Net" } } }, "localname": "InterestRevenueOrExpenseNetAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/SupplementalFinancialInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "auth_ref": [ "r22", "r157" ], "calculation": { "http://www.abbvie.com/role/SupplementalFinancialInformationDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.", "label": "Inventory, Finished Goods, Net of Reserves", "terseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoodsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/SupplementalFinancialInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r2", "r45", "r156" ], "calculation": { "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.abbvie.com/role/SupplementalFinancialInformationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventories", "totalLabel": "Inventories" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets", "http://www.abbvie.com/role/SupplementalFinancialInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNetAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Inventory, Net [Abstract]", "terseLabel": "Inventories" } } }, "localname": "InventoryNetAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/SupplementalFinancialInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "auth_ref": [ "r24", "r157" ], "calculation": { "http://www.abbvie.com/role/SupplementalFinancialInformationDetails": { "order": 3.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.", "label": "Inventory, Raw Materials, Net of Reserves", "verboseLabel": "Raw materials" } } }, "localname": "InventoryRawMaterialsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/SupplementalFinancialInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "auth_ref": [ "r23", "r157" ], "calculation": { "http://www.abbvie.com/role/SupplementalFinancialInformationDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.", "label": "Inventory, Work in Process, Net of Reserves", "terseLabel": "Work-in-process" } } }, "localname": "InventoryWorkInProcessNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/SupplementalFinancialInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInterest": { "auth_ref": [ "r79", "r131" ], "calculation": { "http://www.abbvie.com/role/SupplementalFinancialInformationDetails": { "order": 2.0, "parentTag": "us-gaap_InterestIncomeExpenseNonoperatingNet", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.", "label": "Investment Income, Interest", "negatedLabel": "Interest income" } } }, "localname": "InvestmentIncomeInterest", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/SupplementalFinancialInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentTypeAxis": { "auth_ref": [ "r411", "r412", "r413", "r414" ], "lang": { "en-US": { "role": { "documentation": "Information by type of investments.", "label": "Investment Type [Axis]", "terseLabel": "Investment Type [Axis]" } } }, "localname": "InvestmentTypeAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresFairValueMeasuresDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentTypeCategorizationMember": { "auth_ref": [ "r411", "r412", "r413", "r414" ], "lang": { "en-US": { "role": { "documentation": "Asset obtained to generate income or appreciate in value.", "label": "Investments [Domain]", "terseLabel": "Investment Type Categorization [Member]" } } }, "localname": "InvestmentTypeCategorizationMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresFairValueMeasuresDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InvestmentsFairValueDisclosure": { "auth_ref": [ "r324" ], "calculation": { "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresFairValueMeasuresDetails": { "order": 4.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.", "label": "Investments, Fair Value Disclosure", "terseLabel": "Time deposits" } } }, "localname": "InvestmentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresFairValueMeasuresDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r371", "r373" ], "calculation": { "http://www.abbvie.com/role/LeasesCostDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease, Cost", "totalLabel": "Total lease cost" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/LeasesCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r371" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Summary of lease costs recognized in the condensed consolidated statement of earnings" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_LeasesOfLesseeDisclosureTextBlock": { "auth_ref": [ "r352", "r374" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.", "label": "Leases of Lessee Disclosure [Text Block]", "terseLabel": "Leases" } } }, "localname": "LeasesOfLesseeDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_LegalMattersAndContingenciesTextBlock": { "auth_ref": [ "r204" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.", "label": "Legal Matters and Contingencies [Text Block]", "terseLabel": "Legal Proceedings and Contingencies" } } }, "localname": "LegalMattersAndContingenciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/LegalProceedingsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]", "terseLabel": "Lessee, Lease, Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/LeasesBalanceSheetDisclosureDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r362" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]", "terseLabel": "Lessee, Lease, Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/LeasesBalanceSheetDisclosureDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r361" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/LeasesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r372" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Summary of future maturities of AbbVie's operating lease liabilities" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r372" ], "calculation": { "http://www.abbvie.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.abbvie.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetailsCalc2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Payments, Due", "totalLabel": "Total lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r372" ], "calculation": { "http://www.abbvie.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetails": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due after Year Five", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r372" ], "calculation": { "http://www.abbvie.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Five", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r372" ], "calculation": { "http://www.abbvie.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four", "terseLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r372" ], "calculation": { "http://www.abbvie.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three", "terseLabel": "2021" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r372" ], "calculation": { "http://www.abbvie.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two", "terseLabel": "2020" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r372" ], "calculation": { "http://www.abbvie.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease having an initial or remaining lease term in excess of one year due in remainder of fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year", "terseLabel": "2019" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r372" ], "calculation": { "http://www.abbvie.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetailsCalc2": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "terseLabel": "Less: Interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities [Abstract]", "terseLabel": "Liabilities" } } }, "localname": "LiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/LeasesBalanceSheetDisclosureDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r21", "r386", "r402" ], "calculation": { "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and Equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r39" ], "calculation": { "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosure": { "auth_ref": [ "r324" ], "calculation": { "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresBasesUsedToMeasureApproximateFairValuesOfFinancialInstrumentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresFairValueMeasuresDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value of financial and nonfinancial obligations.", "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure", "totalLabel": "Total liabilities" } } }, "localname": "LiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresBasesUsedToMeasureApproximateFairValuesOfFinancialInstrumentsDetails", "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresFairValueMeasuresDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities, Fair Value Disclosure [Abstract]", "terseLabel": "Liabilities" } } }, "localname": "LiabilitiesFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresBasesUsedToMeasureApproximateFairValuesOfFinancialInstrumentsDetails", "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresFairValueMeasuresDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent": { "auth_ref": [], "calculation": { "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregated carrying amounts of obligations as of the balance sheet date, excluding long-term debt, incurred as part of the normal operations that are expected to be paid after one year or beyond the normal operating cycle, if longer. Alternate captions include Total Deferred Credits and Other Liabilities.", "label": "Liabilities, Other than Long-term Debt, Noncurrent", "terseLabel": "Other long-term liabilities" } } }, "localname": "LiabilitiesOtherThanLongtermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/BasisOfPresentationDetails", "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LicensingAgreementsMember": { "auth_ref": [ "r273" ], "lang": { "en-US": { "role": { "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).", "label": "Licensing Agreements [Member]", "terseLabel": "License agreements" } } }, "localname": "LicensingAgreementsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/GoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r35" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Bridge credit agreement maximum borrowing capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/LicensingAcquisitionsAndOtherArrangementsProposedAcquisitionOfAllerganPlcDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LoansPayableMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Borrowing supported by a written promise to pay an obligation.", "label": "Loans Payable [Member]", "terseLabel": "Term loan facilities", "verboseLabel": "Term loan agreement" } } }, "localname": "LoansPayableMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresDebtAndCreditFacilitiesDetails", "http://www.abbvie.com/role/LicensingAcquisitionsAndOtherArrangementsProposedAcquisitionOfAllerganPlcDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebtAndCapitalLeaseObligations": { "auth_ref": [ "r12" ], "calculation": { "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt and capital lease obligation due after one year or beyond the normal operating cycle, if longer.", "label": "Long-term Debt and Capital Lease Obligations", "terseLabel": "Long-term debt and finance lease obligations" } } }, "localname": "LongTermDebtAndCapitalLeaseObligations", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent": { "auth_ref": [ "r38" ], "calculation": { "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt and capital leases due within one year or the normal operating cycle, if longer.", "label": "Long-term Debt and Capital Lease Obligations, Current", "terseLabel": "Current portion of long-term debt and finance lease obligations" } } }, "localname": "LongTermDebtAndCapitalLeaseObligationsCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermInvestments": { "auth_ref": [ "r29" ], "calculation": { "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).", "label": "Long-term Investments", "terseLabel": "Investments" } } }, "localname": "LongTermInvestments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r41" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails", "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresFinancialInstrumentsDetails", "http://www.abbvie.com/role/LicensingAcquisitionsAndOtherArrangementsProposedAcquisitionOfAllerganPlcDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r41", "r208" ], "lang": { "en-US": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails", "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresFinancialInstrumentsDetails", "http://www.abbvie.com/role/LicensingAcquisitionsAndOtherArrangementsProposedAcquisitionOfAllerganPlcDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingenciesByNatureOfContingencyAxis": { "auth_ref": [ "r195", "r196", "r197", "r199", "r200", "r201", "r203", "r205", "r206" ], "lang": { "en-US": { "role": { "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.", "label": "Loss Contingency Nature [Axis]", "terseLabel": "Loss Contingency Nature [Axis]" } } }, "localname": "LossContingenciesByNatureOfContingencyAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/LegalProceedingsAndContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Loss Contingencies [Line Items]", "terseLabel": "Legal Proceedings and Contingencies" } } }, "localname": "LossContingenciesLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/LegalProceedingsAndContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesTable": { "auth_ref": [ "r195", "r196", "r197", "r199", "r200", "r201", "r203", "r205", "r206" ], "lang": { "en-US": { "role": { "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.", "label": "Loss Contingencies [Table]", "terseLabel": "Loss Contingencies [Table]" } } }, "localname": "LossContingenciesTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/LegalProceedingsAndContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingencyAccrualAtCarryingValue": { "auth_ref": [ "r195" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of loss contingency liability.", "label": "Loss Contingency Accrual", "terseLabel": "Recorded accrual balance for litigation" } } }, "localname": "LossContingencyAccrualAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/LegalProceedingsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyDamagesAwardedValue": { "auth_ref": [ "r195", "r198", "r202" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of damages awarded to the plaintiff in the legal matter.", "label": "Loss Contingency, Damages Awarded, Value", "terseLabel": "Damages awarded against company" } } }, "localname": "LossContingencyDamagesAwardedValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/LegalProceedingsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyNatureDomain": { "auth_ref": [ "r195", "r196", "r197", "r199", "r200", "r201", "r203", "r205", "r206" ], "lang": { "en-US": { "role": { "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.", "label": "Loss Contingency, Nature [Domain]", "terseLabel": "Loss Contingency Nature [Domain]" } } }, "localname": "LossContingencyNatureDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/LegalProceedingsAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingencyNewClaimsFiledNumber": { "auth_ref": [ "r198" ], "lang": { "en-US": { "role": { "documentation": "The total number of new claims filed pertaining to a loss contingency during the period.", "label": "Loss Contingency, New Claims Filed, Number", "terseLabel": "Number of parties to lawsuit (in investment funds)" } } }, "localname": "LossContingencyNewClaimsFiledNumber", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/LegalProceedingsAndContingenciesDetails" ], "xbrltype": "integerItemType" }, "us-gaap_LossContingencyNumberOfPlaintiffs": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of plaintiffs that have filed claims pertaining to a loss contingency.", "label": "Loss Contingency, Number of Plaintiffs", "terseLabel": "Number of healthcare benefit providers who filed lawsuits" } } }, "localname": "LossContingencyNumberOfPlaintiffs", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/LegalProceedingsAndContingenciesDetails" ], "xbrltype": "integerItemType" }, "us-gaap_LossContingencyPendingClaimsNumber": { "auth_ref": [ "r198" ], "lang": { "en-US": { "role": { "documentation": "Number of pending claims pertaining to a loss contingency.", "label": "Loss Contingency, Pending Claims, Number", "terseLabel": "Number of claims pending" } } }, "localname": "LossContingencyPendingClaimsNumber", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/LegalProceedingsAndContingenciesDetails" ], "xbrltype": "integerItemType" }, "us-gaap_MaximumLengthOfTimeHedgedInCashFlowHedge1": { "auth_ref": [ "r320" ], "lang": { "en-US": { "role": { "documentation": "Maximum length of time over which the entity is hedging its exposure to the variability in future cash flows for forecasted transactions, excluding those forecasted transactions related to the payment of variable interest on existing financial instruments, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Maximum Length of Time Hedged in Cash Flow Hedge", "terseLabel": "Approximate length of time over which accumulated gains and losses will be recognized in Cost of products sold" } } }, "localname": "MaximumLengthOfTimeHedgedInCashFlowHedge1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresFinancialInstrumentsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r93" ], "calculation": { "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Cash flows from financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]", "terseLabel": "Cash flows from financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r93" ], "calculation": { "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Cash flows from investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]", "terseLabel": "Cash flows from investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r93", "r94", "r97" ], "calculation": { "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Cash flows from operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]", "terseLabel": "Cash flows from operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r64", "r67", "r72", "r97", "r120", "r391", "r405" ], "calculation": { "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfEarningsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.abbvie.com/role/EarningsPerShareDetails": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0 }, "http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveIncomeDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "negatedTotalLabel": "Total reclassifications, net of tax", "terseLabel": "Net earnings", "totalLabel": "Net earnings" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited", "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfEarningsUnaudited", "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfEquityUnaudited", "http://www.abbvie.com/role/EarningsPerShareDetails", "http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r108", "r112" ], "calculation": { "http://www.abbvie.com/role/EarningsPerShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "totalLabel": "Earnings available to common shareholders" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/EarningsPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "auth_ref": [ "r112", "r113" ], "calculation": { "http://www.abbvie.com/role/EarningsPerShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Diluted", "totalLabel": "Earnings available to common shareholders" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/EarningsPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetInvestmentHedgingMember": { "auth_ref": [ "r294" ], "lang": { "en-US": { "role": { "documentation": "Hedges of a net investment in a foreign operation.", "label": "Net Investment Hedging [Member]", "terseLabel": "Net investment hedges", "verboseLabel": "Net investment hedging activity" } } }, "localname": "NetInvestmentHedgingMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveIncomeDetails", "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails", "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/BasisOfPresentationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": { "auth_ref": [ "r107", "r109", "r110" ], "lang": { "en-US": { "role": { "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.", "label": "New Accounting Pronouncements or Change in Accounting Principle [Table]", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/BasisOfPresentationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/BasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonUsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Countries excluding the United States of America (US).", "label": "Non-US [Member]", "terseLabel": "International" } } }, "localname": "NonUsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CollaborationWithJanssenBiotechIncDetails", "http://www.abbvie.com/role/SegmentInformationDisaggregationOfRevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NondesignatedMember": { "auth_ref": [ "r295" ], "lang": { "en-US": { "role": { "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Not Designated as Hedging Instrument [Member]", "terseLabel": "Not designated as hedging instrument", "verboseLabel": "Not designated as hedges" } } }, "localname": "NondesignatedMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails", "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments", "terseLabel": "Number of operating segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/SegmentInformationAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent": { "auth_ref": [ "r61", "r70" ], "calculation": { "http://www.abbvie.com/role/EquityAccumulatedOtherComprehensiveLossDetails": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax, before reclassification adjustments, of other comprehensive income (loss), attributable to parent.", "label": "OCI, before Reclassifications, Net of Tax, Attributable to Parent", "terseLabel": "Other comprehensive income (loss) before reclassifications" } } }, "localname": "OciBeforeReclassificationsNetOfTaxAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/EquityAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [], "calculation": { "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfEarningsUnaudited": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Operating earnings" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfEarningsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r364", "r373" ], "calculation": { "http://www.abbvie.com/role/LeasesCostDetails": { "order": 1.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Operating lease cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/LeasesCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Operating Lease Liabilities, Payments Due [Abstract]", "terseLabel": "Operating leases" } } }, "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r356" ], "calculation": { "http://www.abbvie.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetailsCalc2": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Present value of lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r356" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Current operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/LeasesBalanceSheetDisclosureDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r356" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Noncurrent operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/LeasesBalanceSheetDisclosureDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r360", "r367" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Operating cash flows from operating leases" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/LeasesCashFlowDisclosureDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r355" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/LeasesBalanceSheetDisclosureDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r370", "r373" ], "lang": { "en-US": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted-average discount rate for operating leases" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/LeasesWeightedAverageRemainingLeaseTermAndDiscountRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r369", "r373" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted-average remaining lease term for operating leases" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/LeasesWeightedAverageRemainingLeaseTermAndDiscountRateDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r0", "r288" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/BasisOfPresentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r32" ], "calculation": { "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/BasisOfPresentationDetails", "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r284", "r285", "r286" ], "calculation": { "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": { "order": 4.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.", "label": "Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent", "verboseLabel": "Marketable security activities, net of tax expense (benefit) of $\u2014 for the three months and $\u2014 for the six months ended June 30, 2019 and $\u2014 for the three months and $\u2014 for the six months ended June 30, 2018" } } }, "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent": { "auth_ref": [ "r284", "r285", "r286" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of tax expense (benefit), after reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.", "label": "Other Comprehensive Income (Loss), Available-for-sale Securities, Tax, Portion Attributable to Parent", "terseLabel": "Marketable security activities, tax expense (benefit)" } } }, "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeParentheticalUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r56", "r58", "r284", "r286" ], "calculation": { "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": { "order": 3.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan, attributable to parent.", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent", "negatedLabel": "Pension and post-employment benefits, net of tax expense (benefit) of $6 for the three months and $12 for the six months ended June 30, 2019 and $7 for the three months and $16 for the six months ended June 30, 2018" } } }, "localname": "OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansTaxPortionAttributableToParent": { "auth_ref": [ "r284", "r285", "r286" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after reclassification adjustment, of tax (expense) benefit for (increase) decrease in accumulated other comprehensive income for defined benefit plan, attributable to parent.", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax, Attributable to Parent", "negatedLabel": "Pension and post-employment benefits, tax expense (benefit)" } } }, "localname": "OtherComprehensiveIncomeDefinedBenefitPlansTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeParentheticalUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r284", "r285", "r286" ], "calculation": { "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent", "terseLabel": "Foreign currency translation adjustments, net of tax expense (benefit) of $5 for the three months and $6 for the six months ended June 30, 2019 and $(16) for the three months and $(19) for the six months ended June 30, 2018" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent": { "auth_ref": [ "r284", "r285", "r286" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax, Portion Attributable to Parent", "terseLabel": "Foreign currency translation adjustments, tax expense (benefit)" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeParentheticalUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent": { "auth_ref": [ "r58" ], "calculation": { "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": { "order": 5.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent", "terseLabel": "Cash flow hedging activities, net of tax expense (benefit) of $(2) for the three months and $(9) for the six months ended June 30, 2019 and $18 for the three months and $17 for the six months ended June 30, 2018" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent": { "auth_ref": [ "r59" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax, Parent", "terseLabel": "Cash flow hedging activities, tax expense (benefit)" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeParentheticalUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": { "auth_ref": [ "r51", "r58", "r300", "r306", "r317" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax", "terseLabel": "Pre-tax gains (losses) from derivative instruments designated as cash flow hedges recognized in other comprehensive income" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax": { "auth_ref": [ "r308" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.", "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax", "terseLabel": "Pre-tax gains (losses) from net investment hedge instruments recognized in other comprehensive income" } } }, "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r65", "r68", "r284", "r285", "r286" ], "calculation": { "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.abbvie.com/role/EquityAccumulatedOtherComprehensiveLossDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "terseLabel": "Other comprehensive income, net of tax", "totalLabel": "Other comprehensive income (loss)" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited", "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfEquityUnaudited", "http://www.abbvie.com/role/EquityAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherDebtSecuritiesMember": { "auth_ref": [ "r149", "r227", "r331" ], "lang": { "en-US": { "role": { "documentation": "Investments in debt securities classified as other.", "label": "Other Debt Obligations [Member]", "terseLabel": "Other debt securities" } } }, "localname": "OtherDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresAvailableForSaleSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherExpenses": { "auth_ref": [ "r78", "r407" ], "calculation": { "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfEarningsUnaudited": { "order": 5.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense classified as other.", "label": "Other Expenses", "terseLabel": "Other expense" } } }, "localname": "OtherExpenses", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfEarningsUnaudited", "http://www.abbvie.com/role/LicensingAcquisitionsAndOtherArrangementsOtherLicensingAcquisitionsActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesMember": { "auth_ref": [ "r297", "r316" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other liabilities.", "label": "Other Liabilities [Member]", "terseLabel": "Other long-term liabilities" } } }, "localname": "OtherLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNoncashIncomeExpense": { "auth_ref": [ "r97" ], "calculation": { "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.", "label": "Other Noncash Income (Expense)", "negatedLabel": "Other, net" } } }, "localname": "OtherNoncashIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncurrentAssetsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other noncurrent assets.", "label": "Other Noncurrent Assets [Member]", "terseLabel": "Other assets" } } }, "localname": "OtherNoncurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresFinancialInstrumentsDetails", "http://www.abbvie.com/role/LeasesBalanceSheetDisclosureDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNoncurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.", "label": "Other Noncurrent Liabilities [Member]", "terseLabel": "Other long-term liabilities" } } }, "localname": "OtherNoncurrentLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/LeasesBalanceSheetDisclosureDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r80" ], "calculation": { "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfEarningsUnaudited": { "order": 4.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "negatedLabel": "Other expense, net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfEarningsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember": { "auth_ref": [ "r223", "r234", "r235", "r243" ], "lang": { "en-US": { "role": { "documentation": "Plan designed to provide other postretirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes pension benefits.", "label": "Other Postretirement Benefits Plan [Member]", "terseLabel": "Other post-employment plans" } } }, "localname": "OtherPostretirementBenefitPlansDefinedBenefitMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/PostEmploymentBenefitsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic": { "auth_ref": [ "r116" ], "calculation": { "http://www.abbvie.com/role/EarningsPerShareDetails": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of earnings (loss) distributed and earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two-class method.", "label": "Participating Securities, Distributed and Undistributed Earnings (Loss), Basic", "terseLabel": "Earnings allocated to participating securities" } } }, "localname": "ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/EarningsPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted": { "auth_ref": [ "r116" ], "calculation": { "http://www.abbvie.com/role/EarningsPerShareDetails": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of earnings (loss) distributed and earnings (loss) allocated to participating securities for the diluted earnings (loss) per share or per unit calculation under the two-class method.", "label": "Participating Securities, Distributed and Undistributed Earnings (Loss), Diluted", "terseLabel": "Earnings allocated to participating securities" } } }, "localname": "ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/EarningsPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": { "auth_ref": [ "r91" ], "calculation": { "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.", "label": "Payment for Contingent Consideration Liability, Financing Activities", "negatedTerseLabel": "Payments of contingent consideration liabilities" } } }, "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentOfFinancingAndStockIssuanceCosts": { "auth_ref": [ "r92" ], "calculation": { "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities.", "label": "Payment of Financing and Stock Issuance Costs", "negatedTerseLabel": "Debt issuance costs" } } }, "localname": "PaymentOfFinancingAndStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r88" ], "calculation": { "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedLabel": "Purchases of treasury stock" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDividends": { "auth_ref": [ "r88" ], "calculation": { "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.", "label": "Payments of Dividends", "negatedLabel": "Dividends paid" } } }, "localname": "PaymentsOfDividends", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "auth_ref": [ "r141" ], "calculation": { "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow for purchase of marketable security.", "label": "Payments to Acquire Marketable Securities", "negatedLabel": "Purchases of investment securities" } } }, "localname": "PaymentsToAcquireMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireOtherInvestments": { "auth_ref": [ "r84" ], "calculation": { "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow to acquire investments classified as other.", "label": "Payments to Acquire Other Investments", "negatedLabel": "Acquisitions and investments", "verboseLabel": "Cash outflows related to acquisitions and investments" } } }, "localname": "PaymentsToAcquireOtherInvestments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://www.abbvie.com/role/LicensingAcquisitionsAndOtherArrangementsOtherLicensingAcquisitionsActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r83" ], "calculation": { "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Acquisitions of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionPlansDefinedBenefitMember": { "auth_ref": [ "r222", "r234", "r235", "r243" ], "lang": { "en-US": { "role": { "documentation": "Plan designed to provide participant with pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes other postretirement benefits.", "label": "Pension Plan [Member]", "terseLabel": "Defined benefit plans" } } }, "localname": "PensionPlansDefinedBenefitMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/PostEmploymentBenefitsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PortionAtFairValueFairValueDisclosureMember": { "auth_ref": [ "r336" ], "lang": { "en-US": { "role": { "documentation": "Measured at fair value for financial reporting purposes.", "label": "Portion at Fair Value Measurement [Member]", "terseLabel": "Portion at Fair Value Measurement [Member]" } } }, "localname": "PortionAtFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresBasesUsedToMeasureApproximateFairValuesOfFinancialInstrumentsDetails", "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresFairValueMeasuresDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PostemploymentBenefitsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Postemployment Benefits [Abstract]" } } }, "localname": "PostemploymentBenefitsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_PostemploymentBenefitsDisclosureTextBlock": { "auth_ref": [ "r224" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for postemployment benefits, which may include supplemental unemployment benefits, obligations recognized for all types of benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement. Disclosure may also include discussion that an obligation for postemployment benefits is not accrued in accordance with regulation only because the amount cannot be reasonably estimated.", "label": "Postemployment Benefits Disclosure [Text Block]", "terseLabel": "Post-Employment Benefits" } } }, "localname": "PostemploymentBenefitsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/PostEmploymentBenefits" ], "xbrltype": "textBlockItemType" }, "us-gaap_PrepaidExpenseAndOtherAssets": { "auth_ref": [], "calculation": { "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.", "label": "Prepaid Expense and Other Assets", "terseLabel": "Prepaid expenses and other" } } }, "localname": "PrepaidExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets.", "label": "Prepaid Expenses and Other Current Assets [Member]", "terseLabel": "Prepaid expenses and other" } } }, "localname": "PrepaidExpensesAndOtherCurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromIssuanceOfDebt": { "auth_ref": [ "r86" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.", "label": "Proceeds from Issuance of Debt", "terseLabel": "Amount drawn under credit agreement" } } }, "localname": "ProceedsFromIssuanceOfDebt", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/LicensingAcquisitionsAndOtherArrangementsProposedAcquisitionOfAllerganPlcDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromOtherShortTermDebt": { "auth_ref": [ "r86" ], "calculation": { "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from short-term debt classified as other.", "label": "Proceeds from Other Short-term Debt", "terseLabel": "Proceeds from issuance of other short-term borrowings" } } }, "localname": "ProceedsFromOtherShortTermDebt", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": { "auth_ref": [ "r87", "r92", "r106" ], "calculation": { "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.", "label": "Proceeds from (Payments for) Other Financing Activities", "terseLabel": "Other, net" } } }, "localname": "ProceedsFromPaymentsForOtherFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRepaymentsOfCommercialPaper": { "auth_ref": [ "r86", "r90", "r99" ], "calculation": { "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The net cash inflow or cash outflow from issuing (borrowing) and repaying commercial paper.", "label": "Proceeds from (Repayments of) Commercial Paper", "terseLabel": "Net change in commercial paper borrowings" } } }, "localname": "ProceedsFromRepaymentsOfCommercialPaper", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": { "auth_ref": [ "r82" ], "calculation": { "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.", "label": "Proceeds from Sale, Maturity and Collection of Investments", "terseLabel": "Sales and maturities of investment securities" } } }, "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r85", "r256" ], "calculation": { "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from exercise of stock options granted under share-based compensation arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from the exercise of stock options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductConcentrationRiskMember": { "auth_ref": [ "r124" ], "lang": { "en-US": { "role": { "documentation": "Reflects the percentage that revenues during the period from a specified product are to a specified benchmark, such as total net revenues, segment revenues or product line revenues. May also reflect the percentage contribution the product made to operating results. Risk is materially adverse effects of a loss of sales of a significant product or line of products, which could occur upon loss of rights to sell, distribute or license others; loss of patent or copyright protection; or technological obsolescence.", "label": "Product Concentration Risk [Member]", "terseLabel": "HUMIRA" } } }, "localname": "ProductConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresConcentrationsOfRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r30", "r182" ], "calculation": { "http://www.abbvie.com/role/SupplementalFinancialInformationDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Property and equipment, gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/SupplementalFinancialInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment [Member]", "terseLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/LeasesBalanceSheetDisclosureDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r6", "r7", "r184", "r403" ], "calculation": { "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.abbvie.com/role/SupplementalFinancialInformationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets", "http://www.abbvie.com/role/SupplementalFinancialInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNetAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Property, Plant and Equipment, Net [Abstract]", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentNetAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/SupplementalFinancialInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r6", "r184" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of property and equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/SupplementalFinancialInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]", "terseLabel": "Significant amounts reclassified out of each component of AOCI" } } }, "localname": "ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax": { "auth_ref": [ "r61", "r63" ], "calculation": { "http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveIncomeDetails": { "order": 2.0, "parentTag": "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before tax of reclassification adjustments of other comprehensive income (loss).", "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax", "terseLabel": "Amortization of actuarial losses and other" } } }, "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": { "auth_ref": [ "r61", "r63", "r70" ], "calculation": { "http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveIncomeDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss).", "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax", "totalLabel": "Total reclassifications, net of tax" } } }, "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent": { "auth_ref": [ "r61", "r70" ], "calculation": { "http://www.abbvie.com/role/EquityAccumulatedOtherComprehensiveLossDetails": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.", "label": "Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent", "negatedTerseLabel": "Net losses (gains) reclassified from accumulated other comprehensive loss" } } }, "localname": "ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/EquityAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationFromAociCurrentPeriodTax": { "auth_ref": [ "r59", "r62", "r267" ], "calculation": { "http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveIncomeDetails": { "order": 1.0, "parentTag": "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income (loss).", "label": "Reclassification from AOCI, Current Period, Tax", "negatedLabel": "Tax benefit" } } }, "localname": "ReclassificationFromAociCurrentPeriodTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Axis]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Axis]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Domain]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Domain]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identifies item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Member]", "terseLabel": "Reclassification out of accumulated other comprehensive income" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about items reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Table]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Table]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]", "terseLabel": "Schedule of the significant amounts reclassified out of each component of accumulated other comprehensive loss" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/EquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities": { "auth_ref": [ "r89" ], "calculation": { "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with security instruments that either represent a creditor or an ownership relationship with the holder of the investment security with a maturity of beyond one year or normal operating cycle, if longer. Includes repayments of (a) debt, (b) capital lease obligations, (c) mandatory redeemable capital securities, and (d) any combination of (a), (b), or (c).", "label": "Repayments of Long-term Debt, Long-term Capital Lease Obligations, and Capital Securities", "negatedTerseLabel": "Repayments of long-term debt and finance lease obligations" } } }, "localname": "RepaymentsOfLongTermDebtAndCapitalSecurities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfOtherShortTermDebt": { "auth_ref": [ "r90" ], "calculation": { "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow for the payment of debt classified as other, maturing within one year or the operating cycle, if longer.", "label": "Repayments of Other Short-term Debt", "negatedTerseLabel": "Repayments of other short-term borrowings", "terseLabel": "Repayments of other short-term borrowings" } } }, "localname": "RepaymentsOfOtherShortTermDebt", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresDebtAndCreditFacilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff": { "auth_ref": [ "r170" ], "calculation": { "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfEarningsUnaudited": { "order": 4.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.", "label": "Research and Development Asset Acquired Other than Through Business Combination, Written-off", "verboseLabel": "Acquired in-process research and development" } } }, "localname": "ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfEarningsUnaudited", "http://www.abbvie.com/role/LicensingAcquisitionsAndOtherArrangementsOtherLicensingAcquisitionsActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": { "auth_ref": [ "r259" ], "calculation": { "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfEarningsUnaudited": { "order": 3.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.", "label": "Research and Development Expense (Excluding Acquired in Process Cost)", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfEarningsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/EquityStockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringAndRelatedActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Restructuring and Related Activities [Abstract]" } } }, "localname": "RestructuringAndRelatedActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": { "auth_ref": [ "r194" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.", "label": "Restructuring and Related Activities Disclosure [Text Block]", "terseLabel": "Restructuring Plans" } } }, "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/RestructuringPlans" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestructuringCharges": { "auth_ref": [ "r96", "r186", "r190", "r193" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.", "label": "Restructuring Charges", "terseLabel": "Restructuring charges" } } }, "localname": "RestructuringCharges", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/RestructuringPlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringReserve": { "auth_ref": [ "r187", "r191" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.", "label": "Restructuring Reserve", "periodEndLabel": "Accrued balance end of the period", "periodStartLabel": "Accrued balance beginning of the period" } } }, "localname": "RestructuringReserve", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/RestructuringPlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringReserveRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Restructuring Reserve [Roll Forward]", "terseLabel": "Restructuring reserve activity" } } }, "localname": "RestructuringReserveRollForward", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/RestructuringPlansDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r18", "r210", "r401" ], "calculation": { "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Retained earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Retained earnings" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_RetirementPlanTypeAxis": { "auth_ref": [ "r222", "r223", "r234", "r235", "r243" ], "lang": { "en-US": { "role": { "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.", "label": "Retirement Plan Type [Axis]", "terseLabel": "Retirement Plan Type [Axis]" } } }, "localname": "RetirementPlanTypeAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/PostEmploymentBenefitsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RetirementPlanTypeDomain": { "auth_ref": [ "r222", "r223", "r234", "r235", "r243" ], "lang": { "en-US": { "role": { "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.", "label": "Retirement Plan Type [Domain]", "terseLabel": "Retirement Plan Type [Domain]" } } }, "localname": "RetirementPlanTypeDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/PostEmploymentBenefitsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Revenue from Contract with Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r216", "r217", "r218" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Net revenues" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/SegmentInformationDisaggregationOfRevenueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r75", "r129", "r130", "r135" ], "calculation": { "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfEarningsUnaudited": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "terseLabel": "Net revenues", "verboseLabel": "Total net revenues" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfEarningsUnaudited", "http://www.abbvie.com/role/SegmentInformationDisaggregationOfRevenueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": { "auth_ref": [ "r368", "r373" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability", "terseLabel": "Right-of-use assets obtained in exchange for new finance lease liabilities" } } }, "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/LeasesCashFlowDisclosureDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r368", "r373" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Right-of-use assets obtained in exchange for new operating lease liabilities" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/LeasesCashFlowDisclosureDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Revenue from sale of goods and services rendered, in the normal course of business, after sales returns and allowances, and sales discounts, when it serves as a benchmark in a concentration of risk calculation.", "label": "Sales Revenue, Net [Member]", "terseLabel": "Total revenues" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresConcentrationsOfRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScenarioForecastMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The reporting scenario used to indicate financial results forecast for a future period.", "label": "Scenario, Forecast [Member]", "terseLabel": "Scenario, forecast" } } }, "localname": "ScenarioForecastMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/LicensingAcquisitionsAndOtherArrangementsProposedAcquisitionOfAllerganPlcDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScenarioUnspecifiedDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Any scenario, that is, the particular reporting scenario is left unspecified. Scenarios distinguish among different kinds of business reporting facts, as for example actual versus budgeted figures.", "label": "Scenario, Unspecified [Domain]", "terseLabel": "Scenario, Unspecified [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/LicensingAcquisitionsAndOtherArrangementsProposedAcquisitionOfAllerganPlcDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r61" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Summary of changes in balances of each component of accumulated other comprehensive loss" } } }, "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/EquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Securities, Available-for-sale [Line Items]", "terseLabel": "Available-for-sale Securities" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresAvailableForSaleSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": { "auth_ref": [ "r146", "r147", "r150", "r151", "r152", "r153", "r395", "r396" ], "lang": { "en-US": { "role": { "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.", "label": "Schedule of Available-for-sale Securities [Table]", "terseLabel": "Schedule of Available-for-sale Securities [Table]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresAvailableForSaleSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r271", "r272" ], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/LicensingAcquisitionsAndOtherArrangementsProposedAcquisitionOfAllerganPlcDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r282" ], "lang": { "en-US": { "role": { "documentation": "Schedule of contractual arrangements that involve two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity. Additionally, the element may include all other transactions of the entity categorized collectively, if such comparison of collaborative arrangements as a component of all transactions of the entity is desired.", "label": "Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]", "terseLabel": "Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CollaborationWithJanssenBiotechIncDetails", "http://www.abbvie.com/role/LicensingAcquisitionsAndOtherArrangementsOtherLicensingAcquisitionsActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock": { "auth_ref": [ "r282" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of contractual arrangements that involve two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity. Additionally, the element may include all other transactions of the entity categorized collectively, if such comparison of collaborative arrangements as a component of all transactions of the entity is desired.", "label": "Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table Text Block]", "terseLabel": "Schedule of profit and cost sharing relationship" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CollaborationWithJanssenBiotechIncTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": { "auth_ref": [ "r234", "r235", "r236", "r237", "r242" ], "lang": { "en-US": { "role": { "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Defined Benefit Plans Disclosures [Table]", "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table]" } } }, "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/PostEmploymentBenefitsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r306" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the effective portion of the gains and losses on derivative instruments designated (and non-derivative instruments) designated and qualifying in cash flow hedges and net investment hedges that was recognized in other comprehensive income (loss) during the current period.", "label": "Schedule of Derivative Instruments, Effect on Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Schedule of pre-tax amounts of derivatives recognized in other comprehensive income (loss)" } } }, "localname": "ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": { "auth_ref": [ "r298", "r307", "r313" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.", "label": "Derivative Instruments, Gain (Loss) [Table Text Block]", "terseLabel": "Summary of pre-tax amounts and location of derivatives recognized in the condensed consolidated statements of earnings" } } }, "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": { "auth_ref": [ "r304" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.", "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]", "terseLabel": "Summary of amounts and location of derivatives on the condensed consolidated balance sheets" } } }, "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDividendsPayableTextBlock": { "auth_ref": [ "r100" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of all or some of the information related to dividends declared, but not paid, as of the financial reporting date.", "label": "Schedule of Dividends Payable [Table Text Block]", "terseLabel": "Summary of quarterly cash dividends" } } }, "localname": "ScheduleOfDividendsPayableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/EquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r120" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of diluted earnings per share, impact of two-class method" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/EarningsPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r245", "r252", "r257" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.", "label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]", "terseLabel": "Summary of share-based compensation expense" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/EquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r323" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Summary of bases used to measure assets and liabilities carried at fair value on a recurring basis" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r168", "r173" ], "lang": { "en-US": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/GoodwillAndIntangibleAssetsDefiniteLivedIntangibleAssetsDetails", "http://www.abbvie.com/role/GoodwillAndIntangibleAssetsSummaryOfIntangibleAssetsNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r168", "r173" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Summary of definite-lived intangible assets" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/GoodwillAndIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfGoodwillTextBlock": { "auth_ref": [ "r164", "r165" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.", "label": "Schedule of Goodwill [Table Text Block]", "terseLabel": "Summary of changes in the carrying amount of goodwill" } } }, "localname": "ScheduleOfGoodwillTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/GoodwillAndIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r176", "r179" ], "lang": { "en-US": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity.", "label": "Schedule of Indefinite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Indefinite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/GoodwillAndIntangibleAssetsIndefiniteLivedIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r176", "r179" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.", "label": "Schedule of Indefinite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Summary of indefinite-lived intangible assets" } } }, "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/GoodwillAndIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r5", "r25", "r26", "r27" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Schedule of inventories" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/SupplementalFinancialInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNetBenefitCostsTableTextBlock": { "auth_ref": [ "r229" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.", "label": "Schedule of Net Benefit Costs [Table Text Block]", "terseLabel": "Summary of net periodic benefit costs" } } }, "localname": "ScheduleOfNetBenefitCostsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/PostEmploymentBenefitsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": { "auth_ref": [ "r188", "r189", "r192" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.", "label": "Restructuring and Related Costs [Table Text Block]", "terseLabel": "Summary of the cash activity in the restructuring reserve" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/RestructuringPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r247", "r255" ], "lang": { "en-US": { "role": { "documentation": "Components of an equity-based arrangement under which compensation is awarded to employees, typically comprised of compensation expense; changes in the quantity and fair value of the shares (or other type of equity) granted, exercised, forfeited, and issued and outstanding pertaining to that plan; and cash flow effects resulting from the equity-based payment arrangement. Component disclosures are by type of award and plan name.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/EquityRsusAndPerformanceSharesDetails", "http://www.abbvie.com/role/EquityStockBasedCompensationDetails", "http://www.abbvie.com/role/EquityStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShortTermDebtTable": { "auth_ref": [ "r36" ], "lang": { "en-US": { "role": { "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.", "label": "Schedule of Short-term Debt [Table]", "terseLabel": "Schedule of Short-term Debt [Table]" } } }, "localname": "ScheduleOfShortTermDebtTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresDebtAndCreditFacilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r138" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "Segment Information" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/SegmentInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r77", "r155" ], "calculation": { "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfEarningsUnaudited": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfEarningsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [ "r81" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling, General and Administrative Expenses [Member]", "terseLabel": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/EquityStockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SeniorNotesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.", "label": "Senior Notes [Member]", "terseLabel": "Senior notes" } } }, "localname": "SeniorNotesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails", "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r95" ], "calculation": { "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.", "label": "Share-based Compensation", "terseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r250" ], "lang": { "en-US": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Shares granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/EquityRsusAndPerformanceSharesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r249" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "terseLabel": "Fair market value of awards vested (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/EquityRsusAndPerformanceSharesDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/EquityRsusAndPerformanceSharesDetails", "http://www.abbvie.com/role/EquityStockBasedCompensationDetails", "http://www.abbvie.com/role/EquityStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Stock options granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/EquityStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r251" ], "lang": { "en-US": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted-average grant-date fair value of the stock options granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/EquityStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r244", "r248" ], "lang": { "en-US": { "role": { "documentation": "Equity-based compensation award.", "label": "Equity Award [Domain]", "terseLabel": "Equity Award [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/EquityRsusAndPerformanceSharesDetails", "http://www.abbvie.com/role/EquityStockOptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share Price", "terseLabel": "Closing price of AbbVie's common stock" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/LicensingAcquisitionsAndOtherArrangementsProposedAcquisitionOfAllerganPlcDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareRepurchaseProgramAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by share repurchase program.", "label": "Share Repurchase Program [Axis]", "terseLabel": "Share Repurchase Program [Axis]" } } }, "localname": "ShareRepurchaseProgramAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/EquityStockRepurchaseProgramDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareRepurchaseProgramDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the share repurchase program.", "label": "Share Repurchase Program [Domain]", "terseLabel": "Share Repurchase Program [Domain]" } } }, "localname": "ShareRepurchaseProgramDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/EquityStockRepurchaseProgramDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermBorrowings": { "auth_ref": [ "r8", "r384", "r400" ], "calculation": { "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.", "label": "Short-term Debt", "terseLabel": "Short-term borrowings" } } }, "localname": "ShortTermBorrowings", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets", "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresDebtAndCreditFacilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShortTermDebtLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Short-term Debt [Line Items]", "terseLabel": "Short-Term Borrowings" } } }, "localname": "ShortTermDebtLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresDebtAndCreditFacilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtTypeAxis": { "auth_ref": [ "r36" ], "lang": { "en-US": { "role": { "documentation": "Information by type of short-term debt arrangement.", "label": "Short-term Debt, Type [Axis]", "terseLabel": "Short-term Debt, Type [Axis]" } } }, "localname": "ShortTermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresDebtAndCreditFacilitiesDetails", "http://www.abbvie.com/role/LicensingAcquisitionsAndOtherArrangementsProposedAcquisitionOfAllerganPlcDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtTypeDomain": { "auth_ref": [ "r33" ], "lang": { "en-US": { "role": { "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.", "label": "Short-term Debt, Type [Domain]", "terseLabel": "Short-term Debt, Type [Domain]" } } }, "localname": "ShortTermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresDebtAndCreditFacilitiesDetails", "http://www.abbvie.com/role/LicensingAcquisitionsAndOtherArrangementsProposedAcquisitionOfAllerganPlcDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShortTermDebtWeightedAverageInterestRate": { "auth_ref": [ "r34" ], "lang": { "en-US": { "role": { "documentation": "Weighted average interest rate of short-term debt outstanding calculated at point in time.", "label": "Short-term Debt, Weighted Average Interest Rate, at Point in Time", "terseLabel": "Weighted-average interest rate on commercial paper (as a percent)" } } }, "localname": "ShortTermDebtWeightedAverageInterestRate", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresDebtAndCreditFacilitiesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShortTermInvestments": { "auth_ref": [ "r10", "r387", "r388", "r389", "r398" ], "calculation": { "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.", "label": "Short-term Investments", "terseLabel": "Short-term investments" } } }, "localname": "ShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShortTermInvestmentsMember": { "auth_ref": [ "r387", "r388", "r398", "r409" ], "lang": { "en-US": { "role": { "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet.", "label": "Short-term Investments [Member]", "terseLabel": "Short-term investments" } } }, "localname": "ShortTermInvestmentsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresAvailableForSaleSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShortTermLeaseCost": { "auth_ref": [ "r365", "r373" ], "calculation": { "http://www.abbvie.com/role/LeasesCostDetails": { "order": 4.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.", "label": "Short-term Lease, Cost", "terseLabel": "Short-term lease cost" } } }, "localname": "ShortTermLeaseCost", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/LeasesCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShortTermLeasesPolicyTextBlock": { "auth_ref": [ "r354" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy election for short-term lease to recognize lease payments on straight-line basis over lease term and variable lease payments as incurred.", "label": "Short-term Leases [Policy Text Block]", "terseLabel": "Short-Term Leases" } } }, "localname": "ShortTermLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/LeasesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShorttermDebtFairValue": { "auth_ref": [], "calculation": { "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresBasesUsedToMeasureApproximateFairValuesOfFinancialInstrumentsDetails": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "This element represents the portion of the balance sheet assertion valued at fair value by the entity whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission. This item represents the amount of short-term debt existing as of the balance sheet date.", "label": "Short-term Debt, Fair Value", "terseLabel": "Short-term borrowings" } } }, "localname": "ShorttermDebtFairValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresBasesUsedToMeasureApproximateFairValuesOfFinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r13", "r14", "r15", "r209" ], "lang": { "en-US": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r44", "r209" ], "lang": { "en-US": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfEquityUnaudited", "http://www.abbvie.com/role/EquityAccumulatedOtherComprehensiveLossDetails", "http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfEquityUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementScenarioAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by scenario to be reported. Scenarios distinguish among different kinds of business reporting facts, as for example actual versus budgeted figures.", "label": "Scenario [Axis]", "terseLabel": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/LicensingAcquisitionsAndOtherArrangementsProposedAcquisitionOfAllerganPlcDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfEquityUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "auth_ref": [ "r14", "r15", "r209", "r210" ], "lang": { "en-US": { "role": { "documentation": "Number of shares (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of any shares forfeited. Shares issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.", "label": "Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures", "terseLabel": "Stock-based compensation plans and other (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "auth_ref": [ "r14", "r15", "r210", "r246", "r251" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value of stock (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of stock value of such awards forfeited. Stock issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.", "label": "Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures", "terseLabel": "Stock-based compensation plans and other" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount remaining of a stock repurchase plan authorized.", "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount", "terseLabel": "Remaining share repurchase authorization amount" } } }, "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/EquityStockRepurchaseProgramDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r15", "r19", "r20", "r139" ], "calculation": { "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total stockholders\u2019 equity (deficit)" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets", "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfEquityUnaudited", "http://www.abbvie.com/role/EquityAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders\u2019 equity (deficit)" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders' Equity Note [Abstract]" } } }, "localname": "StockholdersEquityNoteAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/LicensingAcquisitionsAndOtherArrangementsProposedAcquisitionOfAllerganPlcDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r375" ], "lang": { "en-US": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/LicensingAcquisitionsAndOtherArrangementsProposedAcquisitionOfAllerganPlcDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r375" ], "lang": { "en-US": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/LicensingAcquisitionsAndOtherArrangementsProposedAcquisitionOfAllerganPlcDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r381" ], "lang": { "en-US": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/FinancialInstrumentsAndFairValueMeasuresAvailableForSaleSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockMember": { "auth_ref": [ "r43", "r211" ], "lang": { "en-US": { "role": { "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Treasury Stock [Member]", "terseLabel": "Treasury stock" } } }, "localname": "TreasuryStockMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockShares": { "auth_ref": [ "r43", "r211" ], "lang": { "en-US": { "role": { "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.", "label": "Treasury Stock, Shares", "terseLabel": "Common stock held in treasury, at cost (in shares)" } } }, "localname": "TreasuryStockShares", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockSharesAcquired": { "auth_ref": [ "r15", "r209", "r210" ], "lang": { "en-US": { "role": { "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.", "label": "Treasury Stock, Shares, Acquired", "negatedTerseLabel": "Purchases of treasury stock (in shares)", "terseLabel": "Shares repurchased (in shares)" } } }, "localname": "TreasuryStockSharesAcquired", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfEquityUnaudited", "http://www.abbvie.com/role/EquityStockRepurchaseProgramDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockValue": { "auth_ref": [ "r43", "r211", "r214" ], "calculation": { "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.", "label": "Treasury Stock, Value", "negatedLabel": "Common stock held in treasury, at cost, 302,685,326 shares as of June 30, 2019 and 297,686,473 as of December 31, 2018" } } }, "localname": "TreasuryStockValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "auth_ref": [ "r209", "r210", "r211" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.", "label": "Treasury Stock, Value, Acquired, Cost Method", "negatedTerseLabel": "Purchases of treasury stock", "terseLabel": "Payment for shares repurchased" } } }, "localname": "TreasuryStockValueAcquiredCostMethod", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfEquityUnaudited", "http://www.abbvie.com/role/EquityStockRepurchaseProgramDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Adoption and early adoption of sources of change to generally accepted accounting principles (GAAP) in the United States. The FASB released the FASB Accounting Standards Codification as the authoritative source of literature effective for interim and annual periods ending after September 15, 2009. As part of the Codification process, the FASB issues Accounting Standards Updates to amend the Codification but otherwise the Accounting Standards Updates are not authoritative in their own right. All previous accounting standards (such as FASB Statements of Financial Accounting Standards, FASB Interpretations, FASB Staff Positions, Emerging Issues Task Force Consensuses, other pronouncements of the FASB or other designated bodies, or other forms of GAAP are considered accounting pronouncements) were superseded upon the adoption of the Codification. For an interim period, references to the superseded standards are included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.", "label": "Type of Adoption [Domain]", "terseLabel": "Type of Adoption [Domain]" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/BasisOfPresentationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r282" ], "lang": { "en-US": { "role": { "documentation": "Information by category of arrangement, including but not limited to collaborative arrangements and non-collaborative arrangements.", "label": "Type of Arrangement and Non-arrangement Transactions [Axis]", "terseLabel": "Type of Arrangement and Non-arrangement Transactions [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CollaborationWithJanssenBiotechIncDetails", "http://www.abbvie.com/role/LicensingAcquisitionsAndOtherArrangementsOtherLicensingAcquisitionsActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableLeaseCost": { "auth_ref": [ "r366", "r373" ], "calculation": { "http://www.abbvie.com/role/LeasesCostDetails": { "order": 5.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.", "label": "Variable Lease, Cost", "terseLabel": "Variable lease cost" } } }, "localname": "VariableLeaseCost", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/LeasesCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r113", "r119" ], "calculation": { "http://www.abbvie.com/role/EarningsPerShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-US": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted-average diluted shares outstanding (in shares)", "totalLabel": "Weighted-average diluted shares outstanding (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfEarningsUnaudited", "http://www.abbvie.com/role/EarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r111", "r119" ], "calculation": { "http://www.abbvie.com/role/EarningsPerShareDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted-average basic shares outstanding (in shares)", "verboseLabel": "Weighted-average basic shares outstanding (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.abbvie.com/role/CondensedConsolidatedStatementsOfEarningsUnaudited", "http://www.abbvie.com/role/EarningsPerShareDetails" ], "xbrltype": "sharesItemType" } }, "unitCount": 17 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h)(1)(i))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(n)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22580-107794" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1448-109256" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1377-109256" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1505-109256" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1252-109256" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1500-109256" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=SL5780133-109256" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=SL5780133-109256" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1337-109256" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109256448&loc=d3e4984-109258" }, "r122": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599" }, "r138": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "http://asc.fasb.org/topic&trid=2134510" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=109979856&loc=d3e26610-111562" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=109979856&loc=d3e26853-111562" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "9A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=109979856&loc=SL6284427-111562" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aaa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27198-111563" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27232-111563" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27290-111563" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27290-111563" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27337-111563" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27340-111563" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)-(d)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27357-111563" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=84241550&loc=SL75117539-209714" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=68048583&loc=d3e3636-108311" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=68049868&loc=d3e3927-108312" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.BB)", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13854-109267" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b),(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4(b))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r194": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "420", "URI": "http://asc.fasb.org/topic&trid=2175745" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14326-108349" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14615-108349" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14394-108349" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14435-108349" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14435-108349" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14453-108349" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14472-108349" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14557-108349" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14557-108349" }, "r204": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=115931803&loc=d3e12021-110248" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=115931803&loc=d3e12053-110248" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23309-112656" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656" }, "r215": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "50", "Topic": "505", "URI": "http://asc.fasb.org/subtopic&trid=2208855" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130539-203045" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130543-203045" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=108792157&loc=SL49130690-203046-203046" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=108792157&loc=SL49130690-203046-203046" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "712", "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "712", "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664" }, "r224": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "712", "URI": "http://asc.fasb.org/topic&trid=2197446" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(j)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e2410-114920" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e2417-114920" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e2439-114920" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e2709-114920" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e2709-114920" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e2709-114920" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e2709-114920" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=112275985&loc=d3e4179-114921" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=SL79508275-113901" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r258": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=d3e31917-109318" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=d3e31931-109318" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=d3e31958-109318" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e39076-109324" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324" }, "r269": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=84229725&loc=d3e961-128460" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5419-128473" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5504-128473" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=109124213&loc=d3e6578-128477" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=109124213&loc=d3e6613-128477" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911338&loc=d3e6819-128478" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r283": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "808", "URI": "http://asc.fasb.org/topic&trid=5833765" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r288": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579240-113959" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.12)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579245-113959" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5580258-113959" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)(i)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)(ii)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)(iii)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41638-113959" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "4CCC", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL109998896-113959" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "4E", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624181-113959" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41641-113959" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41678-113959" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "182", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109975725&loc=SL5629052-113961" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109974929&loc=SL110061190-113977" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "25", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109977999&loc=d3e76258-113986" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=112277219&loc=d3e80748-113994" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=112277219&loc=d3e80748-113994" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=112277219&loc=d3e80784-113994" }, "r322": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "815", "URI": "http://asc.fasb.org/topic&trid=2229140" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19190-110258" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "2C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=SL7498348-110258" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19279-110258" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=SL6742756-110258" }, "r335": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "820", "URI": "http://asc.fasb.org/topic&trid=2155941" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=75026489&loc=d3e13220-108610" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=109250915&loc=d3e13433-108611" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=109250915&loc=d3e13467-108611" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=109250915&loc=d3e13476-108611" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=109250915&loc=d3e13531-108611" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=109250915&loc=d3e13537-108611" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=109250915&loc=d3e13537-108611" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14172-108612" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30690-110894" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30700-110894" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r352": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "840", "URI": "http://asc.fasb.org/topic&trid=2208923" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=113997351&loc=SL77916155-209984" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888369&loc=SL77918418-209957" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918638-209977" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918666-209980" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971" }, "r374": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888251" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=SL51823488-111719" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=68078379&loc=d3e122625-111746" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(4))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Subparagraph": "b.", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6477933&loc=d3e60009-112784" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62557-112803" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(g))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6801-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04.7)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=99384497&loc=SL65671331-158438" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6484115&loc=d3e19393-158473" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(2)(i))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611133-123010" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12C(1)(a))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611225-123010" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13(1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611282-123010" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column A))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611379-123010" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=6589523&loc=d3e617274-123014" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024" }, "r417": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r418": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r419": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-13" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r420": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1-" }, "r421": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r422": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r423": { "Article": "12", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "13", "Sentence": "Column B" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b),(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i),(j),(k)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i-k)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=d3e637-108580" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=d3e640-108580" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=d3e681-108580" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669686-108580" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "17A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL34724391-108580" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL34724394-108580" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=d3e557-108580" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=109228884&loc=d3e1436-108581" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4,6)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(b))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3179-108585" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3521-108585" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3044-108585" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3098-108585" } }, "version": "2.1" } ZIP 94 0001551152-19-000023-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001551152-19-000023-xbrl.zip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ʾ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�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

  •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